<html class="gs_el_sm gs_pfcs"><head><title>‪Robert Coleman‬ - ‪Google Scholar‬</title><meta http-equiv="Content-Type" content="text/html;charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="referrer" content="origin-when-cross-origin"><meta name="viewport" content="width=device-width,initial-scale=1,minimum-scale=1,maximum-scale=2"><meta name="format-detection" content="telephone=no"><link rel="shortcut icon" href="/favicon.ico"><link rel="canonical" href="https://scholar.google.com/citations?user=UIrmjcIAAAAJ&amp;hl=en"><meta name="description" content="‪University of Sheffield‬ - ‪‪Cited by 67,016‬‬ - ‪Oncology‬ - ‪breast cancer‬ - ‪bone disease‬ - ‪trials‬"><meta property="og:description" content="‪University of Sheffield‬ - ‪‪Cited by 67,016‬‬ - ‪Oncology‬ - ‪breast cancer‬ - ‪bone disease‬ - ‪trials‬"><meta property="og:title" content="Robert Coleman"><meta property="og:image" content="https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=UIrmjcIAAAAJ&amp;citpid=2"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>html,body,form,table,div,h1,h2,h3,h4,h5,h6,img,ol,ul,li,button{margin:0;padding:0;border:0;}table{border-collapse:collapse;border-width:0;empty-cells:show;}html,body{height:100%}#gs_top{position:relative;box-sizing:border-box;min-height:100%;min-width:964px;-webkit-tap-highlight-color:rgba(0,0,0,0);}#gs_top>*:not(#x){-webkit-tap-highlight-color:rgba(204,204,204,.5);}.gs_el_ph #gs_top,.gs_el_ta #gs_top{min-width:320px;}#gs_top.gs_nscl{position:fixed;width:100%;}body,td,input,button{font-size:13px;font-family:Arial,sans-serif;line-height:1.24;}body{background:#fff;color:#222;-webkit-text-size-adjust:100%;-moz-text-size-adjust:none;}.gs_gray{color:#777777}.gs_red{color:#dd4b39}.gs_grn{color:#006621}.gs_lil{font-size:11px}.gs_med{font-size:16px}.gs_hlt{font-weight:bold;}a:link{color:#1a0dab;text-decoration:none}a:visited{color:#660099;text-decoration:none}a:hover,a:hover .gs_lbl{text-decoration:underline}a:active,a:active .gs_lbl,a .gs_lbl:active{color:#d14836}.gs_el_tc a:hover,.gs_el_tc a:hover .gs_lbl{text-decoration:none}.gs_pfcs a:focus,.gs_pfcs button:focus,.gs_pfcs input:focus,.gs_pfcs label:focus{outline:none}.gs_a,.gs_a a:link,.gs_a a:visited{color:#006621}.gs_a a:active{color:#d14836}a.gs_fl:link,.gs_fl a:link{color:#1a0dab}a.gs_fl:visited,.gs_fl a:visited{color:#660099}a.gs_fl:active,.gs_fl a:active{color:#d14836}.gs_fl{color:#777777}.gs_ctc,.gs_ctu{vertical-align:middle;font-size:11px;font-weight:bold}.gs_ctc{color:#1a0dab}.gs_ctg,.gs_ctg2{font-size:13px;font-weight:bold}.gs_ctg{color:#1a0dab}a.gs_pda,.gs_pda a{padding:7px 0 5px 0}.gs_alrt{background:#f9edbe;border:1px solid #f0c36d;padding:0 16px;text-align:center;box-shadow:0 2px 4px rgba(0,0,0,.2);border-radius:2px;}.gs_spc{display:inline-block;width:12px}.gs_br{width:0;font-size:0}.gs_ibl{display:inline-block;}.gs_scl:after{content:"";display:table;clear:both;}.gs_ind{padding-left:8px;text-indent:-8px}.gs_ico,.gs_icm{display:inline-block;background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png);background-position:-23px -161px;background-size:169px;width:21px;height:21px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_ico,.gs_icm{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);}}.gs_el_ta .gs_nta,.gs_ota,.gs_el_ph .gs_nph,.gs_oph{display:none}.gs_el_ta .gs_ota,.gs_el_ph .gs_oph{display:inline}.gs_el_ta div.gs_ota,.gs_el_ph div.gs_oph{display:block}.gs_sth_g{visibility:hidden;max-height:0;}.gs_sth_vis .gs_sth_g{max-height:1000px;}.gs_sth_vis .gs_sth_b{position:fixed;top:0;}@keyframes gs_anm_spin{0%{transform:rotate(0deg);}100%{transform:rotate(360deg);}}.gs_rimg{display:block;background-color:#e5e5e5;border-radius:50%;overflow:hidden;position:relative;z-index:1;}.gs_rimg>img{position:absolute;margin:auto;left:0;top:0;bottom:0;right:0;}.gs_in_txtw{display:inline-block;vertical-align:middle;}.gs_in_txtb{display:block;}.gs_in_txt{color:#000;background-color:#fff;font-size:16px;box-sizing:border-box;height:29px;line-height:23px;border:1px solid #d9d9d9;border-top-color:#c0c0c0;padding:3px 6px 1px 8px;border-radius:1px;outline:none;-webkit-appearance:none;-moz-appearance:none;}.gs_el_tc .gs_in_txt{font-size:18px;}.gs_in_txtb .gs_in_txt{width:100%;}.gs_in_txt:hover{border-color:#b9b9b9;border-top-color:#a0a0a0;box-shadow:inset 0 1px 2px rgba(0,0,0,.1);}.gs_in_txte .gs_in_txt{border-color:#dd4b39;}.gs_in_txt:focus{border-color:#4d90fe;box-shadow:inset 0 1px 2px rgba(0,0,0,.3);}.gs_in_txt:disabled{color:#b8b8b8;border-color:#f1f1f1;box-shadow:none;}.gs_in_txtm .gs_in_txt{font-size:13px;height:24px;line-height:16px;padding:3px 6px;}.gs_el_tc .gs_in_txtm .gs_in_txt{height:29px;line-height:21px;}.gs_in_txts{font-size:13px;line-height:18px;color:#666;}.gs_in_txte .gs_in_txts{color:#dd4b39;}button{position:relative;z-index:1;box-sizing:border-box;font-size:13px;cursor:pointer;height:29px;line-height:normal;min-width:72px;padding:0 8px;color:#444;border:1px solid rgba(0,0,0,.1);border-radius:3px;text-align:center;background-color:#f5f5f5;-webkit-user-select:none;user-select:none;}button.gs_btn_rnd{border-radius:14px;padding:0 12px;}button.gs_btn_rnd.gs_btn_rndci{padding-left:4px;}button.gs_btn_lrge{height:41px;min-width:82px;padding:0 9px;}button.gs_btn_lrge.gs_btn_rnd{border-radius:20px;padding:0 16px;}button.gs_btn_lrge.gs_btn_rnd.gs_btn_rndci{padding-left:10px;}button.gs_btn_cir{border-radius:14.5px;min-width:29px;}button.gs_btn_lrge.gs_btn_cir{border-radius:20.5px;min-width:41px;}button.gs_btn_mini{padding:0;border:0;}.gs_el_ph button.gs_btn_mph,.gs_el_ta button.gs_btn_mta{height:41px;}button .gs_wr{position:relative;display:inline-block;width:100%;height:100%;}button .gs_wr:before{content:"";width:0;height:100%;}button .gs_wr:before,button .gs_ico,button .gs_rdt,button .gs_lbl,button .gs_icm{display:inline-block;vertical-align:middle;}button .gs_wr{font-size:13px;text-transform:none;}.gs_btn_lrge .gs_wr{font-size:15px;}.gs_btn_lsb .gs_wr{font-size:11px;font-weight:bold;}.gs_btn_lsu .gs_wr{font-size:11px;text-transform:uppercase;}.gs_btn_lrge.gs_btn_lsb .gs_wr,.gs_btn_lrge.gs_btn_lsu .gs_wr{font-size:13px;}.gs_btn_half,.gs_el_ta .gs_btn_hta,.gs_el_ph .gs_btn_hph{min-width:36px;}.gs_btn_lrge.gs_btn_half,.gs_el_ta .gs_btn_lrge.gs_btn_hta,.gs_el_ph .gs_btn_lrge.gs_btn_hph,.gs_el_ta .gs_btn_mta,.gs_el_ph .gs_btn_mph{min-width:41px;}.gs_btn_slt{border-radius:3px 0 0 3px;}.gs_btn_srt{margin-left:-1px;border-radius:0 3px 3px 0;}.gs_btn_smd{margin-left:-1px;border-radius:0;}button:hover{z-index:2;color:#222;border-color:rgba(0,0,0,.2);background-color:#f8f8f8;}button.gs_sel{background-color:#dcdcdc;}button:active{z-index:2;background-color:#f1f1f1;}button:focus{z-index:2;}button::-moz-focus-inner{padding:0;border:0}button:-moz-focusring{outline:1px dotted ButtonText}.gs_pfcs button:-moz-focusring{outline:none}a.gs_in_ib{position:relative;display:inline-block;line-height:16px;padding:6px 0 7px 0;-webkit-user-select:none;user-select:none;}a.gs_btn_lrge{height:40px;padding:0;}a.gs_in_ib .gs_lbl{display:inline-block;padding-left:21px;color:#222;}a.gs_in_ib .gs_lbl:not(:empty){padding-left:29px;}button.gs_in_ib .gs_lbl:not(:empty){padding-left:4px;}a.gs_in_ib:active .gs_lbl,a.gs_in_ib .gs_lbl:active,a.gs_in_ib :active~.gs_lbl{color:#d14836;}.gs_el_ta .gs_btn_hta .gs_lbl,.gs_el_ph .gs_btn_hph .gs_lbl,.gs_el_ta .gs_btn_mta .gs_lbl,.gs_el_ph .gs_btn_mph .gs_lbl,.gs_el_ta .gs_btn_cta .gs_lbl,.gs_el_ph .gs_btn_cph .gs_lbl{display:none;}a.gs_in_ib .gs_ico{position:absolute;top:3px;left:0;}.gs_in_ib.gs_md_li .gs_ico{left:14px;}.gs_el_tc .gs_in_ib.gs_md_li .gs_ico{top:11px;}.gs_in_ib.gs_md_li.gs_md_lix .gs_ico{top:10px;left:16px;}a.gs_btn_lrge .gs_ico{top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}.gs_in_ib .gs_ico{opacity:.55;}.gs_in_ib:hover .gs_ico{opacity:.72;}.gs_in_ib:active .gs_ico,.gs_in_ib .gs_ico:active,.gs_in_ib :active~.gs_ico{opacity:1;}.gs_in_ib:disabled .gs_ico,.gs_in_ib.gs_dis .gs_ico{opacity:.28;}.gs_in_ib.gs_btn_act .gs_ico,.gs_in_ib.gs_btn_cre .gs_ico{opacity:1;}.gs_btn_act:disabled .gs_ico,.gs_btn_cre:disabled .gs_ico{opacity:.72;}.gs_rdt{position:relative;width:0;height:21px;}.gs_rdt:before{content:"";position:absolute;top:2px;right:1px;width:5px;height:5px;border-radius:50%;background-color:#dd4b39;}button.gs_btn_flat{border-color:transparent;background-color:transparent;}button.gs_btn_flat:hover{background-color:rgba(0,0,0,.05);}button.gs_btn_flat:active{background-color:rgba(0,0,0,.1);}button.gs_btn_flat.gs_btn_flact{color:#1a0dab;}button.gs_btn_act{color:#fff;-webkit-font-smoothing:antialiased;background-color:#4d90fe;}button.gs_btn_act:hover{color:#fff;background-color:#3983fe;}button.gs_btn_act.gs_sel{background-color:#2f6bcc;}button.gs_btn_act:active{background-color:#357ae8;}button.gs_btn_cre{color:#fff;-webkit-font-smoothing:antialiased;background-color:#d14836;}button.gs_btn_cre:hover{color:#fff;background-color:#c53727;}button.gs_btn_cre.gs_sel{background-color:#992b1e;}html:not(.gs_pfcs) .gs_btn_act:focus:not(:active){box-shadow:inset 0 0 0 1px rgba(255,255,255,.5);}button.gs_btn_cre:active{background-color:#b0281a;}button:disabled,button:disabled:hover,button:disabled:active{cursor:default;color:#b8b8b8;border-color:rgba(0,0,0,.05);background-color:transparent;z-index:0;}button.gs_btn_flat:disabled{color:#b8b8b8;border-color:transparent;}button.gs_btn_act:disabled{color:#fff;background-color:#a6c8ff;}button.gs_btn_cre:disabled{color:#fff;background-color:#e8a49b;}a.gs_in_ib.gs_dis{cursor:default;pointer-events:none}a.gs_in_ib.gs_dis .gs_lbl{color:#b8b8b8;text-decoration:none}.gs_ttp{position:absolute;top:100%;right:50%;z-index:10;pointer-events:none;visibility:hidden;opacity:0;transition:visibility 0s .13s,opacity .13s ease-out;}button:hover .gs_ttp,button:focus .gs_ttp,a:hover .gs_ttp,a:focus .gs_ttp{transition:visibility 0s .3s,opacity .13s ease-in .3s;visibility:visible;opacity:1;}.gs_md_tb.gs_sel .gs_ttp{transition:none;visibility:hidden;}button.gs_btn_lrge.gs_btn_cir .gs_ttp{top:75%;}.gs_ttp .gs_aro,.gs_ttp .gs_aru{position:absolute;top:-2px;right:-5px;width:0;height:0;line-height:0;font-size:0;border:5px solid transparent;border-top:none;border-bottom-color:#595959;z-index:1;}.gs_ttp .gs_aro{top:-3px;right:-6px;border-width:6px;border-top:none;border-bottom-color:white;}.gs_ttp .gs_txt{display:block;position:relative;top:2px;right:-50%;padding:4px 6px;background:#595959;color:white;font-size:11px;font-weight:bold;line-height:normal;white-space:nowrap;border:1px solid white;border-radius:3px;box-shadow:inset 0 1px 4px rgba(0,0,0,.2);}.gs_press,.gs_in_se,.gs_tan{touch-action:none;}.gs_in_se .gs_lbl:not(:empty){padding-right:14px;}.gs_in_se .gs_icm{position:absolute;top:50%;margin-top:-5.5px;right:0;width:7px;height:11px;background-position:-21px -88px;opacity:.55;}.gs_in_se:hover .gs_icm{opacity:.72;}.gs_in_se:active .gs_icm{opacity:1;}.gs_in_se:disabled .gs_icm{opacity:.28;}.gs_el_ta .gs_btn_hta .gs_icm,.gs_el_ph .gs_btn_hph .gs_icm,.gs_el_ta .gs_btn_mta .gs_icm,.gs_el_ph .gs_btn_mph .gs_icm,.gs_el_ta .gs_btn_cta .gs_icm,.gs_el_ph .gs_btn_cph .gs_icm{display:none;}.gs_btn_mnu .gs_icm{margin-top:-3.5px;height:7px;background-position:0 -110px;}.gs_in_se.gs_btn_act .gs_icm,.gs_in_se.gs_btn_cre .gs_icm{margin-top:-3.5px;height:7px;background-position:-42px -44px;opacity:1;}.gs_btn_act:disabled .gs_icm,.gs_btn_cre:disabled .gs_icm{opacity:.72;}button.gs_btnG .gs_ico{width:21px;height:21px;background-position:-92px -253px;}button .gs_bs{position:absolute;top:50%;left:50%;margin-top:-10px;margin-left:-10px;box-sizing:border-box;width:20px;height:20px;border-radius:50%;border:2px solid #eee;border-top-color:#4d90fe;visibility:hidden;animation:gs_anm_spin .8s linear infinite;}button.gs_bsp .gs_bs{visibility:visible;transition:visibility 0s .4s;}.gs_md_d{text-transform:none;white-space:nowrap;position:absolute;top:0;left:0;border:1px solid #ccc;border-color:rgba(0,0,0,.2);background:#fff;box-shadow:0 2px 4px rgba(0,0,0,.2);z-index:1100;text-align:left;visibility:hidden;max-height:0;margin-top:-1000px;opacity:0;transition:opacity .13s,visibility 0s .13s,max-height 0s .13s,margin-top 0s .13s;}.gs_md_d.gs_vis{visibility:visible;max-height:10000px;margin-top:0;opacity:1;transition:all 0s;}.gs_el_tc .gs_md_d{transform-origin:100% 0;transform:scale(1,0);transition:opacity .218s ease-out,transform 0s .218s,visibility 0s .218s,max-height 0s .218s,margin-top 0s .218s;}.gs_el_ios .gs_md_d{-webkit-backface-visibility:hidden;}.gs_el_tc .gs_md_d.gs_ttzi{transform-origin:50% 50%;transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_ttzr{transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_vis{transform:scale(1,1);transition:transform .218s ease-out;}.gs_md_r{position:relative;display:inline-block;}.gs_md_rmb>.gs_md_d{top:29px}.gs_md_rmbl>.gs_md_d{top:41px}.gs_md_ul{list-style-type:none;word-wrap:break-word;display:inline-block;vertical-align:top;}.gs_md_ul.gs_md_ul_tb{display:block;}.gs_md_li,.gs_in_cb.gs_md_li,.gs_md_li:link,.gs_md_li:visited{display:block;padding:6px 44px 6px 16px;font-size:13px;line-height:16px;color:#222;cursor:pointer;text-decoration:none;position:relative;z-index:0;}a.gs_md_li:hover .gs_lbl,a.gs_md_li:active .gs_lbl{text-decoration:none}.gs_el_tc .gs_md_li{padding-top:14px;padding-bottom:10px;}.gs_md_li.gs_md_lix{font-size:16px;line-height:20px;padding:12px 16px 8px 16px;}.gs_md_li:before{content:"";background-color:#f1f1f1;position:absolute;left:0;right:0;top:0;bottom:0;opacity:0;transition:opacity .13s;z-index:-1;}.gs_md_li:hover:before,.gs_md_li:focus:before{opacity:1;transition:all 0s;}a.gs_in_ib.gs_md_li .gs_lbl{color:#222}a.gs_in_ib.gs_md_li.gs_in_gray .gs_lbl{color:#444}.gs_md_li:active:before{background-color:#ddd}.gs_md_li.gs_sel,a.gs_in_ib.gs_md_li.gs_sel .gs_lbl{color:#d14836}.gs_md_d:focus,.gs_md_li:focus{outline:none}a.gs_md_lix .gs_lbl,a.gs_md_lix .gs_lbl:not(:empty){padding:0 0 0 40px;}a.gs_in_cb:link,a.gs_in_cb:visited,a.gs_in_cb:active,a.gs_in_cb:hover{cursor:pointer;color:#222;text-decoration:none;}.gs_in_cb,.gs_in_ra{position:relative;line-height:16px;display:inline-block;-webkit-user-select:none;user-select:none;}.gs_in_cb.gs_md_li{padding:6px 44px 6px 16px;}.gs_in_cb input,.gs_in_ra input{position:absolute;top:1px;left:1px;width:15px;height:15px;margin:0;padding:0;opacity:0;z-index:2;}.gs_in_ra input{top:0;left:0}.gs_el_tc .gs_in_cb input{top:9px}.gs_el_tc .gs_in_ra input{top:8px}.gs_in_cb.gs_in_cbj input{top:15px;left:15px}.gs_in_cb label,.gs_in_cb .gs_lbl,.gs_in_ra label{display:inline-block;padding-left:21px;min-height:16px;}.gs_in_cb label:empty:before,.gs_in_cb .gs_lbl:empty:before,.gs_in_ra label:empty:before{content:"\200b";}.gs_el_tc .gs_in_cb label,.gs_el_tc .gs_in_cb .gs_lbl,.gs_el_tc .gs_in_ra label{padding-top:8px;padding-bottom:5px;}.gs_in_cb.gs_in_cbj label,.gs_in_cb.gs_in_cbj .gs_lbl{padding:13px 0 12px 41px;}.gs_in_cbb,.gs_in_cbb label,.gs_in_cbb .gs_lbl{display:block;}.gs_in_cb .gs_cbx,.gs_in_ra .gs_cbx{position:absolute}.gs_in_cb .gs_cbx{top:2px;left:2px;width:11px;height:11px;border:1px solid #c6c6c6;border-radius:1px;}.gs_md_li .gs_cbx{top:8px;left:18px}.gs_el_tc .gs_in_cb .gs_cbx{top:10px}.gs_el_tc .gs_md_li .gs_cbx{top:16px}.gs_in_cb.gs_in_cbj .gs_cbx{top:15px;left:15px}.gs_el_tc .gs_in_ra .gs_cbx{top:8px}.gs_in_ra .gs_cbx{top:0;left:0;border:1px solid #c6c6c6;width:13px;height:13px;border-radius:7px;}.gs_in_cb:hover .gs_cbx,.gs_in_ra:hover .gs_cbx{border-color:#666;box-shadow:inset 0 1px 1px rgba(0,0,0,.1);}button.gs_in_cb:hover .gs_cbx{border-color:#c6c6c6;}.gs_in_cb :focus~label,.gs_in_ra :focus~label{outline:1px dotted #222;outline:auto -webkit-focus-ring-color;}.gs_pfcs .gs_in_cb :focus~label,.gs_pfcs .gs_in_ra :focus~label{outline:none;}.gs_in_cb:active .gs_cbx,.gs_in_ra:active .gs_cbx,.gs_in_cb .gs_cbx:active,.gs_in_ra .gs_cbx:active,.gs_in_cb :active~.gs_cbx,.gs_in_ra :active~.gs_cbx{border-color:#666;background-color:#ebebeb;}button.gs_in_cb:active .gs_cbx{border-color:#a6a6a6;}.gs_in_cb :disabled~.gs_cbx,.gs_in_ra :disabled~.gs_cbx,button.gs_in_cb:disabled .gs_cbx{border-color:#f1f1f1;box-shadow:none;}.gs_in_cb :disabled~label,.gs_in_ra :disabled~label{color:#b8b8b8;}.gs_in_cb.gs_err .gs_cbx{border-color:#eda29b;}.gs_in_cb .gs_chk,.gs_in_ra .gs_chk{position:absolute;z-index:1;top:-3px;left:-2px;width:21px;height:21px;}.gs_md_li .gs_chk{top:3px;left:14px}.gs_el_tc .gs_in_cb .gs_chk{top:5px}.gs_el_tc .gs_md_li .gs_chk{top:11px}.gs_in_cb.gs_in_cbj .gs_chk{top:10px;left:11px}.gs_in_ra .gs_chk{top:4px;left:4px;width:7px;height:7px;border-radius:4px;}.gs_el_tc .gs_in_ra .gs_chk{top:12px}.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -69px -67px;opacity:.62;}.gs_in_ra input:checked~.gs_chk{background-color:#666}.gs_in_cb.gs_par .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -21px -44px;opacity:.55;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk,.gs_in_cb.gs_par .gs_chk{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);background-size:169px;}}.gs_in_cb input:checked:disabled~.gs_chk{opacity:.22}.gs_in_ra input:checked:disabled~.gs_chk{background-color:#f1f1f1}.gs_ico_x{background-position:-113px -22px;opacity:.55;}.gs_ico_x:hover{opacity:.72;}.gs_ico_x:active{opacity:1;}.gs_ico_X{background-position:-71px 0;opacity:.55;}.gs_ico_X:hover{opacity:.72;}.gs_ico_X:active{opacity:1;}.gs_el_tc .gs_ico_Xt{background-origin:content-box;background-clip:content-box;padding:10px 6px 10px 14px;}.gs_ico_P{background-position:0 0;opacity:.55;}.gs_ico_P:hover{opacity:.72;}.gs_ico_P:active{opacity:1;}.gs_btnP .gs_ico{background-position:-21px 0;}.gs_btnC .gs_ico{background-position:0 -66px;}.gs_btnL .gs_ico{background-position:-92px -44px;}.gs_ico_LB{background-position:-50px -44px;height:16px;}.gs_btnJ .gs_ico{background-position:-92px -22px;}.gs_btnM .gs_ico{background-position:-92px 0;}.gs_btnMW .gs_ico{background-position:-21px -22px;}.gs_btnSB .gs_ico{background-position:0 -44px;}.gs_btnTSB .gs_ico{background-position:-115px -253px;}.gs_btnPL .gs_ico{background-position:-148px -66px;}.gs_btnPR .gs_ico{background-position:-21px -66px;}.gs_btnPLW .gs_ico{background-position:-0 -230px;}.gs_btnPRW .gs_ico{background-position:-23px -230px;}.gs_btnZI .gs_ico{background-position:-148px -22px;}.gs_btnZO .gs_ico{background-position:-127px -44px;}.gs_btnDE .gs_ico{background-position:-134px 0;}.gs_btnFI .gs_ico{background-position:-50px -66px;}.gs_btnAD .gs_ico{background-position:-141px -88px;opacity:.55;}.gs_btnAD:hover .gs_ico{opacity:.72;}.gs_btnAD:active .gs_ico,.gs_btnAD .gs_ico:active,.gs_btnAD :active~.gs_ico{opacity:1;}.gs_btnBA .gs_ico{background-position:-50px -22px;}.gs_btnADD .gs_ico{background-position:-92px -66px;}.gs_btnMRG .gs_ico{background-position:-113px 0;}.gs_btnLBL .gs_ico{background-position:0 -161px;}.gs_btnCNCL .gs_ico{background-position:-71px 0;}.gs_btnDWL .gs_ico{background-position:-28px -88px;}.gs_btnMNU .gs_ico{background-position:0 -88px;}.gs_btnMNT .gs_ico{background-position:-46px -161px;}.gs_btnALT .gs_ico{background-position:-92px -161px;}.gs_btnART .gs_ico{background-position:-115px -161px;}.gs_btnGSL .gs_ico{background-position:-69px -161px;}.gs_btnCLS .gs_ico{background-position:-138px -161px;}.gs_btnXBLU .gs_ico{background-position:-138px -253px;}.gs_btnSSB .gs_ico{background-position:0 -276px;}.gs_btnSSW .gs_ico{background-position:-23px -276px;}.gs_btnFLT .gs_ico{background-position:0 -184px;}.gs_btnXT .gs_ico{background-position:-46px -184px;}.gs_btnPD .gs_ico{background-position:-69px -184px;}.gs_btnPU .gs_ico {background-position:-92px -276px;}.gs_btnCP .gs_ico{background-position:-92px -184px;}.gs_btnTP .gs_ico{background-position:-138px -184px;}.gs_btnML .gs_ico{background-position:-115px -276px;}.gs_btnCHK .gs_ico{background-position:-71px -66px;}.gs_btnDNB .gs_ico{background-position:-115px -230px;}.gs_btnDNW .gs_ico{background-position:0 -207px;}.gs_btnACA .gs_ico{background-position:-23px -207px;}.gs_btnAPT .gs_ico{background-position:-46px -207px;}.gs_btnAPTW .gs_ico{background-position:-92px -230px;}.gs_btnAFL .gs_ico{background-position:-69px -207px;}.gs_btnAN .gs_ico{background-position:-46px -276px;}.gs_btnAI .gs_ico{background-position:-69px -276px;}.gs_btnPBL .gs_ico{background-position:-92px -207px;}.gs_btnUCT .gs_ico{background-position:-115px -207px;}.gs_btnVRF .gs_ico{background-position:-138px -207px;}.gs_btnLSI .gs_ico{background-position:-46px -230px;}.gs_btnLSG .gs_ico{background-position:-69px -230px;}.gs_btnMOR .gs_ico{background-position:-23px -253px;}.gs_btnADV .gs_ico{background-position:-46px -253px;}.gs_btnPRO .gs_ico{background-position:-69px -253px;}.gs_ico_star{background-position:-71px -44px;width:13px;height:13px;}.gs_btnPLSW .gs_ico{background-position:-138px -230px;}.gs_btnPDF .gs_ico{background-position:0 -253px;}.gs_btnS .gs_ico{background-position:-138px -276px;}.gs_btnUNS .gs_ico{background-position:0 -299px;}.gs_btnMORR .gs_ico{background-position:-23px -299px;}.gs_btnTW .gs_ico{background-position:-46px -299px;}.gs_btnIN .gs_ico{background-position:-69px -299px;}.gs_btnFB .gs_ico{background-position:-92px -299px;}#gs_hdr_drs,#gs_hdr_drw{position:fixed;top:0;left:0;width:100%;height:100%;z-index:1200;visibility:hidden;}#gs_hdr_drs{opacity:0;background-color:#fff;transition:opacity .15s,visibility 0s .15s;}.gs_el_ta #gs_hdr_drs,.gs_el_ph #gs_hdr_drs{background-color:#666;}#gs_hdr_drs.gs_vis{visibility:visible;opacity:.5;transition:opacity .15s,visibility 0s;}.gs_el_tc #gs_hdr_drs{transition:opacity .218s,visibility 0s .218s;}.gs_el_tc #gs_hdr_drs.gs_vis{transition:opacity .218s,visibility 0s;}#gs_hdr_drw{overflow:auto;width:228px;background-color:#fff;box-shadow:2px 2px 4px rgba(0,0,0,.15);outline:none;transform:translate(-100%,0);transition:transform .15s ease-in-out,visibility 0s .15s;}#gs_hdr_drw.gs_vis{visibility:visible;transform:translate(0,0);transition:transform .15s ease-in-out,visibility 0s;}.gs_el_tc #gs_hdr_drw{transition:transform .3s cubic-bezier(.4,0,.6,1),visibility 0s .3s;}.gs_el_tc #gs_hdr_drw.gs_vis{transition:transform .225s cubic-bezier(0,0,.2,1),visibility 0s;}#gs_hdr_drw.gs_abt,.gs_el_tc #gs_hdr_drw.gs_abt{transition:none;}#gs_hdr_drw_in{position:relative;box-sizing:border-box;min-height:100%;padding:0 0 8px 0;}.gs_el_ta #gs_hdr_drw_in,.gs_el_ph #gs_hdr_drw_in{padding:0 0 65px 0;}#gs_hdr_drw_top{position:relative;height:63px;border-bottom:1px solid #e5e5e5;margin-bottom:8px;}.gs_el_ta #gs_hdr_drw_top,.gs_el_ph #gs_hdr_drw_top{height:57px;}#gs_hdr_drw_mnu,#gs_hdr_drw_lgo{position:absolute;top:0;height:100%;}#gs_hdr_drw_mnu{left:0;width:55px;}#gs_hdr_drw_lgo{left:56px;}.gs_hdr_drw_sec:before{display:block;content:" ";height:0;border-bottom:1px solid #e5e5e5;margin:8px 0;}.gs_hdr_drw_sec:first-child:before{display:none;}#gs_hdr_drw_bot{display:none;}.gs_el_ta #gs_hdr_drw_bot,.gs_el_ph #gs_hdr_drw_bot{display:block;position:absolute;left:0;bottom:0;width:100%;height:65px;}#gs_hdr_drw_bot .gs_md_li:before{opacity:0;}#gs_hdr_drw_bot .gs_hdr_pp{display:block;position:absolute;bottom:14px;left:15px;pointer-events:none;}#gs_hdr_drw_bot .gs_lbl{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}#gs_hdr{position:relative;height:63px;background-color:#f5f5f5;border-bottom:1px solid #e5e5e5;display:flex;}.gs_el_ta #gs_hdr,.gs_el_ph #gs_hdr{height:57px;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_lgo,#gs_hdr_lgt,#gs_hdr_md,#gs_hdr_sre,#gs_hdr_act{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}#gs_hdr_md{flex:1 1 auto;}#gs_hdr .gs_hdr_mbo,#gs_hdr .gs_hdr_mbo,.gs_el_ta #gs_hdr .gs_hdr_dso,.gs_el_ph #gs_hdr .gs_hdr_dso{display:none;}.gs_el_ta #gs_hdr .gs_hdr_mbo,.gs_el_ph #gs_hdr .gs_hdr_mbo{display:inline-block;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_sre{width:55px;margin-right:1px;}#gs_hdr_lgo,#gs_hdr_drw_lgo{width:149px;background:no-repeat url('/intl/en/scholar/images/1x/scholar_logo_24dp.png') 0% 50%;background-size:149px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){#gs_hdr_lgo,#gs_hdr_drw_lgo{background-image:url('/intl/en/scholar/images/2x/scholar_logo_24dp.png');}}#gs_hdr_lgo{margin-right:31px;}.gs_el_ph #gs_hdr_lgo{margin-right:0;}#gs_hdr_lgt{min-width:164px;margin-right:16px;}#gs_hdr_lgt:empty{display:none;}#gs_hdr_md{margin-right:16px;min-width:1px;}#gs_hdr_lgt,#gs_hdr_md h1{padding:19px 0 0 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:20px;line-height:25px;font-weight:normal;color:#666;max-width:100%;text-align:left;}.gs_el_ta #gs_hdr_md h1,.gs_el_ph #gs_hdr_md h1{padding:16px 0 0 0;}#gs_hdr_srch{padding:14px 0 0 0;max-width:600px;}.gs_el_ta #gs_hdr_srch,.gs_el_ph #gs_hdr_srch{padding:10px 0 0 0;max-width:none;}#gs_hdr_frm{position:relative;padding-right:39px;}#gs_hdr_tsi{height:38px;border-radius:2px 0 0 2px;}#gs_hdr_tsi::-ms-clear{display:none;}#gs_hdr_tsc{display:none;position:absolute;top:3px;right:41px;width:21px;height:21px;padding:6px 10px 7px 10px;}.gs_in_acw[dir="rtl"]~#gs_hdr_tsc{right:auto;left:1px;}#gs_hdr_tsb{position:absolute;top:0;right:0;width:40px;height:38px;border-radius:0 2px 2px 0;}#gs_hdr_frm_ac{top:37px;right:40px;}.gs_el_ph #gs_hdr_frm_ac{right:0;}.gs_el_ph .gs_hdr_ifc #gs_hdr_mnu,.gs_el_ph .gs_hdr_ifc #gs_hdr_bck,.gs_hdr_src #gs_hdr_srch,.gs_hdr_src #gs_hdr_lgt,.gs_hdr_srx #gs_hdr_sre,.gs_hdr_srx #gs_hdr_md h1,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_mbo,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_dso,.gs_el_ta .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_mnu,.gs_el_ph .gs_hdr_srx #gs_hdr_bck{display:none;}.gs_el_ph .gs_hdr_ifc #gs_hdr_md,.gs_el_ph .gs_hdr_srx #gs_hdr_md{margin-left:16px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="ltr"]{padding-right:41px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="rtl"]{padding-left:41px;}.gs_el_tc .gs_hdr_tsc .gs_in_acw~#gs_hdr_tsc{display:block;}#gs_hdr_act{min-width:64px;max-width:200px;text-align:right;float:right;}.gs_el_ta #gs_hdr_act,.gs_el_ph #gs_hdr_act{display:none;}#gs_hdr_act_i,#gs_hdr_act_s{display:inline-block;padding:23px 24px 23px 16px;max-width:100%;box-sizing:border-box;font-size:13px;line-height:17px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;color:#444;}#gs_hdr_act_s{text-transform:uppercase;}.gs_el_sm #gs_hdr_act_i,.gs_el_sm #gs_hdr_act_s{padding:23px 16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ta #gs_hdr_act_s,.gs_el_ph #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_s{padding:20px 16px;}#gs_hdr_act_i:active,#gs_hdr_act_s:active{color:#d14836;}#gs_hdr_act_i,.gs_el_sm #gs_hdr_act_i{padding-top:15px;padding-bottom:16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_i{padding-top:12px;padding-bottom:13px;}#gs_hdr_act_i .gs_hdr_pp{vertical-align:top;}#gs_hdr_act_d{top:63px;left:auto;right:24px;min-width:288px;max-width:400px;}.gs_el_sm #gs_hdr_act_d{right:16px;}.gs_el_ta #gs_hdr_act_d{top:57px;}.gs_el_ph #gs_hdr_act_d{top:57px;min-width:280px;max-width:280px;max-width:90vw;}/* Account dialog body. */#gs_hdr_act_aw,#gs_hdr_act_ap,.gs_hdr_act_am,#gs_hdr_act_ab{display:block;padding:10px 20px;word-wrap:break-word;white-space:normal;}#gs_hdr_act_aw{background-color:#fef9db;font-size:11px;}#gs_hdr_act_ap,.gs_hdr_act_am{border-bottom:1px solid #ccc;}#gs_hdr_act_ap{padding:20px;}.gs_el_ph #gs_hdr_act_ap{padding:10px;}#gs_hdr_act_apb{margin-top:12px;}#gs_hdr_act_aa:link,#gs_hdr_act_aa:visited{float:right;margin-left:8px;color:#1a0dab;}#gs_hdr_act_aa:active{color:#d14836}.gs_hdr_act_am:link,.gs_hdr_act_am:visited{color:#222;text-decoration:none;background:#fbfbfb;}.gs_hdr_act_am:hover,.gs_hdr_act_am:focus{background:#f1f1f1;}.gs_hdr_act_am:active{background:#eee;}#gs_hdr_act_ab{background:#fbfbfb;padding:10px 0;display:table;width:100%;white-space:nowrap;}#gs_hdr_act_aba,#gs_hdr_act_abs{display:table-cell;padding:0 20px;}#gs_hdr_act_abs{text-align:right;}.gs_el_ph #gs_hdr_act_aba,.gs_el_ph #gs_hdr_act_abs{display:block;padding:10px;text-align:center;}.gs_el_ph #gs_hdr_act_aba button,.gs_el_ph #gs_hdr_act_abs button{width:100%;}#gs_hdr_act_a1,#gs_hdr_act_a2{position:absolute;top:-9px;right:7.5px;width:0;height:0;z-index:1;border:8.5px solid transparent;border-top:none;border-bottom-color:#333;border-bottom-color:rgba(0,0,0,.2);}#gs_hdr_act_a2{top:-8px;border-bottom-color:#fff;}.gs_hdr_act_mw #gs_hdr_act_a2{border-bottom-color:#fef9db;}.gs_hdr_pp{border-radius:50%;overflow:hidden;}#gs_hdr_act_ap .gs_hdr_pp,.gs_hdr_act_am .gs_hdr_pp{float:left;}#gs_hdr_act_ap .gs_hdr_pm{margin-left:116px;}.gs_hdr_act_am .gs_hdr_pm{margin:6px 0 0 58px;}#gs_ab{position:relative;height:41px;border-bottom:1px solid #e5e5e5;display:flex;white-space:nowrap;background-color:#fff;z-index:1000;}.gs_el_ta #gs_ab.gs_nta,.gs_el_ph #gs_ab.gs_nph{display:none;}#gs_ab_g{height:42px;}.gs_sth_vis #gs_ab{position:fixed;}#gs_ab_ico,#gs_ab_ttl,#gs_ab_md,#gs_ab_btns{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}.gs_el_ph #gs_ab_md{display:block;}#gs_ab_ico{width:55px;margin-right:1px;}#gs_ab_ico .gs_ico{position:absolute;top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}#gs_ab_ttl{min-width:172px;padding-right:8px;}.gs_el_sm #gs_ab_ttl{min-width:68px;}.gs_el_ta #gs_ab_ttl,.gs_el_ph #gs_ab_ttl{min-width:0;}#gs_ab_ttl,#gs_ab_ttll{font-size:18px;color:#666;text-transform:none;}.gs_el_sm #gs_ab_ttl,.gs_el_sm #gs_ab_ttll{font-size:16px;}#gs_ab_ttll{overflow:hidden;text-overflow:ellipsis;max-width:200px;}#gs_ab_md{flex:1 0 auto;}.gs_ab_st #gs_ab_md{flex:1 1 auto;font-size:13px;line-height:17px;padding:0 8px;color:#999;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gs_ab_st #gs_ab_md{visibility:hidden;padding:0;}#gs_ab_btns{margin-right:8px;}.gs_el_sm #gs_ab_btns{margin-right:0;}.gs_el_ta #gs_ab_btns,.gs_el_ph #gs_ab_btns{margin-right:4px;}#gs_ab_ttl:before,#gs_ab_md:before,#gs_ab_btns:before{content:"";display:inline-block;width:0;height:100%;vertical-align:middle;}#gs_ab_md>button,#gs_ab_btns>button,#gs_ab_md>.gs_in_ib,#gs_ab_btns>.gs_in_ib,#gs_ab_md>.gs_md_r,#gs_ab_btns>.gs_md_r,#gs_ab .gs_ab_mdw,#gs_ab .gs_ab_btw{margin:0 8px;vertical-align:middle;}#gs_ab .gs_ab_mdw,.gs_ab_btw{display:inline-block;margin:0;}#gs_ab_btns>.gs_in_ib{margin:0 16px 0 8px;}#gs_ab .gs_ab_btw{margin:0 12px 0 16px;}.gs_el_ta .gs_ab_sel #gs_ab_ico,.gs_el_ph .gs_ab_sel #gs_ab_ico,.gs_el_ta .gs_ab_sel #gs_ab_ttl,.gs_el_ph .gs_ab_sel #gs_ab_ttl,.gs_el_ta .gs_ab_sel #gs_ab_btns,.gs_el_ph .gs_ab_sel #gs_ab_btns{display:none;}#gs_bdy{display:table;table-layout:fixed;width:100%;}#gs_bdy_sb{vertical-align:top;width:228px;word-wrap:break-word;display:none;}.gs_el_sm #gs_bdy_sb{}.gs_el_ta #gs_bdy_sb,.gs_el_ph #gs_bdy_sb{}.gs_bdy_sb_sec{margin:0 40px 0 56px;}.gs_bdy_sb_sec:before{display:block;content:" ";height:0;margin:13px 0;border-top:1px solid #eee;}.gs_bdy_sb_sec:first-child:before{margin:21px 0 0 0;border:none;}#gs_bdy_sb ul{list-style-type:none;}.gs_bdy_sb_sec a:link,.gs_bdy_sb_sec a:visited{color:#222;}.gs_bdy_sb_sec a:active{color:#d14836;}.gs_bdy_sb_sel a:link,.gs_bdy_sb_sel a:visited{color:#d14836;text-decoration:none;}.gs_el_tc .gs_bdy_sb_sec li.gs_ind,.gs_el_tc .gs_bdy_sb_sec li.gs_ind a{padding-top:8px;padding-bottom:5px;}.gs_el_tc .gs_bdy_sb_sec:first-child li.gs_ind:first-child{margin-top:-8px;}#gs_bdy_sb .gs_ind,#gs_bdy_sb .gs_inw{margin-bottom:4px;}.gs_el_tc #gs_bdy_sb .gs_ind,.gs_el_tc #gs_bdy_sb .gs_inw{margin-bottom:0;}#gs_bdy_ccl{display:table-cell;vertical-align:top;padding:0 24px 0 16px;}.gs_el_sm #gs_bdy_ccl{padding:0 16px;}.gs_el_ta #gs_bdy_ccl,.gs_el_ph #gs_bdy_ccl{padding:0 16px;}.gs_el_ph #gs_bdy_ccl{padding:0;}#gs_ftr_sp{height:62px;}.gs_el_sm #gs_ftr_sp{height:57px;}#gs_ftr{position:absolute;bottom:0;left:0;width:100%;white-space:nowrap;border-top:1px solid #e4e4e4;background-color:#f2f2f2;display:flex;}#gs_ftr_rt{box-sizing:border-box;max-width:100%;overflow-x:auto;margin-left:auto;padding:0 12px;}.gs_el_sm #gs_ftr_rt{padding:0 8px;}.gs_el_ph #gs_ftr_rt:after{content:" ";position:absolute;top:0;right:0;width:16px;height:100%;background-image:linear-gradient(to right,rgba(242,242,242,0),rgba(242,242,242,1) 80%);}#gs_ftr_rt a{display:inline-block;line-height:16px;padding:12px;white-space:nowrap;}.gs_el_sm #gs_ftr_rt a{padding:12px 8px;}#gs_ftr_rt a:link,#gs_ftr_rt a:visited{color:#666}#gs_ftr_rt a:active{color:#d14836}#gsc_a_t{width:100%;table-layout:fixed;}#gsc_a_tr0,#gsc_a_trh{box-sizing:border-box;}#gsc_a_tr0 th.gsc_a_x,#gsc_a_tr0 th.gsc_a_t,#gsc_a_tr0 th.gsc_a_c,#gsc_a_tr0 th.gsc_a_y{height:0;}#gsc_a_trh{z-index:700;background-color:#f5f5f5;height:42px;}.gs_el_ta #gsc_a_trh,.gs_el_ph #gsc_a_trh,.gs_el_ta #gsc_a_t td,.gs_el_ph #gsc_a_t td{background-color:#fff;border-bottom:1px solid #e5e5e5;}#gsc_a_t th.gsc_a_x,#gsc_a_t th.gsc_a_t,#gsc_a_t th.gsc_a_c,#gsc_a_t th.gsc_a_y{box-sizing:border-box;text-transform:uppercase;vertical-align:middle;padding-top:0;padding-bottom:0;}#gsc_x_all{z-index:1;}.gsc_a_x,.gsc_a_t,.gsc_a_c,.gsc_a_y,.gsc_a_e{font-weight:normal;padding:16px 16px 0 16px;vertical-align:top;text-align:right;}.gsc_a_c{padding:16px 8px 0 8px;}.gs_el_sm .gsc_a_x,.gs_el_sm .gsc_a_t,.gs_el_sm .gsc_a_c{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_x,.gs_el_ta .gsc_a_t,.gs_el_ta .gsc_a_c,.gs_el_ph .gsc_a_x,.gs_el_ph .gsc_a_t,.gs_el_ph .gsc_a_c{padding:12px 8px;}.gs_el_sm .gsc_a_y{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_y{padding-bottom:12px;}.gsc_a_x{width:41px;padding:4px 0 0 0;}.gs_el_sm .gsc_a_x{padding:0;}.gsc_a_t{text-align:left;}.gs_el_ph .gsc_a_t{padding-left:16px;}#gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:16px;}.gs_el_ph #gsc_a_ta{display:none}.gs_el_ph .gsc_a_c{padding-right:16px;}th.gsc_a_c{width:64px;white-space:nowrap;}.gsc_art_sel #gsc_a_ta,.gsc_art_sel #gsc_a_ca,.gsc_art_sel .gsc_a_h{display:none;}.gsc_a_ac,.gsc_a_hc{margin-top:3px;}th.gsc_a_y{width:88px;white-space:nowrap;}.gs_el_sm th.gsc_a_y{width:58px;}.gs_el_ph th.gsc_a_y,.gs_el_ph td.gsc_a_y{width:0;padding:0;}.gs_el_ph .gsc_a_h{display:none}@media print{#gs_top th.gsc_a_y{width:58pt;}#gs_top #gsc_a_tr0{display:none}#gs_top #gsc_a_trh{position:static}}.gsc_a_e{padding:16px;text-align:center;}.gsc_a_a{padding:8px 0}.gsc_a_at{padding:8px 0;font-size:16px}a.gsc_a_acm{text-decoration:line-through;}a.gsc_a_acm:hover,a.gs_a_acm:active{text-decoration:underline;}.gsc_a_m{position:absolute;}.gs_el_ph .gsc_a_m{display:block;position:static;}.gsc_a_am{font-size:24px;position:absolute;top:-18px;left:-2px;padding:8px 12px 4px 8px;}.gs_el_ph .gsc_a_am{display:inline-block;position:static;padding:6px 16px;margin-bottom:-6px;}#gsc_a_sp{visibility:hidden;}#gsc_a_sp.gs_vis{visibility:visible;padding:16px 0;height:25px;border-bottom:1px solid #ccc;}#gsc_a_sp:after{display:block;height:100%;content:" ";background:url('/intl/en/scholar/images/spinner.gif') no-repeat 50% 50%;opacity:0;}#gsc_a_sp.gs_vis:after{opacity:1;transition:opacity 0s .4s;}#gsc_a_err{display:none;padding:28px 0;}#gsc_a_err.gs_vis{display:block;}#gsc_md_iad{width:800px;max-width:94%;}.gs_el_ph #gsc_md_iad{width:100%;max-width:100%;}#gsc_md_iad .gs_md_prg{min-height:400px;}.gs_el_ph #gsc_iads_res .gs_md_prg{margin:0 16px;}#gsc_iad_tart,.gsc_iad_tsel.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tart #gsc_iad_tgrp,.gsc_iad_tsel #gsc_iad_tgrp,#gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tart,#gsc_napb_hdr #gsc_iad_tgrp{display:none;}#gsc_iad_tgrp,.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tsel #gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tsel{display:inline-block;}#gsc_iad_t:not(.gsc_iad_tsel) #gsc_iad_tsel{pointer-events:none;color:#b5b5b5;}.gs_el_ph #gsc_napb #gsc_iads_frm{margin:0 16px;}#gsc_iads_res{position:relative;margin:8px 0 16px 0;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_md_iad #gsc_iads_res{margin:8px -16px 16px -16px;}.gs_el_ph #gsc_napb #gsc_iads_pp{margin-right:16px;}#gsc_iadb_hdr{display:table;table-layout:fixed;width:100%;}#gsc_iadb_hdr_cb,#gsc_iadb_hdr_instr{display:table-cell;vertical-align:middle;height:41px;}#gsc_iadb_hdr_cb{width:41px;}#gsc_iadb_hdr_cb:empty{width:0;}.gs_el_ph #gsc_iadb_hdr_cb:empty{width:16px;}#gsc_iadb_hdr_instr{font-size:16px;}.gs_el_ph #gsc_iadb_hdr_instr{padding-right:16px;}.gsc_oic{position:relative;}.gsc_oic_cb{font-weight:normal;border-top:1px solid #e5e5e5;border-bottom:1px solid #e5e5e5;background-color:#fcfcfc;padding-right:16px;}.gsc_oict{display:block;overflow:hidden;}.gsc_oict_name{display:block;font-size:16px;line-height:20px;word-wrap:break-word;}.gsc_oict_inf{display:block;float:right;margin-left:16px;white-space:nowrap;}.gsc_oict_all,.gsc_oict_prf{font-size:13px;text-transform:uppercase;line-height:20px;}.gsc_oict_all[data-a]{color:#1a0dab;cursor:pointer;}.gsc_oict_all[data-a]:hover{text-decoration:underline;}.gsc_oict_all[data-a]:active{color:#d14836;}.gsc_oict_prf{padding-left:8px;margin-left:8px;border-left:1px solid #e0e0e0;}.gsc_oict_prf:empty{display:none;}.gs_el_ph .gsc_oict_all,.gs_el_ph .gsc_oict_prf{float:right;clear:both;margin:0;padding:0;border:none;}.gs_el_ph .gsc_oict_prf{margin-top:2px;}.gsc_oic_res{margin:8px 0 12px 41px;}.gs_el_ph .gsc_oic_res{margin-right:16px;}.gsc_oic_res h4{font-size:13px;font-weight:normal;}.gsc_oic_dis .gsc_oic_name,.gsc_oic_dis .gsc_oic_all,.gsc_oic_dis .gsc_oic_prf{color:#777;}.gsc_oic_dis .gsc_oict_all[data-a]{color:#1a0dab;opacity:.66;}.gsc_oic_dis .gsc_oic_res{opacity:.5;}.gsc_iadb_art{border-top:1px solid #e5e5e5;overflow:hidden;}.gsc_iadb_art_cb{float:left;}.gsc_iadb_art_added{float:right;margin:12px;font-size:11px;text-transform:uppercase;color:#777;}.gs_el_ph .gsc_iadb_art_added{display:block;float:none;text-align:right;margin:8px 16px;}.gsc_iadb_art_added:empty{display:none;}.gsc_iadb_art_body{margin:12px 0 12px 41px;}.gs_el_ph .gsc_iadb_art_body{margin:12px 16px 12px 41px;}.gsc_iadb_art_body h3{font-size:13px;font-weight:normal;}.gsc_iadb_art_dis .gsc_iadb_art_body{opacity:.5;}#gsc_md_mopt,#gsc_md_cbyd,#gsc_md_cbym{width:600px;}.gs_el_ta #gsc_md_mopt,.gs_el_ta #gsc_md_cbyd,.gs_el_ta #gsc_md_cbym{width:500px;}.gs_el_ph #gsc_md_mopt,.gs_el_ph #gsc_md_cbyd,.gs_el_ph #gsc_md_cbym{width:100%;}.gsc_mob_art{vertical-align:top;padding:8px 0;}.gs_el_tc .gsc_mob_art>.gs_in_ra{margin-top:-8px;}.gsc_mob_cby{vertical-align:top;text-align:right;padding:8px 12px;position:relative;}.gsc_mob_ttl,.gsc_mob_pub{display:block;}.gsc_mob_pub{color:#666;}.gsc_mob_cbym{text-decoration:line-through}.gsc_mob_cbm{font-size:24px;position:absolute;padding:4px 0 0 4px;line-height:16px;}.gs_fsvg line{stroke:#222222}a:link .gs_fsvg{fill:#1a0dab;}a:link .gs_fsvg line{stroke:#1a0dab;}a:visited .gs_fsvg{fill:#660099;}a:visited .gs_fsvg line{stroke:#660099;}a:active .gs_fsvg{fill:#d14836;}a:active .gs_fsvg line{stroke:#d14836;}a .gs_fsvg{border-bottom:1px solid transparent;}a:hover .gs_fsvg,a:focus .gs_fsvg{border-bottom-color:inherit;}.gs_fsml{font-size:13px}.gs_fscp{font-variant:small-caps}.gsh_clim{display:table-row}.gsh_clil,.gsh_clic{display:table-cell;padding-bottom:8px}.gsh_clil{padding-right:8px;}.gsh_lla{list-style-type:lower-alpha}.gsh_lua{list-style-type:upper-alpha}.gsh_llr{list-style-type:lower-roman}.gsh_lur{list-style-type:upper-roman}.gsh_l>li{margin-left:32px;}.gsh_h3{font-size:inherit;font-weight:normal}.gsh_h3,.gsh_csp{margin:16px 0}.gsh_h3+.gsh_csp{margin-top:-8px}.gsh_ovln{text-decoration:overline}.gsh_small .gsh_l .gsh_csp{margin:8px 0}.gsh_small .gsh_csp:first-child,.gsh_small .gsh_h3:first-child{margin-top:0}.gsh_small .gsh_csp:last-child{margin-bottom:0}.gsh_dspfr{text-align:center}.gsh_dspfr svg{margin:8px 0}.gs_pp_tn,.gs_el_ta .gs_pp_mo_tn,.gs_el_ph .gs_pp_mo_tn{width:32px;height:32px;}.gs_pp_sm,.gs_el_ta .gs_pp_mo_sm,.gs_el_ph .gs_pp_mo_sm{width:56px;height:56px;}.gs_pp_nm,.gs_el_ta .gs_pp_mo_nm,.gs_el_ph .gs_pp_mo_nm{width:128px;height:128px;}.gs_ai_pho{float:left;}.gs_ai_t{margin-left:72px;}.gs_ai_pho_pst+.gs_ai_t{margin-left:48px;}.gs_ai_t.gs_ai_pss{margin-left:64px;}.gs_ai_pho_pst+.gs_ai_t.gs_ai_pss{margin-left:40px;}.gs_ai_name{font-size:17px;font-weight:normal;margin-bottom:4px;}.gs_ai_name a{padding:6px 0 4px 0;}.gs_ai_name.gs_ai_name_nlsb{font-size:15px;}.gs_ai_name.gs_ai_name_nlsb a:link,.gs_ai_name.gs_ai_name_nlsb a:visited{padding:7px 0 5px 0; color:#222;}.gs_ai_name.gs_ai_name_nlsb a:active{color:#d14836;}.gs_ai_int{margin-top:5px;}.gs_ai_eml:empty,.gs_ai_int:empty,.gs_ai_cby:empty{display:none;}.gs_ai_one_int{vertical-align:top;font-size:13px;margin-right:8px;white-space:nowrap;display:inline-block;max-width:200px;text-overflow:ellipsis;overflow:hidden;}.gs_el_tc a.gs_ai_one_int{padding:8px 0 5px 0;}.gs_el_ph .gs_ai_eml,.gs_el_ph .gs_ai_cby{margin-top:8px;}.gs_ai_ilnl .gs_ai_int,.gs_ai_ilnl .gs_ai_cby{margin-top:8px;color:#666;}.gs_ai.gs_ai_chpr{position:relative;}.gs_ai_chpr .gs_ai_t{margin-right:276px;}.gs_el_sm .gs_ai_chpr .gs_ai_t{margin-right:156px;}.gs_el_ph .gs_ai_chpr .gs_ai_t{margin-right:0;}.gs_ai_chpr .gs_ai_cby{position:absolute;top:4px;right:0;text-align:right;}.gs_el_sm .gs_ai_chpr .gs_ai_cby,.gs_el_ta .gs_ai_chpr .gs_ai_cby{width:132px;word-wrap:break-word;}.gs_el_ph .gs_ai_chpr .gs_ai_cby{text-align:left;position:static;width:auto;}#gsc_bdy{position:relative;max-width:1200px;margin:0 auto;}.gs_el_ph #gsc_bdy,.gs_el_ta #gsc_bdy{display:flex;flex-flow:column;}.gsc_lcl{position:relative;margin:0 350px 0 0;order:3;}.gs_el_sm .gsc_lcl{margin-right:334px;}.gs_el_ta .gsc_lcl,.gs_el_ph .gsc_lcl{margin:0;}#gsc_prf_t_wrp{position:relative;order:2;overflow:hidden;}.gs_el_tc #gsc_prf_t_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;right:0;width:12px;height:100%;background-image:linear-gradient(to right,rgba(247,247,247,0),rgba(247,247,247,1) 80%);}#gsc_prf_t{width:100%;background-color:#f5f5f5;display:none;white-space:nowrap;overflow-x:auto;padding:0 4px;}.gs_el_ta #gsc_prf_t,.gs_el_ph #gsc_prf_t{display:block;}#gsc_prf_t:after{content:"\00A0";padding:0 4px;}.gsc_prf_tab,.gsc_prf_tab:link{font-size:13px;text-transform:uppercase;padding:13px 12px;display:inline-block;color:#666;cursor:pointer;}.gsc_prf_tab:hover{color:#000;text-decoration:none}.gsc_prf_tab:active{color:#4d90fe;}.gsc_prf_tab[aria-selected="true"]{border-bottom:2px solid #4d90fe;color:#0461f9;cursor:default;}.gs_el_ta #gsc_art,.gs_el_ph #gsc_art,.gs_el_ta #gsc_rsb_cit,.gs_el_ph #gsc_rsb_cit,.gs_el_ta #gsc_rsb_mnd,.gs_el_ph #gsc_rsb_mnd,.gs_el_ta #gsc_rsb_awd,.gs_el_ph #gsc_rsb_awd,.gs_el_ta #gsc_rsb_co,.gs_el_ph #gsc_rsb_co{display:none;}#gsc_bdy[data-tab="gsc_prf_t-art"] #gsc_art,#gsc_bdy[data-tab="gsc_prf_t-cit"] #gsc_rsb_cit,#gsc_bdy[data-tab="gsc_prf_t-mnd"] #gsc_rsb_mnd,#gsc_bdy[data-tab="gsc_prf_t-awd"] #gsc_rsb_awd,#gsc_bdy[data-tab="gsc_prf_t-ath"] #gsc_rsb_co{display:block;}.gsc_rsb{float:right;width:317px;order:4;border-left:1px solid #eee;margin-top:32px;}.gs_el_sm .gsc_rsb{margin-top:16px;}.gs_el_ph .gsc_rsb,.gs_el_ta .gsc_rsb{float:none;width:auto;border:none;margin:0;}.gsc_rsb_s{margin:0 0 48px 16px;position:relative;}.gs_el_sm .gsc_rsb_s{margin:0 0 32px 16px;}.gs_el_ph .gsc_rsb_s,.gs_el_ta .gsc_rsb_s{margin:0;}.gsc_rsb_s:last-child{margin-bottom:0;}.gsc_rsb_header{padding:8px 8px 12px 8px;border-bottom:1px solid #e5e5e5;font-weight:normal;font-size:15px;}.gs_el_sm .gsc_rsb_header{padding:4px 8px 9px 8px;}.gs_el_ph .gsc_rsb_header,.gs_el_ta .gsc_rsb_header{display:none;}.gsc_rsb_action{position:absolute;top:-3px;right:-2px;}.gs_el_sm .gsc_rsb_action{top:-8px;}.gsc_rsb_tap{display:block;position:absolute;right:2px;top:12px;opacity:.5;z-index:1;}.gs_el_ta .gsc_rsb_tap,.gs_el_ph .gsc_rsb_tap{top:24px;right:10px;}.gsc_rsb_hm{border-bottom:1px solid #e5e5e5;padding:3px 6px;}#gsc_rsb_gpl{display:block;margin-top:3px;padding:6px 16px;line-height:15px;color:#0461f9;border:1px solid #4d90fe;border-radius:2px;text-align:center;text-transform:uppercase;}.gs_el_sm #gsc_rsb_gpl{margin-top:0;}.gs_el_ta #gsc_rsb_gpl,.gs_el_ph #gsc_rsb_gpl{display:none;}#gsc_rsb_st{width:100%;}.gsc_rsb_std{text-align:right;padding-right:8px;}.gs_el_ta .gsc_rsb_std,.gs_el_ph .gsc_rsb_std{padding-right:16px;}.gsc_rsb_sc1{text-align:left;padding:2px 8px;}.gs_el_sm .gsc_rsb_sc1{padding:0 8px;}.gs_el_ta .gsc_rsb_sc1,.gs_el_ph .gsc_rsb_sc1{padding:4px 16px;}.gsc_rsb_sth{font-weight:normal;padding:8px 8px 8px 0;border-bottom:1px solid #e5e5e5;text-align:right;}.gs_el_sm .gsc_rsb_sth{padding:4px 8px 4px 0;}.gs_el_ta .gsc_rsb_sth,.gs_el_ph .gsc_rsb_sth{padding:16px 16px 16px 0;}#gsc_rsb_st tbody:before,#gsc_rsb_st tbody:after{content:'';display:block;height:8px;}.gs_el_sm #gsc_rsb_st tbody:before,.gs_el_sm #gsc_rsb_st tbody:after{height:4px;}.gs_el_ph #gsc_hist_opn,.gs_el_ta #gsc_hist_opn{display:none;}.gsc_rsb_f{max-width:118px;word-wrap:break-word;white-space:normal;}.gs_el_ta .gsc_rsb_f{max-width:none;}.gsc_rsb_f:link,.gsc_rsb_f:visited{color:#222;}.gsc_rsb_m_na{color:#dd4b39;}.gsc_rsb_m_a{color:#006621;float:right;position:relative;}.gsc_rsb_m_bar{width:100%;height:4px;margin:8px 0 8px 0;background:#006621;}.gsc_rsb_m_bar_na{background:#dd4b39;width:100%;height:100%;z-index:1;}.gsc_rsb_m{padding:8px;}.gs_el_ta .gsc_rsb_m,.gs_el_ph .gsc_rsb_m{padding:8px 16px;}.gsc_rsb_m_desc{padding-top:16px;color:#777;}.gsc_rsb_m_s{font-size:24px;position:absolute;line-height:0.3;}#gsc_lwp_mndt_lnk{text-transform:uppercase;margin-left:16px;margin-right:-9px;text-align:right;font-size:13px;padding:12px 9px;border-radius:3px;}#gsc_lwp_mndt_lnk:hover,#gsc_lwp_mndt_lnk:active,#gsc_lwp_mndt_lnk:visited{text-decoration:none;color:#1a0dab;}#gsc_lwp_mndt_lnk:hover{background-color:rgba(0,0,0,.05);}#gsc_lwp_mndt_lnk:active{background-color:rgba(0,0,0,.1);}.gsc_rsb_m_title{padding-bottom:12px;}.gsc_rsb_m_header{display:flex;align-items:flex-end;justify-content:space-between;padding:0 8px;}.gs_el_sm .gsc_rsb_m_header{padding:0 8px;}.gsc_rsb_hmv{text-align:center;padding-top:16px;}.gsc_rsb_a{list-style:none;}.gsc_rsb_a>li{position:relative;}.gs_el_ta .gsc_rsb_a>li,.gs_el_ph .gsc_rsb_a>li{border-bottom:1px solid #e5e5e5;}.gsc_rsb_a>li:first-child{margin-top:8px;}.gsc_rsb_a_pht{float:left;width:32px;height:32px;}.gsc_rsb_a_desc{margin:0 33px 0 48px;min-height:32px;display:block;}.gs_el_ph .gsc_rsb_a_desc,.gs_el_ta .gsc_rsb_a_desc{margin:0 33px 0 64px;min-height:56px;}.gsc_rsb_a_desc a{color:#222;}.gsc_rsb_a_ext{display:block;color:#777;font-size:13px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gsc_rsb_a_ext,.gs_el_ta .gsc_rsb_a_ext{white-space:normal;}.gsc_rsb_a_ext2{display:none;}.gs_el_ph .gsc_rsb_a_ext2,.gs_el_ta .gsc_rsb_a_ext2{display:block;}.gsc_rsb_aa{display:block;padding:8px;line-height:normal;cursor:pointer;}.gs_el_ph .gsc_rsb_aa,.gs_el_ta .gsc_rsb_aa{font-size:17px;padding:12px 16px;}.gsc_rsb_aa:hover,.gsc_rsb_aa:active{text-decoration:none;background:#f1f1f1;}.gsc_rsb_aa a:hover{text-decoration:none;}#gsc_prf_w{order:1;padding:32px 0;overflow:hidden;}.gs_el_sm #gsc_prf_w{padding:16px 0;}#gsc_prf_pu{float:left;width:128px;height:128px;text-align:center;}.gs_el_ph #gsc_prf_pu{float:none;width:100%;margin:0 0 8px 0;}#gsc_prf_pua{line-height:0;width:128px;height:128px;}.gs_el_ph #gsc_prf_pua{margin:0 auto;}#gsc_prf_pufi{width:0;height:0;overflow:hidden;}.gsc_prf_pufo #gsc_prf_pufi{width:auto;height:auto;overflow:visible;position:relative;z-index:10;}.gsc_prf_pufo #gsc_prf_pufi2{display:inline-block;background:#fcfcfc;padding:8px 8px 8px 0;}.gsc_prf_puic{position:absolute;bottom:0;width:100%;padding:8px 0;background-color:#000;opacity:.6;}.gsc_prf_pel{cursor:pointer;}#gsc_prf_i{margin:0 16px 0 160px;}.gs_el_sm #gsc_prf_i{margin:0 16px 0 144px;}.gs_el_ph #gsc_prf_i{margin:0 16px;text-align:center;}#gsc_prf_btne{vertical-align:top;margin:-9px 4px;}.gs_el_ph #gsc_prf_btne{position:absolute;top:60px;right:8px;margin:0;}#gsc_prf_btnf{float:right;margin:3px 0 16px 16px;}.gs_el_sm #gsc_prf_btnf{margin-top:0;}.gs_el_ph #gsc_prf_btnf{float:none;margin:0;position:absolute;top:8px;right:8px;border-radius:50%;}#gsc_prf_btnf .gs_lbl{padding:0 4px;}#gsc_prf_in{font-size:24px;line-height:24px;padding:3px 0 12px 0;word-wrap:break-word;}.gs_el_sm #gsc_prf_in{font-size:22px;padding:3px 0 8px 0;}.gs_el_ph #gsc_prf_in{font-size:20px;padding:0 0 2px 0;}.gsc_prf_il{font-size:15px;line-height:18px;padding:1px 0;}.gs_el_ph .gsc_prf_il{font-size:13px;line-height:16px;}.gsc_prf_ila:link,.gsc_prf_ila:visited{text-decoration:underline;color:#222;}#gsc_prf_int{margin-top:5px;}#gsc_prf_int:empty{display:none;}.gsc_prf_inta{margin-right:16px;white-space:nowrap;max-width:200px;text-overflow:ellipsis;overflow:hidden;vertical-align:top;}.gsc_prf_inta:last-child{margin:0}.gs_el_tc .gsc_prf_ila,.gs_el_tc .gsc_prf_inta{padding:8px 0 5px 0;}.gsc_md_pro_tt,.gsc_md_pro_ch #gsc_md_pro_lgtm,#gsc_md_pro_save{display:none;}.gsc_md_pro_ed #gsc_md_pro_ted,.gsc_md_pro_aa #gsc_md_pro_taa,.gsc_md_pro_ra #gsc_md_pro_tra,.gsc_md_pro_an #gsc_md_pro_tan,.gsc_md_pro_ai #gsc_md_pro_tai,.gsc_md_pro_ch #gsc_md_pro_save{display:inline-block;}.gsc_md_pro_el{color:#777;}.gsc_md_pro_ev{padding:4px 0 16px 0;}#gsc_dd_add-d,#gsc_dd_exp-d,#gsc_dd_sort-d,#gsc_dd_mor-d{top:42px;}#gsc_dd_add-d,#gsc_dd_mor-d,#gsc_dd_sort-d{white-space:normal;word-wrap:break-word;width:208px;width:-webkit-max-content;width:max-content;min-width:100px;max-width:208px;}.gs_el_ph #gsc_dd_add-d{left:-9px;}.gs_el_ph #gsc_dd_exp-d{left:auto;right:12px;}.gs_el_ph #gsc_dd_mor-d{left:-58px;}.gs_el_ph #gsc_dd_sort-d{left:10px;}.gs_el_ph #gsc_dd_sort-r{margin-left:-10px;}.gsc_dd_sec,#gsc_dd_exp-d{padding:8px 0;}.gs_el_tc .gsc_dd_sec,.gs_el_tc #gsc_dd_exp-d{padding:4px 0 8px 0;}.gsc_dd_sep{border-top:1px solid #ebebeb;}#gsc_dd_mor-s .gsc_dd_mor-sel,#gsc_dd_sort-s .gsc_dd_sort-sel{color:#dd4b39;}#gsc_dd_mor-p{padding:14px 44px 14px 16px;color:#777;}.gs_el_tc #gsc_dd_mor-p{padding:18px 44px 18px 16px;}.gsc_art_sel #gsc_dd_add-r,.gsc_art_sel #gsc_dd_mor-r,#gsc_btn_mer,#gsc_btn_del,#gsc_dd_exp-r{display:none;}#gsc_dd_mor-r,.gsc_art_sel #gsc_btn_mer,.gsc_art_sel #gsc_btn_del,.gsc_art_sel #gsc_dd_exp-r{display:inline-block;}html:not(.gs_el_ph) #gsc_dd_sort-r{display:none;}#gsc_lwp{margin:24px 0;text-align:center;}.gs_el_sm #gsc_lwp{margin:16px 0;}#gsc_bpf{display:inline-block;verticle-align:middle;}#gsc_a_nn{display:inline-block;vertical-align:middle;padding-right:16px;font-size:13px;}.gs_el_ph #gsc_a_nn{display:none;}@media print{#gs_top #gs_md_s,#gs_top #gs_md_w,#gs_top #gs_hdr,#gs_top #gs_hdr_drs,#gs_top #gs_hdr_drw,#gs_top #gs_ftr,#gs_top #gsc_nag,#gs_top #gsc_prf_nbar_btns,#gs_top #gsc_prf_btne,#gs_top #gsc_prf_btnf,#gs_top #gsc_prf_ivh,#gs_top #gsc_prf_puf,#gs_top #gsc_rsb_co,#gs_top #gsc_bdy #gsc_rsb_co,#gs_top .gsc_g_hist_wrp,#gs_top #gsc_prf_t_wrp,#gs_top .gsc_rsb_header,#gs_top .gsc_a_tb,#gs_top .gsc_a_x,#gs_top #gsc_lwp,#gs_top .gsc_prf_puic,#gs_top #gsc_dd_add-r,#gs_top #gsc_dd_mor-r,#gs_top #gsc_dd_sort-r{display:none;}#gs_top,#gs_top #gsc_bdy,#gs_top #gsc_prf_w,#gs_top #gsc_prf,#gs_top #gsc_prf_pu,#gs_top #gsc_prf_pua,#gs_top #gsc_prf_i,#gs_top .gsc_rsb_s,#gs_top .gsc_lcl,#gs_top .gsc_rsb,#gs_top #gsc_a_tw,#gs_top #gsc_a_t,#gs_top .gsc_prf_il,#gs_top .gsc_prf_ila,#gs_top .gsc_prf_inta,#gs_top #gsc_rsb_st{background:none;border:none;padding:0;margin:0;height:auto;width:auto;min-width:0;max-width:none;float:none;display:block;position:static;color:black;font-weight:normal;font-size:12pt;text-decoration:none;}#gs_top .gsc_a_ac,#gs_top .gsc_a_a,#gs_top #gsc_a_ca,#gs_top .gsc_a_at,#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std,#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh,#gs_top .gsc_a_m,#gs_top .gsc_a_am{color:black;font-weight:normal;font-size:12pt;padding:0;margin:0;background:none;border:none;}#gs_top #gsc_a_trh,#gs_top #gsc_a_trh th{height:0;}#gs_top #gsc_a_ta,#gs_top #gsc_a_ca,#gs_top #gsc_a_ha,#gs_top .gsc_a_a{font-size:11pt;}#gs_top .gsc_a_ac{font-size:10pt}#gs_top #gsc_prf_pu{width:80pt;height:auto;float:left;margin:0 7pt 7pt 0;}#gs_top #gsc_prf_pua{left:auto;transform:none;border-radius:0;}#gs_top #gsc_prf_pua>img{position:static;}#gs_top #gsc_prf_i{margin:0 7pt 7pt 87pt;text-align:left;}#gs_top #gsc_prf_in{font-size:18pt;line-height:18pt;padding:0 0 4pt 0;}#gs_top .gsc_prf_il{padding:2pt 0;}#gs_top #gsc_prf_w{float:left;width:64%;}#gs_top .gsc_rsb{float:right;width:35%;}#gs_top #gsc_art{clear:both;}#gs_top #gsc_rsb_st{display:table;width:100%;max-width:none;margin-top:3pt;}#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std{font-size:10pt;}#gs_top th.gsc_rsb_sc1,#gs_top .gsc_rsb_sth{border-bottom:1pt solid #ccc;}#gs_top .gsc_rsb_f{max-width:60pt;}#gs_top .gsc_rsb_sth{padding-left:14pt;}#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh{padding:6pt 0;}#gs_top #gsc_a_trh{border-bottom:1pt solid #ccc;}#gs_top #gsc_a_ca{display:block;width:auto;}#gs_top #gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:12pt;}#gs_top .gsc_a_h{display:inline;font-size:10pt;}#gs_top .gsc_a_at{color:#008;}#gs_top .gsc_a_m,#gs_top .gsc_a_am{display:inline;position:absolute;}#gs_top .gsc_a_am{padding: 11pt 0 0 8pt;}#gs_top .gsc_a_t .gs_gray{color:black;font-size:10pt;}}.gsc_lwpds_frm{position:relative;height:29px;}.gsc_lwpds_tsiw{position:absolute;top:0;left:0;right:38px;}.gsc_lwpds_tsiw input{border-radius:3px 0 0 3px;}.gsc_lwpds_tsbw{position:absolute;top:0;right:0;}.gsc_lwpds_tsbw button{border-radius:0 3px 3px 0;}.gsc_pgn{text-align:right;font-weight:bold;line-height:29px;}.gsc_pgn_ppn{margin:0 8px;}.gsc_ccb_ck{padding:11px 10px 9px 10px;}.gsc_ccb_svg{stroke:#666;stroke-width:2px;fill:#fff;width:21px;height:21px;vertical-align:top;}.gsc_ccb_lim .gsc_ccb_svg,.gsc_ccb_dis .gsc_ccb_svg{fill:#e2e2e2;stroke:#fff;}.gsc_ccb_lim .gsc_ccb_svg>circle,.gsc_ccb_dis .gsc_ccb_svg>circle{stroke:#e2e2e2;}.gsc_ccb_on .gsc_ccb_svg{fill:#4d90fe;stroke:#fff;}.gsc_ccb_on .gsc_ccb_svg>circle{stroke:#4d90fe;}.gsc_ccb_del:active .gsc_ccb_svg>circle,.gsc_ccb_add:active .gsc_ccb_svg>circle{fill:#2f6de1;}#gsc_md_cod{width:800px;max-width:94%;}.gs_el_ph #gsc_md_cod{width:100%;max-width:100%;}#gsc_md_cod .gs_md_prg{min-height:400px;}.gsc_codb_instr{font-size:16px;margin:1em 0;}#gsc_cods_res{position:relative;margin-bottom:24px;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_cods_res{margin-bottom:16px;}.gsc_cods_hide,.gsc_cod_sugg #gsc_cod_tedit,.gsc_cod_sugg #gsc_cods_frm,.gsc_cod_sugg #gsc_cods_pp,.gsc_cod_lc #gsc_cod_tadd,.gsc_cod_changed #gsc_cod_tedit,.gsc_cod_changed #gsc_cod_tadd,.gsc_cod_lim #gsc_cod_tedit,.gsc_cod_lim #gsc_cod_tadd{display:none;}#gsc_cods_frm{margin:0 0 24px 0;}.gs_el_ph #gsc_cods_frm{margin:0 0 16px 0;}.gsc_ucoar{padding:24px 0;border-bottom:1px solid #eee;}.gs_el_ph .gsc_ucoar{padding:16px 0px;}.gsc_ucoar:first-child{padding-top:0;}.gsc_ucoar:last-child{border-bottom:none;}.gsc_ucoar_cb{float:right;margin-top:-8px;}#gsc_cod_trev{display:none;color:#666;pointer-events:none;}.gsc_cod_changed #gsc_cod_trev,.gsc_cod_lim #gsc_cod_trev{display:inline-block;}.gsc_cod_changed #gsc_cod_trev{color:#1a0dab;pointer-events:auto;}.gsc_fol_cr{margin:0 0 8px 0;}.gs_el_tc .gsc_fol_cr{margin:0;}.gs_el_tc .gsc_fol_cr:first-child{margin-top:-8px;}#gsc_fol_ml{display:block;color:#777;padding:12px 0 4px 0;}</style><script>!function(GSP){/*

 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
var aa="function"==typeof Object.create?Object.create:function(a){var b=function(){};b.prototype=a;return new b},ba;if("function"==typeof Object.setPrototypeOf)ba=Object.setPrototypeOf;else{var da;a:{var ea={a:!0},fa={};try{fa.__proto__=ea;da=fa.a;break a}catch(a){}da=!1}ba=da?function(a,b){a.__proto__=b;if(a.__proto__!==b)throw new TypeError(a+" is not extensible");return a}:null}
var ha=ba,ia=function(a,b){a.prototype=aa(b.prototype);a.prototype.constructor=a;if(ha)ha(a,b);else for(var c in b)if("prototype"!=c)if(Object.defineProperties){var d=Object.getOwnPropertyDescriptor(b,c);d&&Object.defineProperty(a,c,d)}else a[c]=b[c];a.na=b.prototype},ja=function(){},ka=function(a,b){var c=Array.prototype.slice.call(arguments,1);return function(){var d=c.slice();d.push.apply(d,arguments);return a.apply(this,d)}};var g=function(){this.o=this.o;this.F=this.F};g.prototype.o=!1;g.prototype.isDisposed=function(){return this.o};g.prototype.T=function(){this.o||(this.o=!0,this.H())};g.prototype.H=function(){if(this.F)for(;this.F.length;)this.F.shift()()};function la(a){var b=[],c=0,d;for(d in a)b[c++]=d;return b};function l(a,b){a.classList.add(b)}function n(a,b){a.classList.remove(b)}function p(a,b){return a.classList?a.classList.contains(b):!1}function q(a,b,c){c=void 0!==c?c:!p(a,b);(c?l:n)(a,b)};function r(a){return 0<=(navigator.userAgent||"").indexOf(a)}var ma=r("iPhone")||r("iPad")||r("iPod"),na=r("iPhone")||r("Android")&&r("Mobile");function oa(){if(void 0===b){var a=window.screen;a={width:window.innerWidth,height:window.innerHeight,ma:a.width,la:a.height}}else a=b;var b=a;a=b.width;var c=b.height,d=b.ma;b=b.la;var e=4;if(600>a||48E4>d*b||na)e=1;else if(982>a)e=2;else if(1136>a||590>c)e=3;return e}var pa,qa=/[?&]tc=([01])/.exec(location.search||"");
pa=qa?0<+qa[1]:r("Android")?!0:window.matchMedia&&window.matchMedia("(pointer)").matches?window.matchMedia("(pointer:coarse)").matches:!r("Firefox")||r("Mobile")||r("Tablet")?ma||"ontouchstart"in window||0<(navigator.msMaxTouchPoints||0):!1;function ra(){if(void 0==sa){sa=!1;try{var a=Object.defineProperty({},"passive",{get:function(){sa=!0}});window.addEventListener("testPassive",ja,a);window.removeEventListener("testPassive",ja,a)}catch(b){}}return sa}var sa;var ta=function(a){this.Y=a},ua=new ta("INPUT"),va=new ta("TABLE");function t(a){return document.getElementById(a)}function x(a){return a.id||(a.id="gs_id"+wa++)}function xa(a){a=(void 0===a?null:a)||document.body;return"rtl"==(a?window.getComputedStyle(a,null):null).direction}
function ya(a){var b=[];a=a.elements;for(var c=a.length,d=0;d<c;d++){var e=a[d],f=encodeURIComponent(e.name||""),h=e.type;!f||e.disabled||!("checkbox"!=h&&"radio"!=h||e.checked)||b.push(f+"="+encodeURIComponent(e.value||""))}return b.join("&")}function za(a,b){var c=a.elements[b];c||(c=document.createElement(ua.Y),c.type="hidden",c.name=b,a.appendChild(c));return c}function Aa(a){t("gsc_md_cbyd_c").href=a&&a.match(Ba)?a:"javascript:void(0)"}function Ca(a){a.match(Ba)&&(window.location.href=a)}
var wa=100,Da=/\S+/g,Ba=/^(?:https?:|[^:/?#]*(?:[/?#]|$))/i,Ea=/^(?:#|\/[a-z0-9_-]*(?:[?].*)?$)/i;function y(a){return a.hasOwnProperty("gs_uid")?a.gs_uid:a.gs_uid=++Fa}var Fa=0;var z=function(){this.i=[];this.A={};this.O=this.v=0};z.prototype.add=function(a){var b=y(a);this.A[b]||(this.i.push(a),this.A[b]=this.i.length,++this.v)};z.prototype.remove=function(a){a=y(a);var b=this.A[a];b&&(this.i[b-1]=null,delete this.A[a],2*--this.v<this.i.length&&!this.O&&Ga(this))};z.prototype.notify=function(a){var b=this.i;try{++this.O;for(var c=0;c<b.length;c++){var d=b[c];d&&d.apply(null,arguments)}}finally{!--this.O&&2*this.v<b.length&&Ga(this)}};
var Ga=function(a){var b=a.i,c=b.length;a=a.A;for(var d=0,e=0;e<c;e++){var f=b[e];f&&(b[d]=f,a[y(f)]=++d)}b.length=d};function B(a,b,c,d,e){Ha(a,b,c,void 0===d?!1:d,void 0===e?!1:e,Ia)}function C(a,b,c,d){Ha(a,b,c,void 0===d?!1:d,!1,Ja)}function Ka(a,b,c,d){function e(h){C(f,a,e,c);b(h)}var f=document;c=void 0===c?!1:c;B(f,a,e,c,void 0===d?!1:d)}function D(a){La?La.add(a):a()}var Ma=window.requestAnimationFrame?function(a){window.requestAnimationFrame(a)}:function(a){setTimeout(a,33)};function Na(a){a.stopPropagation();a.preventDefault()}
function Oa(a){return(a.ctrlKey?1:0)|(a.altKey?2:0)|(a.metaKey?4:0)|(a.shiftKey?8:0)}function Ia(a,b,c,d,e){var f=a.addEventListener;e=e&&ra();f.call(a,b,c,e?{passive:e,capture:d}:d)}function Ja(a,b,c,d){a.removeEventListener(b,c,d)}function Ha(a,b,c,d,e,f){if("string"===typeof b)f(a,b,c,d,e);else for(var h=b.length,k=0;k<h;k++)f(a,b[k],c,d,e)}function Pa(){La.notify();La=null}function Qa(){"complete"==document.readyState&&(C(document,"readystatechange",Qa),Pa())}
var La,Ra=!!document.attachEvent,Sa=document.readyState;if(Ra?"complete"!=Sa:"loading"==Sa)La=new z,Ra?B(document,"readystatechange",Qa):Ka("DOMContentLoaded",Pa);function Ta(){Ka(["mousedown","touchstart"],function(){q(document.documentElement,"gs_pfcs",!0);B(document,"keydown",Ua,!0)},!0,!0)}function Ua(a){9==a.keyCode&&(q(document.documentElement,"gs_pfcs",!1),C(document,"keydown",Ua,!0),Ta())}Ta();function Va(a,b,c,d,e){var f=t(a);Wa(f,function(){l(f,"gs_vis");b&&b()},function(){n(f,"gs_vis");c&&c()},d,e)}function Wa(a,b,c,d,e){var f=x(a);if(!E[f]){var h=document.activeElement;Xa(Ya(a),!0);b&&b();G.push(function(k){delete E[f];try{k||(e||h).focus()}catch(m){}c&&c()});E[f]=G.length;h&&a.contains(h)||setTimeout(function(){var k=d,m=k&&"text"==k.type;if(!k||m&&pa)k=a;try{k.focus(),m&&(k.value=k.value)}catch(w){}},0)}}function H(a){Xa((E[a]||1E6)-1,!1)}
function Za(a){a=void 0===a?!1:a;G.pop()(a)}function Xa(a,b){for(b=void 0===b?!1:b;G.length>a;)Za(b||G.length>a+1)}function Ya(a){for(var b=0;a&&!(b=E[a.id]||0);)a=a.parentNode;return b}var G=[],E={};B(document,"click",function(a){var b=G.length;b&&!Oa(a)&&b>Ya(a.target)&&Za(!0)});B(document,"keydown",function(a){27==a.keyCode&&!Oa(a)&&G.length&&Za()});
B(document,"focus",function(a){var b=G.length;if(b)for(var c=Ya(a.target);c<b;){var d="",e;for(e in E)if(E[e]==b){d=e;break}a:{d=(t(d).getAttribute("data-wfc")||"").match(Da)||[];for(var f=0;f<d.length;f++){var h=t(d[f]);if(h&&h.offsetWidth){d=h;break a}}d=void 0}if(d){Na(a);d.focus();break}else Za(!0),--b}},!0);var $a={},ab={},bb;try{bb=window.sessionStorage}catch(a){};function J(a){return"object"==typeof a?a:null}function cb(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.pushState(b,"",a):window.location.assign(a)}function ib(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.replaceState(b,"",a):window.location.replace(a)}function fb(a){var b=[],c;for(c in a)b.push(encodeURIComponent(c)+"="+encodeURIComponent(a[c]));return(a=b.sort().join("&"))?"#"+a:""}
function jb(a){var b={};a=a.split("&");for(var c=0;c<a.length;c++){var d=a[c],e=d.indexOf("=");if(e+1){var f=d.substr(0,e);d=d.substr(e+1)}else f=d,d="";f&&(b[decodeURIComponent(f)]=decodeURIComponent(d))}return b}function kb(a){var b=a.indexOf("#")+1;return jb(b?a.substr(b):"")}function lb(a){var b=a.indexOf("?")+1;a=b?a.substr(b):"";b=a.indexOf("#");return jb(b+1?a.substr(0,b):a)}function mb(a,b){for(var c in b){var d=b[c];void 0!==d?a[c]=d:delete a[c]}}
function eb(a){var b=kb(window.location.hash);mb(b,a);return b}function db(a){var b=gb||J(window.history.state),c={},d;for(d in b)c[d]=b[d];mb(c,a);return c}function nb(){setTimeout(function(){if(!ob){var a=window.history.state;ob=!0;gb=J(a);rb.notify()}sb=!1},0)}var rb=new z,gb,ob=!1,sb=!0,hb="pushState"in window.history,tb;
if("undefined"==typeof GSP)tb=!1;else{var ub=.001*Date.now(),vb=GSP.eventId,wb=!1,K,xb=bb;if(!("nh"in $a)){var yb=xb&&xb.getItem("nh"),zb;if(yb)try{zb=JSON.parse(yb)}catch(a){}ab.nh=zb}K=ab.nh;K instanceof Array||(K=[]);for(var Ab=K.length,Bb=0,Cb=0;Cb<Ab;Cb++){var Db=K[Cb];if(Db instanceof Array&&2==Db.length){var Eb=Db[1]==vb;wb=wb||Eb;10>=Ab-Cb&&+Db[0]>ub-86400&&!Eb&&(K[Bb++]=Db)}}K.length=Bb;K.push([ub,vb]);var Fb=K,Gb=bb;ab.nh=Fb;try{Gb&&Gb.setItem("nh",JSON.stringify(Fb))}catch(a){}tb=wb}
var Hb=tb;"onpageshow"in window?B(window,"pageshow",nb):D(nb);B(window,hb?"popstate":"hashchange",function(a){"loading"!=document.readyState&&(a=a.state,ob=!0,gb=J(a),rb.notify())});function Ib(){Jb&&(C(t("gs_alrt_l"),"click",Jb),Jb=void 0)}function Kb(){var a=Lb();l(a,"gs_anm");l(a,"gs_vis");B(document,"click",Mb);clearTimeout(Nb);Nb=setTimeout(Mb,4E3);++Ob;setTimeout(Pb,0)}function Mb(){Ob||(C(document,"click",Mb),clearTimeout(Nb),Nb=void 0,Ib(),n(Lb(),"gs_vis"))}function Lb(){return t("gs_alrt")}function Pb(){Ob=0}var Nb,Ob=0,Jb;D(function(){var a=t("gs_alrt_m");a&&(a.innerHTML&&!Hb&&Kb(),B(window,"pagehide",function(){Ob=0;Mb();n(Lb(),"gs_anm")}))});function Qb(a,b,c){var d=new XMLHttpRequest;d.onreadystatechange=function(){if(4==d.readyState){var e=d.status,f=d.responseText,h=d.responseURL,k=window.location,m=k.protocol;k="//"+k.host+"/";h&&h.indexOf(m+k)&&h.indexOf("https:"+k)&&(e=0,f="");c(e,f)}};d.open(b?"POST":"GET",a,!0);d.setRequestHeader("X-Requested-With","XHR");b&&d.setRequestHeader("Content-Type","application/x-www-form-urlencoded");b?d.send(b):d.send();return d}function Rb(a){a&&(a.onreadystatechange=ja,a.abort())};var Sb=function(a,b,c){this.type=a;this.currentTarget=this.target=b;this.g=void 0===c?null:c;this.P=!1};Sb.prototype.stopPropagation=function(){this.g&&this.g.stopPropagation();this.P=!0};var L=function(a){a.g&&Na(a.g);a.P=!0};var M=function(a,b){this.R=a;this.ka=b},Tb=function(a,b,c){this.R=a;this.types=b;this.listener=c};function Ub(a,b){var c=b.length;if(c){var d=y(a),e=Vb[d];if(!e){e=Vb[d]=[];d=Wb(b[0].R);for(var f in d){var h=Xb[f];h||(h=Xb[f]=Object.create(null));for(var k in d[f]){var m=h[k];m||(m=h[k]=[]);m.push(a)}}Yb(a,e,b[0],Zb);for(f=1;f<c;f++)Yb(a,e,b[f],$b)}}}function O(a,b,c){ac(new Sb(a,b,void 0===c?null:c))}
function P(a,b,c){var d=bc;"string"===typeof b&&(cc[0]=b,b=cc);var e=b.length;a=Wb(a);for(var f in a)for(var h in a[f])for(var k=0;k<e;k++)d(f,h,b[k],c)}function Wb(a){"string"===typeof a&&(dc[0]=a,a=dc);for(var b=a.length,c=Object.create(null),d=0;d<b;d++){var e=a[d],f=e.charAt(0),h=e.substr(1);if("#"!=f&&"."!=f||!h)throw Error("bad selector: "+e);(e=c[f])||(e=c[f]=Object.create(null));e[h]=!0}return c}
function bc(a,b,c,d){var e=ec[c];e||("touchstart"!=c&&"mouseover"!=c&&"mouseout"!=c&&B(document,c,fc,"focus"==c||"blur"==c),e=ec[c]=Object.create(null));(c=e[a])||(c=e[a]=Object.create(null));(a=c[b])||(a=c[b]=new z);a.add(d)}function fc(a){var b=a.target;b&&3==b.nodeType&&(b=b.parentNode);ac(new Sb(a.type,b,a))}
function ac(a){for(var b=a.target;b&&b!=document&&!b.disabled&&!p(b,"gs_dis");){a.currentTarget=b;var c=b.id;if(c&&!gc("#",c,a))break;c=b.classList||[];for(var d=c.length,e=0;e<d;e++)if(!gc(".",c[e],a))return;b=b.parentNode}}function gc(a,b,c){var d=ec[c.type];(b=(a=d&&d[a])&&a[b])&&b.notify(c);return!c.P}function Yb(a,b,c,d){var e=c.R;c=c.ka;for(var f in c){var h=ka(d,a,c[f]);P(e,f,h);b.push(new Tb(e,f,h))}}function Zb(a,b,c){var d=c.currentTarget;a=hc(a,d)||a;a=ic(a,d);b.call(a,c)}
function $b(a,b,c){a:{for(var d=c.currentTarget;d&&d!=document;){var e=hc(a,d);if(e){a=ic(e,d);break a}d=d.parentNode}a=void 0}a&&b.call(a,c)}function ic(a,b){var c=jc(b),d=kc[c];d||(d=kc[c]=[]);for(var e=d.length,f=0;f<e;f++){var h=d[f];if(h instanceof a)return h}b=new a(b);d.push(b);a=y(a);(d=lc[a])||(d=lc[a]=[]);d.push(c);return b}function hc(a,b){var c,d=b.id;d&&(c=mc(a,c,"#",d));b=b.classList||[];d=b.length;for(var e=0;e<d;e++)c=mc(a,c,".",b[e]);return c}
function mc(a,b,c,d){c=(d=(c=Xb[c])&&c[d])?d.length:0;for(var e=0;e<c;e++){var f=d[e];!(f===a||f.prototype instanceof a)||b&&!(f===b||f.prototype instanceof b)||(b=f)}return b}function jc(a){var b=a.getAttribute("data-duid");b||a.setAttribute("data-duid",b=""+nc++);return b}var ec=Object.create(null),dc=[""],cc=[""],Xb=Object.create(null),Vb=Object.create(null),lc=Object.create(null),kc=Object.create(null),nc=100;window.gs_evt_dsp=fc;function oc(){var a=".gs_md_li";if("string"===typeof a){var b=a.charAt(0),c=a.slice(1);if("#"==b)a=function(d){return d.id==c&&0<d.offsetWidth};else if("."==b)a=function(d){return p(d,c)&&0<d.offsetWidth};else throw Error("bad selector: "+a);}return a}function pc(a,b){return a&&((void 0===b?0:b)?a.lastElementChild:a.firstElementChild)}function qc(a,b){return a&&((void 0===b?0:b)?a.previousElementSibling:a.nextElementSibling)}function rc(a,b,c){c=void 0===c?!1:c;return sc(a,b,oc(),c,!1)}
function sc(a,b,c,d,e){for(var f;b&&a;){if(c(b)){if(e)return b}else for(f=pc(b,d);f;f=qc(f,d))if(e=sc(f,f,c,d,!0))return e;for(e=!0;;){if(b==a)return null;f=b.parentNode;if(b=qc(b,d))break;b=f}}return null};function tc(a){return!!p(a,"gs_sel")+2*!!p(a,"gs_par")}function uc(a){return+a.getAttribute("data-s")}function vc(a,b,c){c=void 0===c?!1:c;q(a,"gs_sel",1==b);q(a,"gs_par",2==b);a.setAttribute("aria-checked",wc[b]);c||a.setAttribute("data-s",""+b)}var wc=["false","true","mixed"];var Q=function(){this.j=Object.create(null);this.l=0};Q.prototype.clear=function(){this.j=Object.create(null);this.l=0};Q.prototype.has=function(a){return a in this.j};Q.prototype.get=function(a){return this.j[a]};Q.prototype.set=function(a,b){this.has(a)||this.l++;this.j[a]=b};Q.prototype.delete=function(a){this.has(a)&&(delete this.j[a],this.l--)};var xc=function(a){var b=window,c=this;this.i=new z;this.V=0;this.S=[b,a,function(){c.V++||Ma(d)},!1];var d=function(){c.V=0;c.i.notify()}};xc.prototype.addListener=function(a){this.i.v||B.apply(null,this.S);this.i.add(a)};xc.prototype.removeListener=function(a){this.i.remove(a);this.i.v||C.apply(null,this.S)};var yc=new xc("scroll"),zc=new xc("resize");var Ac=new z;function Bc(){var a=document.documentElement,b=oa();b={gs_el_ph:1==b,gs_el_ta:2==b,gs_el_sm:4!=b,gs_el_tc:pa||1==b};var c;for(c in b){var d=b[c];if(p(a,c)!=d){var e=!0;q(a,c,d)}}e&&Ac.notify()}q(document.documentElement,"gs_el_ios",ma);Bc();zc.addListener(Bc);B(window,["pageshow","load"],Bc);function R(a,b,c,d){function e(){var u=ca&&p(h,"gs_el_ph");q(F,"gs_vis",!u);h.style.overflowY=Yd&&!u?"scroll":""}function f(){var u=h.clientHeight,I=+A.getAttribute("data-h");I||(w.style.maxHeight="none",I=m.offsetHeight);I=Math.max((u-I)/2,10);u=Math.max(u-48-2*I,10);var Jc=ca&&p(h,"gs_el_ph");m.style.top=Jc?"auto":I+"px";w.style.maxHeight=Jc?"none":u+"px";Cc(w)}b=void 0===b?"":b;c=void 0===c?"":c;d=void 0===d?"":d;var h=document.documentElement,k=t("gs_top"),m=t(a),w=t(a+"-bdy"),v=t(m.getAttribute("data-cid")||
m.id+"-bdy")||m,F=t(m.getAttribute("data-shd")||"gs_md_s"),A=Dc(m),ca=!!A&&p(A,"gs_md_wmw"),N=window.pageYOffset,Yd=k.scrollHeight>h.clientHeight,pb=!!E[a],qb=pb?"":S,Lc=b&&"#"!=b[0]&&!d,$d=a==S&&b==Ec&&c==T;Fc=b;Lc?(pb?q(v,"gs_md_ldg",!0):Gc(m,v,'<div class="gs_md_prg">'+t("gs_md_ldg").innerHTML+"</div>"),O("gs-md-ldin",v)):(d&&Gc(m,v,d),O("gs-md-lded",v));qb&&(++Hc,H(qb),--Hc);S=a;Ec=b;T=c;Ic=d;$d||Hc||(Kc+=1,(qb?ib:cb)(Mc(),Nc()));pb||Wa(m,function(){A&&l(A,"gs_vis");l(m,"gs_vis");q(m,"gs_abt",
sb);Oc(a);Ac.add(e);e();A&&w&&(f(),zc.addListener(f));l(k,"gs_nscl");k.style.top=-N+"px"},function(){Ac.remove(e);zc.removeListener(f);A&&n(A,"gs_vis");n(m,"gs_vis");n(m,"gs_abt");n(F,"gs_vis");h.style.overflowY="";n(k,"gs_nscl");k.style.top="auto";Rb(U);U=null;window.scrollTo(0,N);S=Ec=T=Ic="";var u=Kc;Kc=0;Hc||(0<u?window.history.go(-u):ib(Mc(),Nc()))},Pc(m),Qc(m));Lc&&(Rb(U),U=null,U=Qb(b,c,function(u,I){U=null;u=200==u;Gc(m,v,u?I:Rc());u&&a==S&&b==Ec&&c==T&&(Ic=I,ib(Mc(),Nc()));O("gs-md-lded",
v)}))}function Dc(a){a=a.parentNode;return p(a,"gs_md_wnw")?a:null}function Pc(a){return(a=a.getAttribute("data-ifc"))?t(a):null}function Qc(a){return(a=a.getAttribute("data-cfc"))?t(a):null}
function Gc(a,b,c){q(b,"gs_md_ldg",!1);for(var d=b.querySelectorAll("[data-duid]"),e=d.length,f={},h=0;h<e;h++){for(var k=jc(d[h]),m=kc[k],w=m?m.length:0,v=0;v<w;v++){var F=m[v],A=y(F.constructor),ca=f[A];ca||(ca=f[A]={});ca[k]=!0;F&&"function"==typeof F.T&&F.T()}delete kc[k]}for(var N in f){N=+N;d=f[N];h=(e=lc[N])?e.length:0;for(m=k=0;m<h;m++)w=e[m],w in d||(e[k++]=w);k?e.length=k:delete lc[N]}b.innerHTML=c;Oc(a.id);Rb(U);U=null}
function Oc(a){if(a=document.querySelector("#"+a+">.gs_md_bdy"))a.scrollTop=a.scrollLeft=0,Cc(a)}function Cc(a){var b=a.style,c="padding"+(xa(a)?"Left":"Right");b[c]="";var d=a.offsetWidth-a.clientWidth;2<d&&(a=parseInt(window.getComputedStyle(a,null)[c],10)||0,b[c]=Math.max(a-d,0)+"px")}function Rc(){return'<div class="gs_md_prg"><div class="gs_alrt">'+t("gs_md_err").innerHTML+"</div></div>"}function Mc(){return{d:S||void 0,u:Ec||void 0,p:T?"1":void 0}}function Nc(){return{n:Kc,p:T,h:Ic}}
var U=null,Fc="",S="",Ec="",T="",Ic="",Kc=0,Hc=0;rb.add(function(){var a=kb(window.location.hash),b=a.d||"",c=b?t(b):null;++Hc;if(c){c=a.u||"";a=0<+a.p;var d=gb||J(window.history.state)||{},e=+d.n||0,f=""+(d.p||"");d=""+(d.h||"");c.match(Ea)||(c="");a!=!!f?R(b,"","",Rc()):b==S&&c==Ec&&f==T&&d==Ic||R(b,c,f,d);Kc=e}else S&&H(S);--Hc});var Sc=function(a){g.call(this);this.D=a;this.K=Object.create(null);this.C=null;a=a.querySelectorAll(".gs_in_txtw>input[type=text]");for(var b=a.length;b--;){var c=a[b],d=c.parentNode.querySelector(".gs_in_txts");c=c.name;d&&c&&(this.K[c]=d.innerHTML)}};ia(Sc,g);Sc.prototype.H=function(){Rb(this.C);this.D=this.C=null;g.prototype.H.call(this)};
Sc.prototype.ga=function(a){var b=this;L(a);if((a=this.D)&&!this.C){var c="json=&"+ya(a);Tc(this,!0);this.C=Qb(a.action,c,function(d,e){b.C=null;Tc(b,!1);var f=b.D,h=f.getAttribute("data-alrt");if(h=h?t(h):null)h.innerHTML="";try{var k=200==d&&JSON.parse(e)}catch(A){}k&&"object"==typeof k||(Uc(h,t("gs_md_err").innerHTML),k={});if(d=k.L)Ca(""+d);else{(d=k.M)&&Uc(h,d);d=1E6;if(h&&h.innerHTML){var m=h;d=h.getBoundingClientRect().top}f=f.elements;k=k.E;"object"==typeof k||(k=Object.create(null));for(var w in b.K){h=
f[w];e=void 0;var v=""+(k[w]||""),F=h.parentNode.querySelector(".gs_in_txts");q(h.parentNode,"gs_in_txte",!!v);F&&(F.innerHTML=v||b.K[w]||"");v&&(e=h.getBoundingClientRect().top)<d&&(m=h,d=e)}m&&m.scrollIntoView&&(0>d||d+20>window.innerHeight)&&m.scrollIntoView()}})}};
var Tc=function(a,b){a=a.D;var c=a.getAttribute("data-bsel");a=c?document.querySelectorAll(c):a.querySelectorAll("button");for(c=a.length;c--;){var d=a[c];d.disabled=b;q(d,"gs_bsp",b)}},Uc=function(a,b){if(a)a.innerHTML=b;else{var c=void 0===c?"":c;var d=void 0===d?"":d;var e=void 0===e?[]:e;t("gs_alrt_m").innerHTML=b;Lb().action=d.match(Ba)?d:"";a=t("gs_alrt_l");a.textContent=c;c=t("gs_alrt_h");c.innerHTML="";for(var f in e)b=document.createElement("input"),b.type="hidden",b.name=f,b.value=e[f],
c.appendChild(b);Ib();q(a,"gs_fm_s",!0);Kb()}};Ub(Sc,[new M(".gs_ajax_frm",{submit:Sc.prototype.ga})]);var Vc=[[1,0,1],[2,0,1]];P(".gs_cb_gen","click",function(a){var b=a.currentTarget,c=tc(b),d=2==+b.getAttribute("data-s");vc(b,Vc[+d][c],!0);O("gs-change",b,a.g)});P(".gs_cb_gen",["keydown","keyup"],function(a){var b=a.currentTarget,c=a.g.keyCode;"BUTTON"!=b.tagName||13!=c&&32!=c||(L(a),"keydown"==a.type&&b.click())});P([".gs_cb_gen",".gs_md_li"],"keydown",function(a){var b=a.currentTarget,c=b.tagName,d=a.g.keyCode;"BUTTON"!=c&&(32==d||13==d&&"A"!=c)&&(L(a),b.click())});var Wc=["click","contextmenu","mouseup"].concat(navigator.sendBeacon?[]:["mousedown","touchstart"]),Xc="",Yc=null;function Zc(){Yc=null}function $c(a){navigator.sendBeacon?navigator.sendBeacon(a):Yc&&a==Yc.src||((Yc=new Image).src=a,setTimeout(Zc,1E3))}function ad(){var a=lb(document.location.href).hl||"";a="/scholar_bfnav?url="+encodeURIComponent(document.location.href)+"&hl="+encodeURIComponent(a)+"&ei="+GSP.eventId;$c(a)}D(function(){Xc=Hb?"&bn=1":"";Hb&&ad()});
B(window,"pageshow",function(a){a.persisted&&(Xc="&bn=1",ad())});
B(document,Wc,function(a){if(!("click"==a.type&&a.button||"mouseup"==a.type&&1!=a.button)){var b,c;a:{for(a=a.target;a;){var d=a.nodeName;if("A"==d)break a;if("SPAN"==d||"B"==d||"I"==d||"EM"==d||"IMG"==d)a=a.parentNode;else break}a=null}a&&(b=a.getAttribute("href"))&&(c=a.getAttribute("data-clk"))&&(b="/scholar_url?url="+encodeURIComponent(b)+"&"+c+"&ws="+window.innerWidth+"x"+window.innerHeight+"&at=",c=encodeURIComponent,a=(a=a.getAttribute("data-clk-atid"))&&t(a),b=b+c(a&&a.innerText||"")+Xc,$c(b))}},
!1,!0);P(".gs_fm_s","click",function(a){a=a.currentTarget.getAttribute("data-fm")||"";(a=t(a))&&a.submit()});var V=function(a){this.m=x(a.querySelector(".gs_md_d"));this.G=x(a.querySelector(".gs_md_tb"))};V.prototype.I=function(a){var b=t(this.m);return void 0!==a?rc(b,b,a):null};V.prototype.open=function(a){a=this.I(a);if(p(t(this.G),"gs_sel"))try{a&&a.focus()}catch(c){}else{var b=t(this.G);Va(this.m,function(){l(b,"gs_sel")},function(){n(b,"gs_sel")},a,b)}};V.prototype.close=function(){H(this.m)};V.prototype.Z=function(a){L(a);p(t(this.G),"gs_sel")?this.close():this.open("keydown"==a.g.type?!1:void 0)};
V.prototype.U=function(a){var b=a.g.keyCode;if(38==b||40==b)L(a),this.open(38==b)};V.prototype.aa=function(a){a.target.id==this.m&&this.U(a)};Ub(V,[new M(".gs_md_rmb",{}),new M(".gs_md_tb",{"gs-press":V.prototype.Z,keydown:V.prototype.U}),new M(".gs_md_d",{keydown:V.prototype.aa})]);var W=function(a){V.call(this,a);this.ia=x(a.querySelector(".gs_md_in"));this.ja=x(a.querySelector(".gs_md_tb .gs_lbl"))};ia(W,V);W.prototype.I=function(){return t(this.m).querySelector(".gs_md_li[aria-selected]")};W.prototype.ba=function(a){bd(this,a)};W.prototype.J=function(a){var b=a.g.keyCode;13!=b&&32!=b||bd(this,a)};
var bd=function(a,b){var c=b.currentTarget,d=t(a.ia),e=a.I();c!=e&&(d.value=c.getAttribute("data-v"),t(a.ja).innerHTML=c.innerHTML,e&&cd(e,!1),cd(c,!0));L(b);a.close();O("gs-change",d,b.g)},cd=function(a,b){q(a,"gs_sel",b);b?a.setAttribute("aria-selected","true"):a.removeAttribute("aria-selected")};Ub(W,[new M(".gs_md_ris",{}),new M(".gs_md_li",{click:W.prototype.ba,keydown:W.prototype.J})]);P("#gs_lp","click",function(a){L(a);R("gs_lp_d")});P("#gs_lp_cur","click",function(a){L(a);H("gs_lp_d")});var dd=function(a){this.W=x(a)};dd.prototype.J=function(a){var b=a.currentTarget,c=a.g.keyCode;if(38==c||40==c){var d=t(this.W);d=rc(d,b,38==c)||rc(d,d,38==c)}else if(37==c||39==c)a:{c=!!(37==c^xa(b.parentNode));d=b.parentNode;var e=d.children,f=e.length;if(d.id!=this.W){for(;e[--f]!=b;);d=qc(d,c)||pc(d.parentNode,c);e=d.children;if(f=Math.min(f+1,e.length))if(d=e[f-1],p(d,"gs_md_li")&&d.offsetLeft!=b.offsetLeft)break a}d=void 0}d&&(L(a),d.focus())};
Ub(dd,[new M(".gs_md_ulr",{}),new M(".gs_md_li",{keydown:dd.prototype.J})]);P("#gs_hdr_mnu","click",function(a){L(a);R("gs_hdr_drw")});P("#gs_hdr_drw_mnu","click",function(a){L(a);H("gs_hdr_drw")});P("#gs_hdr_act_i","click",function(a){L(a);1==oa()?Ca(document.querySelector("#gs_hdr_drw_bot>a").href):Va("gs_hdr_act_d")});P("#gs_hdr_drw","keydown",function(a){var b=a.g.keyCode;if(38==b||40==b){var c=a.currentTarget;if(b=rc(c,c,38==b))L(a),b.focus()}});
P("#gs_hdr_tsi",["focus","blur"],function(a){function b(){var h=d.getBoundingClientRect().top-10;10<Math.abs(h)&&window.scrollBy(0,h);clearTimeout(e);c()}function c(){C(window,f,b)}var d=a.target;a="focus"==a.type;q(t("gs_hdr"),"gs_hdr_ifc",a);if(a&&pa&&!(749<window.innerHeight)){var e=setTimeout(c,1E3),f=["scroll","resize"];B(window,f,b)}});P("#gs_hdr_tsi",["input","gs-change"],function(a){q(t("gs_hdr_frm"),"gs_hdr_tsc",!!a.currentTarget.value)});
P("#gs_hdr_tsc","mousedown",function(a){L(a);var b=t("gs_hdr_tsi");b.value="";b.focus();O("input",b,a.g)});P("#gs_hdr_sre","click",function(a){L(a);var b=t("gs_hdr");Va("gs_hdr_frm",function(){n(b,"gs_hdr_src");l(b,"gs_hdr_srx")},function(){l(b,"gs_hdr_src");n(b,"gs_hdr_srx")},t("gs_hdr_tsi"))});P(".gs_md_x","click",function(a){(a=a.currentTarget.getAttribute("data-mdx"))&&H(a)});var X=function(){},ed,fd;X.prototype.$=function(a){a.g.button||(L(a),gd(a))};X.prototype.ca=function(a){hd(a)&&(L(a),gd(a))};X.prototype.da=function(a){hd(a)&&L(a)};X.prototype.ea=function(a){if(!a.g.button){L(a);var b=a.g;b&&(id=b.clientX||0,jd=b.clientY||0,B(document,kd,ld,!0),clearTimeout(ed),ed=setTimeout(md,2E3));gd(a)}};X.prototype.ha=function(a){L(a);if(nd){var b=a.g;if(b=(b=b&&b.touches)&&1==b.length&&b[0])od=b.clientX,pd=b.clientY,B(document,qd,rd,!0),clearTimeout(fd),fd=setTimeout(sd,2E3)}gd(a)};
var hd=function(a){a=a.g.keyCode;return 32==a||13==a},gd=function(a){O("gs-press",a.currentTarget,a.g)},md=function(){C(document,kd,ld,!0);clearTimeout(ed);ed=void 0},ld=function(a){"mousedown"!=a.type&&10>Math.abs(a.clientX-id)&&10>Math.abs(a.clientY-jd)?(Na(a),"click"==a.type&&md()):md()},sd=function(){C(document,qd,rd,!0);clearTimeout(fd);fd=void 0},rd=function(a){"touchstart"!=a.type&&10>Math.abs(a.clientX-od)&&10>Math.abs(a.clientY-pd)?(Na(a),"click"==a.type&&sd()):sd()},id=0,jd=0,kd=["mousedown",
"mouseup","click"],nd=r("Android")&&!r("Chrome"),od=0,pd=0,qd=["touchstart","mousedown","mouseup","click"];Ub(X,[new M(".gs_press",{click:X.prototype.$,keydown:X.prototype.ca,keyup:X.prototype.da,mousedown:X.prototype.ea,touchstart:X.prototype.ha})]);function td(){var a=0>ud.getBoundingClientRect().top;vd!=a&&(vd=a,q(wd,"gs_sth_vis",a),a?xd():(yd.style.left="",yd.style.width="",zd()))}function xd(){if(vd){var a=ud.getBoundingClientRect();yd.style.left=a.left+"px";yd.style.width=a.width+"px";zd()}}function zd(){O("gs-sth-change",t("gs_sth"))}var wd,ud,yd,vd=!1;D(function(){if(wd=t("gs_sth"))ud=wd.querySelector(".gs_sth_g"),yd=wd.querySelector(".gs_sth_b"),yc.addListener(td),zc.addListener(xd),td()});function Ad(){var a=t("gsc_rsb_co");if(a){a=a.querySelectorAll("img.gs_pp_df");for(var b=0;b<a.length;b++){var c=a[b];c.getAttribute("data-srcset")&&(c.setAttribute("srcset",c.getAttribute("data-srcset")),c.removeAttribute("data-srcset"));c.getAttribute("data-src")&&(c.setAttribute("src",c.getAttribute("data-src")),c.removeAttribute("data-src"))}}};var Bd=/\S+@\S+\.\S+/;function Cd(a){return p(a,"gsc_ccb_dis")||p(a,"gsc_ccb_lim")}function Dd(){for(var a=0>=Ed(),b=t("gsc_cods_res").querySelectorAll(".gsc_ccb_add"),c=b.length;c--;){var d=b[c];p(d,"gsc_ccb_on")||q(d,"gsc_ccb_lim",a)}};var Fd=function(a){this.X=a};Fd.prototype.fa=function(a){L(a);a=a.currentTarget.getAttribute("data-a");this.X.setAttribute("data-a",a||"");O("gsc-navigate",this.X)};var Gd=[new M(".gsc_pgn",{}),new M([".gsc_pgn_ppr",".gsc_pgn_pnx"],{click:Fd.prototype.fa})];function Hd(a,b){b=void 0===b?"":b;var c=t("gsc_md_cod");a+=fb({t:Id});R(c.id,a,"",b)}function Jd(a){if(Id!=a){var b=t("gsc_md_cod");n(b,Id);l(b,a);Id=a}}function Kd(){var a=kb(Fc).t;"gsc_cod_sugg"!=a&&"gsc_cod_lc"!=a||Jd(a)}function Ld(){var a=Md();a=a?a.value:"";var b=(t("gsc_cods_urls").getAttribute("data-sa")||"").replace(Nd,"$1"+encodeURIComponent(a));a=a?b:t("gsc_cods_urls").getAttribute("data-lc")||"";Hd(a)}
function Od(a){var b=t("gsc_cods_frm");if(b){b=b.elements;var c=b[1];b[0].disabled=c.disabled=a;q(c,"gs_bsp",a)}a=a?null:t("gsc_codb_data");if(c=t("gsc_cods_pp")){var d=a&&a.getAttribute("data-prev");b=a&&a.getAttribute("data-next");var e=a&&a.getAttribute("data-start"),f=a&&a.getAttribute("data-end");c.querySelector(".gsc_pgn_ppn").textContent=e&&f?e+" - "+f:"";e=c.querySelector(".gsc_pgn_ppr");e.disabled=!d;e.setAttribute("data-a",d||"");c=c.querySelector(".gsc_pgn_pnx");c.disabled=!b;c.setAttribute("data-a",
b||"")}a&&(Pd=+a.getAttribute("data-max")||0,za(t("gsc_cods_save"),"xsrf").value=a.getAttribute("data-xsrf")||"")}function Qd(){var a=0<Y.l||0<Z.l,b=Ed(),c=0>=b;t("gsc_cod_done").disabled=!a||0>b;q(t("gsc_cod_t"),"gsc_cod_changed",a);a=t("gsc_cod_trev");a.textContent=a.getAttribute(c?"data-lim":"data-txt")||"";q(t("gsc_cod_t"),"gsc_cod_lim",c)}function Ed(){return Pd-Y.l+("gsc_cod_sugg"==Id?0:Z.l)}function Md(){return t("gsc_cods_tsi")}
function Rd(a){for(var b="",c=la(a.j),d=c.length;d--;)b+=a.get(c[d]);return b}var Id="gsc_cod_lc",Pd=0,Nd=/([?&]mauthors=)([^&]*)/,Y=new Q,Z=new Q;function Sd(a){q(t("gsc_a_sp"),"gs_vis",0==a);q(t("gsc_a_err"),"gs_vis",2==a)}function Td(){return document.querySelectorAll("#gsc_a_t input[type=checkbox]")}function Ud(){O("gsc-works-change",t("gsc_a_t"))}function Vd(){var a=t("gsc_x_all");if(a){var b=document.querySelectorAll("#gsc_a_t input[type=checkbox]:checked");var c=b.length;var d=Td().length;c=c?c==d?1:2:0;vc(a,c);2==c&&(Wd=b)}Ud()}var Wd=[];var Xd="",Zd=0,ae=0;function be(a){for(var b=[!1,!1,!1],c=0;c<b.length;c++){var d=t(ce[c]);d&&(b[c]=!!a(d))}return b}function de(){var a=t("gsc_fol_m");if(a){var b=t("gsc_fol_b");if(!(a=!Bd.test(a.value))){a:{a=be(tc);for(var c=be(uc),d=0;d<a.length;d++)if(a[d]!=c[d]){a=!0;break a}a=!1}a=!a}b.disabled=a}}var ce=["gsc_fol_a","gsc_fol_c","gsc_fol_r"],ee=["follow_articles_btn","follow_citations_btn","follow_related_btn"];function fe(){p(document.documentElement,"gs_el_ph")||p(document.documentElement,"gs_el_ta")||Ad()};function ge(a){if(a){a.id&&a.removeAttribute("id");for(var b=0;b<a.children.length;b++)ge(a.children[b])}};function he(){var a=t("gsc_prf_pufii");if(r("MSIE ")){var b=t("gsc_prf_puf");Va("gsc_prf_pufi",function(){l(b,"gsc_prf_pufo")},function(){n(b,"gsc_prf_pufo")},a)}else a.click()};function ie(){var a=document.querySelectorAll(".gsc_prf_pnl"),b=document.documentElement;b=p(b,"gs_el_ph")||p(b,"gs_el_ta");for(var c=0;c<a.length;c++)a[c].setAttribute("role",b?"tabpanel":"region")};var je=kb(window.location.hash),ke=je.u||"";"gs_md_cita-d"==je.d&&ke.match(Ea)&&0<=ke.indexOf("view_citation")&&Ca(ke);P("#gsc_md_cod","gs-md-ldin",function(){Kd();Od(!0)});P("#gsc_md_cod","gs-md-lded",function(){Kd();Od(!1);for(var a=t("gsc_cods_res").querySelectorAll(".gsc_ccb_ck"),b=a.length;b--;){var c=a[b];if(!Cd(c)){var d=c.getAttribute("data-authorid")||"";d=(p(c,"gsc_ccb_add")?Y:Z).has(d);q(c,"gsc_ccb_on",d)}}Dd();Qd();a=lb(Fc);(b=Md())&&(b.value=a.mauthors||"")});
P("#gsc_cods_frm","gsc-lwpds-submit",Ld);P("#gsc_cods_pp","gsc-navigate",function(a){(a=a.currentTarget.getAttribute("data-a"))&&Hd(a)});
P([".gsc_ccb_add",".gsc_ccb_del"],"click",function(a){a=a.currentTarget;if(!Cd(a)){var b=!p(a,"gsc_ccb_on");q(a,"gsc_ccb_on",b);var c=p(a,"gsc_ccb_add")?".gsc_ccb_del":".gsc_ccb_add",d=a.parentNode;(c=d&&d.querySelector(c))&&n(c,"gsc_ccb_on");c=a.getAttribute("data-authorid")||"";Y.delete(c);Z.delete(c);b&&(p(a,"gsc_ccb_add")?Y:Z).set(c,t("gsc_ucoar-"+c).outerHTML);Dd();Qd()}});
P("#gsc_cod_trev","click",function(){var a=t("gsc_cods_res").cloneNode(!0),b=a.querySelector("#gsc_codb_content");b||(b=document.createElement("div"),b.id="gsc_codb_content",a.appendChild(b));var c=Rd(Y)+Rd(Z);b.innerHTML=c;(b=Md())&&(b.value="");Hd("",a.innerHTML)});P("#gsc_cod_done","click",function(){var a=t("gsc_cods_save");za(a,"colleague_add").value=la(Y.j).join(",");za(a,"colleague_del").value=la(Z.j).join(",");a.submit()});
P(["#gsc_coauth_opn",".gsc_rsb_btne",".gsc_rsb_btnv"],"click",function(){Jd("gsc_cod_lc");Pd=0;Y.clear();Z.clear();var a=Md();a&&(a.value="");Ld()});P(".gsc_rsb_aa",["click","keydown"],function(a){if("keydown"!=a.type||a.g&&!Oa(a.g)&&13==a.g.keyCode)a.g&&Na(a.g),(a=(a=a.currentTarget.querySelector("a"))?a.getAttribute("href"):"")&&Ca(a)});P("#gsc_prf_t-ath","click",function(){Ad()});D(function(){Ac.add(fe);fe()});P(".gsc_lwpds_frm","submit",function(a){L(a);O("gsc-lwpds-submit",a.target)});
var le=window.location.href.split("#")[0];Xd=le.replace(/([?&])(cstart|pagesize)=[^&]*/g,"$1");Zd=Math.max(+le.replace(/.*[?&]cstart=([^&]*).*/,"$1")||0,0);ae=+le.replace(/.*[?&]pagesize=([^&]*).*/,"$1")||0;ae=Math.max(Math.min(ae,100),20);
P("#gsc_bpf_more","click",function(a){var b=a.currentTarget,c=ae,d=100>c?100-c:100;a=(Xd+"&cstart="+(Zd+c)+"&pagesize="+d).replace(/([?&])&+/g,"$1");Sd(0);b.disabled=!0;Qb(a,"json=1",function(e,f){b.disabled=!1;try{var h=200==e&&JSON.parse(f)}catch(m){}if(h&&"object"==typeof h){ae=c+=d;Sd(1);e=t("gsc_a_b");f=document.createElement(va.Y);f.innerHTML=""+h.B;f=Array.prototype.slice.call(f.rows);for(var k=0;k<f.length;k++)e.appendChild(f[k]);Vd();if(e=t("gsc_a_nn"))f=e.innerHTML.replace(/[0-9]+$/,""+
t("gsc_a_b").rows.length),e.innerHTML=f;b.disabled=!h.N}else Sd(2)})});P(["#gsc_fol_a","#gsc_fol_c","#gsc_fol_r"],"gs-change",de);P("#gsc_fol_m","input",de);P("#gsc_fol_f","submit",function(a){a.g&&a.g.preventDefault();a=t("gsc_fol_f");var b=t("gsc_fol_inp");b.innerHTML="";for(var c=be(tc),d=be(uc),e=0;e<c.length;e++)if(c[e]!=d[e]){var f=ee[e],h=document.createElement("input");h.type="hidden";h.name=c[e]?f:"un"+f;b.appendChild(h)}O("gsc-fol-submit",a)});P("#gsc_fol_f","gsc-fol-submit",function(a){a.currentTarget.submit()});
P("#gsc_md_hist","gs-md-lded",function(){var a=t("gsc_md_hist_c");if(!a.innerHTML){var b=document.getElementsByClassName("gsc_g_hist_wrp");1==b.length&&(a.appendChild(b[0].cloneNode(!0)),ge(a.lastChild))}});P(["#gsc_hist_opn",".gsc_md_hist_b"],"click",function(){var a=document.documentElement;!t("gsc_hist_opn")||p(a,"gs_el_ph")||p(a,"gs_el_ta")||R("gsc_md_hist")});
P("#gsc_lwp_mndt_lnk","click",function(a){var b=a.currentTarget.getAttribute("href")+"&tzom="+(new Date).getTimezoneOffset();window.location.assign(b);a.g.preventDefault()});P("#gsc_prf_btne","click",function(){var a=t("gsc_md_pro-d");a.setAttribute("data-ifc","");R(a.id,fb({t:"gsc_md_pro_ed"}))});P("#gsc_prf_btnf","click",function(){R("gsc_md_fol")});P("#gsc_md_fol_pub","click",function(){t("gsc_fol_mpf").submit()});P("#gsc_prf_iv_tg","click",function(){q(t("gsc_prf_w"),"gsc_prf_why")});
P(".gsc_prf_pel",["click","keydown"],function(a){("keydown"!=a.type||13==a.g.keyCode&&a.g&&!Oa(a.g))&&he()});P("#gsc_prf_pufii","change",function(){t("gsc_prf_puf").submit()});P(".gsc_prf_tab","click",function(a){var b=t("gsc_bdy");b.setAttribute("data-tab",a.currentTarget.id);b=b.querySelectorAll(".gsc_prf_tab");for(var c=0;c<b.length;c++){var d=b[c];d.setAttribute("aria-selected",""+(d==a.currentTarget))}});D(function(){Ac.add(ie);ie()});
P("#gsc_md_cbyd","gs-md-ldin",function(){var a=t("gsc_md_cbyd_merge");a&&(a.disabled=!0);Aa("")});P("#gsc_md_cbyd","gs-md-lded",function(){var a=t("gsc_md_cbyd_f"),b=t("gsc_md_cbyd_merge"),c=Fc,d=lb(c).s||"";c=kb(c).c||"";a.elements.s.value=d;Aa(c);b&&a.elements.choose&&(b.disabled=!1,b.getBoundingClientRect().bottom<window.innerHeight&&b.focus())});
P("#gsc_md_cbym",["gs-md-ldin","gs-md-lded"],function(){var a=lb(Fc).s||"",b=t("gsc_md_cbym_e");b&&a&&0>a.indexOf("&")&&b.setAttribute("data-href",(b.getAttribute("data-href")||"").replace(/(&citation_for_view=)[^&]*/,"$1"+a))});P("#gsc_md_cbym_e","click",function(a){a=a.currentTarget.getAttribute("data-href")||"";R("gs_md_cita-d",a)});Ub(Fd,Gd);D(function(){return setTimeout(Vd,0)});P(".gsc_a_x","change",Vd);
P("#gsc_x_all","gs-change",function(a){a=tc(a.currentTarget);for(var b=2==a?Wd:Td(),c=b.length;c--;)b[c].checked=0!=a;Ud()});P(".gsc_a_acm","click",function(a){L(a);var b=a.currentTarget;a=b.href;var c=b.getAttribute("data-eid")||"";b=b.getAttribute("data-eud")||"";a=t("gsc_md_cbyd_f").action+"&update_op=merge_options&s="+(b+","+c)+fb({c:a});R("gsc_md_cbyd",a)});
P(".gsc_a_am","click",function(a){a=a.currentTarget.getAttribute("data-eid")||"";a=(t("gsc_md_cbym_l").getAttribute("data-act")||"")+"&update_op=merge_options&s="+a;R("gsc_md_cbym",a)});P("#gs_sth","gs-sth-change",function(a){var b=t("gsc_a_tr0"),c=t("gsc_a_trh"),d=b.querySelector(".gsc_a_t"),e=c.querySelector(".gsc_a_t");p(a.currentTarget,"gs_sth_vis")?(e.style.width=d.offsetWidth+"px",b.style.height=c.offsetHeight+"px"):e.style.width=b.style.height="auto"});
P("#gs_md_cita-b-save","click",function(){var a=t("gsc_ecd_form");za(a,"continue").value=window.location.pathname+window.location.search;O("submit",a)});P(".gsc_ecd_form_tsel","click",function(a){var b=t("gsc_ecd_table"),c=za(t("gsc_ecd_form"),"articletype");a=a.currentTarget;c.value=a.getAttribute("data-type")||"";b.className=a.getAttribute("data-class")||"";b=document.querySelectorAll("#gsc_ecd_citation_type button");for(c=b.length;c--;)q(b[c],"gs_sel",b[c]==a)});
}({"customAC":2,"eventId":"GARSYcGGDPKTy9YP0q2C4Ac"});</script></head><body><div id="gs_top" onclick=""><style>#gs_md_s,.gs_md_wnw{z-index:1200;position:fixed;top:0;left:0;width:100%;height:100%;visibility:hidden;}#gs_md_s{background-color:#fff;opacity:.5;}.gs_el_ta #gs_md_s,.gs_el_ph #gs_md_s{background-color:#666;}.gs_md_wnw{transition:all 0s .218s;}#gs_md_s.gs_vis,.gs_md_wnw.gs_vis{visibility:visible;transition:all 0s;}.gs_md_wnw>.gs_md_d{position:relative;margin:0 auto;width:464px;box-shadow:2px 2px 8px rgba(0,0,0,.2);white-space:normal;}.gs_el_ta .gs_md_wnw>.gs_md_d,.gs_el_ph .gs_md_wnw>.gs_md_d{box-shadow:2px 2px 8px rgba(0,0,0,.65);}.gs_el_ph .gs_md_wnw>.gs_md_d{width:80%;max-width:440px;}.gs_el_ph .gs_md_wmw>.gs_md_d{width:100%;height:100%;max-width:none;border:none;box-shadow:none;transform:translate(0,100%);transform:translate(0,100vh);transition:transform .27s cubic-bezier(.4,0,.6,1),opacity 0s .27s,visibility 0s .27s,max-height 0s .27s;}.gs_el_ph .gs_md_wmw>.gs_md_d.gs_vis{transform:translate(0,0);transition:transform .3s cubic-bezier(0,0,.2,1);}.gs_md_wmw>.gs_md_d.gs_abt,.gs_el_ph .gs_md_wmw>.gs_md_d.gs_abt{transition:none;}.gs_md_hdr{display:flex;align-items:center;height:47px;border-bottom:1px solid #e0e0e0;border-bottom-color:rgba(0,0,0,.12);background-color:#f5f5f5;}.gs_md_hdr>a,.gs_md_hdr>a.gs_btn_lrge{flex:0 0 auto;width:41px;height:47px;}.gs_el_ph .gs_md_hdr>a{margin:0 2px 0 0;}.gs_el_ph a.gs_md_hdr_c{margin:0 0 0 2px;}.gs_md_hdr_b{margin:0 41px 0 16px;}.gs_el_ph .gs_md_hdr_b{margin:0 16px;}.gs_md_hdr_t:empty~.gs_md_hdr_b{margin-left:0;}.gs_md_hdr_b:empty{width:41px;margin:0;}.gs_el_ph .gs_md_hdr_b:empty{margin-right:2px;}.gs_md_hdr_b:empty:not(:last-child){display:none;}.gs_md_hdr_b>button{min-width:51px;height:33px;}.gs_md_hdr_t{flex:1 1 auto;font-size:18px;font-weight:normal;color:#666;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;text-align:center;}.gs_md_bdy{overflow-y:auto;box-sizing:border-box;padding:24px 41px 0 41px;}.gs_md_bdy:after{display:block;content:"";clear:both;padding-bottom:24px;}.gs_el_ph .gs_md_bdy{padding:16px 16px 0 16px;}.gs_el_ph .gs_md_bdy:after{padding-bottom:16px;}.gs_el_ph .gs_md_wmw .gs_md_bdy{position:absolute;width:100%;top:48px;bottom:0;}.gs_md_lbl{display:block;font-size:16px;margin:0 0 16px 0;word-wrap:break-word;}.gs_md_btns{margin:24px 0 0 0;white-space:nowrap;}.gs_el_ph .gs_md_btns{margin:16px 0 0 0;}.gs_md_btns button{margin-right:16px;}.gs_md_btns button:last-child{margin-right:0;}.gs_md_prg{margin:24px 0;text-align:center;}.gs_md_prg .gs_alrt{padding:4px 16px;}.gs_md_ldg:before{content:"";position:absolute;top:0;left:0;bottom:0;right:0;background-color:#fff;opacity:.5;z-index:100;}</style><div id="gs_md_ldg" style="display:none">Loading...</div><div id="gs_md_err" style="display:none">The system can't perform the operation now. Try again later.</div><div id="gs_md_s"></div><div data-h="0" class="gs_md_wnw"><div id="gsc_md_hist" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_hist-t" data-wfc="gsc_md_hist-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_hist-x" role="button" aria-label="Cancel" data-mdx="gsc_md_hist" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_hist-t" class="gs_md_hdr_t">Citations per year</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_hist-bdy" class="gs_md_bdy"><style>#gsc_md_hist{width:80%;max-width:386px;}#gsc_md_hist_c{position:relative;width:100%;}</style><div id="gsc_md_hist_c"></div></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbyd" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbyd-t" data-cid="gsc_md_cbyd_l" data-wfc="gsc_md_cbyd-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbyd-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbyd" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbyd-t" class="gs_md_hdr_t">Duplicate citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbyd-bdy" class="gs_md_bdy"><form id="gsc_md_cbyd_f" action="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works" method="post"><input type="hidden" name="s" value=""><div class="gs_md_lbl">The following articles are merged in Scholar. Their <a id="gsc_md_cbyd_c" href="javascript:void(0)">combined citations</a> are counted only for the first article.</div><div id="gsc_md_cbyd_l"></div></form></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbym" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbym-t" data-cid="gsc_md_cbym_l" data-wfc="gsc_md_cbym-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbym-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbym" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbym-t" class="gs_md_hdr_t">Merged citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbym-bdy" class="gs_md_bdy"><div class="gs_md_lbl">This "Cited by" count includes citations to the following articles in Scholar. The ones marked <span id="gsc_md_cbym_s">*</span> may be different from the article in the profile.</div><div id="gsc_md_cbym_l" data-act="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works"></div></div></div></div><div data-h="900" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cod" class="gs_md_d gs_ttzi gsc_cod_lc" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cod-t" data-cid="gsc_cods_res" data-wfc="gsc_md_cod-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cod-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cod" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cod-t" class="gs_md_hdr_t"><span id="gsc_cod_t"><span id="gsc_cod_tadd">Add co-authors</span><span id="gsc_cod_tedit">Co-authors</span><a id="gsc_cod_trev" href="javascript:void(0)" data-txt="Review" data-lim="Limit reached"></a></span></h2><div class="gs_md_hdr_b"><button type="button" id="gsc_cod_done" aria-label="Add co-authors" disabled="" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gsc_md_cod-bdy" class="gs_md_bdy"><div id="gsc_cods_urls" class="gsc_cods_hide" data-ls="" data-lc="/citations?view_op=list_colleagues&amp;hl=en&amp;json=&amp;user=UIrmjcIAAAAJ" data-sa=""></div><form id="gsc_cods_save" action="" method="POST"><input type="hidden" name="colleague_add"><input type="hidden" name="colleague_del"></form><div id="gsc_cods_res"></div></div></div></div><div data-h="800" class="gs_md_wnw gs_md_wmw"><div id="gs_md_cita-d" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gs_md_cita-d-t" data-cid="gs_md_cita-l" data-wfc="gs_md_cita-d-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gs_md_cita-d-x" role="button" aria-label="Cancel" data-mdx="gs_md_cita-d" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gs_md_cita-d-t" class="gs_md_hdr_t"></h2><div class="gs_md_hdr_b"><button type="button" id="gs_md_cita-b-save" aria-label="Save" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gs_md_cita-d-bdy" class="gs_md_bdy"><style>#gs_md_cita-d{width:90%;max-width:1000px;}.gs_el_ph #gs_md_cita-d{width:100%;max-width:none;}#gs_md_cita-d .gs_md_prg{min-height:600px;}</style><div id="gs_md_cita-l" aria-live="assertive"></div></div></div></div><div data-h="0" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_fol" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_fol-t" data-wfc="gsc_md_fol-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_fol-x" role="button" aria-label="Cancel" data-mdx="gsc_md_fol" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_fol-t" class="gs_md_hdr_t">Follow this author</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_fol-bdy" class="gs_md_bdy"><form method="post" id="gsc_fol_f" action="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYVNVmAHVPWyQvSHZ0Xxgzf_NyeYqIUUl"><input type="hidden" name="user" value="UIrmjcIAAAAJ"><div id="gsc_fol_inp"></div><div id="gsc_fol_cb"><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_a" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles by this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_c" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New citations to this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_r" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles related to this author's research</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div></div><div id="gsc_fol_email"><label id="gsc_fol_ml" for="gsc_fol_m">Email address for updates</label><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="email_for_op" value="" id="gsc_fol_m" maxlength="100" autocapitalize="off" autocorrect="off"></div></div><div class="gs_md_btns"><button type="submit" id="gsc_fol_b" disabled="" class=" gs_btn_act gs_btn_lrge gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">Done</span></span></button></div></form></div></div></div><!--[if lte IE 9]><div class="gs_alrt" style="padding:16px"><div>Sorry, some features may not work in this version of Internet Explorer.</div><div>Please use <a href="//www.google.com/chrome/">Google Chrome</a> or <a href="//www.mozilla.com/firefox/">Mozilla Firefox</a> for the best experience.</div></div><![endif]--><div id="gs_hdr_drs"></div><div id="gs_hdr_drw" class="gs_md_ulr" role="dialog" tabindex="-1" data-shd="gs_hdr_drs" data-wfc="gs_hdr_drw_mnu" data-cfc="gs_hdr_mnu"><div id="gs_hdr_drw_in"><div id="gs_hdr_drw_top"><a href="javascript:void(0)" id="gs_hdr_drw_mnu" role="button" aria-controls="gs_hdr_drw" aria-label="Options" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_drw_lgo" href="/schhp?hl=en" aria-label="Homepage"></a></div><div><div class="gs_hdr_drw_sec"><a href="/citations?hl=en" role="menuitem" class="gs_btnPRO gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My profile</span></a><a href="/scholar?scilib=1&amp;hl=en" role="menuitem" class="gs_btnL gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My library</span></a><a href="/citations?view_op=metrics_intro&amp;hl=en" role="menuitem" class="gs_btnJ gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Metrics</span></a><a href="/scholar_alerts?view_op=list_alerts&amp;hl=en" role="menuitem" class="gs_btnM gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Alerts</span></a></div><div class="gs_hdr_drw_sec"><a href="/scholar_settings?hl=en" role="menuitem" class="gs_btnP gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Settings</span></a></div></div><div id="gs_hdr_drw_bot" class="gs_hdr_drw_sec"><a href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den" class=" gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Sign in</span></a></div></div></div><div id="gs_hdr" role="banner" class="gs_hdr_src"><a href="javascript:void(0)" id="gs_hdr_mnu" role="button" aria-controls="gs_hdr_drw" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_lgo" class="" href="/schhp?hl=en" aria-label="Homepage"></a><div id="gs_hdr_md"><div id="gs_hdr_srch"><form id="gs_hdr_frm" action="/citations"><input type="hidden" name="view_op" value="search_authors"><input type="hidden" name="hl" value="en"><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="mauthors" value="" id="gs_hdr_tsi" placeholder="Search profiles" size="50" maxlength="2048" autocapitalize="off" aria-label="Search"></div><span id="gs_hdr_tsc"><span class="gs_ico gs_ico_X"></span></span><button type="submit" id="gs_hdr_tsb" name="btnG" aria-label="Search" class="gs_btnG gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></form></div></div><a href="javascript:void(0)" id="gs_hdr_sre" role="button" aria-controls="gs_hdr_frm" aria-label="Search" class="gs_btnTSB gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><div id="gs_hdr_act"><a id="gs_hdr_act_s" href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den">Sign in</a></div></div><style>#gs_alrt{position:fixed;bottom:48px;left:16px;max-width:384px;z-index:1250;display:flex;justify-content:space-between;align-items:center;font-size:13px;line-height:16px;color:#e2e2e2;background:#333;text-align:left;border-radius:3px;box-shadow:0 3px 5px -1px rgba(0,0,0,.2),0 6px 10px 0 rgba(0,0,0,.14),0 1px 18px 0 rgba(0,0,0,.12);visibility:hidden;transform-origin:center;transform:scale(0.8,0.8) translate(0,100%);}.gs_el_ph #gs_alrt{bottom:0;left:0;width:100%;max-width:none;border-radius:0;box-shadow:none;transform:scale(1,1) translate(0,100%);}#gs_alrt.gs_vis{visibility:visible;transform:scale(1,1) translate(0,0);}#gs_alrt.gs_anm{transition:transform .067s cubic-bezier(.4,0,1,1),visibility 0s .067s;}#gs_alrt.gs_vis.gs_anm{transition:transform .067s cubic-bezier(0,0,.2,1);}.gs_el_ph #gs_alrt.gs_anm{transition:transform .084s cubic-bezier(.4,0,1,1),visibility 0s .084s;}.gs_el_ph #gs_alrt.gs_vis.gs_anm{transition:transform .1s cubic-bezier(0,0,.2,1);}#gs_alrt_m{display:block;padding:16px;}#gs_alrt_l{display:block;padding:8px;margin:0 8px 0 -8px;border-radius:3px;color:#fcc934;text-transform:uppercase;text-decoration:none;}#gs_alrt_l:hover{background-color:rgba(255,255,255,.05)}#gs_alrt_l:active{background-color:rgba(255,255,255,.1)}#gs_alrt_l:empty{display:none}#gs_alrt_m a{padding:8px 0;color:#e2e2e2;text-decoration:underline;}#gs_alrt_m a:active{color:#f6aea9}</style><form action="" method="post" id="gs_alrt"><span id="gs_alrt_m"></span><span id="gs_alrt_h"></span><a id="gs_alrt_l" href="javascript:void(0)" class="gs_fm_s" data-fm="gs_alrt"></a></form><div id="gs_bdy"><div id="gs_bdy_sb" role="navigation"><div id="gs_bdy_sb_in"></div></div><div id="gs_bdy_ccl" role="main"><div id="gsc_bdy" class="gs_scl" data-tab="gsc_prf_t-art"><div class="gsc_rsb" role="navigation"><a id="gsc_rsb_gpl" class="gsc_rsb_s" href="/citations?hl=en">Get my own profile</a><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_cit" role="region" aria-labelledby="gsc_prf_t-cit"><h3 class="gsc_rsb_header"><span class="gsc_rsb_title">Cited by</span><button type="button" id="gsc_hist_opn" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu gsc_rsb_action"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></h3><table id="gsc_rsb_st"><thead><tr><th class="gsc_rsb_sth"></th><th class="gsc_rsb_sth">All</th><th class="gsc_rsb_sth">Since 2016</th></tr></thead><tbody><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="This is the number of citations to all publications. The second column has the &quot;recent&quot; version of this metric which is the number of new citations in the last 5 years to all publications.">Citations</a></td><td class="gsc_rsb_std">67016</td><td class="gsc_rsb_std">23855</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="h-index is the largest number h such that h publications have at least h citations. The second column has the &quot;recent&quot; version of this metric which is the largest number h such that h publications have at least h new citations in the last 5 years.">h-index</a></td><td class="gsc_rsb_std">117</td><td class="gsc_rsb_std">69</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="i10-index is the number of publications with at least 10 citations. The second column has the &quot;recent&quot; version of this metric which is the number of publications that have received at least 10 new citations in the last 5 years.">i10-index</a></td><td class="gsc_rsb_std">495</td><td class="gsc_rsb_std">291</td></tr></tbody></table><style>.gsc_g_t{position:absolute;bottom:0;color:#777;font-size:11px;}.gsc_g_a{position:absolute;bottom:13px;width:15px;background:#777;}.gsc_g_a:hover,.gsc_g_a:focus,.gsc_g_a:active{text-decoration:none;cursor:default;}.gsc_g_al{position:absolute;bottom:15px;left:7px;color:#222;background:white;font-size:11px;padding:1px;border:1px solid #777;border-radius:1px;visibility:hidden;opacity:0;transition:opacity .218s,visibility 0s .218s;}.gsc_g_a:hover .gsc_g_al,.gsc_g_a:focus .gsc_g_al,.gsc_g_a:active .gsc_g_al{visibility:visible;opacity:1;transition:all 0s;}#gsc_md_hist{max-width:902px;}.gsc_md_hist_w{position:relative;overflow:hidden;margin-right:43px;}.gs_md_bdy .gsc_md_hist_w,.gs_el_ph .gsc_md_hist_w,.gs_el_ta .gsc_md_hist_w{overflow-x:auto;padding-bottom:16px;}.gsc_md_hist_b{position:relative;height:174px;width:100%;}.gsc_md_hist_b .gsc_g_a{bottom:auto;}.gsc_md_hist_b .gsc_g_t{bottom:auto;top:161px;}.gsc_md_hist_b:after{position:absolute;right:856px;content:"\00A0";}.gsc_g_hist_x{position:relative;margin-right:45px;}.gsc_g_hist_xl{position:absolute;right:8px;width:35px;}.gs_el_ta .gsc_g_hist_xl,.gs_el_ph .gsc_g_hist_xl{right:16px;}.gsc_g_hist_wrp{padding-top:32px;position:relative;}.gs_el_ta .gsc_g_hist_wrp,.gs_el_ph .gsc_g_hist_wrp{padding-right:8px;}.gs_md_bdy .gsc_g_hist_wrp{border-top:0;}.gs_el_tc .gs_md_bdy .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ph .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ta .gsc_g_hist_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;left:0;width:20px;height:100%;background-image:linear-gradient(to left,rgba(255,255,255,0),rgba(255,255,255,1) 80%);}.gsc_g_x,.gsc_g_xt{position:absolute;left:0;border-bottom:1px solid #eee;width:100%;text-align:right;}.gsc_g_x{border-bottom:1px solid #eee;}.gsc_g_xtl{position:absolute;color:#777;}.gsc_g_gtr{position:absolute;}.gsc_g_a:last-child .gsc_g_al{right:0;left:auto;}</style><div class="gsc_g_hist_wrp" dir="rtl"><div class="gsc_g_hist_x"><div class="gsc_g_x" style="top:160px;"></div><div class="gsc_g_xt" style="top:0px;"></div><div class="gsc_g_xt" style="top:80px;"></div><div class="gsc_g_xt" style="top:120px;"></div><div class="gsc_g_xt" style="top:40px;"></div></div><div class="gsc_g_hist_xl"><div class="gsc_g_xtl" style="top:153px;">0</div><div class="gsc_g_xtl" style="top:-7px;">4300</div><div class="gsc_g_xtl" style="top:73px;">2150</div><div class="gsc_g_xtl" style="top:113px;">1075</div><div class="gsc_g_xtl" style="top:33px;">3225</div></div><div class="gsc_md_hist_w"><div class="gsc_md_hist_b"><span class="gsc_g_t" style="right:803px">1996</span><span class="gsc_g_t" style="right:771px">1997</span><span class="gsc_g_t" style="right:739px">1998</span><span class="gsc_g_t" style="right:707px">1999</span><span class="gsc_g_t" style="right:675px">2000</span><span class="gsc_g_t" style="right:643px">2001</span><span class="gsc_g_t" style="right:611px">2002</span><span class="gsc_g_t" style="right:579px">2003</span><span class="gsc_g_t" style="right:547px">2004</span><span class="gsc_g_t" style="right:515px">2005</span><span class="gsc_g_t" style="right:483px">2006</span><span class="gsc_g_t" style="right:451px">2007</span><span class="gsc_g_t" style="right:419px">2008</span><span class="gsc_g_t" style="right:387px">2009</span><span class="gsc_g_t" style="right:355px">2010</span><span class="gsc_g_t" style="right:323px">2011</span><span class="gsc_g_t" style="right:291px">2012</span><span class="gsc_g_t" style="right:259px">2013</span><span class="gsc_g_t" style="right:227px">2014</span><span class="gsc_g_t" style="right:195px">2015</span><span class="gsc_g_t" style="right:163px">2016</span><span class="gsc_g_t" style="right:131px">2017</span><span class="gsc_g_t" style="right:99px">2018</span><span class="gsc_g_t" style="right:67px">2019</span><span class="gsc_g_t" style="right:35px">2020</span><span class="gsc_g_t" style="right:3px">2021</span><a href="javascript:void(0)" class="gsc_g_a" style="right:808px;top:154px;height:6px;z-index:26"><span class="gsc_g_al">178</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:776px;top:153px;height:7px;z-index:25"><span class="gsc_g_al">200</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:744px;top:151px;height:9px;z-index:24"><span class="gsc_g_al">251</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:712px;top:146px;height:14px;z-index:23"><span class="gsc_g_al">378</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:680px;top:145px;height:15px;z-index:22"><span class="gsc_g_al">417</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:648px;top:140px;height:20px;z-index:21"><span class="gsc_g_al">542</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:616px;top:133px;height:27px;z-index:20"><span class="gsc_g_al">744</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:584px;top:123px;height:37px;z-index:19"><span class="gsc_g_al">1002</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:552px;top:115px;height:45px;z-index:18"><span class="gsc_g_al">1219</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:520px;top:94px;height:66px;z-index:17"><span class="gsc_g_al">1784</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:488px;top:78px;height:82px;z-index:16"><span class="gsc_g_al">2205</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:456px;top:70px;height:90px;z-index:15"><span class="gsc_g_al">2431</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:424px;top:57px;height:103px;z-index:14"><span class="gsc_g_al">2784</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:392px;top:41px;height:119px;z-index:13"><span class="gsc_g_al">3212</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:360px;top:25px;height:135px;z-index:12"><span class="gsc_g_al">3646</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:328px;top:20px;height:140px;z-index:11"><span class="gsc_g_al">3765</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:296px;top:6px;height:154px;z-index:10"><span class="gsc_g_al">4163</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:264px;top:11px;height:149px;z-index:9"><span class="gsc_g_al">4021</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:232px;top:13px;height:147px;z-index:8"><span class="gsc_g_al">3954</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:200px;top:8px;height:152px;z-index:7"><span class="gsc_g_al">4096</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:168px;top:2px;height:158px;z-index:6"><span class="gsc_g_al">4255</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:136px;top:16px;height:144px;z-index:5"><span class="gsc_g_al">3880</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:104px;top:1px;height:159px;z-index:4"><span class="gsc_g_al">4276</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:72px;top:13px;height:147px;z-index:3"><span class="gsc_g_al">3959</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:40px;top:11px;height:149px;z-index:2"><span class="gsc_g_al">4017</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:8px;top:35px;height:125px;z-index:1"><span class="gsc_g_al">3364</span></a></div></div></div></div><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_mnd" role="region" aria-labelledby="gsc_prf_t-mnd"><div class="gsc_rsb_header gsc_rsb_m_header"><div class="gsc_rsb_m_title">Public access</div><a href="/citations?view_op=list_mandates&amp;hl=en&amp;user=UIrmjcIAAAAJ" id="gsc_lwp_mndt_lnk">View all</a></div><div class="gsc_rsb_hm gs_ota gs_oph"><button type="button" onclick="window.location='/citations?view_op\x3dlist_mandates\x26hl\x3den\x26user\x3dUIrmjcIAAAAJ'" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></div><div class="gsc_rsb_m"><div class="gsc_rsb_m_a"><span>50 articles</span></div><div class="gsc_rsb_m_na"><div>8 articles</div></div><div class="gsc_rsb_m_bar"><div class="gsc_rsb_m_bar_na" style="width:14%"></div></div><div class="gsc_rsb_m_a"><span>available</span></div><div class="gsc_rsb_m_na"><span>not available</span></div><div class="gsc_rsb_m_desc">Based on funding mandates</div></div></div></div><div class="gsc_lcl" role="main" id="gsc_prf_w"><div id="gsc_prf"><button type="button" id="gsc_prf_btnf" class="gs_btnMW gs_in_ib gs_btn_act gs_btn_lsu gs_btn_mph"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Follow</span></span></button><div id="gsc_prf_pu"><div id="gsc_prf_pua" class="gs_rimg"><style>#gsc_prf_pup-img{width:96px;height:128px;}@media print{#gs_top #gsc_prf_pup-img{width:60pt;height:80pt;}}</style><img alt="Robert Coleman" sizes="print 60px,96px" src="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=UIrmjcIAAAAJ&amp;citpid=2" id="gsc_prf_pup-img" srcset="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=UIrmjcIAAAAJ&amp;citpid=2 96w,https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=UIrmjcIAAAAJ&amp;citpid=2 192w"></div></div><div id="gsc_prf_i"><div id="gsc_prf_in">Robert Coleman</div><div class="gsc_prf_il"><a href="/citations?view_op=view_org&amp;hl=en&amp;org=9829198446306616343" class="gsc_prf_ila">University of Sheffield</a></div><div class="gsc_prf_il" id="gsc_prf_ivh">Verified email at sheffield.ac.uk</div><div class="gsc_prf_il" id="gsc_prf_int"><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:oncology" class="gsc_prf_inta gs_ibl">Oncology</a><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:breast_cancer" class="gsc_prf_inta gs_ibl">breast cancer</a><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:bone_disease" class="gsc_prf_inta gs_ibl">bone disease</a><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:trials" class="gsc_prf_inta gs_ibl">trials</a></div></div></div></div><div id="gsc_prf_t_wrp" role="navigation"><div id="gsc_prf_t" role="tablist"><a id="gsc_prf_t-art" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_art" aria-selected="true">Articles</a><a id="gsc_prf_t-cit" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_cit">Cited by</a><a id="gsc_prf_t-mnd" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_mnd">Public access</a></div></div><div class="gsc_lcl gsc_prf_pnl" id="gsc_art" role="region" aria-labelledby="gsc_prf_t-art"><form method="post" action="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYVNVmAHVPWyQvSHZ0Xxgzf_NyeYqIUUl"><div id="gsc_a_tw"><table id="gsc_a_t"><thead><tr id="gsc_a_tr0" aria-hidden="true"><th class="gsc_a_t"></th><th class="gsc_a_c"></th><th class="gsc_a_y"></th></tr><tr id="gsc_a_trh"><th class="gsc_a_t" scope="col"><span id="gsc_a_ta"><a href="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works&amp;sortby=title" class="gsc_a_a">Title</a></span><div id="gsc_dd_sort-r" class="gs_md_r gs_md_rmb gs_md_rmbl"><button type="button" id="gsc_dd_sort-b" aria-controls="gsc_dd_sort-d" aria-haspopup="true" ontouchstart="gs_evt_dsp(event)" class=" gs_in_se gs_btn_mnu gs_btn_flat gs_btn_lrge gs_btn_half gs_btn_lsu gs_press gs_md_tb"><span class="gs_wr"><span class="gs_lbl">Sort</span><span class="gs_icm"></span></span></button><div id="gsc_dd_sort-d" class="gs_md_d gs_md_ulr" role="menu" tabindex="-1"><div id="gsc_dd_sort-s" class="gs_oph gsc_dd_sec gsc_dd_sep"><a role="menuitem" href="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works" tabindex="-1" class="gs_md_li gsc_dd_sort-sel">Sort by citations</a><a role="menuitem" href="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" tabindex="-1" class="gs_md_li">Sort by year</a><a role="menuitem" href="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works&amp;sortby=title" tabindex="-1" class="gs_md_li">Sort by title</a></div></div></div></th><th class="gsc_a_c" scope="col" dir="rtl"><span id="gsc_a_ca"><div class="gs_nph">Cited by</div><div class="gs_oph">Cited by</div></span></th><th class="gsc_a_y" scope="col"><span class="gsc_a_h" id="gsc_a_ha"><a href="/citations?hl=en&amp;user=UIrmjcIAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" class="gsc_a_a">Year</a></span></th></tr></thead><tbody id="gsc_a_b"><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:4TOpqqG69KYC" class="gsc_a_at">Alpha emitter radium-223 and survival in metastatic prostate cancer</a><div class="gs_gray">C Parker, S Nilsson, D Heinrich, SI Helle, JM O'sullivan, SD Fosså, ...</div><div class="gs_gray">New England Journal of Medicine 369 (3), 213-223<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15722760994772151186" class="gsc_a_ac gs_ibl">2746</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:u5HHmVD_uO8C" class="gsc_a_at">A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer</a><div class="gs_gray">RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, ...</div><div class="gs_gray">New England Journal of Medicine 350 (11), 1081-1092<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14299782978644688481,11549437494818062573" class="gsc_a_ac gs_ibl">2203</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:Y0pCki6q_DkC" class="gsc_a_at">Clinical features of metastatic bone disease and risk of skeletal morbidity</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Clinical cancer research 12 (20), 6243s-6249s<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3028134836843677306" class="gsc_a_ac gs_ibl">2147</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:9yKSN-GCB0IC" class="gsc_a_at">Metastatic bone disease: clinical features, pathophysiology and treatment strategies</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer treatment reviews 27 (3), 165-176<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7936647089556888650" class="gsc_a_ac gs_ibl">1973</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:d1gkVwhDpl0C" class="gsc_a_at">Skeletal complications of malignancy</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18406402156491741613" class="gsc_a_ac gs_ibl">1855</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:u-x6o8ySG0sC" class="gsc_a_at">2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial</a><div class="gs_gray">I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ...</div><div class="gs_gray">The lancet 369 (9555), 29-36<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=282538715095826308" class="gsc_a_ac gs_ibl">1786</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:UeHWp8X0CEIC" class="gsc_a_at">The clinical course of bone metastases from breast cancer</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">British journal of cancer 55 (1), 61-66<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6174782600276160940" class="gsc_a_ac gs_ibl">1272</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:qjMakFHDy7sC" class="gsc_a_at">Adjuvant docetaxel for node-positive breast cancer</a><div class="gs_gray">M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ...</div><div class="gs_gray">New England Journal of Medicine 352 (22), 2302-2313<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5764214403767037977" class="gsc_a_ac gs_ibl">1242</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:rDsFeusoTZkC" class="gsc_a_at">Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women&nbsp;…</a><div class="gs_gray">P McGale, C Correa, D Cutter, F Duane, M Ewertz, R Gray, G Mannu, ...</div><div class="gs_gray">The Lancet 383 (9935), 2127-35<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11643664208232530249" class="gsc_a_ac gs_ibl">1208</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:2osOgNQ5qMEC" class="gsc_a_at">Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind&nbsp;…</a><div class="gs_gray">LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ...</div><div class="gs_gray">Cancer journal (Sudbury, Mass.) 7 (5), 377-387<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14567232492020125504" class="gsc_a_ac gs_ibl">1118</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:zYLM7Y9cAGgC" class="gsc_a_at">Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or&nbsp;…</a><div class="gs_gray">LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7373355226990478762" class="gsc_a_ac gs_ibl">1015</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:IjCSPb-OGe4C" class="gsc_a_at">Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial</a><div class="gs_gray">RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ...</div><div class="gs_gray">The Lancet 369 (9561), 559-570<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5881138988115398742" class="gsc_a_ac gs_ibl">1011</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:qzPvQt7yPGwC" class="gsc_a_at">Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial</a><div class="gs_gray">MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ...</div><div class="gs_gray">The Lancet 379 (9810), 39-46<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10052891917141734572" class="gsc_a_ac gs_ibl">846</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:Tyk-4Ss8FVUC" class="gsc_a_at">Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.</a><div class="gs_gray">W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, ...</div><div class="gs_gray">Journal of Clinical Oncology 15 (6), 2183-2193<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8187434381318355020" class="gsc_a_ac gs_ibl">800</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:1YatL4jblGcC" class="gsc_a_at">Roman statutes</a><div class="gs_gray">MH Crawford</div><div class="gs_gray">Institute of Classical Studies, School of Advanced Study, University of London<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7038207606441680789" class="gsc_a_ac gs_ibl">761</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:-c_eYhz9dBkC" class="gsc_a_at">Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma</a><div class="gs_gray">PA Vasey, GC Jayson, A Gordon, H Gabra, R Coleman, R Atkinson, ...</div><div class="gs_gray">Journal of the National Cancer Institute 96 (22), 1682-1691<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5754891229296920189" class="gsc_a_ac gs_ibl">703</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:1wZ_wKGpLuwC" class="gsc_a_at">Adjuvant ovarian suppression in premenopausal breast cancer</a><div class="gs_gray">PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...</div><div class="gs_gray">New England Journal of Medicine 372 (5), 436-446<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16443895082843501123" class="gsc_a_ac gs_ibl">669</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:mo9XK3BEATIC" class="gsc_a_at">Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases: A double‐blind, randomized dose–response study</a><div class="gs_gray">JR Berenson, LS Rosen, A Howell, L Porter, RE Coleman, W Morley, ...</div><div class="gs_gray">Cancer 91 (7), 1191-1200<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7169558570992014604,1566532832427657630" class="gsc_a_ac gs_ibl">639</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:8k81kl-MbHgC" class="gsc_a_at">Pathologic fractures correlate with reduced survival in patients with malignant bone disease</a><div class="gs_gray">F Saad, A Lipton, R Cook, YM Chen, M Smith, R Coleman</div><div class="gs_gray">Cancer 110 (8), 1860-1867<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16583300458735077134" class="gsc_a_ac gs_ibl">610</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;citation_for_view=UIrmjcIAAAAJ:YsMSGLbcyi4C" class="gsc_a_at">Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</a><div class="gs_gray">JE Brown, RJ Cook, P Major, A Lipton, F Saad, M Smith, KA Lee, M Zheng, ...</div><div class="gs_gray">Journal of the National Cancer Institute 97 (1), 59-69<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11290212181157201314" class="gsc_a_ac gs_ibl">609</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:eQOLeE2rZwMC" class="gsc_a_at">Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid</a><div class="gs_gray">RE Coleman, P Major, A Lipton, JE Brown, KA Lee, M Smith, F Saad, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (22), 4925-4935<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14033551851483354474" class="gsc_a_ac gs_ibl">596</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:WF5omc3nYNoC" class="gsc_a_at">A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.</a><div class="gs_gray">JJ Body, T Facon, RE Coleman, A Lipton, F Geurs, M Fan, D Holloway, ...</div><div class="gs_gray">Clinical cancer research 12 (4), 1221-1228<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6746414288693723499" class="gsc_a_ac gs_ibl">571</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:ufrVoPGSRksC" class="gsc_a_at">Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel</a><div class="gs_gray">M Aapro, PA Abrahamsson, JJ Body, RE Coleman, R Colomer, L Costa, ...</div><div class="gs_gray">Annals of oncology 19 (3), 420-432<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11012472726735853134" class="gsc_a_ac gs_ibl">556</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:hqOjcs7Dif8C" class="gsc_a_at">Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial</a><div class="gs_gray">RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ...</div><div class="gs_gray">The Lancet 366 (9482), 293-300<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16856068416444439664,14968049913793450199,1983099682076515916" class="gsc_a_ac gs_ibl">527</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:hqOjcs7Dif8C">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:_FxGoFyzp5QC" class="gsc_a_at">Bisphosphonates: clinical experience</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The oncologist 9, 14-27<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=569146328284983273" class="gsc_a_ac gs_ibl">523</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:BmWJbWwHJAwC" class="gsc_a_at">Bone health in cancer patients: ESMO Clinical Practice Guidelines</a><div class="gs_gray">R Coleman, JJ Body, M Aapro, P Hadji, J Herrstedt, ...</div><div class="gs_gray">Annals of oncology 25, iii124-iii137<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18276317566551753146" class="gsc_a_ac gs_ibl">487</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:3fE2CSJIrl8C" class="gsc_a_at">Breast-cancer adjuvant therapy with zoledronic acid</a><div class="gs_gray">RE Coleman, H Marshall, D Cameron, D Dodwell, R Burkinshaw, ...</div><div class="gs_gray">N Engl J Med 365, 1396-1405<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5350003082089222157" class="gsc_a_ac gs_ibl">482</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:09LM3QYkMKUC" class="gsc_a_at">Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials</a><div class="gs_gray">Early Breast Cancer Trialists' Collaborative Group</div><div class="gs_gray">The Lancet 386 (10001), 1353-1361<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8961398456782724141,6532735469622799514" class="gsc_a_ac gs_ibl">451</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:0EnyYjriUFMC" class="gsc_a_at">Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup&nbsp;…</a><div class="gs_gray">RE Coleman, LM Banks, SI Girgis, LS Kilburn, E Vrdoljak, J Fox, ...</div><div class="gs_gray">The lancet oncology 8 (2), 119-127<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10455255235847449714" class="gsc_a_ac gs_ibl">447</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:LkGwnXOMwfcC" class="gsc_a_at">A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases</a><div class="gs_gray">JJ Body, P Greipp, RE Coleman, T Facon, F Geurs, JP Fermand, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15225022867553633235" class="gsc_a_ac gs_ibl">442</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:KWzIFqRkAKkC" class="gsc_a_at">Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind&nbsp;…</a><div class="gs_gray">O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ...</div><div class="gs_gray">The Lancet Oncology 15 (7), 738-746<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15804587638008149331" class="gsc_a_ac gs_ibl">441</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:UebtZRa9Y70C" class="gsc_a_at">Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion</a><div class="gs_gray">LS Rosen, DH Gordon, W Dugan Jr, P Major, PD Eisenberg, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12002257690512284372" class="gsc_a_ac gs_ibl">439</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:Se3iqnhoufwC" class="gsc_a_at">Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized&nbsp;…</a><div class="gs_gray">R Paridaens, L Biganzoli, P Bruning, JGM Klijn, T Gamucci, S Houston, ...</div><div class="gs_gray">Journal of clinical oncology 18 (4), 724-724<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4853438603240855230" class="gsc_a_ac gs_ibl">435</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:roLk4NBRz8UC" class="gsc_a_at">The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel</a><div class="gs_gray">SP Jagdev, RE Coleman, CM Shipman, A Rostami-H, PI Croucher</div><div class="gs_gray">British journal of cancer 84 (8), 1126-1134<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13751734641978048316" class="gsc_a_ac gs_ibl">431</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:5nxA0vEk-isC" class="gsc_a_at">Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases</a><div class="gs_gray">A Lipton, GG Steger, J Figueroa, C Alvarado, P Solal-Celigny, JJ Body, ...</div><div class="gs_gray">Journal of Clinical Oncology 25 (28), 4431-4437<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4203611774289236206" class="gsc_a_ac gs_ibl">414</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:Zph67rFs4hoC" class="gsc_a_at">Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230</a><div class="gs_gray">R Eastell, JE Adams, RE Coleman, A Howell, RA Hannon, J Cuzick, ...</div><div class="gs_gray">Journal of Clinical Oncology 26 (7), 1051-1057<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1894458425992492841" class="gsc_a_ac gs_ibl">407</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:KYgttONoxcsC" class="gsc_a_at">Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial</a><div class="gs_gray">M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...</div><div class="gs_gray">The lancet oncology 18 (12), 1688-1700<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5317198856395288567" class="gsc_a_ac gs_ibl">402</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:1pC5hbHeJ6IC" class="gsc_a_at">Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials</a><div class="gs_gray">B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...</div><div class="gs_gray">The Lancet Oncology 19 (1), 27-39<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18291794641849774086" class="gsc_a_ac gs_ibl">388</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:MXK_kJrjxJIC" class="gsc_a_at">Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer</a><div class="gs_gray">O Sartor, RH Reid, PJ Hoskin, DP Quick, PJ Ell, RE Coleman, JA Kotler, ...</div><div class="gs_gray">Urology 63 (5), 940-945<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11140245782926199768" class="gsc_a_ac gs_ibl">366</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:qxL8FJ1GzNcC" class="gsc_a_at">Randomized trial of exercise therapy in women treated for breast cancer</a><div class="gs_gray">AJ Daley, H Crank, JM Saxton, N Mutrie, R Coleman, A Roalfe</div><div class="gs_gray">Journal of Clinical Oncology 25 (13), 1713-1721<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16900377346533899173" class="gsc_a_ac gs_ibl">355</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:kNdYIx-mwKoC" class="gsc_a_at">Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study</a><div class="gs_gray">H Eidtmann, R De Boer, N Bundred, A Llombart-Cussac, N Davidson, ...</div><div class="gs_gray">Annals of Oncology 21 (11), 2188-2194<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16021389317357838010" class="gsc_a_ac gs_ibl">337</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:LPZeul_q3PIC" class="gsc_a_at">Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results</a><div class="gs_gray">R Coleman, R De Boer, H Eidtmann, A Llombart, N Davidson, P Neven, ...</div><div class="gs_gray">Annals of oncology 24 (2), 398-405<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15274471754211431100" class="gsc_a_ac gs_ibl">307</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:QlnOKEPDpKwC" class="gsc_a_at">Tailoring adjuvant endocrine therapy for premenopausal breast cancer</a><div class="gs_gray">PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ...</div><div class="gs_gray">New England Journal of Medicine 379 (2), 122-137<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6241841389939823638" class="gsc_a_ac gs_ibl">302</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:M05iB0D1s5AC" class="gsc_a_at">Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study&nbsp;…</a><div class="gs_gray">RTD Oliver, GM Mead, GJS Rustin, JK Joffe, N Aass, R Coleman, R Gabe, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (8), 957-962<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15050554749189846002" class="gsc_a_ac gs_ibl">292</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:ZeXyd9-uunAC" class="gsc_a_at">Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group</a><div class="gs_gray">DM Reid, J Doughty, R Eastell, SD Heys, A Howell, EV McCloskey, ...</div><div class="gs_gray">Cancer treatment reviews 34, S3-S18<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17388692697740438246" class="gsc_a_ac gs_ibl">285</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:YOwf2qJgpHMC" class="gsc_a_at">Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid</a><div class="gs_gray">A Lipton, R Cook, F Saad, P Major, P Garnero, E Terpos, JE Brown, ...</div><div class="gs_gray">Cancer 113 (1), 193-201<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4706170707918502537" class="gsc_a_ac gs_ibl">283</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:9ZlFYXVOiuMC" class="gsc_a_at">Clinical course and prognostic factors following bone recurrence from breast cancer</a><div class="gs_gray">RE Coleman, P Smith, RD Rubens</div><div class="gs_gray">British journal of cancer 77 (2), 336-340<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1568806554896317379" class="gsc_a_ac gs_ibl">282</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:M3ejUd6NZC8C" class="gsc_a_at">Practical guidance for the management of aromatase inhibitor-associated bone loss</a><div class="gs_gray">P Hadji, JJ Body, MS Aapro, A Brufsky, RE Coleman, T Guise, A Lipton, ...</div><div class="gs_gray">Annals of Oncology 19 (8), 1407-1416<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18104229575140122406" class="gsc_a_ac gs_ibl">277</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:_kc_bZDykSQC" class="gsc_a_at">Exploring the anti-tumour activity of bisphosphonates in early breast cancer</a><div class="gs_gray">MC Winter, I Holen, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 34 (5), 453-475<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=195425793210744451" class="gsc_a_ac gs_ibl">277</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:KlAtU1dfN6UC" class="gsc_a_at">Markers of bone turnover for the management of patients with bone metastases from prostate cancer</a><div class="gs_gray">P Garnero, N Buchs, J Zekri, R Rizzoli, RE Coleman, PD Delmas</div><div class="gs_gray">British journal of cancer 82 (4), 858-864<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1632226884903706068" class="gsc_a_ac gs_ibl">263</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:RoXSNcbkSzsC" class="gsc_a_at">Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)</a><div class="gs_gray">EJ Rathbone, JE Brown, HC Marshall, M Collinson, V Liversedge, ...</div><div class="gs_gray">J Clin Oncol 31 (21), 2685-2691<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17671830888013062132" class="gsc_a_ac gs_ibl">262</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:ULOm3_A8WrAC" class="gsc_a_at">Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment&nbsp;…</a><div class="gs_gray">L Biganzoli, T Cufer, P Bruning, R Coleman, L Duchateau, AH Calvert, ...</div><div class="gs_gray">Journal of clinical oncology 20 (14), 3114-3121<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11214954078581294671" class="gsc_a_ac gs_ibl">258</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:M0j1y4EgrScC" class="gsc_a_at">Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial</a><div class="gs_gray">R Coleman, D Cameron, D Dodwell, R Bell, C Wilson, E Rathbone, ...</div><div class="gs_gray">The lancet oncology 15 (9), 997-1006<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14240174308619517127,16026099773993890641" class="gsc_a_ac gs_ibl">254</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:aqlVkmm33-oC" class="gsc_a_at">Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO‐FAST study&nbsp;…</a><div class="gs_gray">NJ Bundred, ID Campbell, N Davidson, RH DeBoer, H Eidtmann, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17421256521241860382" class="gsc_a_ac gs_ibl">254</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:qUcmZB5y_30C" class="gsc_a_at">Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer</a><div class="gs_gray">PD Ottewell, H Mönkkönen, M Jones, DV Lefley, RE Coleman, I Holen</div><div class="gs_gray">Journal of the National Cancer Institute 100 (16), 1167-1178<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6259955740659229791" class="gsc_a_ac gs_ibl">251</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:QIV2ME_5wuYC" class="gsc_a_at">Risks and benefits of bisphosphonates</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">British journal of cancer 98 (11), 1736-1740<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16768631759648816499" class="gsc_a_ac gs_ibl">249</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:7PzlFSSx8tAC" class="gsc_a_at">The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer</a><div class="gs_gray">RE Coleman, MC Winter, D Cameron, R Bell, D Dodwell, MM Keane, ...</div><div class="gs_gray">British journal of cancer 102 (7), 1099-1105<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16521263018447020500" class="gsc_a_ac gs_ibl">221</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:P2d6BWbXU0IC" class="gsc_a_at">Introduction: Tracking the global/local</a><div class="gs_gray">R Wilsonand, W Dissanayake</div><div class="gs_gray">Global/Local, 1-18<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11177097444189649851,5264119275265320537,15758926931380625497" class="gsc_a_ac gs_ibl">220</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:L8Ckcad2t8MC" class="gsc_a_at">Bone scan flare predicts successful systemic therapy for bone metastases</a><div class="gs_gray">RE Coleman, G Mashiter, KB Whitaker, DW Moss, RD Rubens, ...</div><div class="gs_gray">J Nucl Med 29 (8), 1354-1359<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5239076440919303655" class="gsc_a_ac gs_ibl">220</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:hC7cP41nSMkC" class="gsc_a_at">Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic&nbsp;…</a><div class="gs_gray">TRJ Evans, A Yellowlees, E Foster, H Earl, DA Cameron, AW Hutcheon, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (13), 2988-95<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12349108673054643875" class="gsc_a_ac gs_ibl">218</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:-f6ydRqryjwC" class="gsc_a_at">The skeletal metastatic complications of renal cell carcinoma</a><div class="gs_gray">J Zekri, N Ahmed, RE Coleman, BW Hancock</div><div class="gs_gray">International journal of oncology 19 (2), 379-382<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17378879043387640874" class="gsc_a_ac gs_ibl">216</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:Z5m8FVwuT1cC" class="gsc_a_at">Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial</a><div class="gs_gray">JR Mackey, M Martin, T Pienkowski, J Rolski, JP Guastalla, A Sami, ...</div><div class="gs_gray">The Lancet Oncology 14 (1), 72-80<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16976738366778334103" class="gsc_a_ac gs_ibl">214</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:e5wmG9Sq2KIC" class="gsc_a_at">Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer</a><div class="gs_gray">JE Lester, D Dodwell, OP Purohit, SA Gutcher, SP Ellis, R Thorpe, ...</div><div class="gs_gray">Clinical Cancer Research 14 (19), 6336-6342<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2982225333294531215" class="gsc_a_ac gs_ibl">204</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:R3hNpaxXUhUC" class="gsc_a_at">Management of bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The oncologist 5 (6), 463-470<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9592931705588555389" class="gsc_a_ac gs_ibl">204</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:3s1wT3WcHBgC" class="gsc_a_at">Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment</a><div class="gs_gray">P Hadji, MS Aapro, JJ Body, NJ Bundred, A Brufsky, RE Coleman, ...</div><div class="gs_gray">Annals of oncology 22 (12), 2546-2555<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15904904062795256079" class="gsc_a_ac gs_ibl">198</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:hMod-77fHWUC" class="gsc_a_at">Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial</a><div class="gs_gray">P Ellis, P Barrett-Lee, L Johnson, D Cameron, A Wardley, S O'Reilly, ...</div><div class="gs_gray">The Lancet 373 (9676), 1681-1692<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8983547638518078434" class="gsc_a_ac gs_ibl">197</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:KqnX2w3egDsC" class="gsc_a_at">Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of&nbsp;…</a><div class="gs_gray">J Verweij, SM Lee, W Ruka, J Buesa, R Coleman, R van Hoessel, ...</div><div class="gs_gray">Journal of Clinical Oncology 18 (10), 2081-2086<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3021540298843948507" class="gsc_a_ac gs_ibl">195</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:mVmsd5A6BfQC" class="gsc_a_at">Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease</a><div class="gs_gray">JJF Vinholes, OP Purohit, ME Abbey, R Eastell, RE Coleman</div><div class="gs_gray">Annals of oncology 8 (12), 1243-1250<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1364266411720821228" class="gsc_a_ac gs_ibl">195</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:hFOr9nPyWt4C" class="gsc_a_at">Integrated analysis of zoledronic acid for prevention of aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole</a><div class="gs_gray">A Brufsky, N Bundred, R Coleman, R Lambert‐Falls, R Mena, P Hadji, ...</div><div class="gs_gray">The Oncologist 13 (5), 503-514<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18419830644225443573" class="gsc_a_ac gs_ibl">189</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:f2IySw72cVMC" class="gsc_a_at">Bisphosphonates in oncology</a><div class="gs_gray">RE Coleman, EV McCloskey</div><div class="gs_gray">Bone 49 (1), 71-76<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10592491579790401728" class="gsc_a_ac gs_ibl">188</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:dhFuZR0502QC" class="gsc_a_at">A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy</a><div class="gs_gray">OP Purohit, CR Radstone, C Anthony, JA Kanis, RE Coleman</div><div class="gs_gray">British journal of cancer 72 (5), 1289-1293<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11205231998845566326" class="gsc_a_ac gs_ibl">187</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:4DMP91E08xMC" class="gsc_a_at">High-dose intravenous pamidronate for metastatic bone pain</a><div class="gs_gray">OP Purohit, C Anthony, CR Radstone, J Owen, RE Coleman</div><div class="gs_gray">British journal of cancer 70 (3), 554-558<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4227153160054425735" class="gsc_a_ac gs_ibl">187</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:IWHjjKOFINEC" class="gsc_a_at">Sequence‐and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells</a><div class="gs_gray">HL Neville‐Webbe, A Rostami‐Hodjegan, CA Evans, RE Coleman, ...</div><div class="gs_gray">International journal of cancer 113 (3), 364-371<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9761376852713868828" class="gsc_a_ac gs_ibl">186</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:mB3voiENLucC" class="gsc_a_at">Bone resorption predicts for skeletal complications in metastatic bone disease</a><div class="gs_gray">JE Brown, CS Thomson, SP Ellis, SA Gutcher, OP Purohit, RE Coleman</div><div class="gs_gray">British journal of cancer 89 (11), 2031-2037<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6691863988590843163" class="gsc_a_ac gs_ibl">185</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:XiVPGOgt02cC" class="gsc_a_at">Effects of bone-targeted agents on cancer progression and mortality</a><div class="gs_gray">R Coleman, M Gnant, G Morgan, P Clezardin</div><div class="gs_gray">Journal of the National Cancer Institute 104 (14), 1059-1067<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3784554337525378076" class="gsc_a_ac gs_ibl">179</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:bEWYMUwI8FkC" class="gsc_a_at">Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy</a><div class="gs_gray">A Lipton, GG Steger, J Figueroa, C Alvarado, P Solal-Celigny, JJ Body, ...</div><div class="gs_gray">Clinical Cancer Research 14 (20), 6690-6696<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13217752971347500278" class="gsc_a_ac gs_ibl">176</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:t6usbXjVLHcC" class="gsc_a_at">Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies</a><div class="gs_gray">E Amir, M Clemons, CA Purdie, N Miller, P Quinlan, W Geddie, ...</div><div class="gs_gray">Cancer treatment reviews 38 (6), 708-714<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14774848340540111568" class="gsc_a_ac gs_ibl">173</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:maZDTaKrznsC" class="gsc_a_at">Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?</a><div class="gs_gray">M Clemons, RE Coleman, S Verma</div><div class="gs_gray">Cancer treatment reviews 30 (4), 325-332<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6907456940128125487" class="gsc_a_ac gs_ibl">173</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:r0BpntZqJG4C" class="gsc_a_at">The role of bisphosphonates in breast and prostate cancers.</a><div class="gs_gray">JE Brown, H Neville-Webbe, RE Coleman</div><div class="gs_gray">Endocrine-related cancer 11 (2), 207-224<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7646285432164378718" class="gsc_a_ac gs_ibl">169</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:4JMBOYKVnBMC" class="gsc_a_at">Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment&nbsp;…</a><div class="gs_gray">MJ Piccart, J Klijn, R Paridaens, M Nooij, L Mauriac, R Coleman, ...</div><div class="gs_gray">Journal of Clinical Oncology 15 (9), 3149-3155<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7886461383409434399" class="gsc_a_ac gs_ibl">166</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:blknAaTinKkC" class="gsc_a_at">Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer</a><div class="gs_gray">F Efficace, L Biganzoli, M Piccart, C Coens, K Van Steen, T Cufer, ...</div><div class="gs_gray">European Journal of Cancer 40 (7), 1021-1030<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11484143959536680957" class="gsc_a_ac gs_ibl">165</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:TFP_iSt0sucC" class="gsc_a_at">Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer</a><div class="gs_gray">RJ Cook, R Coleman, J Brown, A Lipton, P Major, YJ Hei, F Saad, ...</div><div class="gs_gray">Clinical Cancer Research 12 (11), 3361-3367<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17817951077746885466" class="gsc_a_ac gs_ibl">163</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:M3NEmzRMIkIC" class="gsc_a_at">Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity</a><div class="gs_gray">V Hirsh, PP Major, A Lipton, RJ Cook, CJ Langer, MR Smith, JE Brown, ...</div><div class="gs_gray">Journal of Thoracic Oncology 3 (3), 228-236<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11501219486713794621" class="gsc_a_ac gs_ibl">159</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:HDshCWvjkbEC" class="gsc_a_at">Bisphosphonates in breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Annals of oncology 16 (5), 687-695<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4395277230961766218" class="gsc_a_ac gs_ibl">153</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:dhpJJ7xvgBgC" class="gsc_a_at">Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA. 31</a><div class="gs_gray">KA Gelmon, FM Boyle, B Kaufman, DG Huntsman, A Manikhas, A Di Leo, ...</div><div class="gs_gray">J Clin Oncol 33 (14), 1574-1583<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10183672377942053688" class="gsc_a_ac gs_ibl">152</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:NhqRSupF_l8C" class="gsc_a_at">Placental site trophoblastic tumour: clinical features and management</a><div class="gs_gray">A Hassadia, A Gillespie, J Tidy, M Wells, R Coleman, B Hancock</div><div class="gs_gray">Gynecologic oncology 99 (3), 603-607<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17121279936948313106" class="gsc_a_ac gs_ibl">147</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:uoeYKOKFegwC" class="gsc_a_at">Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG&nbsp;…</a><div class="gs_gray">P Hadji, MS Aapro, JJ Body, M Gnant, ML Brandi, JY Reginster, ...</div><div class="gs_gray">Journal of bone oncology 7, 1-12<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8887201481247806848" class="gsc_a_ac gs_ibl">146</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:EUQCXRtRnyEC" class="gsc_a_at">Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions</a><div class="gs_gray">R Coleman, J Brown, E Terpos, A Lipton, MR Smith, R Cook, P Major</div><div class="gs_gray">Cancer treatment reviews 34 (7), 629-639<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2576774861010763058" class="gsc_a_ac gs_ibl">144</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:SdhP9T11ey4C" class="gsc_a_at">Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study</a><div class="gs_gray">JM Bliss, LS Kilburn, RE Coleman, JF Forbes, AS Coates, SE Jones, ...</div><div class="gs_gray">J Clin Oncol 30 (7), 709-717<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14043594376369767000" class="gsc_a_ac gs_ibl">143</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:ns9cj8rnVeAC" class="gsc_a_at">Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis</a><div class="gs_gray">HL Neville-Webbe, NA Cross, CL Eaton, R Nyambo, CA Evans, ...</div><div class="gs_gray">Breast cancer research and treatment 86 (3), 271-282<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11983944298312516243" class="gsc_a_ac gs_ibl">142</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:RHpTSmoSYBkC" class="gsc_a_at">Clinical evidence for topotecan-paclitaxel non–cross-resistance in ovarian cancer</a><div class="gs_gray">M Gore, W ten Bokkel Huinink, J Carmichael, A Gordon, N Davidson, ...</div><div class="gs_gray">Journal of clinical oncology 19 (7), 1893-1900<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15070728534262149746" class="gsc_a_ac gs_ibl">142</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:R6EwkKsDylYC" class="gsc_a_at">Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel</a><div class="gs_gray">P Hadji, RE Coleman, C Wilson, TJ Powles, P Clézardin, M Aapro, ...</div><div class="gs_gray">Annals of Oncology 27 (3), 379-390<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5605155776630200448" class="gsc_a_ac gs_ibl">140</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:5awf1xo2G04C" class="gsc_a_at">Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III&nbsp;…</a><div class="gs_gray">R Coleman, E Woodward, J Brown, D Cameron, R Bell, D Dodwell, ...</div><div class="gs_gray">Breast cancer research and treatment 127 (2), 429-438<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17464364541940906362" class="gsc_a_ac gs_ibl">139</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:iH-uZ7U-co4C" class="gsc_a_at">Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment</a><div class="gs_gray">J Vinholes, R Coleman, R Eastell</div><div class="gs_gray">Cancer treatment reviews 22 (4), 289-331<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1482154460315143428" class="gsc_a_ac gs_ibl">139</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:RJujIP1NYNUC" class="gsc_a_at">Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II&nbsp;…</a><div class="gs_gray">JF Forbes, I Sestak, A Howell, B Bonanni, N Bundred, C Levy, ...</div><div class="gs_gray">The Lancet 387 (10021), 866-873<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10519483751141669322" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:QhqSGEHatosC" class="gsc_a_at">Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized&nbsp;…</a><div class="gs_gray">K Fizazi, L Bosserman, G Gao, T Skacel, R Markus</div><div class="gs_gray">The Journal of urology 182 (2), 509-516<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14893432489793526839,2341190483091127028" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:vV6vV6tmYwMC" class="gsc_a_at">Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations</a><div class="gs_gray">RE Coleman, WW Bolten, M Lansdown, S Dale, C Jackisch, D Merkel, ...</div><div class="gs_gray">Cancer treatment reviews 34 (3), 275-282<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5250195803750024621" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:35N4QoGY0k4C" class="gsc_a_at">Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival?</a><div class="gs_gray">I Holen, SS Cross, HL Neville-Webbe, NA Cross, SP Balasubramanian, ...</div><div class="gs_gray">Breast cancer research and treatment 92 (3), 207-215<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5677367709761591025" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:RYcK_YlVTxYC" class="gsc_a_at">The detection of circulating breast cancer cells in blood</a><div class="gs_gray">AM Gilbey, D Burnett, RE Coleman, I Holen</div><div class="gs_gray">Journal of clinical pathology 57 (9), 903-911<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9333482449089559572" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=UIrmjcIAAAAJ:NMxIlDl6LWMC" class="gsc_a_at">The anti-tumour activity of bisphosphonates</a><div class="gs_gray">HL Neville-Webbe, I Holen, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 28 (6), 305-319<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16187712862677432007" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:j3f4tGmQtD8C" class="gsc_a_at">Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.</a><div class="gs_gray">K Possinger, M Kaufmann, R Coleman, NS Stuart, M Helsing, ...</div><div class="gs_gray">Anti-cancer drugs 10 (2), 155-162<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3077836501852795500" class="gsc_a_ac gs_ibl">138</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_Qo2XoVZTnwC" class="gsc_a_at">Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)</a><div class="gs_gray">RE Coleman, PJ Woll, M Miles, W Scrivener, RD Rubens</div><div class="gs_gray">British journal of cancer 58 (5), 621-625<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10959828817993683133" class="gsc_a_ac gs_ibl">135</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bNB6FdaCRgEC" class="gsc_a_at">Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer</a><div class="gs_gray">RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, ...</div><div class="gs_gray">N Engl J Med 350 (11), 1081-1092<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2763226481652664041" class="gsc_a_ac gs_ibl">133</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KxtntwgDAa4C" class="gsc_a_at">Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy</a><div class="gs_gray">JA Tidy, AM Gillespie, N Bright, CR Radstone, RE Coleman, BW Hancock</div><div class="gs_gray">Gynecologic oncology 78 (3), 309-312<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7673642005871954143" class="gsc_a_ac gs_ibl">133</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XiSMed-E-HIC" class="gsc_a_at">Metastasis and bone loss: advancing treatment and prevention</a><div class="gs_gray">RE Coleman, A Lipton, GD Roodman, TA Guise, BF Boyce, AM Brufsky, ...</div><div class="gs_gray">Cancer treatment reviews 36 (8), 615-620<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16211862204007151698" class="gsc_a_ac gs_ibl">126</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:F9HO9s0W2bwC" class="gsc_a_at">Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in&nbsp;…</a><div class="gs_gray">S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ...</div><div class="gs_gray">Annals of Oncology 26 (5), 873-879<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5756733481186939346" class="gsc_a_ac gs_ibl">125</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:isC4tDSrTZIC" class="gsc_a_at">Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?</a><div class="gs_gray">JF Smyth, RE Coleman, M Nicolson, WM Gallmeier, RC Leonard, ...</div><div class="gs_gray">British Medical Journal 303 (6815), 1423-1426<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4951829548815050038" class="gsc_a_ac gs_ibl">125</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0d9pApVQ-n0C" class="gsc_a_at">Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer&nbsp;…</a><div class="gs_gray">R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ...</div><div class="gs_gray">The lancet 393 (10179), 1440-1452<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7421697248031980451" class="gsc_a_ac gs_ibl">124</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EmjvLWWcsQIC" class="gsc_a_at">Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer</a><div class="gs_gray">AD Steg, AA Katre, B Goodman, HD Han, AM Nick, RL Stone, ...</div><div class="gs_gray">Clinical cancer research 17 (17), 5674-5685<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7566935848210432707" class="gsc_a_ac gs_ibl">123</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Oo_WeVVXg5wC" class="gsc_a_at">Enhanced MAF oncogene expression and breast cancer bone metastasis</a><div class="gs_gray">M Pavlovic, A Arnal-Estapé, F Rojo, A Bellmunt, M Tarragona, M Guiu, ...</div><div class="gs_gray">JNCI: Journal of the National Cancer Institute 107 (12)<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15787367998511604789,12947856495646088156" class="gsc_a_ac gs_ibl">122</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:Oo_WeVVXg5wC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NaGl4SEjCO4C" class="gsc_a_at">TAC improves DFS and OS over FAC in Node Positive early breast cancer patients, BCIRG001 55 months follow up</a><div class="gs_gray">M Martin</div><div class="gs_gray">Proc San Antonio Breast Cancer Symposium 2003<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6160777179795169151" class="gsc_a_ac gs_ibl">122</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:O3NaXMp0MMsC" class="gsc_a_at">Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity</a><div class="gs_gray">A Lipton, RJ Cook, P Major, MR Smith, RE Coleman</div><div class="gs_gray">The oncologist 12 (9), 1035-1043<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8285483899797405375" class="gsc_a_ac gs_ibl">121</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xUD2GqFNeDMC" class="gsc_a_at">Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of&nbsp;…</a><div class="gs_gray">M Dowsett, J Cuzick, A Howell, I Jackson</div><div class="gs_gray">British journal of cancer 85 (3), 317-324<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10804507657650110252,5401597209421741766" class="gsc_a_ac gs_ibl">121</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RmcNAhKkducC" class="gsc_a_at">IL-1 drives breast cancer growth and bone metastasis in vivo</a><div class="gs_gray">I Holen, DV Lefley, SE Francis, S Rennicks, S Bradbury, RE Coleman, ...</div><div class="gs_gray">Oncotarget 7 (46), 75571<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16870107944820355734" class="gsc_a_ac gs_ibl">119</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BqipwSGYUEgC" class="gsc_a_at">Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro</a><div class="gs_gray">HL Neville-Webbe, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">Tumor Biology 27 (2), 92-103<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9738891377107792225" class="gsc_a_ac gs_ibl">119</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pqnbT2bcN3wC" class="gsc_a_at">The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers</a><div class="gs_gray">JFR Robertson, W Jaeger, JJ Syzmendera, C Selby, R Coleman, ...</div><div class="gs_gray">European Journal of Cancer 35 (1), 47-53<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4771705046146520094" class="gsc_a_ac gs_ibl">118</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:k_IJM867U9cC" class="gsc_a_at">Bone metastases and breast cancer</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">Cancer treatment reviews 12 (4), 251-270<span class="gs_oph">, 1985</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10395933055584279028" class="gsc_a_ac gs_ibl">118</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1985</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_xSYboBqXhAC" class="gsc_a_at">Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?</a><div class="gs_gray">SS Cross, Z Yang, NJ Brown, SP Balasubramanian, CA Evans, ...</div><div class="gs_gray">International journal of cancer 118 (8), 1901-1908<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14473632925890457259" class="gsc_a_ac gs_ibl">117</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WHBERAHVdrEC" class="gsc_a_at">Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study</a><div class="gs_gray">S Nilsson, P Cislo, O Sartor, NJ Vogelzang, RE Coleman, JM O'Sullivan, ...</div><div class="gs_gray">Annals of Oncology 27 (5), 868-874<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1384023526445741922" class="gsc_a_ac gs_ibl">116</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lSLTfruPkqcC" class="gsc_a_at">The clinical use of bone resorption markers in patients with malignant bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer 94 (10), 2521-2533<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12007660420700586633" class="gsc_a_ac gs_ibl">116</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:s2G-WRnXBicC" class="gsc_a_at">Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events</a><div class="gs_gray">MR Smith, RE Coleman, L Klotz, K Pittman, P Milecki, S Ng, KN Chi, ...</div><div class="gs_gray">Annals of Oncology 26 (2), 368-374<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11966600251980001776" class="gsc_a_ac gs_ibl">115</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:artPoR2Yc-kC" class="gsc_a_at">Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial</a><div class="gs_gray">P Barrett-Lee, A Casbard, J Abraham, K Hood, R Coleman, P Simmonds, ...</div><div class="gs_gray">The Lancet Oncology 15 (1), 114-122<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3381984923815193095,10584142233211095905" class="gsc_a_ac gs_ibl">114</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SeFeTyx0c_EC" class="gsc_a_at">Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone&nbsp;…</a><div class="gs_gray">C Parker, S Nilsson, D Heinrich, JM O'Sullivan, SD Fossa, A Chodacki, ...</div><div class="gs_gray">J Clin Oncol 30 (Suppl), LBA4512<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5310787841676673602" class="gsc_a_ac gs_ibl">114</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4OULZ7Gr8RgC" class="gsc_a_at">Working with voices</a><div class="gs_gray">R Coleman, M Smith</div><div class="gs_gray">Keepwell<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15699070559010431227" class="gsc_a_ac gs_ibl">113</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yD5IFk8b50cC" class="gsc_a_at">Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease</a><div class="gs_gray">HL Neville-Webbe, RE Coleman</div><div class="gs_gray">European journal of cancer 46 (7), 1211-1222<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17453074243817561511" class="gsc_a_ac gs_ibl">110</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J_g5lzvAfSwC" class="gsc_a_at">Reappraisal of the baseline bone scan in breast cancer.</a><div class="gs_gray">RE Coleman, RD Rubens, I Fogelman</div><div class="gs_gray">Journal of nuclear medicine: official publication, Society of Nuclear&nbsp;…<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1986035208116970239" class="gsc_a_ac gs_ibl">108</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JV2RwH3_ST0C" class="gsc_a_at">Osteoclast inhibition for the treatment of bone metastases</a><div class="gs_gray">RE Coleman, OP Purohit</div><div class="gs_gray">Cancer treatment reviews 19 (1), 79-103<span class="gs_oph">, 1993</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18092954114210882583" class="gsc_a_ac gs_ibl">107</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1993</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RGFaLdJalmkC" class="gsc_a_at">Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease</a><div class="gs_gray">SP Jagdev, OP Purohit, S Heatley, C Herling, RE Coleman</div><div class="gs_gray">Annals of oncology 12 (10), 1433-1438<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7361258534876550439" class="gsc_a_ac gs_ibl">106</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:l7t_Zn2s7bgC" class="gsc_a_at">Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic&nbsp;…</a><div class="gs_gray">G Atalay, L Biganzoli, F Renard, R Paridaens, T Cufer, R Coleman, ...</div><div class="gs_gray">European journal of cancer 39 (17), 2439-2449<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1738518895817494303" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xtRiw3GOFMkC" class="gsc_a_at">Development of rainbow trout microsatellite markers from repeat enriched libraries</a><div class="gs_gray">CE Rexroad Iii, RL Coleman, AL Gustafson, WK Hershberger, J Killefer</div><div class="gs_gray">Marine Biotechnology 4 (1), 12-16<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17977976294523301017" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YFjsv_pBGBYC" class="gsc_a_at">Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease</a><div class="gs_gray">RE Coleman, OP Purohit, C Black, JJF Vinholes, K Schlosser, H Huss, ...</div><div class="gs_gray">Annals of oncology 10 (3), 311-316<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10236905972301757819" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LO7wyVUgiFcC" class="gsc_a_at">Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial</a><div class="gs_gray">E Scott, AJ Daley, H Doll, N Woodroofe, RE Coleman, N Mutrie, H Crank, ...</div><div class="gs_gray">Cancer Causes &amp; Control 24 (1), 181-191<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11996164535754532267" class="gsc_a_ac gs_ibl">104</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:70eg2SAEIzsC" class="gsc_a_at">Use of bisphosphonates in cancer patients</a><div class="gs_gray">JJ Body, RE Coleman, M Piccart</div><div class="gs_gray">Cancer treatment reviews 22 (4), 265-287<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14776575930140097768" class="gsc_a_ac gs_ibl">104</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GnPB-g6toBAC" class="gsc_a_at">Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer</a><div class="gs_gray">M Soukop, B McQuade, E Hunter, A Stewart, S Kaye, J Cassidy, D Kerr, ...</div><div class="gs_gray">Oncology 49 (4), 295-304<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16185418785020931775" class="gsc_a_ac gs_ibl">104</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kiex5tMzGo8C" class="gsc_a_at">An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223</a><div class="gs_gray">O Sartor, RE Coleman, S Nilsson, D Heinrich, SI Helle, JM O’Sullivan, ...</div><div class="gs_gray">Annals of Oncology 28 (5), 1090-1097<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5646159866735411498" class="gsc_a_ac gs_ibl">103</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:b0M2c_1WBrUC" class="gsc_a_at">The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases</a><div class="gs_gray">RE Coleman, JJ Seaman</div><div class="gs_gray">Seminars in oncology 28, 11-16<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7184015658369294163" class="gsc_a_ac gs_ibl">103</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UxriW0iASnsC" class="gsc_a_at">EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast&nbsp;…</a><div class="gs_gray">A Hamilton, L Biganzoli, R Coleman, L Mauriac, P Hennebert, A Awada, ...</div><div class="gs_gray">Annals of oncology 13 (6), 910-918<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14742926224691973524" class="gsc_a_ac gs_ibl">102</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:olpn-zPbct0C" class="gsc_a_at">Bone metastases</a><div class="gs_gray">RE Coleman, J Brown, I Holen</div><div class="gs_gray">Abeloff's Clinical Oncology, 809-830. e3<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6739412810352577094" class="gsc_a_ac gs_ibl">100</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8AbLer7MMksC" class="gsc_a_at">The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease</a><div class="gs_gray">M Pezeshki, BW Hancock, P Silcocks, JE Everard, J Coleman, ...</div><div class="gs_gray">Gynecologic oncology 95 (3), 423-429<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2327324830488761831" class="gsc_a_ac gs_ibl">100</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u_35RYKgDlwC" class="gsc_a_at">Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo</a><div class="gs_gray">PD Ottewell, B Deux, H Mönkkönen, S Cross, RE Coleman, P Clezardin, ...</div><div class="gs_gray">Clinical Cancer Research 14 (14), 4658-4666<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13457635263793836769" class="gsc_a_ac gs_ibl">99</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:p2g8aNsByqUC" class="gsc_a_at">Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours</a><div class="gs_gray">C Van Poznak, SS Cross, M Saggese, C Hudis, KS Panageas, L Norton, ...</div><div class="gs_gray">Journal of clinical pathology 59 (1), 56-63<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13647168233141024024" class="gsc_a_ac gs_ibl">98</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:a0OBvERweLwC" class="gsc_a_at">Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study</a><div class="gs_gray">GD Hall, JM Brown, RE Coleman, M Stead, KS Metcalf, KR Peel, C Poole, ...</div><div class="gs_gray">British journal of cancer 91 (4), 621-626<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=93878848467216426" class="gsc_a_ac gs_ibl">98</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AXkvAH5U_nMC" class="gsc_a_at">The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome</a><div class="gs_gray">PM Savage, A Sita-Lumsden, S Dickson, R Iyer, J Everard, R Coleman, ...</div><div class="gs_gray">Journal of Obstetrics and Gynaecology 33 (4), 406-411<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6872787899236690710" class="gsc_a_ac gs_ibl">97</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OU6Ihb5iCvQC" class="gsc_a_at">Rapid communication: Thirty-eight polymorphic microsatellite markers for mapping in rainbow trout.</a><div class="gs_gray">CE Rexroad, RL Coleman, WK Hershberger, J Killefer</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9854011834540500420" class="gsc_a_ac gs_ibl">97</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Tiz5es2fbqcC" class="gsc_a_at">Bone secondaries in breast cancer: the solitary metastasis</a><div class="gs_gray">DI Boxer, CE Todd, R Coleman, I Fogelman</div><div class="gs_gray">J Nucl Med 30 (8), 1318-20<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17081283936112862271" class="gsc_a_ac gs_ibl">97</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4fKUyHm3Qg0C" class="gsc_a_at">From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies</a><div class="gs_gray">PD Ottewell, RE Coleman, I Holen</div><div class="gs_gray">Breast cancer research and treatment 96 (2), 101-113<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13120407267672768692" class="gsc_a_ac gs_ibl">96</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eMMeJKvmdy0C" class="gsc_a_at">Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone</a><div class="gs_gray">PD Ottewell, JK Woodward, DV Lefley, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">Molecular cancer therapeutics 8 (10), 2821-2832<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8990282911812255553" class="gsc_a_ac gs_ibl">94</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1l3MdapXzAoC" class="gsc_a_at">GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial</a><div class="gs_gray">RCF Leonard, DJA Adamson, G Bertelli, J Mansi, A Yellowlees, J Dunlop, ...</div><div class="gs_gray">Annals of Oncology 28 (8), 1811-1816<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5154199593835145860,372186292627446981" class="gsc_a_ac gs_ibl">93</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:1l3MdapXzAoC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:j8SEvjWlNXcC" class="gsc_a_at">Consensus on the utility of bone markers in the malignant bone disease setting</a><div class="gs_gray">R Coleman, L Costa, F Saad, R Cook, P Hadji, E Terpos, P Garnero, ...</div><div class="gs_gray">Critical reviews in oncology/hematology 80 (3), 411-432<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3056802896214521949" class="gsc_a_ac gs_ibl">93</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xlVdBZVQT58C" class="gsc_a_at">Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</a><div class="gs_gray">PA Vasey, R Atkinson, R Coleman, M Crawford, M Cruickshank, ...</div><div class="gs_gray">British journal of cancer 84 (2), 170-178<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6769126366254279764" class="gsc_a_ac gs_ibl">93</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rO6llkc54NcC" class="gsc_a_at">Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients</a><div class="gs_gray">MA Cornbleet, RC Stuart-Harris, IE Smith, RE Coleman, RD Rubens, ...</div><div class="gs_gray">European Journal of Cancer and Clinical Oncology 20 (9), 1141-1146<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8400986655868410515" class="gsc_a_ac gs_ibl">93</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g5m5HwL7SMYC" class="gsc_a_at">A phase II, multicentre, UK study of vinorelbine in advanced breast cancer</a><div class="gs_gray">CJ Twelves, NA Dobbs, A Curnow, RE Coleman, AL Stewart, CJ Tyrrell, ...</div><div class="gs_gray">British journal of cancer 70 (5), 990-993<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11032496884006841974" class="gsc_a_ac gs_ibl">92</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bFI3QPDXJZMC" class="gsc_a_at">Biochemical prediction of response of bone metastases to treatment</a><div class="gs_gray">RE Coleman, KB Whitaker, DW Moss, G Mashiter, I Fogelman, ...</div><div class="gs_gray">British journal of cancer 58 (2), 205-210<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7744195188432840382" class="gsc_a_ac gs_ibl">92</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:abG-DnoFyZgC" class="gsc_a_at">The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia</a><div class="gs_gray">HL Neville-Webbe, RE Coleman</div><div class="gs_gray">Palliative medicine 17 (6), 539-553<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7599147513492707623" class="gsc_a_ac gs_ibl">91</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WJVC3Jt7v1AC" class="gsc_a_at">Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia</a><div class="gs_gray">J Tidy, R Osborne, R Coleman, BW Hancock, TA Lawrie</div><div class="gs_gray">Cochrane Database of Systematic Reviews<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17748456550568166464" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bnK-pcrLprsC" class="gsc_a_at">Potential anticancer properties of bisphosphonates</a><div class="gs_gray">HL Neville-Webbe, M Gnant, RE Coleman</div><div class="gs_gray">Seminars in oncology 37, S53-S65<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8284516878917642919" class="gsc_a_ac gs_ibl">89</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SP6oXDckpogC" class="gsc_a_at">Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model</a><div class="gs_gray">PD Ottewell, DV Lefley, SS Cross, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">International journal of cancer 126 (2), 522-532<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=501319973215083632" class="gsc_a_ac gs_ibl">89</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2P1L_qKh6hAC" class="gsc_a_at">Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.</a><div class="gs_gray">J Vinholes, CY Guo, OP Purohit, R Eastell, RE Coleman</div><div class="gs_gray">Journal of clinical oncology 15 (1), 131-138<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=719443914987967835" class="gsc_a_ac gs_ibl">89</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:n3vGvpFsckwC" class="gsc_a_at">Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function&nbsp;…</a><div class="gs_gray">JM Saxton, EJ Scott, AJ Daley, MN Woodroofe, N Mutrie, H Crank, ...</div><div class="gs_gray">Breast Cancer Research 16 (2), 1-10<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2341226707549967853" class="gsc_a_ac gs_ibl">88</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Fu2w8maKXqMC" class="gsc_a_at">Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial</a><div class="gs_gray">R Eastell, J Adams, G Clack, A Howell, J Cuzick, J Mackey, ...</div><div class="gs_gray">Annals of oncology 22 (4), 857-862<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13108902260599626137" class="gsc_a_ac gs_ibl">88</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dfsIfKJdRG4C" class="gsc_a_at">Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)</a><div class="gs_gray">RE Coleman, HC Thorpe, D Cameron, D Dodwell, R Burkinshaw, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), S4-5-S4-5<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10006018534841136823" class="gsc_a_ac gs_ibl">88</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vRqMK49ujn8C" class="gsc_a_at">Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">European journal of cancer 45 (11), 1909-1915<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5428157986609406564" class="gsc_a_ac gs_ibl">87</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:V3AGJWp-ZtQC" class="gsc_a_at">Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study</a><div class="gs_gray">DM Greenfield, SJ Walters, RE Coleman, BW Hancock, R Eastell, ...</div><div class="gs_gray">The Journal of Clinical Endocrinology &amp; Metabolism 92 (9), 3476-3482<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5789970969922759435" class="gsc_a_ac gs_ibl">87</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fPk4N6BV_jEC" class="gsc_a_at">A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer</a><div class="gs_gray">DW Miles, IE Smith, RE Coleman, AH Calvert, MJ Lind</div><div class="gs_gray">European Journal of Cancer 37 (11), 1366-1371<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15059857124214990536" class="gsc_a_ac gs_ibl">87</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qhW0HyKmSusC" class="gsc_a_at">Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer</a><div class="gs_gray">PA Vasey, J Paul, A Birt, EJ Junor, NS Reed, RP Symonds, R Atkinson, ...</div><div class="gs_gray">Journal of clinical oncology 17 (7), 2069-2069<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7797146912130115713,9870083555170979465" class="gsc_a_ac gs_ibl">87</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QD3KBmkZPeQC" class="gsc_a_at">Management of cancer treatment-induced bone loss</a><div class="gs_gray">RE Coleman, E Rathbone, JE Brown</div><div class="gs_gray">Nature Reviews Rheumatology 9 (6), 365-374<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15732744961149163485" class="gsc_a_ac gs_ibl">86</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ldfaerwXgEUC" class="gsc_a_at">High dose pamidronate: clinical and biochemical effects in metastatic bone disease</a><div class="gs_gray">RE Coleman, OP Purohit, JJ Vinholes, J Zekri</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1989251256119514880" class="gsc_a_ac gs_ibl">86</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5qfkUJPXOUwC" class="gsc_a_at">Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease</a><div class="gs_gray">L Walkington, J Webster, BW Hancock, J Everard, RE Coleman</div><div class="gs_gray">British journal of cancer 104 (11), 1665-1669<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6377510976795361986" class="gsc_a_ac gs_ibl">85</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NJ774b8OgUMC" class="gsc_a_at">Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease</a><div class="gs_gray">E Terpos, J Berenson, RJ Cook, A Lipton, RE Coleman</div><div class="gs_gray">Leukemia 24 (5), 1043-1049<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8677541883263598898" class="gsc_a_ac gs_ibl">85</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:10A3hb2jUxYC" class="gsc_a_at">Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials</a><div class="gs_gray">R Coleman, M Gnant, A Paterson, T Powles, G Von Minckwitz, K Pritchard, ...</div><div class="gs_gray">Cancer Research 73<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9548529634149921151" class="gsc_a_ac gs_ibl">84</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u9iWguZQMMsC" class="gsc_a_at">Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program</a><div class="gs_gray">PP Major, RE Coleman</div><div class="gs_gray">Seminars in oncology 28, 17-24<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15348305307130270645" class="gsc_a_ac gs_ibl">83</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZHo1McVdvXMC" class="gsc_a_at">Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease</a><div class="gs_gray">RE Coleman, S Houston, I James, A Rodger, RD Rubens, RCF Leonard, ...</div><div class="gs_gray">British journal of cancer 65 (5), 766-768<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12426508594426697192" class="gsc_a_ac gs_ibl">83</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-TLX1-BxFiYC" class="gsc_a_at">Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management</a><div class="gs_gray">S D'Oronzo, R Coleman, J Brown, F Silvestris</div><div class="gs_gray">Journal of bone oncology 15, 100205<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10561551121453517539" class="gsc_a_ac gs_ibl">82</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nb7KW1ujOQ8C" class="gsc_a_at">A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)</a><div class="gs_gray">RE Coleman, L Biganzoli, P Canney, L Dirix, L Mauriac, P Chollet, ...</div><div class="gs_gray">European journal of cancer 42 (7), 882-887<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7017086606526026488" class="gsc_a_ac gs_ibl">82</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pyW8ca7W8N0C" class="gsc_a_at">Chemotherapy for ovarian cancer--a consensus statement on standard practice.</a><div class="gs_gray">M Adams, RP A'hern, AH Calvert, J Carmichael, PI Clark, RE Coleman, ...</div><div class="gs_gray">British journal of cancer 78 (11), 1404<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8669117565211668473" class="gsc_a_ac gs_ibl">81</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5Ul4iDaHHb8C" class="gsc_a_at">Monitoring of bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">European Journal of Cancer 34 (2), 252-259<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9061504294202519038" class="gsc_a_ac gs_ibl">80</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zA6iFVUQeVQC" class="gsc_a_at">Metabolic effects of pamidronate in patients with metastatic bone disease</a><div class="gs_gray">J Vinholes, CY Guo, OP Purohit, R Eastell, RE Coleman</div><div class="gs_gray">British journal of cancer 73 (9), 1089-1095<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7299053061595286877" class="gsc_a_ac gs_ibl">80</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_Ybze24A_UAC" class="gsc_a_at">Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects</a><div class="gs_gray">F Khan, J Everard, S Ahmed, RE Coleman, M Aitken, BW Hancock</div><div class="gs_gray">British journal of cancer 89 (12), 2197-2201<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5048457577913649775" class="gsc_a_ac gs_ibl">79</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:j5aT6aphRxQC" class="gsc_a_at">A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease</a><div class="gs_gray">R Coleman, AK Aksnes, B Naume, C Garcia, G Jerusalem, M Piccart, ...</div><div class="gs_gray">Breast cancer research and treatment 145 (2), 411-418<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10564710337563625301" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RtRctb2lSbAC" class="gsc_a_at">Endocrine aspects of bone metastases</a><div class="gs_gray">LC Hofbauer, TD Rachner, RE Coleman, F Jakob</div><div class="gs_gray">The lancet Diabetes &amp; endocrinology 2 (6), 500-512<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17676563070060800162" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wKETBy42zhYC" class="gsc_a_at">Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study</a><div class="gs_gray">A Awada, AA Garcia, S Chan, GHM Jerusalem, RE Coleman, MT Huizing, ...</div><div class="gs_gray">The lancet oncology 14 (12), 1216-1225<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8892028864369896797" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:edDO8Oi4QzsC" class="gsc_a_at">Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis</a><div class="gs_gray">A Valachis, NP Polyzos, RE Coleman, M Gnant, H Eidtmann, AM Brufsky, ...</div><div class="gs_gray">The oncologist 18 (4), 353<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15670910493245783690" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ALROH1vI_8AC" class="gsc_a_at">Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients</a><div class="gs_gray">JE Brown, RJ Cook, A Lipton, RE Coleman</div><div class="gs_gray">Clinical Cancer Research 18 (22), 6348-6355<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4567739967150923757" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kzcrU_BdoSEC" class="gsc_a_at">Follow-up care for cancer survivors: views of the younger adult</a><div class="gs_gray">K Absolom, C Eiser, G Michel, SJ Walters, BW Hancock, RE Coleman, ...</div><div class="gs_gray">British Journal of Cancer 101 (4), 561-567<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4781219459569732925" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9pM33mqn1YgC" class="gsc_a_at">Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?</a><div class="gs_gray">P Hadji, M Gnant, JJ Body, NJ Bundred, A Brufsky, RE Coleman, ...</div><div class="gs_gray">Cancer treatment reviews 38 (6), 798-806<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4133435645163852682" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ye4kPcJQO24C" class="gsc_a_at">The use of bisphosphonates in cancer treatment</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Annals of the New York Academy of Sciences 1218 (1), 3-14<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17379331469828659828" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:P5F9QuxV20EC" class="gsc_a_at">The anti-tumor potential of zoledronic acid</a><div class="gs_gray">P Croucher, S Jagdev, R Coleman</div><div class="gs_gray">The Breast 12, S30-S36<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9116173955694356026" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cFHS6HbyZ2cC" class="gsc_a_at">The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of&nbsp;…</a><div class="gs_gray">H Eidtmann, NJ Bundred, R DeBoer, A Llombart, N Davidson, P Neven, ...</div><div class="gs_gray">Cancer Research 69 (2 Supplement), 44<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16458489221293847716" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VOx2b1Wkg3QC" class="gsc_a_at">Characteristics of women with recurrent molar pregnancies</a><div class="gs_gray">PC Lorigan, S Sharma, N Bright, RE Coleman, BW Hancock</div><div class="gs_gray">Gynecologic oncology 78 (3), 288-292<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3940868524732176465" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hMsQuOkrut0C" class="gsc_a_at">Prevention and treatment of bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Nature reviews Clinical oncology 9 (2), 76-78<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4819924554789571415" class="gsc_a_ac gs_ibl">75</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eflP2zaiRacC" class="gsc_a_at">Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid</a><div class="gs_gray">JE Brown, SP Ellis, JE Lester, S Gutcher, T Khanna, OP Purohit, ...</div><div class="gs_gray">Clinical Cancer Research 13 (18), 5406-5410<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8871564785312483936" class="gsc_a_ac gs_ibl">75</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CHSYGLWDkRkC" class="gsc_a_at">Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.</a><div class="gs_gray">GJ Rustin, AE Nelstrop, M Crawford, J Ledermann, HE Lambert, ...</div><div class="gs_gray">Journal of clinical oncology 15 (1), 172-176<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11025547767789131708" class="gsc_a_ac gs_ibl">75</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gNZucvRojEcC" class="gsc_a_at">Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial</a><div class="gs_gray">R Coleman, DM Finkelstein, C Barrios, M Martin, H Iwata, R Hegg, ...</div><div class="gs_gray">The Lancet Oncology 21 (1), 60-72<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13025024311778358143" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1yQoGdGgb4wC" class="gsc_a_at">Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?</a><div class="gs_gray">OS Din, D Dodwell, RJ Wakefield, RE Coleman</div><div class="gs_gray">Breast cancer research and treatment 120 (3), 525-538<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17853680263795522121" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WbkHhVStYXYC" class="gsc_a_at">Osteocalcin: a potential marker of metastatic bone disease and response to treatment</a><div class="gs_gray">RE Coleman, G Mashiter, I Fogelman, KD Whitaker, M Caleffi, DW Moss, ...</div><div class="gs_gray">European Journal of Cancer and Clinical Oncology 24 (7), 1211-1217<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17801751763869892140" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kz9GbA2Ns4gC" class="gsc_a_at">Denosumab in patients with cancer—a surgical strike against the osteoclast</a><div class="gs_gray">JE Brown, RE Coleman</div><div class="gs_gray">Nature reviews Clinical oncology 9 (2), 110-118<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15244138451093849402" class="gsc_a_ac gs_ibl">73</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:K3LRdlH-MEoC" class="gsc_a_at">The causes and treatment of bone loss associated with carcinoma of the breast</a><div class="gs_gray">J Lester, D Dodwell, E McCloskey, R Coleman</div><div class="gs_gray">Cancer treatment reviews 31 (2), 115-142<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13763450482997011704" class="gsc_a_ac gs_ibl">73</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:orDZ08hpP44C" class="gsc_a_at">Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line</a><div class="gs_gray">F Nutter, I Holen, HK Brown, SS Cross, CA Evans, M Walker, RE Coleman, ...</div><div class="gs_gray">Endocrine-related cancer 21 (2), 327-341<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3229186027295005950" class="gsc_a_ac gs_ibl">72</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uc_IGeMz5qoC" class="gsc_a_at">Prognostic factors for skeletal complications from metastatic bone disease in breast cancer</a><div class="gs_gray">JE Brown, RJ Cook, A Lipton, L Costa, RE Coleman</div><div class="gs_gray">Breast cancer research and treatment 123 (3), 767-779<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8770254090068625853" class="gsc_a_ac gs_ibl">72</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tS2w5q8j5-wC" class="gsc_a_at">Future directions in the treatment and prevention of bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">American journal of clinical oncology 25 (6), S32-S38<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2101126939378512480" class="gsc_a_ac gs_ibl">72</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:08ZZubdj9fEC" class="gsc_a_at">International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients</a><div class="gs_gray">JJ Body, R Coleman, P Clezardin, C Ripamonti, R Rizzoli, M Aapro</div><div class="gs_gray">European Journal of Cancer 43 (5), 852-858<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4744856098439496056" class="gsc_a_ac gs_ibl">70</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dshw04ExmUIC" class="gsc_a_at">Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial</a><div class="gs_gray">RCF Leonard, M Lind, C Twelves, R Coleman, S Van Belle, C Wilson, ...</div><div class="gs_gray">Journal of the National Cancer Institute 96 (14), 1076-1083<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11899742570592427529" class="gsc_a_ac gs_ibl">70</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DwWRdx-KAo4C" class="gsc_a_at">CAPG and GIPC1: breast cancer biomarkers for bone metastasis development and treatment</a><div class="gs_gray">JA Westbrook, DA Cairns, J Peng, V Speirs, AM Hanby, I Holen, SL Wood, ...</div><div class="gs_gray">Journal of the National Cancer Institute 108 (4), djv360<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3223410144596469565" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UarirCmVI0EC" class="gsc_a_at">A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A* 0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer</a><div class="gs_gray">RL Prue, F Vari, KJ Radford, H Tong, MY Hardy, R D’Rozario, ...</div><div class="gs_gray">Journal of Immunotherapy 38 (2), 71-76<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14510423803331427435" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:W5xh706n7nkC" class="gsc_a_at">Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study</a><div class="gs_gray">RE Coleman, LM Banks, SI Girgis, E Vrdoljak, J Fox, SJ Cawthorn, A Patel, ...</div><div class="gs_gray">Breast cancer research and treatment 124 (1), 153-161<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7860135057188090586,13503789903049257137" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-_dYPAW6P2MC" class="gsc_a_at">Follow-up care for cancer survivors: the views of clinicians</a><div class="gs_gray">DM Greenfield, K Absolom, C Eiser, SJ Walters, G Michel, BW Hancock, ...</div><div class="gs_gray">British Journal of Cancer 101 (4), 568-574<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16529866188148711517" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tOudhMTPpwUC" class="gsc_a_at">Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment</a><div class="gs_gray">CL Eaton, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 29 (3), 189-198<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4162856260781062519" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5kvG9DmRKWYC" class="gsc_a_at">The role of community‐based and philanthropic organizations in meeting cancer patient and caregiver needs</a><div class="gs_gray">RA Shelby, KL Taylor, JF Kerner, E Coleman, D Blum</div><div class="gs_gray">CA: A Cancer Journal for Clinicians 52 (4), 229-246<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15579453399960822067" class="gsc_a_ac gs_ibl">69</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qOpkhvVCMvUC" class="gsc_a_at">Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in&nbsp;…</a><div class="gs_gray">CC Parker, RE Coleman, O Sartor, NJ Vogelzang, D Bottomley, ...</div><div class="gs_gray">European urology 73 (3), 427-435<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13410661847861175291" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BwyfMAYsbu0C" class="gsc_a_at">The treatment of early breast cancer in women over the age of 70</a><div class="gs_gray">A Ring, M Reed, R Leonard, I Kunkler, H Muss, H Wildiers, L Fallowfield, ...</div><div class="gs_gray">British journal of cancer 105 (2), 189-193<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6800851340361499710" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tkaPQYYpVKoC" class="gsc_a_at">Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer</a><div class="gs_gray">MR Smith, RJ Cook, R Coleman, J Brown, A Lipton, P Major, YJ Hei, ...</div><div class="gs_gray">Urology 70 (2), 315-319<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16069059281961668460" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uWQEDVKXjbEC" class="gsc_a_at">A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix</a><div class="gs_gray">RE Coleman, PG Harper, C Gallagher, R Osborne, EM Rankin, ...</div><div class="gs_gray">Cáncer Chemotherapy and pharmacology 18 (3), 280-283<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4142377806615126204" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ddB7do2jUx8C" class="gsc_a_at">Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.</a><div class="gs_gray">RE Coleman, D Finkelstein, CH Barrios, M Martin, H Iwata, JA Glaspy, ...</div><div class="gs_gray">Journal of Clinical Oncology 36 (15_suppl), 501-501<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9568781251292699491" class="gsc_a_ac gs_ibl">67</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:654Jc7Ppz2kC" class="gsc_a_at">Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial</a><div class="gs_gray">NJ Vogelzang, RE Coleman, JM Michalski, S Nilsson, JM O'Sullivan, ...</div><div class="gs_gray">Clinical genitourinary cancer 15 (1), 42-52. e8<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13895729165329649418" class="gsc_a_ac gs_ibl">67</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:738O_yMBCRsC" class="gsc_a_at">The potential of melanoma antigen expression in cancer therapy</a><div class="gs_gray">AM Gillespie, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 25 (4), 219-227<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3906412500011347847" class="gsc_a_ac gs_ibl">67</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:q3oQSFYPqjQC" class="gsc_a_at">Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference</a><div class="gs_gray">RE Coleman, TA Guise, A Lipton, GD Roodman, JR Berenson, JJ Body, ...</div><div class="gs_gray">Clinical cancer research 14 (20), 6387-6395<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17984421715486527062" class="gsc_a_ac gs_ibl">65</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9vf0nzSNQJEC" class="gsc_a_at">Questioning specialists’ attitudes to breast cancer follow-up in primary care</a><div class="gs_gray">P Donnelly, L Hiller, S Bathers, S Bowden, R Coleman</div><div class="gs_gray">Annals of Oncology 18 (9), 1467-1476<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2899632144970111361" class="gsc_a_ac gs_ibl">65</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cTy_cm4PQvYC" class="gsc_a_at">Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial</a><div class="gs_gray">C Parker, SE Finkelstein, JM Michalski, JM O'Sullivan, Ø Bruland, ...</div><div class="gs_gray">European urology 70 (5), 875-883<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15668079169514992835" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lmc2jWPfTJgC" class="gsc_a_at">Quality of life, self‐esteem, fatigue, and sexual function in young men after cancer: a controlled cross‐sectional study</a><div class="gs_gray">DM Greenfield, SJ Walters, RE Coleman, BW Hancock, JA Snowden, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16342746275548754379" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:D03iK_w7-QYC" class="gsc_a_at">Effect of anastrozole on bone mineral density: 5-year results from the’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 24 (18_suppl), 511-511<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5606010489972278774" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_AkkBXT-jcoC" class="gsc_a_at">Metastatic prostate cancer and the bone: significance and therapeutic options</a><div class="gs_gray">BA Gartrell, R Coleman, E Efstathiou, K Fizazi, CJ Logothetis, MR Smith, ...</div><div class="gs_gray">European urology 68 (5), 850-858<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8572378754424792106" class="gsc_a_ac gs_ibl">63</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wbdj-CoPYUoC" class="gsc_a_at">Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies</a><div class="gs_gray">RE Coleman, JJ Body, JR Gralow, A Lipton</div><div class="gs_gray">Cancer treatment reviews 34, S31-S42<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6428835386466402514" class="gsc_a_ac gs_ibl">63</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fQNAKQ3IYiAC" class="gsc_a_at">Current and future status of adjuvant therapy for breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=554883872994917280" class="gsc_a_ac gs_ibl">62</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sSrBHYA8nusC" class="gsc_a_at">The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases</a><div class="gs_gray">PT Daley-Yates, DJ Dodwell, M Pongchaidecha, RE Coleman, A Howell</div><div class="gs_gray">Calcified tissue international 49 (6), 433-435<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13643099333707665087" class="gsc_a_ac gs_ibl">62</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tuHXwOkdijsC" class="gsc_a_at">Anti-tumour activity of bisphosphonates in preclinical models of breast cancer</a><div class="gs_gray">I Holen, RE Coleman</div><div class="gs_gray">Breast cancer research 12 (6), 1-13<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6514007727397137207" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uLbwQdceFCQC" class="gsc_a_at">Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized&nbsp;…</a><div class="gs_gray">B Pajk, T Cufer, P Canney, P Ellis, D Cameron, E Blot, J Vermorken, ...</div><div class="gs_gray">The Breast 17 (2), 180-185<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15209135534652108186" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dTyEYWd-f8wC" class="gsc_a_at">The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer</a><div class="gs_gray">JKL Woodward, I Holen, RE Coleman, DJ Buttle</div><div class="gs_gray">Bone 41 (6), 912-927<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2320996946304679581" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tYavs44e6CUC" class="gsc_a_at">Magnesium depletion in patients receiving cisplatin-based chemotherapy</a><div class="gs_gray">E Hodgkinson, HL Neville-Webbe, RE Coleman</div><div class="gs_gray">Clinical oncology 18 (9), 710-718<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8909683389870326651" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JaLtl8ASYokC" class="gsc_a_at">Glucocorticoids in cancer therapy</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Biotherapy 4 (1), 37-44<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3864595874335730494" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AkvegQHRDQ8C" class="gsc_a_at">Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind&nbsp;…</a><div class="gs_gray">I Sestak, S Singh, J Cuzick, GM Blake, R Patel, F Gossiel, R Coleman, ...</div><div class="gs_gray">The Lancet Oncology 15 (13), 1460-1468<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9740449693104259507" class="gsc_a_ac gs_ibl">60</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:geHnlv5EZngC" class="gsc_a_at">Bisphosphonates in the treatment of skeletal metastases</a><div class="gs_gray">PF Conte, R Coleman</div><div class="gs_gray">Seminars in oncology 31, 59-63<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15025753369252850507" class="gsc_a_ac gs_ibl">60</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UHK10RUVsp4C" class="gsc_a_at">Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line&nbsp;…</a><div class="gs_gray">A Bottomley, L Biganzoli, T Cufer, RE Coleman, C Coens, F Efficace, ...</div><div class="gs_gray">Journal of clinical oncology 22 (13), 2576-2586<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10404082111817898738" class="gsc_a_ac gs_ibl">60</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nrtMV_XWKgEC" class="gsc_a_at">Determinants of adherence to exercise in women treated for breast cancer</a><div class="gs_gray">AJ Daley, H Crank, N Mutrie, JM Saxton, R Coleman</div><div class="gs_gray">European Journal of Oncology Nursing 11 (5), 392-399<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5202384521187733451" class="gsc_a_ac gs_ibl">59</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2MdNiwGT7yoC" class="gsc_a_at">Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment</a><div class="gs_gray">C Tulotta, DV Lefley, K Freeman, WM Gregory, AM Hanby, PR Heath, ...</div><div class="gs_gray">Clinical Cancer Research 25 (9), 2769-2782<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15115833962705079656" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0Kh4an1R61UC" class="gsc_a_at">Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA</a><div class="gs_gray">O Sartor, P Hoskin, RE Coleman, S Nilsson, NJ Vogelzang, O Petrenciuc, ...</div><div class="gs_gray">The Prostate 76 (10), 905-916<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10784536440848640751" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mJbmKSuM8toC" class="gsc_a_at">Dengue: update on epidemiology</a><div class="gs_gray">ME Wilson, LH Chen</div><div class="gs_gray">Current infectious disease reports 17 (1), 1-8<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1273050901973269402" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JoZmwDi-zQgC" class="gsc_a_at">The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer.</a><div class="gs_gray">RC Leonard, D Adamson, R Anderson, R Ballinger, G Bertelli, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 590-590<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=526866987123570208" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eJXPG6dFmWUC" class="gsc_a_at">Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro</a><div class="gs_gray">JKL Woodward, HL Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">Anti-cancer drugs 16 (8), 845-854<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5936748460122116060" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1qzjygNMrQYC" class="gsc_a_at">A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma</a><div class="gs_gray">SY Chan, AN Gordon, RE Coleman, JB Hall, MS Berger, ML Sherman, ...</div><div class="gs_gray">Cancer Immunology, Immunotherapy 52 (4), 243-248<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6815295624534729427" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J-pR_7NvFogC" class="gsc_a_at">The role of bisphosphonates in breast cancer: the present and future role of bisphosphonates in the management of patients with breast cancer</a><div class="gs_gray">JE Brown, RE Coleman</div><div class="gs_gray">Breast Cancer Research 4 (1), 1-6<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3825260536072811320" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:B3FOqHPlNUQC" class="gsc_a_at">Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion</a><div class="gs_gray">J Vinholes, R Coleman, D Lacombe, C Rose, M Tubiana-Hulin, P Bastit, ...</div><div class="gs_gray">British journal of cancer 80 (1), 221-228<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5153846857231861747" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MbTKqoTs-1EC" class="gsc_a_at">Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST</a><div class="gs_gray">R Coleman, N Bundred, R De Boer, A Llombarto, I Campbell, P Neven, ...</div><div class="gs_gray">and E-ZO-FAST. Poster presented at 32nd Annual San Antonio Breast Cancer&nbsp;…<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16896655502727882924" class="gsc_a_ac gs_ibl">57</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:h1pkognVyKwC" class="gsc_a_at">Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours</a><div class="gs_gray">D Santini, B Vincenzi, RA Hannon, JE Brown, G Dicuonzo, S Angeletti, ...</div><div class="gs_gray">Oncology reports 15 (5), 1351-1357<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16805633357384437020" class="gsc_a_ac gs_ibl">57</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gYnLYBw1zZMC" class="gsc_a_at">Current perspectives on bone metastases in castrate-resistant prostate cancer</a><div class="gs_gray">C Logothetis, MJ Morris, R Den, RE Coleman</div><div class="gs_gray">Cancer and Metastasis Reviews 37 (1), 189-196<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8177344226444406785" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WC23djZS0W4C" class="gsc_a_at">The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)</a><div class="gs_gray">RA Popescu, R Schäfer, R Califano, R Eckert, R Coleman, JY Douillard, ...</div><div class="gs_gray">Annals of oncology 25 (1), 9-15<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4565457235626865020" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:D_sINldO8mEC" class="gsc_a_at">The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response–exploratory evidence for direct anti-tumor activity in breast cancer.</a><div class="gs_gray">MC Winter, HC Thorpe, R Burkinshaw, SJ Beevers, RE Coleman</div><div class="gs_gray">Cancer Research 69 (2 Supplement), 5101<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17956261608638511112" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LjlpjdlvIbIC" class="gsc_a_at">Doxorubicin‐paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of&nbsp;…</a><div class="gs_gray">L Biganzoli, T Cufer, P Bruning, RE Coleman, L Duchateau, B Rapoport, ...</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18147343849088286078" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Mojj43d5GZwC" class="gsc_a_at">Optimising treatment of bone metastases by Aredia™ and Zometa™</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Breast Cancer 7 (4), 361-369<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4846551666108073501" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dMpQl7XwOw4C" class="gsc_a_at">Raman spectroscopic analysis differentiates between breast cancer cell lines</a><div class="gs_gray">ACS Talari, CA Evans, I Holen, RE Coleman, IU Rehman</div><div class="gs_gray">Journal of Raman Spectroscopy 46 (5), 421-427<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2820457179697250067" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JQOojiI6XY0C" class="gsc_a_at">Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells <i>in vitro</i>: evidence of synergistic interaction</a><div class="gs_gray">HL Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">British journal of cancer 102 (6), 1010-1017<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12584400063903467841" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_B80troHkn4C" class="gsc_a_at">Exercise therapy in women who have had breast cancer: design of the Sheffield women's exercise and well-being project</a><div class="gs_gray">AJ Daley, N Mutrie, H Crank, R Coleman, J Saxton</div><div class="gs_gray">Health Education Research 19 (6), 686-697<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10486986086938106412" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_Re3VWB3Y0AC" class="gsc_a_at">Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and&nbsp;…</a><div class="gs_gray">LS Dobson, PC Lorigan, RE Coleman, BW Hancock</div><div class="gs_gray">British journal of cancer 82 (9), 1547-1552<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13210849938179784675" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:csTP5AdqY_wC" class="gsc_a_at">Bone health in cancer: ESMO clinical practice guidelines</a><div class="gs_gray">R Coleman, P Hadji, JJ Body, D Santini, E Chow, E Terpos, S Oudard, ...</div><div class="gs_gray">Annals of oncology 31 (12), 1650-1663<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=160351591807137226" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DrR-2ekChdkC" class="gsc_a_at">The metastatic microenvironment of breast cancer: clinical implications</a><div class="gs_gray">RE Coleman, W Gregory, H Marshall, C Wilson, I Holen</div><div class="gs_gray">The Breast 22, S50-S56<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17752462893314075774" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PR6Y55bgFSsC" class="gsc_a_at">Zoledronic acid use in cancer patients: more than just supportive care?</a><div class="gs_gray">R Coleman, R Cook, V Hirsh, P Major, A Lipton</div><div class="gs_gray">Cancer 117 (1), 11-23<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3441622979558089104" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eq2jaN3J8jMC" class="gsc_a_at">MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue</a><div class="gs_gray">AM Gillespie, S Rodgers, AP Wilson, J Tidy, RC Rees, RE Coleman, ...</div><div class="gs_gray">British journal of cancer 78 (6), 816-821<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15097842584149776325" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EcS_2O1c4Q0C" class="gsc_a_at">nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results&nbsp;…</a><div class="gs_gray">DA Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, ...</div><div class="gs_gray">Annals of Oncology 29 (8), 1763-1770<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6002903014972054239" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hkOj_22Ku90C" class="gsc_a_at">Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure</a><div class="gs_gray">N Steele, J Zekri, R Coleman, R Leonard, K Dunn, A Bowman, I Manifold, ...</div><div class="gs_gray">The Breast 15 (3), 429-435<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5365624314382300271" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5ugPr518TE4C" class="gsc_a_at">Placental site trophoblastic tumour: a rare but potentially curable cancer</a><div class="gs_gray">AM Gillespie, D Liyim, JR Goepel, RE Coleman, BW Hancock</div><div class="gs_gray">British journal of cancer 82 (6), 1186-1190<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6855478646407263062" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Cy13deThEpcC" class="gsc_a_at">Patient reactions to met and unmet psychological need: a critical incident analysis</a><div class="gs_gray">G Kent, G Wills, A Faulkner, G Parry, M Whipp, R Coleman</div><div class="gs_gray">Patient education and counseling 28 (2), 187-190<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13250204842049036732" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4fGpz3EwCPoC" class="gsc_a_at">Ovarian failure following cancer treatment: current management and quality of life</a><div class="gs_gray">K Absolom, C Eiser, L Turner, W Ledger, R Ross, H Davies, R Coleman, ...</div><div class="gs_gray">Human Reproduction 23 (11), 2506-2512<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3610141578200527726" class="gsc_a_ac gs_ibl">52</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HE397vMXCloC" class="gsc_a_at">How can we improve the treatment of bone metastases further?</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Current opinion in oncology 10, S7-13<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17665650719053378900" class="gsc_a_ac gs_ibl">52</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mvPsJ3kp5DgC" class="gsc_a_at">3 (Amino-1, 1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">British journal of cancer 56 (4), 465-469<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16676180063033078947" class="gsc_a_ac gs_ibl">52</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gxb_f1p9zx4C" class="gsc_a_at">Cancer treatment and bone health</a><div class="gs_gray">C Handforth, S D’Oronzo, R Coleman, J Brown</div><div class="gs_gray">Calcified tissue international 102 (2), 251-264<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3619000796194798019" class="gsc_a_ac gs_ibl">51</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zLWjf1WUPmwC" class="gsc_a_at">Treatment and secondary prevention of venous thromboembolism in cancer</a><div class="gs_gray">R Coleman, P MacCallum</div><div class="gs_gray">British journal of cancer 102 (1), S17-S23<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16927818718539469937" class="gsc_a_ac gs_ibl">51</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5F1dSjz1ScoC" class="gsc_a_at">Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with&nbsp;…</a><div class="gs_gray">MW Verrill, J Lee, DA Cameron, R Agrawal, RE Coleman, K McAdam, ...</div><div class="gs_gray">Journal of Clinical Oncology 25 (18_suppl), LBA1005-LBA1005<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8016481233437158766,4776256808145417818" class="gsc_a_ac gs_ibl">51</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Y5dfb0dijaUC" class="gsc_a_at">Mitoxantrone in advanced breast cancer—a phase II study with special attention to cardiotoxicity</a><div class="gs_gray">RE Coleman, MN Maisey, RK Knight, RD Rubens</div><div class="gs_gray">European Journal of Cancer and Clinical Oncology 20 (6), 771-776<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9573791479926009190" class="gsc_a_ac gs_ibl">51</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dBzKUGQurMsC" class="gsc_a_at">Bone health during endocrine therapy for cancer</a><div class="gs_gray">TD Rachner, R Coleman, P Hadji, LC Hofbauer</div><div class="gs_gray">The Lancet Diabetes &amp; Endocrinology 6 (11), 901-910<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14006422364235841962" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PELIpwtuRlgC" class="gsc_a_at">Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.</a><div class="gs_gray">E Amir, M Clemons, OC Freedman, N Miller, RE Coleman, C Purdie, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 1007-1007<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11103375494358723017" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WA5NYHcadZ8C" class="gsc_a_at">A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer</a><div class="gs_gray">RE Coleman, S Houston, OP Purohit, RD Rubens, A Kandra, J Ford</div><div class="gs_gray">European Journal of Cancer 34 (6), 820-824<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4452718898835113468" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZqE1mSdD_DYC" class="gsc_a_at">The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid</a><div class="gs_gray">F Taylor, T Grew, J Everard, L Ellis, MC Winter, J Tidy, BW Hancock, ...</div><div class="gs_gray">European Journal of Cancer 49 (15), 3184-3190<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15448040037298924052" class="gsc_a_ac gs_ibl">49</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:e_rmSamDkqQC" class="gsc_a_at">Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates</a><div class="gs_gray">C Wilson, I Holen, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 38 (7), 877-889<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4009388200185408167" class="gsc_a_ac gs_ibl">49</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZfRJV9d4-WMC" class="gsc_a_at">Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer</a><div class="gs_gray">AM Gillespie, TJ Broadhead, SY Chan, J Owen, AP Farnsworth, ...</div><div class="gs_gray">Annals of oncology 11 (6), 735-741<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11574686382701317543" class="gsc_a_ac gs_ibl">48</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sNmaIFBj_lkC" class="gsc_a_at">The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis</a><div class="gs_gray">P Hadji, R Coleman, M Gnant, J Green</div><div class="gs_gray">Annals of oncology 23 (11), 2782-2790<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8134458085356333042" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yB1At4FlUx8C" class="gsc_a_at">Zoledronic acid</a><div class="gs_gray">R Coleman, R Burkinshaw, M Winter, H Neville-Webbe, J Lester, ...</div><div class="gs_gray">Expert opinion on drug safety 10 (1), 133-145<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8075748418972209211" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:i2xiXl-TujoC" class="gsc_a_at">Follow-up care for young adult survivors of cancer: lessons from pediatrics</a><div class="gs_gray">C Eiser, K Absolom, D Greenfield, J Snowden, R Coleman, B Hancock, ...</div><div class="gs_gray">Journal of cancer survivorship: research and practice 1 (1), 75-86<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8808046091642715592" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AXPGKjj_ei8C" class="gsc_a_at">Prednisolone improves the response to primary endocrine treatment for advanced breast cancer</a><div class="gs_gray">RD Rubens, CL Tinson, RE Coleman, RK Knight, D Tong, PJ Winter, ...</div><div class="gs_gray">British journal of cancer 58 (5), 626-630<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6604545324222238394" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2mikiJ1VBVsC" class="gsc_a_at">The role of biomarkers in the management of bone-homing malignancies</a><div class="gs_gray">S D’Oronzo, J Brown, R Coleman</div><div class="gs_gray">Journal of bone oncology 9, 1-9<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1485098843290177327" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:G7txJ4jiatkC" class="gsc_a_at">Scottish Gynecological Cancer Trial Groups. Phase 111 randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as a first line chemotherapy for ovarian carcinoma</a><div class="gs_gray">PA Vasey</div><div class="gs_gray">J Natl Cancer Inst 96, 1682-1691<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7889912181012040916" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:W1ZWpF0a3GIC" class="gsc_a_at">Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)</a><div class="gs_gray">RE Coleman, M Collinson, W Gregory, H Marshall, R Bell, D Dodwell, ...</div><div class="gs_gray">Journal of bone oncology 13, 123-135<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2135113851633866526" class="gsc_a_ac gs_ibl">45</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2u1QkWOsl3MC" class="gsc_a_at">The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer</a><div class="gs_gray">RA Anderson, J Mansi, RE Coleman, DJA Adamson, RCF Leonard</div><div class="gs_gray">European Journal of Cancer 87, 58-64<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9737856862216335970" class="gsc_a_ac gs_ibl">45</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kRWSkSYxWN8C" class="gsc_a_at">Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study)</a><div class="gs_gray">N Bundred, R Coleman, R DeBoer, H Edidtmann, A Frassolati, A Llombart, ...</div><div class="gs_gray">EJC Supplements 2 (4), 48<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=492426307801365260" class="gsc_a_ac gs_ibl">45</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vDijr-p_gm4C" class="gsc_a_at">Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity</a><div class="gs_gray">PP Major, RJ Cook, A Lipton, MR Smith, E Terpos, RE Coleman</div><div class="gs_gray">BMC cancer 9 (1), 1-12<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17699314268121582120" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:epqYDVWIO7EC" class="gsc_a_at">tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage&nbsp;…</a><div class="gs_gray">CJ Poole, L Hiller, HC Howard, JA Dunn, P Canney, AM Wardley, ...</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 506-506<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15478463021502712135" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0KyAp5RtaNEC" class="gsc_a_at">A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx™) in&nbsp;…</a><div class="gs_gray">L Biganzoli, R Coleman, A Minisini, A Hamilton, M Aapro, P Therasse, ...</div><div class="gs_gray">Critical reviews in oncology/hematology 61 (1), 84-89<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8689291030602081805" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:N5tVd3kTz84C" class="gsc_a_at">The role of bisphosphonates in breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The Breast 13 (1), 19-28<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11186414452248340437" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VL0QpB8kHFEC" class="gsc_a_at">New options for outpatient chemotherapy–the role of oral fluoropyrimidines</a><div class="gs_gray">D Cunningham, R Coleman</div><div class="gs_gray">Cancer treatment reviews 27 (4), 211-220<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6118291108614742035" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qQc65DSaYXMC" class="gsc_a_at">Advances in the management of HER2-positive early breast cancer</a><div class="gs_gray">J Baselga, RE Coleman, J Cortés, W Janni</div><div class="gs_gray">Critical reviews in oncology/hematology 119, 113-122<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11759286681538526938" class="gsc_a_ac gs_ibl">43</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:z_wVstp3MssC" class="gsc_a_at">Medical management of hypercalcemia</a><div class="gs_gray">SH Ralston, R Coleman, WD Fraser, SJ Gallagher, DJ Hosking, JS Iqbal, ...</div><div class="gs_gray">Calcified tissue international 74 (1), 1-11<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10353798527843911790" class="gsc_a_ac gs_ibl">43</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:k8Z6L05lTy4C" class="gsc_a_at">The presentation and management of post-partum choriocarcinoma</a><div class="gs_gray">LS Dobson, AM Gillespie, RE Coleman, BW Hancock</div><div class="gs_gray">British journal of cancer 79 (9), 1531-1533<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11132361224900694067" class="gsc_a_ac gs_ibl">43</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:e9bUPLv0EjcC" class="gsc_a_at">open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines</a><div class="gs_gray">K Archibald, R Coleman, C Foster</div><div class="gs_gray">The Lancet 377 (9781), 1915<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8459325477501272284" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:evX43VCCuoAC" class="gsc_a_at">New results from the use of bisphosphonates in cancer patients</a><div class="gs_gray">R Coleman, M Gnant</div><div class="gs_gray">Current opinion in supportive and palliative care 3 (3), 213-218<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2706524599365900241" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EYYDruWGBe4C" class="gsc_a_at">Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer</a><div class="gs_gray">G Chong, A Bhatnagar, D Cunningham, TM Cosgriff, PG Harper, ...</div><div class="gs_gray">Annals of oncology 17 (3), 437-442<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14496486423724553544" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fEOibwPWpKIC" class="gsc_a_at">Bone loss and the aromatase inhibitors</a><div class="gs_gray">J Lester, R Coleman</div><div class="gs_gray">British journal of cancer 93 (1), S16-S22<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2230425849432174975" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dQ2og3OwTAUC" class="gsc_a_at">Should bisphosphonates be the treatment of choice for metastatic bone disease?</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Seminars in oncology 28, 35-41<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9902929720782721052" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wMgC3FpKEyYC" class="gsc_a_at">Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer</a><div class="gs_gray">BA Gartrell, RE Coleman, K Fizazi, K Miller, F Saad, CN Sternberg, ...</div><div class="gs_gray">European urology 65 (2), 278-286<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16179117924218914707" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eGYfIraVYiQC" class="gsc_a_at">Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus</a><div class="gs_gray">P Hadji, R Coleman, M Gnant</div><div class="gs_gray">Critical reviews in oncology/hematology 87 (2), 101-111<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7709579078070653895" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FPJr55Dyh1AC" class="gsc_a_at">Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of vascular research 47 (6), 481-493<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2327858453662697071" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:35r97b3x0nAC" class="gsc_a_at">A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma</a><div class="gs_gray">AR Clamp, FH Blackhall, P Vasey, M Soukop, R Coleman, G Halbert, ...</div><div class="gs_gray">British journal of cancer 89 (7), 1152-1154<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10718324800414085353" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EVUe1p4rgj0C" class="gsc_a_at">Postfeminism and health: Critical psychology and media perspectives</a><div class="gs_gray">S Riley, A Evans, M Robson</div><div class="gs_gray">Routledge<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11946727732641079718" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g9YHGIZn7mcC" class="gsc_a_at">Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK&nbsp;…</a><div class="gs_gray">D Cameron, JP Morden, P Canney, G Velikova, R Coleman, J Bartlett, ...</div><div class="gs_gray">The Lancet Oncology 18 (7), 929-945<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17744999842328078846" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CKf5m1HYVjMC" class="gsc_a_at">Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial</a><div class="gs_gray">C Parker, L Zhan, P Cislo, J Reuning-Scherer, NJ Vogelzang, S Nilsson, ...</div><div class="gs_gray">European Journal of Cancer 71, 1-6<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15179585733660032043" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J-ba04ztB30C" class="gsc_a_at">Bone health in the elderly cancer patient: a SIOG position paper</a><div class="gs_gray">JJ Body, E Terpos, B Tombal, P Hadji, A Arif, A Young, M Aapro, ...</div><div class="gs_gray">Cancer treatment reviews 51, 46-53<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11898433876987084584" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:p__nRnzSRKYC" class="gsc_a_at">Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Clinical breast cancer 7, S29-S35<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10159494202490518220" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tzM49s52ZIMC" class="gsc_a_at">Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases</a><div class="gs_gray">L Costa, A Lipton, RE Coleman</div><div class="gs_gray">Supportive cancer therapy 3 (3), 143-153<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18346266380867280033" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wTekDMGr9GkC" class="gsc_a_at">Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised&nbsp;…</a><div class="gs_gray">R Coleman, A Hall, J Albanell, A Hanby, R Bell, D Cameron, D Dodwell, ...</div><div class="gs_gray">The Lancet Oncology 18 (11), 1543-1552<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1977281169480809237" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0N-VGjzr574C" class="gsc_a_at">Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.</a><div class="gs_gray">RE Coleman, J Wright, S Houston, R Agrawal, OPK Purohit, L Hayward, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), 511-511<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17090047531342059657" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tfDI-GPdlUQC" class="gsc_a_at">Breast cancer follow-up: could primary care be the right venue?</a><div class="gs_gray">M Jiwa, J Thompson, R Coleman, M Reed</div><div class="gs_gray">Current medical research and opinion 22 (4), 625-630<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5727571568204535284" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:t7zJ5fGR-2UC" class="gsc_a_at">Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry</a><div class="gs_gray">CJ Twelves, SM O'Reilly, RE Coleman, MA Richards, RD Rubens</div><div class="gs_gray">British journal of cancer 60 (6), 938-941<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14000735101051033808" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:k6nH7jlkaTkC" class="gsc_a_at">The value of biomarkers in bone metastasis</a><div class="gs_gray">S D'Oronzo, J Brown, R Coleman</div><div class="gs_gray">European journal of cancer care 26 (6), e12725<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16057560620939090472" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8rLWgkbgOXQC" class="gsc_a_at">Treatment of metastatic bone disease and the emerging role of radium-223</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Seminars in nuclear medicine 46 (2), 99-104<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13816578272728032818" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VLnqNzywnoUC" class="gsc_a_at">Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women&nbsp;…</a><div class="gs_gray">JM Saxton, A Daley, N Woodroofe, R Coleman, H Powers, N Mutrie, ...</div><div class="gs_gray">BMC cancer 6 (1), 1-9<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9642999155310555725" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IRz6iEL74y4C" class="gsc_a_at">Textbook of bone metastases</a><div class="gs_gray">C Jasmin, R Capanna, L Coia, R Coleman, G Saillant</div><div class="gs_gray">John Wiley &amp; Sons<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7012370740060274810" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NyGDZy8z5eUC" class="gsc_a_at">Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses</a><div class="gs_gray">A Lipton, R Cook, J Brown, JJ Body, M Smith, R Coleman</div><div class="gs_gray">Clinical Oncology 25 (4), 217-226<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13924273932556018473" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uJ-U7cs_P_0C" class="gsc_a_at">Emerging strategies in bone health management for the adjuvant patient</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Seminars in oncology 34, S11-S16<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4370954380484015708" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BUYA1_V_uYcC" class="gsc_a_at">The management and clinical course of testicular seminoma: 15 years' experience at a single institution</a><div class="gs_gray">JM Coleman, RE Coleman, AR Turner, CR Radstone, AE Champion</div><div class="gs_gray">Clinical Oncology 10 (4), 237-241<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15450860521541260189" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aNch6Af-aFkC" class="gsc_a_at">The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom</a><div class="gs_gray">N Schimdt, L Jacob, R Coleman, K Kostev, P Hadji</div><div class="gs_gray">Breast cancer research and treatment 155 (1), 151-157<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8918295559637199515" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1sJd4Hv_s6UC" class="gsc_a_at">Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST</a><div class="gs_gray">R Coleman, N Bundred, R de Boer, A Llombarto, ID Campbell, P Neven, ...</div><div class="gs_gray">Cancer Res 69 (24), 733s<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6836783211561458244" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:URolC5Kub84C" class="gsc_a_at">Eighteen polymorphic microsatellite markers for rainbow trout (<i>Oncorhynchus mykiss</i>)</a><div class="gs_gray">CE Rexroad III, RL Coleman, WK Hershberger, J Killefer</div><div class="gs_gray">Animal Genetics 33 (1), 76-78<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7660314534236739046" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:H_jBuBxbQIAC" class="gsc_a_at">Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma</a><div class="gs_gray">DM Greenfield, E Boland, Y Ezaydi, RJM Ross, SH Ahmedzai, ...</div><div class="gs_gray">Bone marrow transplantation 49 (7), 907-912<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15066242540098493031" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0urtJCGzaFQC" class="gsc_a_at">Preparing breast cancer patients for survivorship (PREP)–A pilot study of a patient-centred supportive group visit intervention</a><div class="gs_gray">J Thompson, R Coleman, B Colwell, J Freeman, D Greenfield, K Holmes, ...</div><div class="gs_gray">European Journal of Oncology Nursing 18 (1), 10-16<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17124327204098641245" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yTLRzDEmwhEC" class="gsc_a_at">Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the UK experience, 1995-2010.</a><div class="gs_gray">R Agarwal, C Alifrangis, J Everard, PM Savage, D Short, J Tidy, RA Fisher, ...</div><div class="gs_gray">The Journal of reproductive medicine 59 (1-2), 7-12<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11040692321725694138" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3htObqc8RwsC" class="gsc_a_at">Bisphosphonates in the adjuvant treatment of breast cancer</a><div class="gs_gray">MC Winter, RE Coleman</div><div class="gs_gray">Clinical Oncology 25 (2), 135-145<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6640324963157343535" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9Nmd_mFXekcC" class="gsc_a_at">S1-3: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow&nbsp;…</a><div class="gs_gray">R De Boer, N Bundred, H Eidtmann, P Neven, G von Minckwitz, N Martin, ...</div><div class="gs_gray">Cancer Research 71 (24 Supplement), S1-3-S1-3<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1920273583900541611" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xtoqd-5pKcoC" class="gsc_a_at">Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel</a><div class="gs_gray">O Ortmann, O Pagani, A Jones, N Maass, D Noss, H Rugo, ...</div><div class="gs_gray">Cancer treatment reviews 37 (2), 97-104<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12681616460153248856" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tKAzc9rXhukC" class="gsc_a_at">Bisphosphonates in breast cancer: teaching an old dog new tricks</a><div class="gs_gray">MC Winter, RE Coleman</div><div class="gs_gray">Current opinion in oncology 21 (6), 499-506<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4100373003375335451" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZuybSZzF8UAC" class="gsc_a_at">Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)</a><div class="gs_gray">NP O'rourke, EV McCloskey, S Rosini, RE Coleman, JA Kanis</div><div class="gs_gray">British journal of cancer 69 (5), 914-917<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16142814712717429939" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Qh5Z_vBjo80C" class="gsc_a_at">Initial treatment of patients with primary breast Cancer: evidence, controversies, consensus</a><div class="gs_gray">M Untch, J Huober, C Jackisch, A Schneeweiss, SY Brucker, P Dall, ...</div><div class="gs_gray">Geburtshilfe und Frauenheilkunde 77 (06), 633-644<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3387705720042575260" class="gsc_a_ac gs_ibl">33</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XD-gHx7UXLsC" class="gsc_a_at">Assessment of response to treatment</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Bone Metastases, 99-120<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17362098920059576833" class="gsc_a_ac gs_ibl">33</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WZBGuue-350C" class="gsc_a_at">Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference</a><div class="gs_gray">A Lipton, JR Berenson, JJ Body, BF Boyce, OS Bruland, MA Carducci, ...</div><div class="gs_gray">Clinical cancer research 12 (20), 6209s-6212s<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11667554519157637009" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vbGhcppDl1QC" class="gsc_a_at">Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer</a><div class="gs_gray">L El-Helw, RE Coleman</div><div class="gs_gray">The Breast 14 (5), 368-374<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11878300509549102399" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g3aElNc5_aQC" class="gsc_a_at">Skeletal effect of exemestane in the Intergroup Exemestane Study (IES): 2 year bone mineral density (BMD) and bone biomarker data</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Breast Cancer Res Treat 94 (1), S233<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1941828725212008297" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EkHepimYqZsC" class="gsc_a_at">Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">American journal of clinical oncology 25 (6), S25-S31<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14797071439146017242" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kuK5TVdYjLIC" class="gsc_a_at">Anticancer evidence for zoledronic acid across the cancer continuum</a><div class="gs_gray">L Costa, P Harper, RE Coleman, A Lipton</div><div class="gs_gray">Critical reviews in oncology/hematology 77, S31-S37<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=163126096802664783" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ML0RJ9NH7IQC" class="gsc_a_at">Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion</a><div class="gs_gray">JKL Woodward, RE Coleman, I Holen</div><div class="gs_gray">Anti-cancer drugs 16 (1), 11-19<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=523923337807790419" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VaXvl8Fpj5cC" class="gsc_a_at">Bisphosphonates for the prevention of bone metastases.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Seminars in oncology 29 (6 Suppl 21), 43-49<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9706353503167948423" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2KloaMYe4IUC" class="gsc_a_at">Dysfunction of the motivational-affective pain system in patients with IBS: PET brain imaging in response to rectal balloon distension</a><div class="gs_gray">Y Ringel, DA Drossman, TG Turkington, TC Hawk, BH Bradshaw, ...</div><div class="gs_gray">Gastroenterology 4 (118), A444<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=416807688284282922" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:t7izwRedFcYC" class="gsc_a_at">Gender and gentrification</a><div class="gs_gray">W Curran</div><div class="gs_gray">Routledge<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17787304241151901172" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JTtNqH-x4gYC" class="gsc_a_at">Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast&nbsp;…</a><div class="gs_gray">DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Glück, ...</div><div class="gs_gray">Trials 16 (1), 1-10<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13278163289586512044" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LgRImbQfgY4C" class="gsc_a_at">Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia</a><div class="gs_gray">LM El-Helw, RE Coleman, JE Everard, JA Tidy, JM Horsman, ...</div><div class="gs_gray">Gynecologic oncology 113 (3), 306-311<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9296800652205794755" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MLfJN-KU85MC" class="gsc_a_at">Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma</a><div class="gs_gray">JE Brown, SP Ellis, P Silcocks, A Blumsohn, SA Gutcher, C Radstone, ...</div><div class="gs_gray">Clinical cancer research 12 (21), 6480-6486<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8592207349645221767" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YohjEiUPhakC" class="gsc_a_at">Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom</a><div class="gs_gray">JE Lester, D Dodwell, JM Horsman, S Mori, RE Coleman</div><div class="gs_gray">British journal of cancer 94 (1), 30-35<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6456106064291506767" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WqliGbK-hY8C" class="gsc_a_at">Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone&nbsp;…</a><div class="gs_gray">R Coleman, L Rosen, D Gordon, P Major, M Kaminski, J Apffelstaedt, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 76<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8769262427475848821" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AvfA0Oy_GE0C" class="gsc_a_at">Pancreatic metastases from breast cancer: an unusual cause of biliary obstruction</a><div class="gs_gray">J Mountney, AC Maury, AM Jackson, RE Coleman, AG Johnson</div><div class="gs_gray">European journal of surgical oncology: the journal of the European Society&nbsp;…<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8815152324073326921" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yeKNu01O_4gC" class="gsc_a_at">Influence of scan and pathologic criteria on the specificity of cholescintigraphy: concise communication</a><div class="gs_gray">JE Freitas, RE Coleman, CE Nagle, RL Bree, KD Krewer, MD Gross</div><div class="gs_gray">J Nucl Med 24 (10), 876-879<span class="gs_oph">, 1983</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7348972782073411661" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1983</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KIRwYnRZzWQC" class="gsc_a_at">A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom</a><div class="gs_gray">F Taylor, D Short, MC Winter, J Tidy, PM Savage, N Sarwar, BW Hancock, ...</div><div class="gs_gray">Gynecologic oncology 136 (2), 258-263<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5896770432136025434" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ipzZ9siozwsC" class="gsc_a_at">Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma</a><div class="gs_gray">A Lipton, RJ Cook, RE Coleman, MR Smith, P Major, E Terpos, ...</div><div class="gs_gray">Clinical Lymphoma and Myeloma 7 (5), 346-353<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11299742114162224818" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TIZ-Mc8IlK0C" class="gsc_a_at">Supportive care: Uses and abuses of bisphosphonates</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Annals of oncology 11, 179-186<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12330739228821484018" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uWiczbcajpAC" class="gsc_a_at">Current drug treatment guidelines for epithelial ovarian cancer</a><div class="gs_gray">PC Lorigan, T Crosby, RE Coleman</div><div class="gs_gray">Drugs 51 (4), 571-584<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5758588052542673666" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7T2F9Uy0os0C" class="gsc_a_at">Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study</a><div class="gs_gray">HT Mouridsen, M Cornbleet, R Stuart-Harris, I Smith, R Coleman, ...</div><div class="gs_gray">Investigational new drugs 3 (2), 139-148<span class="gs_oph">, 1985</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3532513527723950263" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1985</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:it4f3qIuXWYC" class="gsc_a_at">3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.</a><div class="gs_gray">C Parker, NJ Vogelzang, AO Sartor, RE Coleman, F Fang, I Skjorestad, ...</div><div class="gs_gray">Journal of Clinical Oncology<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3668919436904053897" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZzlSgRqYykMC" class="gsc_a_at">Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer—a randomized biomarker pilot study</a><div class="gs_gray">MC Winter, C Wilson, SP Syddall, SS Cross, A Evans, CE Ingram, IJ Jolley, ...</div><div class="gs_gray">Clinical Cancer Research 19 (10), 2755-2765<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15969023340950273534" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LhH-TYMQEocC" class="gsc_a_at">Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Current opinion in supportive and palliative care 6 (3), 322-329<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3007804287180118611" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:otzGkya1bYkC" class="gsc_a_at">Deaths from gestational trophoblastic neoplasia: any lessons to be learned?</a><div class="gs_gray">SJ Kingdon, RE Coleman, L Ellis, BW Hancock</div><div class="gs_gray">The Journal of reproductive medicine 57 (7-8), 293-296<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11761993701970749270" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:P7Ujq4OLJYoC" class="gsc_a_at">Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice</a><div class="gs_gray">PD Ottewell, HK Brown, M Jones, TL Rogers, SS Cross, NJ Brown, ...</div><div class="gs_gray">Breast cancer research and treatment 133 (2), 523-536<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6714210996606230020" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XvxMoLDsR5gC" class="gsc_a_at">Metastatic cancer to the bone</a><div class="gs_gray">E Chow, JA Finkelstein, RE Coleman</div><div class="gs_gray">DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; practice of oncology&nbsp;…<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18240861063238661595" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w5CyTnyFq80C" class="gsc_a_at">Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia</a><div class="gs_gray">MC Winter, JA Tidy, A Hills, J Ireson, S Gillett, K Singh, BW Hancock, ...</div><div class="gs_gray">Gynecologic oncology 143 (3), 565-570<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12994055970710626545" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ghEM2AJqZyQC" class="gsc_a_at">Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo&nbsp;…</a><div class="gs_gray">RE Coleman, A Lipton, L Costa, RJ Cook, KA Lee, F Saad, JE Brown, ...</div><div class="gs_gray">Journal of bone oncology 2 (2), 70-76<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7043490223861332004" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nZcligLrVowC" class="gsc_a_at">Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug</a><div class="gs_gray">RJ Young, RE Coleman</div><div class="gs_gray">Future oncology 9 (5), 633-643<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7045037261099748513" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rKYHOwt5kWwC" class="gsc_a_at">Acquisition of essential somatic cell cycle regulatory protein expression and implied activity occurs at the second to third cell division in mouse preimplantation embryos</a><div class="gs_gray">Y Xie, T Sun, QT Wang, Y Wang, F Wang, E Puscheck, DA Rappolee</div><div class="gs_gray">FEBS letters 579 (2), 398-408<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6196118217953846939" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gsN89kCJA0AC" class="gsc_a_at">Biochemical markers of malignant bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer and the Skeleton. London: Martin Dunitz, 137-150<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16923585750808790239" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PZE8UkGerEcC" class="gsc_a_at">Hearing voices and the politics of oppression</a><div class="gs_gray">R Coleman</div><div class="gs_gray">This is madness: A critical look at psychiatry and the future of mental&nbsp;…<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12718539459756703995" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-w1eE4La9_EC" class="gsc_a_at">Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomised trials</a><div class="gs_gray">JR Kroep, A Charehbili, RE Coleman, RL Aft, Y Hasegawa, MC Winter, ...</div><div class="gs_gray">European Journal of Cancer 54, 57-63<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13804391604083924268" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0izLItjtcgwC" class="gsc_a_at">The kinetochore protein Cenp‐F is a potential novel target for zoledronic acid in breast cancer cells</a><div class="gs_gray">HK Brown, PD Ottewell, RE Coleman, I Holen</div><div class="gs_gray">Journal of cellular and molecular medicine 15 (3), 501-513<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16598967264868230587" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yqZeyBDMhiUC" class="gsc_a_at">The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The ZO-FAST study 5&nbsp;…</a><div class="gs_gray">R DeBoer, N Bundred, H Eidtmann, A Llombert, P Neven, ...</div><div class="gs_gray">CANCER RESEARCH 70<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13882876695306601497" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jPVjDSAV6m0C" class="gsc_a_at">Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II)</a><div class="gs_gray">S Singh, J Cuzick, R Edwards, G Blake, J Truscott, R Coleman, R Eastell, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11157605365907873429" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:q3CdL3IzO_QC" class="gsc_a_at">A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen</a><div class="gs_gray">SRD Johnston, LA Gumbrell, TRJ Evans, RE Coleman, IE Smith, ...</div><div class="gs_gray">Cancer chemotherapy and pharmacology 53 (4), 341-348<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5236406538839260759" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:umqufdRvDiIC" class="gsc_a_at">Strategy needed for adolescent patients with cancer.</a><div class="gs_gray">RC Leonard, A Gregor, RE Coleman, I Lewis</div><div class="gs_gray">BMJ: British Medical Journal 311 (7001), 387<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5158981344475834856" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4MWp96NkSFoC" class="gsc_a_at">Evaluation of bone disease in breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The Breast 3 (2), 73-78<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1273604578460640171" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tL5YfqkXb3gC" class="gsc_a_at">Levels of distress in breast cancer survivors approaching discharge from routine hospital follow‐up</a><div class="gs_gray">J Thompson, R Coleman, B Colwell, J Freeman, D Greenfield, K Holmes, ...</div><div class="gs_gray">Psycho‐Oncology 22 (8), 1866-1871<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11601188817651817692" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yFnVuubrUp4C" class="gsc_a_at">Bone health management in patients with breast cancer: current standards and emerging strategies</a><div class="gs_gray">MS Aapro, RE Coleman</div><div class="gs_gray">The Breast 21 (1), 8-19<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3101423455669055845" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kh2fBNsKQNwC" class="gsc_a_at">Understanding and optimizing bone health in breast cancer</a><div class="gs_gray">TA Guise, A Brufsky, RE Coleman</div><div class="gs_gray">Current medical research and opinion 26 (sup3), 3-20<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17003278183062775662" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:L7CI7m0gUJcC" class="gsc_a_at">Hypercalcaemia and breast cancer--an increased humoral component in patients with liver metastases.</a><div class="gs_gray">RE Coleman, I Fogelman, RD Rubens</div><div class="gs_gray">European journal of surgical oncology: the journal of the European Society&nbsp;…<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16443233625799638947" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PPrs6GlykQcC" class="gsc_a_at">Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01/04) trial</a><div class="gs_gray">J Brown, E Rathbone, S Hinsley, W Gregory, F Gossiel, H Marshall, ...</div><div class="gs_gray">JNCI: Journal of the National Cancer Institute 110 (8), 871-879<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12758915322782686431" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oFn-K-OQSCAC" class="gsc_a_at">Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study</a><div class="gs_gray">J Lester, D Dodwell, OP Purohit, SA Gutcher, SP Ellis, R Thorpe, ...</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 554-554<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6900374613008982974" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:anf4URPfarAC" class="gsc_a_at">Hormone-and chemotherapy-induced bone loss in breast cancer.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Oncology (Williston Park, NY) 18 (5 Suppl 3), 16-20<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13058703431734441255" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LI9QrySNdTsC" class="gsc_a_at">A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix</a><div class="gs_gray">RE Coleman, JM Clarke, ML Slevin, J Sweetenham, CJ Williams, P Blake, ...</div><div class="gs_gray">Cancer chemotherapy and pharmacology 27 (1), 52-54<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4938568968248739203" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:b1wdh0AR-JQC" class="gsc_a_at">The bone scan and breast cancer</a><div class="gs_gray">I Fogelman, R Coleman</div><div class="gs_gray">Nuclear medicine annual 1988<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6191073742390321607" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:F0CZgh39Fi0C" class="gsc_a_at">Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer</a><div class="gs_gray">JA Westbrook, SL Wood, DA Cairns, K McMahon, R Gahlaut, H Thygesen, ...</div><div class="gs_gray">The Journal of pathology 247 (3), 381-391<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=893561510702573057" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QZWLLlSfqgYC" class="gsc_a_at">Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study</a><div class="gs_gray">C Wilson, R Bell, S Hinsley, H Marshall, J Brown, D Cameron, D Dodwell, ...</div><div class="gs_gray">European Journal of Cancer 94, 70-78<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11153257437117322605" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Bg7qf7VwUHIC" class="gsc_a_at">Gender differences in self‐reported late effects, quality of life and satisfaction with clinic in survivors of lymphoma</a><div class="gs_gray">E Arden‐Close, K Absolom, DM Greenfield, BW Hancock, RE Coleman, ...</div><div class="gs_gray">Psycho‐Oncology 20 (11), 1202-1210<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6000849163214452608" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lvd772isFD0C" class="gsc_a_at">Patient recruitment into a randomised controlled trial of supervised exercise therapy in sedentary women treated for breast cancer</a><div class="gs_gray">AJ Daley, H Crank, N Mutrie, JM Saxton, R Coleman</div><div class="gs_gray">Contemporary clinical trials 28 (5), 603-613<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10332706515586126847" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vkz5F8TaVKkC" class="gsc_a_at">International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients</a><div class="gs_gray">JJ Body, R Coleman, P Clezardin, C Ripamonti, R Rizzoli, M Aapro</div><div class="gs_gray">Eur J Cancer 43 (5), 852-8<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18416624933192315405" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ri6SYOTghG4C" class="gsc_a_at">The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients</a><div class="gs_gray">N Bhala, JM Coleman, CR Radstone, JM Horsman, J George, ...</div><div class="gs_gray">Clinical Oncology 16 (1), 40-47<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15138915880294481144" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:M7yex6snE4oC" class="gsc_a_at">A Phase II study of docetaxel in patients with liver metastases from breast cancer</a><div class="gs_gray">RE Coleman, A Howell, SPH Eggleton, SJ Maling, DW Miles, ...</div><div class="gs_gray">Annals of oncology 11 (5), 541-546<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1383675849067331312" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HbR8gkJAVGIC" class="gsc_a_at">Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis</a><div class="gs_gray">S Sharma, S Jagdev, RE Coleman, BW Hancock, PC Lorigan</div><div class="gs_gray">British journal of cancer 81 (6), 1037-1041<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13196797277821629452" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Dip1O2bNi0gC" class="gsc_a_at">Selection of patients with breast cancer for routine follow-up bone scans</a><div class="gs_gray">RE Coleman, I Fogelman, F Habibollahi, WRS North, RD Rubens</div><div class="gs_gray">Clinical Oncology 2 (6), 328-332<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11211369875401960231" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ILKRHgRFtOwC" class="gsc_a_at">Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study</a><div class="gs_gray">MMD Rubens, T Henning, HR Mouridsen, T Allan</div><div class="gs_gray">Seminars in oncology 11 (3  Suppl 1)<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10679043281962836245" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rmuvC79q63oC" class="gsc_a_at">Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone&nbsp;…</a><div class="gs_gray">AO Sartor, D Heinrich, JM O’Sullivan, SD Fossa, A Chodacki, PJ Wiechno, ...</div><div class="gs_gray">J Clin Oncol 30 (Suppl)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13170084987490234554" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:a3BOlSfXSfwC" class="gsc_a_at">Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?</a><div class="gs_gray">A Lipton, L Costa, RE Coleman</div><div class="gs_gray">Breast disease 33 (2), 59-69<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8068342388362268768" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-95Q15plzcUC" class="gsc_a_at">The voice inside: a practical guide for and about people who hear voices</a><div class="gs_gray">P Baker, M Romme</div><div class="gs_gray">P &amp; P Press<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18066601611836429" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:S16KYo8Pm5AC" class="gsc_a_at">The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease</a><div class="gs_gray">JE Brown, EV McCloskey, JA Dewar, JJ Body, DA Cameron, AN Harnett, ...</div><div class="gs_gray">Calcified tissue international 81 (5), 341-351<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7020330117687804402" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KUbvn5osdkgC" class="gsc_a_at">Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04)</a><div class="gs_gray">R Coleman, H Thorpe, D Cameron, R Bell, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 100<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6881493118989298450" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NXb4pA-qfm4C" class="gsc_a_at">Reducing the global breast cancer burden: the importance of patterns of care research</a><div class="gs_gray">KS Albain, J de la Garza Salazar, T Pienkowski, M Aapro, J Bergh, ...</div><div class="gs_gray">Clinical breast cancer 6 (5), 412-420<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17558888090741591964" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SpbeaW3--B0C" class="gsc_a_at">Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA</a><div class="gs_gray">PC Lorigan, AJ Grierson, JR Goepel, RE Coleman, MH Goyns</div><div class="gs_gray">Cancer letters 104 (1), 27-30<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9219164342203914426" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:z3pV1qEBaUAC" class="gsc_a_at">Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable&nbsp;…</a><div class="gs_gray">J Abraham, R Coleman, A Elias, FA Holmes, K Kalinsky, M Kittaneh, ...</div><div class="gs_gray">Breast cancer research and treatment 171 (1), 11-20<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16553872329015993707" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OR75R8vi5nAC" class="gsc_a_at">Abstract S6-4: Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study.</a><div class="gs_gray">RE Coleman, EJ Rathbone, HC Marshall, C Wilson, JE Brown, F Gossiel, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), S6-4-S6-4<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1454236354786398917" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CB2v5VPnA5kC" class="gsc_a_at">Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?</a><div class="gs_gray">T Young, R Coleman, B Hancock, D Drew, P Wilson, J Tidy</div><div class="gs_gray">Gynecologic oncology 122 (3), 595-599<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4191805397274944837" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ruyezt5ZtCIC" class="gsc_a_at">Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES).</a><div class="gs_gray">J Bliss, L Kilburn, R Coleman, J Forbes, A Coates, S Jones, J Jassem, ...</div><div class="gs_gray">Cancer Research 69 (24 Supplement), 12-12<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6670122321921220849" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WGv8Og3F3KgC" class="gsc_a_at">SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer</a><div class="gs_gray">PA Vasey, R Atkinson, R Osborne, D Parkin, R Symonds, J Paul, ...</div><div class="gs_gray">British journal of cancer 94 (1), 62-68<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9048019087638522747" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IUKN3-7HHlwC" class="gsc_a_at">Conclusion: Bone markers in metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer treatment reviews 32, 27-28<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13309267145884535306" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PoWvk5oyLR8C" class="gsc_a_at">Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma</a><div class="gs_gray">SD Reed, JI Radeva, GA Glendenning, RE Coleman, KA Schulman</div><div class="gs_gray">American journal of clinical oncology 28 (1), 8-16<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10640925711783163586" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:S0RksyIsHSIC" class="gsc_a_at">The dilated cystic duct sign: a potential cause of false-negative cholescintigraphy</a><div class="gs_gray">RE COLEMAN, JE FREITAS, DM FINK-BENNETT, RL BREE</div><div class="gs_gray">Clinical nuclear medicine 9 (3), 134-136<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12417795081601041410" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2SFquFhkCoYC" class="gsc_a_at">nab-Paclitaxel+ Carboplatin or Gemcitabine vs Gemcitabine+ Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the&nbsp;…</a><div class="gs_gray">D Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, ...</div><div class="gs_gray">Liver 20, 31<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=482043464797804989" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pAkWuXOU-OoC" class="gsc_a_at">1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA&nbsp;…</a><div class="gs_gray">S Nilsson, NJ Vogelzang, AO Sartor, D Bottomley, RE Coleman, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (4_suppl), 9-9<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3225493445218831447" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kVjdVfd2voEC" class="gsc_a_at">Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration</a><div class="gs_gray">A Berruti, R Cook, F Saad, C Buttigliero, A Lipton, M Tampellini, KA Lee, ...</div><div class="gs_gray">The oncologist 17 (5), 645<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14673696002730829194" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FiDNX6EVdGUC" class="gsc_a_at">Handbook of cancer-related bone disease</a><div class="gs_gray">RE Coleman, PA Abrahamsson, P Hadji</div><div class="gs_gray">BioScientifica<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4343937515479170287" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mlAyqtXpCwEC" class="gsc_a_at">Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery</a><div class="gs_gray">LJ Murray, S Ramakrishnan, L O'Toole, IH Manifold, OP Purohit, ...</div><div class="gs_gray">The Breast 19 (5), 339-344<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8461763557320315309" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jL-93Qbq4QoC" class="gsc_a_at"><i>tAnGo</i>: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a&nbsp;…</a><div class="gs_gray">AM Wardley, L Hiller, HC Howard, JA Dunn, A Bowman, RE Coleman, ...</div><div class="gs_gray">British journal of cancer 99 (4), 597-603<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14632686526537283711" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PyEswDtIyv0C" class="gsc_a_at">High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening</a><div class="gs_gray">DM Greenfield, J Wright, JE Brown, BW Hancock, HA Davies, L O'toole, ...</div><div class="gs_gray">British journal of cancer 94 (4), 469-472<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15750556593228870788" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_axFR9aDTf0C" class="gsc_a_at">Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study</a><div class="gs_gray">D Serin, M Verrill, A Jones, T Delozier, R Coleman, ED Kreuser, K Mross, ...</div><div class="gs_gray">British journal of cancer 92 (11), 1989-1996<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9179101293642824337" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GO2DTSf4MZMC" class="gsc_a_at">Working with voices II: Victim to victor</a><div class="gs_gray">R Coleman, M Smith</div><div class="gs_gray">P &amp; P Press<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4888521505274226765" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ClCfbGk0d_YC" class="gsc_a_at">Assessment of the effects of breast cancer on bone and the response to therapy</a><div class="gs_gray">JE Brown, RE Coleman</div><div class="gs_gray">The Breast 11 (5), 375-385<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5126301261821455844" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hCrLmN-GePgC" class="gsc_a_at">Small cell carcinoma of the cervix</a><div class="gs_gray">E Sheridan, PC Lorigan, J Goepel, DJ Radstone, RE Coleman</div><div class="gs_gray">Clinical Oncology 8 (2), 102-105<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5824860325280000243" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DUooU5lO8OsC" class="gsc_a_at">A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the&nbsp;…</a><div class="gs_gray">FX Parnis, RE Coleman, PG Harper, D Pickering, C Topham, ...</div><div class="gs_gray">European journal of cancer (Oxford, England: 1990) 31 (10), 1721<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8911968080512434581" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nVrZBo8bIpAC" class="gsc_a_at">Significant differences in UK and US female bone density reference ranges</a><div class="gs_gray">E Noon, S Singh, J Cuzick, TD Spector, FMK Williams, ML Frost, A Howell, ...</div><div class="gs_gray">Osteoporosis international 21 (11), 1871-1880<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11985409641603586642" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PVjk1bu6vJQC" class="gsc_a_at">The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole&nbsp;…</a><div class="gs_gray">R De Boer, H Eidtmann, A Lluch, G Pinotti, J Miller, N Schenk, R Dias, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18107108017081343078" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GtLg2Ama23sC" class="gsc_a_at">Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study</a><div class="gs_gray">JE Lester, SA Gutcher, SP Ellis, R Thorpe, JM Horsman, JE Brown, ...</div><div class="gs_gray">Journal of Clinical Oncology 25 (18_suppl), 553-553<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5337466095702200443" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QYdC8u9Cj1oC" class="gsc_a_at">The role of bone markers in metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer treatment reviews 32, 1-2<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16904127645167180532" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ODE9OILHJdcC" class="gsc_a_at">Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor</a><div class="gs_gray">J Nevin, P Silcocks, B Hancock, R Coleman, R Nakielny, P Lorigan</div><div class="gs_gray">Gynecologic oncology 78 (2), 92-96<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5341049271975159785" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:foquWX3nUaYC" class="gsc_a_at">Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Oncology (Williston Park, NY) 5 (8), 55-60; discussion 60<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4084770281494188369" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:x8G803Bi31IC" class="gsc_a_at">Abstract GS4-03: randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive&nbsp;…</a><div class="gs_gray">G Fleming, PA Francis, I Láng, EM Ciruelos, M Bellet, HR Bonnefoi, ...</div><div class="gs_gray">Cancer Research 78 (4 Supplement), GS4-03-GS4-03<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9832742465525622086" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CmbFvBriOyMC" class="gsc_a_at">Long term follow-up of the Intergroup Exemestane Study (IES)</a><div class="gs_gray">JP Morden, I Alvarez, G Bertelli, AS Coates, R Coleman, L Fallowfield, ...</div><div class="gs_gray">Journal of clinical oncology: official journal of the American Society of&nbsp;…<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5275177956992707730" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MnogvFdIBdwC" class="gsc_a_at">Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Oncology 30 (8), 695-695<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3440239990894893259" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-FonjvnnhkoC" class="gsc_a_at">Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features</a><div class="gs_gray">J Body, R Cook, L Costa, J Brown, E Terpos, F Saad, A Lipton, ...</div><div class="gs_gray">BONE 47, S311-S312<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1980799674709039188" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oNZyr7d5Mn4C" class="gsc_a_at">The effect of zoledronic acid on aromatase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole&nbsp;…</a><div class="gs_gray">A Frassoldati, A Brufsky, N Bundred, R Lambert-Falls, P Hadji, R Mena, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 19, 78-78<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4160018842432859879" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4vMrXwiscB8C" class="gsc_a_at">Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European&nbsp;…</a><div class="gs_gray">L Morales, P Canney, J Dyczka, E Rutgers, R Coleman, T Cufer, ...</div><div class="gs_gray">European Journal of Cancer 43 (2), 331-340<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3050868713410702919" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qYOp8iumCsAC" class="gsc_a_at">A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG)</a><div class="gs_gray">NS Reed, CJ Poole, R Coleman, D Parkin, JD Graham, SB Kaye, ...</div><div class="gs_gray">European journal of cancer 42 (2), 179-185<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11277901796844001920" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FAceZFleit8C" class="gsc_a_at">Pamidronate Disodium in the treatment and management of hypercalcaemia.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Reviews in contemporary pharmacotherapy 9, 147-164<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8636596673005650333" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MvIMIWP2nqIC" class="gsc_a_at">Double-blind randomized trial of pamidronate (AREDIA) for the palliative treatment of metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Proc Annu Meet Am Soc Clin Oncol 15, A1706<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12261871462511834112" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:86PQX7AUzd4C" class="gsc_a_at">A phase II study of sulofenur (LY186641) in gastric cancer.</a><div class="gs_gray">A Kamthan, JH Scarffe, J Walling, S Hatty, B Peters, R Coleman, JF Smyth</div><div class="gs_gray">Anti-cancer drugs 3 (4), 331-335<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7727255873692478013" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XeErXHja3Z8C" class="gsc_a_at">Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice</a><div class="gs_gray">A Goyal, D Dodwell, MW Reed, RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 32 (34), 3902-3902<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2799272894752526359" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oi2SiIJ9l4AC" class="gsc_a_at">Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial</a><div class="gs_gray">JE Lester, D Dodwell, JE Brown, OP Purohit, SA Gutcher, SP Ellis, ...</div><div class="gs_gray">Journal of bone oncology 1 (2), 57-62<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10143400037844073445" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cWzG1nlazyYC" class="gsc_a_at">Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis.</a><div class="gs_gray">W Gregory, H Marshall, R Bell, DA Cameron, RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), 513-513<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9429807316911164587" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5MTHONV0fEkC" class="gsc_a_at">Review of testing and use of adjuvant trastuzumab across a cancer network—are we treating the right patients?</a><div class="gs_gray">SG Coulson, VS Kumar, IM Manifold, MQ Hatton, S Ramakrishnan, ...</div><div class="gs_gray">Clinical Oncology 22 (4), 289-293<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9318036565335664834" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8d8msizDQcsC" class="gsc_a_at">On the horizon: Can bisphosphonates prevent bone metastases?</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast 16, 21-27<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9712274435819226958" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2VqYfGB8ITEC" class="gsc_a_at">An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa&nbsp;…</a><div class="gs_gray">A Brufsky, N Bundred, R Coleman, R Lambert-Falls, R Mena, M Dong, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 100<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17410743102197079721" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HIFyuExEbWQC" class="gsc_a_at">Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours</a><div class="gs_gray">L El-Helw, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 31 (3), 197-209<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17998066936208001338" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FQ36aI_S1AEC" class="gsc_a_at">The politics of the illness</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The construction of power and authority in psychiatry. London, UK&nbsp;…<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12919596300278360789" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_FM0Bhl9EiAC" class="gsc_a_at">Incidence and distribution of bone metastases</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Metastatic bone disease, 20-30<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7747019133270560106" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bz8QjSJIRt4C" class="gsc_a_at">A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer</a><div class="gs_gray">CJ Gallagher, E Wiltshaw, RE Coleman, PG Harper</div><div class="gs_gray">Cancer chemotherapy and pharmacology 24 (1), 54-57<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17830421674045077297" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tSVUDDkujAIC" class="gsc_a_at">2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA</a><div class="gs_gray">O Sartor, RE Coleman, MJ Morris, S Nilsson, N Shore, C Sweeney, ...</div><div class="gs_gray">European Journal of Cancer 3 (51), S484-S485<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10350007123602235289" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6_hjMsCP8ZoC" class="gsc_a_at">Stimmenhören verstehen und bewältigen</a><div class="gs_gray">R Coleman, M Smith</div><div class="gs_gray">Psychiatrie-Verlag<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17376081621680343004" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FiytvqdAVhgC" class="gsc_a_at">Updated survival, quality of life (QOL), and safety data of radium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from&nbsp;…</a><div class="gs_gray">C Parker, RE Coleman, S Nilsson, N Vogelzang, AJ Lloyd, K Staudacher, ...</div><div class="gs_gray">Annals of Oncology 23, ix296<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3340754553901099342" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AHdEip9mkN0C" class="gsc_a_at">Advances in management of bone disease in breast cancer</a><div class="gs_gray">L Walkington, RE Coleman</div><div class="gs_gray">Bone 48 (1), 80-87<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10340718610172924015" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XoXfffV-tXoC" class="gsc_a_at">Fractures negatively affect survival in patients with bone metastases from breast cancer</a><div class="gs_gray">Y Hei, F Saad, R Coleman, Y Chen</div><div class="gs_gray">Breast Cancer Research and Treatment 94<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14872938100824741340" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BrmTIyaxlBUC" class="gsc_a_at">Intergroup exemestane study: 1 year results of the bone sub-protocol</a><div class="gs_gray">R Coleman, L Banks, E Hall, D Price, S Girgis, J Bliss, R Coombes</div><div class="gs_gray">Breast Cancer Research and Treatment 88<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9144636467158246993" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uWy0R8PweswC" class="gsc_a_at">Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer treatment reviews 27 (3), 133-135<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6661221479619052910" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ug5p-4gJ2f0C" class="gsc_a_at">Epirubicin for pretreated advanced ovarian cancer.</a><div class="gs_gray">R Coleman, K Towlson, E Wiltshaw, M Slevin, P Blake, R Stein, ...</div><div class="gs_gray">European journal of cancer (Oxford, England: 1990) 26 (7), 850-851<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15130463289315091327" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:O0MA3yP7Y3UC" class="gsc_a_at">Trace Metal Determination in Fats</a><div class="gs_gray">RD Coleman, JB Thompson, I Branum</div><div class="gs_gray">Analytical Chemistry 20 (4), 365-368<span class="gs_oph">, 1948</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14043408146309267324" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1948</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:m44aUaJR3ikC" class="gsc_a_at">Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of&nbsp;…</a><div class="gs_gray">W Janni, TWP Friedl, T Fehm, V Mueller, W Lichtenegger, J Blohmer, ...</div><div class="gs_gray">Cancer Research 78 (4 Supplement), GS1-06-GS1-06<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8207785999108487444" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:R0GtuAMwyXEC" class="gsc_a_at">The differential anti-tumour effects of zoledronic acid in breast cancer–evidence for a role of the activin signaling pathway</a><div class="gs_gray">C Wilson, P Ottewell, RE Coleman, I Holen</div><div class="gs_gray">BMC cancer 15 (1), 1-11<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=185956848777593044" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zTJoPluU4X4C" class="gsc_a_at">Effects of probiotic and organic acid on performance and organ weights in broiler chicks</a><div class="gs_gray">K Celik, M Mutluay, A Uzatici</div><div class="gs_gray">Archiva Zootechnica 10, 51-56<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=429123262345273717" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OTTXONDVkokC" class="gsc_a_at">Effect of anastrozole on bone mineral density and bone fractures: results from the ‘Arimidex’(anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EJC Supplements 3 (2), 140<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11049643230500765152" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fFSKOagxvKUC" class="gsc_a_at">Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?</a><div class="gs_gray">AM Gillespie, N Siddiqui, RE Coleman, BW Hancock</div><div class="gs_gray">British journal of cancer 79 (7-8), 1270<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6999269052923005083" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:r_AWSJRzSzQC" class="gsc_a_at">The politics of the madhouse</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Handsell Publishing<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13083458442688616620" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DUFsPKDdMi0C" class="gsc_a_at">Material spreader for mounting on a vehicle</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">US Patent 4,124,167<span class="gs_oph">, 1978</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6546880879187211887" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1978</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0CzhzZyukY4C" class="gsc_a_at">UK guidance document: treatment of metastatic breast cancer</a><div class="gs_gray">RE Coleman, G Bertelli, T Beaumont, I Kunkler, D Miles, PD Simmonds, ...</div><div class="gs_gray">Clinical Oncology 24 (3), 169-176<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13195844101833726681" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jgBuDB5drN8C" class="gsc_a_at">Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK</a><div class="gs_gray">OS Din, D Dodwell, MC Winter, S Mori, RE Coleman</div><div class="gs_gray">Clinical Oncology 23 (10), 674-680<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7198828186752375266" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:U4n9YNQMCAIC" class="gsc_a_at">Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast&nbsp;…</a><div class="gs_gray">JL Mansi, A Yellowlees, J Lipscombe, HM Earl, DA Cameron, ...</div><div class="gs_gray">Breast cancer research and treatment 122 (3), 787-794<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12698235665084684877" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HtEfBTGE9r8C" class="gsc_a_at">347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch&nbsp;…</a><div class="gs_gray">MJ Piccart, J Klijn, R Paridaens, M Nooij, L Mauriac, R Coleman, A Awada, ...</div><div class="gs_gray">European Journal of Cancer 31, S75<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8813887609125201619,14056028235574428571" class="gsc_a_ac gs_ibl">14</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:HtEfBTGE9r8C">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yMeIxYmEMEAC" class="gsc_a_at">Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTPPE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study</a><div class="gs_gray">J Verweij, I Judson, W Steward, R Coleman, P Woll, C Van Pottelsberghe, ...</div><div class="gs_gray">European Journal of Cancer 30 (6), 842-843<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11311311262669339922" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dyiPZ63SVtYC" class="gsc_a_at">Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer</a><div class="gs_gray">JM Ubellacker, N Baryawno, N Severe, MJ DeCristo, J Sceneay, ...</div><div class="gs_gray">Cancer research 78 (18), 5300-5314<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=672810362647222480" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pe4chHNxNLUC" class="gsc_a_at">Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an&nbsp;…</a><div class="gs_gray">HM Earl, L Hiller, HC Howard, JA Dunn, J Young, SJ Bowden, ...</div><div class="gs_gray">The Lancet Oncology 18 (6), 755-769<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5040583598707150195" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_OXeSy2IsFwC" class="gsc_a_at">Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function</a><div class="gs_gray">JM Zekri, LM El-Helw, OP Purohit, MQ Hatton, RE Coleman</div><div class="gs_gray">Clinical Oncology 20 (7), 513-516<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14594825305760336633" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:f-E_jMG6T4AC" class="gsc_a_at">Method and system for selecting optimal fishing equipment</a><div class="gs_gray">MS Smith, RK Coleman</div><div class="gs_gray">US Patent 7,243,457<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12341673497598390713,17410421396191668452" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3x-KLxxGyuUC" class="gsc_a_at">Lavorare con le voci</a><div class="gs_gray">R Coleman, M Smith</div><div class="gs_gray">EGA<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15605414335235621508" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_5tno0g5mFcC" class="gsc_a_at">Pharmacokinetics (PK) and pharmacodynamics (PD) of AMG 162, a fully human monoclonal antibody to receptor activator of NF kappa B ligand (RANKL), following a single&nbsp;…</a><div class="gs_gray">MC Peterson, SW Martin, B Stouch, D Chen, DL Holloway, JJ Body, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 8106-8106<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16061345339304735399,9025333142447051314" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3vbIHxFL9FgC" class="gsc_a_at">Metastatic Bone Disease</a><div class="gs_gray">JE Brown, RE Coleman</div><div class="gs_gray">American Journal of Cancer 2 (4), 269-281<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15349035914225523007,11950987404338351764" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4hFrxpcac9AC" class="gsc_a_at">Maintenance treatment with interferon for advanced ovarian cancer</a><div class="gs_gray">G Hall, R Coleman, M Stead, E Gurney, A Phillips, J Brown, D Dassu, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 83, 28-28<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17849467389571962344" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8JTMrWI6FdcC" class="gsc_a_at">Assertive outreach: a step backwards</a><div class="gs_gray">M Smith, R Coleman, P Allott, J Koberstein</div><div class="gs_gray">Nursing times 95 (30), 46-47<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7033009804393295157" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:a9-T7VOCCH8C" class="gsc_a_at">Phase lI study of MTA (LY231514) in patients with locally recurrent or metastatic breast cancer</a><div class="gs_gray">M Lind, IE Smith, RE Coleman, AH Calvert, M Patel, DW Miles</div><div class="gs_gray">PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17&nbsp;…<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12767365350360913946" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mNrWkgRL2YcC" class="gsc_a_at">32. Ibandronate: a well-tolerated new oral bisphosphonate for the treatment of bone metastases.</a><div class="gs_gray">RE Coleman, OP Purohit, C Black, J Vinholes, JA Kanis, K Schlosser, ...</div><div class="gs_gray">The Breast 3 (4), 236<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5038039106473666320" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NDuN12AVoxsC" class="gsc_a_at">Advances in the management of metastatic bone disease</a><div class="gs_gray">RE Coleman, AHG Paterson, PF Conte, CJ Tyrrell, J Walls, ...</div><div class="gs_gray">Breast 3 (3), 181-185<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16142262116393084329" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dBIO0h50nwkC" class="gsc_a_at">A phase II study of mitozantrone in advanced carcinoma of the ovary</a><div class="gs_gray">R Coleman, J Clarke, M Gore, E Wiltshaw, M Slevin, P Harper</div><div class="gs_gray">Cancer chemotherapy and pharmacology 24 (3), 200-202<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17986206341220407589" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:o0tJHVzi6PsC" class="gsc_a_at">Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)</a><div class="gs_gray">JFR Robertson, RE Coleman, KL Cheung, A Evans, C Holcombe, ...</div><div class="gs_gray">Clinical Cancer Research 26 (7), 1574-1585<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1069859237847330889" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pZ2CosqRuhkC" class="gsc_a_at">Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal</a><div class="gs_gray">H Squires, A Pandor, P Thokala, JW Stevens, E Kaltenthaler, M Clowes, ...</div><div class="gs_gray">Pharmacoeconomics 36 (1), 29-38<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8853417124018209624" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uGrg30pLAbkC" class="gsc_a_at">Dosing of zoledronic acid throughout the treatment continuum in breast cancer</a><div class="gs_gray">P Hadji, M Gnant, M Aapro, A Lipton, R Coleman</div><div class="gs_gray">Critical reviews in oncology/hematology 79 (2), 175-188<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13989426243158099039,6786209035943646689" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J3LtWjKFLicC" class="gsc_a_at">P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases</a><div class="gs_gray">M Zheng, L Rosen, D Gordon, M Kaminski, A Howell, A Belch, ...</div><div class="gs_gray">The Breast, S44<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6961270519823489298,10439592185701223875" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dj1AAMDQi3QC" class="gsc_a_at">Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion</a><div class="gs_gray">L Rosen, D Gordon, W Dugan, P Major, P Eisenberg, L Provencher, ...</div><div class="gs_gray">Annals of Oncology 13<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7395568732855858291" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9c2xU6iGI7YC" class="gsc_a_at">Management of bone metastases</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Cancer treatment reviews 23, S69-S75<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16448785332428529670" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:f13iAvnbnnYC" class="gsc_a_at">Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized&nbsp;…</a><div class="gs_gray">PE Goss, CH Barrios, R Bell, DM Finkelstein, H Iwata, M Martin, AH Braun, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), TPS670-TPS670<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13295125136129487682,16005012810223468090" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jU7OWUQzBzMC" class="gsc_a_at">Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer</a><div class="gs_gray">RC Coombes, JM Bliss, M Espie, F Erdkamp, J Wals, A Tres, M Marty, ...</div><div class="gs_gray">Journal of clinical oncology 29 (24), 3247-3254<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11579893006345063474" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:koF6b02d8EEC" class="gsc_a_at">A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who&nbsp;…</a><div class="gs_gray">PE Goss, CH Barrios, R Bell, D Finkelstein, H Iwata, M Martin, AH Braun, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), TPS152-TPS152<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1949673458469720108" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6fxomyk5x4cC" class="gsc_a_at">Ten-year follow-up analysis of the BICRG 001 trial confirms superior DFS and OS benefit of adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) over FAC (fluorouracil&nbsp;…</a><div class="gs_gray">M Martin, J Mackey, T Pienkowski, J Rolski, JP Guastalla, A Sami, ...</div><div class="gs_gray">Cancer Research 70<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1740698566946769162" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6ZxmRoH8BuwC" class="gsc_a_at">Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption</a><div class="gs_gray">L Costa, R Cook, J Body, J Brown, E Terpos, F Saad, A Lipton, ...</div><div class="gs_gray">BONE 47, S302-S303<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5127778713592525727" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MpfHP-DdYjUC" class="gsc_a_at">PET prostate imaging with small planar detectors</a><div class="gs_gray">TG Turkington, MF Smith, TC Hawk, S Majewski, BJ Kross, R Wojcik, ...</div><div class="gs_gray">IEEE Symposium Conference Record Nuclear Science 2004. 5, 2806-2809<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16569698662199350979" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bbjcffOLshcC" class="gsc_a_at">Isolation and characterization of novel tri-and tetranucleotide microsatellite DNA markers for brook trout Salvelinus fontinalis: GenBank submission numbers AY168187, AY168192&nbsp;…</a><div class="gs_gray">TL King, SE Julian, RL Coleman, MK Burnham-Curtis</div><div class="gs_gray">Available: ncbi: nlm. nih. gov/nucleotide<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1619807786960264195" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:F9fV5C73w3QC" class="gsc_a_at">Special problems of adolescents with cancer</a><div class="gs_gray">RCF Leonard, RE Coleman, J O'Regan, A Gregor</div><div class="gs_gray">Journal of Cancer Care 5, 117-120<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6093097948326164645" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ziOE8S1-AIUC" class="gsc_a_at">Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC)(CRUK/05/019)</a><div class="gs_gray">D Cameron, P Barrett-Lee, P Canney, J Banerji, J Bartlett, D Bloomfield, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), S3-3-S3-3<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1686788216896542364" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dFKc6_kCK1wC" class="gsc_a_at">Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer</a><div class="gs_gray">MC Winter, SP Syddall, SS Cross, A Evans, CE Ingram, IJ Jolley, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P1-11-01-P1-11-01<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16239163823932321754" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KbBQZpvPDL4C" class="gsc_a_at">Normalization of bone markers and improved survival during zoledronic acid therapy</a><div class="gs_gray">A Lipton, R Cook, RE Coleman, P Major, E Terpos, J Body, MR Smith, ...</div><div class="gs_gray">Journal of Clinical Oncology 25 (18_suppl), 9013-9013<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9976372190033298513" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OcBU2YAGkTUC" class="gsc_a_at">Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome</a><div class="gs_gray">A Lipton, Y Hei, R Coleman, P Major, R Cook</div><div class="gs_gray">Journal of Clinical Oncology 23 (16_suppl), 532-532<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5729568514499048378" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DJbcl8HfkQkC" class="gsc_a_at">Adsorbent-enhanced methane storage for alternate fuel powered vehicles</a><div class="gs_gray">WE BeVier, JT Mullhaupt, F Notaro, IC Lewis, RE Coleman</div><div class="gs_gray">SAE Technical Paper<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17843329360368221404" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:C2yK8tfAHAgC" class="gsc_a_at">Pion Lifetime, <svg class="gs_fsvg" aria-label="ρπ" width="19px" height="11px" style="vertical-align:-5px;"><g transform="matrix(0.01700, 0.00000, 0.00000, 0.01700, 0.00000, 7.51400)"><g><path transform="scale(0.48828, -0.48828)" d="M 57 -385  Q 57 -373 59 -369  L 262 449  Q 291 559 361 664  T 532 837  T 743 905  Q 832 905 898 858  T 998 736  T 1032 571  Q 1032 472 991 366  T 879 172  T 715 30  T 520 -23  Q 460 -23 407 12  T 324 106  L 203 -377  Q 197 -406 173 -424  T 119 -442  Q 94 -442 75 -427  T 57 -385  Z M 524 31  Q 633 31 713 142  T 836 404  T 879 659  Q 879 737 845 794  T 739 852  Q 650 852 582 784  T 473 626  T 406 436  L 350 207  Q 363 133 408 82  T 524 31  Z "></path><path transform="matrix(0.48828, 0.00000, 0.00000, -0.48828, 517.00000, 0.00000)" d="M 207 35  Q 207 46 215 68  Q 272 187 321 301  T 410 524  T 483 756  H 352  Q 277 756 212 709  T 104 590  Q 100 582 92 582  H 68  Q 49 582 49 602  Q 49 606 53 614  Q 120 728 196 805  T 369 883  H 1112  Q 1133 883 1148 869  T 1163 831  Q 1163 801 1141 778  T 1090 756  H 829  Q 796 595 793 442  Q 793 245 862 86  Q 868 74 868 61  Q 868 39 855 20  T 821 -11  T 778 -23  Q 724 -23 704 65  T 684 236  Q 684 353 704 461  T 768 756  H 545  Q 383 100 350 33  Q 321 -23 270 -23  Q 245 -23 226 -7  T 207 35  Z "></path></g></g></svg> and <svg class="gs_fsvg" aria-label="σπ" width="21px" height="8px" style="vertical-align:-1px;"><g transform="matrix(0.01700, 0.00000, 0.00000, 0.01700, 0.00000, 7.32700)"><g><path transform="scale(0.48828, -0.48828)" d="M 383 -23  Q 292 -23 221 20  T 112 138  T 74 301  Q 74 396 117 501  T 234 693  T 403 831  T 596 883  H 1112  Q 1133 883 1148 869  T 1163 831  Q 1163 801 1141 778  T 1090 756  H 840  Q 899 668 899 543  Q 899 440 859 340  T 748 157  T 582 26  T 383 -23  Z M 385 31  Q 497 31 583 118  T 716 332  T 762 567  Q 762 655 713 705  T 578 756  Q 459 756 375 676  T 250 475  T 209 242  Q 209 154 255 92  T 385 31  Z "></path><path transform="matrix(0.48828, 0.00000, 0.00000, -0.48828, 607.26904, 0.00000)" d="M 207 35  Q 207 46 215 68  Q 272 187 321 301  T 410 524  T 483 756  H 352  Q 277 756 212 709  T 104 590  Q 100 582 92 582  H 68  Q 49 582 49 602  Q 49 606 53 614  Q 120 728 196 805  T 369 883  H 1112  Q 1133 883 1148 869  T 1163 831  Q 1163 801 1141 778  T 1090 756  H 829  Q 796 595 793 442  Q 793 245 862 86  Q 868 74 868 61  Q 868 39 855 20  T 821 -11  T 778 -23  Q 724 -23 704 65  T 684 236  Q 684 353 704 461  T 768 756  H 545  Q 383 100 350 33  Q 321 -23 270 -23  Q 245 -23 226 -7  T 207 35  Z "></path></g></g></svg> Intermediate States, and Sum Rules</a><div class="gs_gray">RA Coleman, JW Moffat</div><div class="gs_gray">Physical Review 186 (5), 1635<span class="gs_oph">, 1969</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5187536601489292022" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1969</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HkunuPqSaCsC" class="gsc_a_at">A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on Human Epidermal Growth Factor Receptor 2 (HER2&nbsp;…</a><div class="gs_gray">R Mahtani, FA Holmes, S Badve, H Caldera, R Coleman, E Mamounas, ...</div><div class="gs_gray">Clinical breast cancer 20 (3), e251-e260<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8016618105854164082" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6e4D8M0GhXMC" class="gsc_a_at">Clinical benefits of bone targeted agents in early breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast 48, S92-S96<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11774739749191318294" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Weau3kkTRIMC" class="gsc_a_at">The role of computed tomography scanning of the thorax in the initial assessment of gestational trophoblastic neoplasia</a><div class="gs_gray">JM Price, C Lo, S Abdi, MC Winter, RE Coleman, J Tidy, BW Hancock</div><div class="gs_gray">International Journal of Gynecologic Cancer 25 (9)<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10394325276045685282" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VBDT71xRUdcC" class="gsc_a_at">Inhibition of BRAF and MEK in BRAF-mutant melanoma</a><div class="gs_gray">KSM Smalley, VK Sondak</div><div class="gs_gray">The Lancet 386 (9992), 410-412<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9285308630654025229" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kw52XkFRtyQC" class="gsc_a_at">Abstract PD07-09: Zoledronate versus ibandronate comparative evaluation (ZICE) trial-first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus&nbsp;…</a><div class="gs_gray">PJ Barrett-Lee, A Casbard, J Abraham, R Grieve, D Wheatley, P Simmons, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), PD07-09-PD07-09<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13740614637001290730" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RJOyoaXV5v8C" class="gsc_a_at">Safety of cytotoxic chemotherapy following radium-223 chloride (ra-223) therapy in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) with&nbsp;…</a><div class="gs_gray">O Sartor, RE Coleman, S Nilsson, N Vogelzang, A Cross, ...</div><div class="gs_gray">Annals of Oncology 23, ix308-ix309<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8655928168267738553" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kJDgFkosVoMC" class="gsc_a_at">A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts</a><div class="gs_gray">HK Brown, PD Ottewell, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">Journal of bone oncology 1 (2), 47-56<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6769171684133356821" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YsrPvlHIBpEC" class="gsc_a_at">Adjuvant therapy with bone-targeted agents</a><div class="gs_gray">C Wilson, RE Coleman</div><div class="gs_gray">Current opinion in supportive and palliative care 5 (3), 241-250<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10874243854393955582" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1lhNe0rCu4AC" class="gsc_a_at">Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey</a><div class="gs_gray">L Fallowfield, V Jenkins, R Coleman</div><div class="gs_gray">The Breast 17 (5), 459-463<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4619203228366824871" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cK4Rrx0J3m0C" class="gsc_a_at">Preserving skeletal wellness throughout the continuum of care in patients with cancer. Introduction.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Seminars in oncology 34 (6 Suppl 4), S1-3<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15463054375990714017,627862192551399187" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OP4eGU-M3BUC" class="gsc_a_at">Using bone turnover markers to direct bisphosphonate therapy: is this a feasible approach?</a><div class="gs_gray">JE Brown, SP Ellis, SA Gutcher, OP Purohit, L Turner, HL Neville-Webbe, ...</div><div class="gs_gray">Cancer Treatment Reviews 31, S30-S30<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6361177818846553963" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3YQzwbzlpKYC" class="gsc_a_at">Revolutionary politics and mental health</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Stockport: Handsell<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9366810901229846596" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vDZJ-YLwNdEC" class="gsc_a_at">Malignant mixed mullerian tumours of gynaecological origin: chemosensitive but aggressive tumours</a><div class="gs_gray">E Krishnan, RE Coleman</div><div class="gs_gray">Clinical Oncology 10 (4), 246-249<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3839166723120759845" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Aul-kAQHnToC" class="gsc_a_at">369 Advanced breast cancer: A phase II trial with gemcitabine (GEM)</a><div class="gs_gray">K Possinger, M Kaufmann, M Helsing, R Coleman, J Blatter</div><div class="gs_gray">European Journal of Cancer 31, S80<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17921852218732970833" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3wLP7v6BnpwC" class="gsc_a_at">The professional and personal needs of oncology staff: the effects of perceived success and failure in helping patients on levels of personal stress and distress</a><div class="gs_gray">G Kent, G Wills, A Faulkner, G Parry, M Whipp, R Coleman</div><div class="gs_gray">J Cancer Nurs 3, 153-158<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6242819960734634512" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HeT0ZceujKMC" class="gsc_a_at">Phase II study of mitoxantrone for liver metastases from breast cancer</a><div class="gs_gray">SM O'Reilly, RE Coleman, RD Rubens</div><div class="gs_gray">Cancer chemotherapy and pharmacology 25 (1), 73-74<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11897124946410635340" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SC9kKMAi-DoC" class="gsc_a_at">An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain</a><div class="gs_gray">S Danson, MR Mulvey, L Turner, J Horsman, KJ Escott, RE Coleman, ...</div><div class="gs_gray">Journal of bone oncology 19, 100261<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9610055785505026783" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ipSP0SfFaZ8C" class="gsc_a_at">Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial</a><div class="gs_gray">JS Walsh, H Marshall, IL Smith, DM Greenfield, J Swain, E Best, J Ashton, ...</div><div class="gs_gray">PLoS medicine 16 (11), e1002960<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13110181751149909389" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7XUxBq3GufIC" class="gsc_a_at">Bone targeted treatments in cancer–The story so far</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Journal of bone oncology 5 (3), 90<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3527236207484211145" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:anDooRL1HQEC" class="gsc_a_at">Late spontaneous resolution of persistent molar pregnancy</a><div class="gs_gray">F Taylor, D Short, R Harvey, MC Winter, J Tidy, BW Hancock, PM Savage, ...</div><div class="gs_gray">BJOG: An International Journal of Obstetrics &amp; Gynaecology 123 (7), 1175-1181<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2770533012373135030" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZOYfmFL0FrgC" class="gsc_a_at">Goserelin, as an ovarian protector during (neo) adjuvant breast cancer chemotherapy, prevents long term altered bone turnover</a><div class="gs_gray">C Wilson, F Gossiel, R Leonard, RA Anderson, DJA Adamson, G Thomas, ...</div><div class="gs_gray">Journal of bone oncology 5 (1), 43-49<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8597654190933935793" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KsTgnNRry18C" class="gsc_a_at">Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international&nbsp;…</a><div class="gs_gray">PE Goss, CH Barrios, A Chan, DM Finkelstein, H Iwata, M Martin, A Braun, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), OT2-3-03-OT2-3-03<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12287805911632846825,467983807742878051" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:iKswqCX-FLkC" class="gsc_a_at">Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first&nbsp;…</a><div class="gs_gray">RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), S1-6-S1-6<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8127685482676296594" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2tRrZ1ZAMYUC" class="gsc_a_at">Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.</a><div class="gs_gray">H Marshall, W Gregory, R Bell, DA Cameron, DJ Dodwell, MM Keane, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), 502-502<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10389419419751744920" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Og1tA8FjbJAC" class="gsc_a_at">Radioisotope and PET imaging of bone metastases</a><div class="gs_gray">RE Coleman, GJR Cook, I Fogelman</div><div class="gs_gray">Textbook of bone metastases, 77-90<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16700692948354210122" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ehil0879vHcC" class="gsc_a_at">Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases</a><div class="gs_gray">L Rosen, D Gordon, S Tchekmedyian, V Hirsh, R Yanagihara, R Coleman</div><div class="gs_gray">Bone 34, S89-S89<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9047511229233093825" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5icHVeHT4IsC" class="gsc_a_at">Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases</a><div class="gs_gray">L Rosen, R Coleman, D Gordon, P Major, M Kaminski, J Apffelstaedt, ...</div><div class="gs_gray">The Breast 12, S42-S43<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16764852261526968013" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PYBJJbyH-FwC" class="gsc_a_at">Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era.</a><div class="gs_gray">G Atalay, L Biganzoli, F Renard, R Paridaens, V Batter, T Cufer, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 76<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9249258836964129122" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ef4XXjhdXvQC" class="gsc_a_at">Setting new standards in bisphosphonate therapy</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">AMERICAN JOURNAL OF CLINICAL ONCOLOGY 25 (6; SUPP/1), S1-S2<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13720954253683676186" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:43bX7VzcjpAC" class="gsc_a_at">VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</a><div class="gs_gray">LM El Helw, PC Lorigan, MH Robinson, RE Coleman, BW Hancock</div><div class="gs_gray">International journal of oncology 16 (4), 777-859<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7986023463562414302" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3_f9JqYsqVQC" class="gsc_a_at">Working to recovery</a><div class="gs_gray">R Coleman, P Baker, K Taylor</div><div class="gs_gray">Victim to Victor III. Gloucester: Handsell Publishing<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13648002399362961392" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8xutWZnSdmoC" class="gsc_a_at">Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate</a><div class="gs_gray">AM Gillespie, PC Lorigan, CR Radstone, JC Waterhouse, RE Coleman, ...</div><div class="gs_gray">British journal of cancer 76 (10), 1382-1386<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13028821245568688518" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bKqednn6t2AC" class="gsc_a_at">New roles for bisphosphonates in cancer therapy</a><div class="gs_gray">R Coleman, K Purohit, J Vinholes</div><div class="gs_gray">Progress in Palliative Care 4 (2), 39-43<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1362529842604584859" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HtS1dXgVpQUC" class="gsc_a_at">Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting.</a><div class="gs_gray">RE Coleman, CJ Twelves, SM O'Reilly, RD Rubens, MA Richards, ...</div><div class="gs_gray">European journal of cancer (Oxford, England: 1990) 27 (8), 1062-1063<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1057274742208545448" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:54SpJiyHbzwC" class="gsc_a_at">Case-based review and clinical guidance on the use of genomic assays for early-stage breast cancer: Breast Cancer Therapy Expert Group (BCTEG)</a><div class="gs_gray">M Kittaneh, S Badve, H Caldera, R Coleman, MP Goetz, R Mahtani, ...</div><div class="gs_gray">Clinical breast cancer 20 (3), 183-193<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10979644614771240446" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OKy9v0bssVUC" class="gsc_a_at">Personality pathology: Developmental perspectives</a><div class="gs_gray">D Gilles, DM Ashcroft, L Rigaud, A Kearns</div><div class="gs_gray">Routledge<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16285195654594627232" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eJjLl3UG7CkC" class="gsc_a_at">A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT-Randomised EuropeAn Celecoxib Trial)</a><div class="gs_gray">RC Coombes, H Tovey, L Kilburn, J Mansi, C Palmieri, J Bartlett, J Hicks, ...</div><div class="gs_gray">CANCER RESEARCH 78 (4)<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12812517497930781576" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J6OZcwVsj5AC" class="gsc_a_at">Adjuvant bone-targeted therapies for postmenopausal breast cancer</a><div class="gs_gray">C Wilson, R Coleman</div><div class="gs_gray">JAMA oncology 2 (4), 423-424<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13292707271319625659" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LlXTz_FrCmAC" class="gsc_a_at">Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age‐matched control study</a><div class="gs_gray">DM Greenfield, A Blewitt, RE Coleman, JS Walsh, JA Snowden, ...</div><div class="gs_gray">Clinical endocrinology 84 (2), 296-304<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8164415061181133384" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oldoQiaHq2UC" class="gsc_a_at">Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience.</a><div class="gs_gray">J Ireson, K Singh, S Gillett, A Hills, J Everard, M Winter, RE Coleman, ...</div><div class="gs_gray">The Journal of reproductive medicine 59 (5-6), 195-198<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11479253035269324199" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YlPif8NxrbYC" class="gsc_a_at">Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data&nbsp;…</a><div class="gs_gray">R Coleman, M Gnant, A Paterson, T Powles, G von Minckwitz, K Pritchard, ...</div><div class="gs_gray">Cancer Research 73 (24 Supplement), S4-07-S4-07<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6372637766130068890" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8dzOF9BpDQoC" class="gsc_a_at">Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer&nbsp;…</a><div class="gs_gray">JM Bliss, P Ellis, L Kilburn, J Bartlett, D Bloomfield, D Cameron, P Canney, ...</div><div class="gs_gray">Cancer Research 72 (24 Supplement), P1-13-03-P1-13-03<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3690503906420565225" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zCSUwVk65WsC" class="gsc_a_at">Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): survival in patients with high bone turnover</a><div class="gs_gray">RJ Cook, V Hirsh, PP Major, F Saad, R Dias, A Lipton, RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 20562-20562<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7291849853159627627" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZpgFv6i7Z4gC" class="gsc_a_at">P53. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: Initial dental safety findings from the AZURE study</a><div class="gs_gray">R Burkinshaw, M Winter, H Thorpe, J Pedlar, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, 40-41<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5308788906640947188" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ak0FvsSvgGUC" class="gsc_a_at">P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover</a><div class="gs_gray">R Coleman, R Cook, F Saad, V Hirsh, P Major, R Dias, A Lipton</div><div class="gs_gray">Cancer Treatment Reviews 34, 43<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8609292772045996593" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9LpHyFPp1DQC" class="gsc_a_at">General mechanisms of metastasis</a><div class="gs_gray">RE Coleman, SA Eccles</div><div class="gs_gray">Textbook of Bone Metastases, 1-25<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4343130007900398103" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4X0JR2_MtJMC" class="gsc_a_at">Rapid, profound, and prolonged suppression of bone turnover with a single SC dose of AMG 162 in women with breast cancer metastatic to bone</a><div class="gs_gray">JJ Body, RE Coleman, A Lipton, R Murphy, DL Holloway, PJ Bekker, ...</div><div class="gs_gray">Journal of Bone and Mineral Research 19 (9), 1593-1593<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11210108553302040991" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yqoGN6RLRZoC" class="gsc_a_at">Why is zoledronic acid (Z) superior to pamidronate (P) for bone metastases from breast cancer (BC) but equivalent in multiple myeloma (MM)</a><div class="gs_gray">RE Coleman, R Cook, P Major</div><div class="gs_gray">Proc Am Soc Clin Oncol 22 (Suppl.), 47<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=105244948295653137" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IaI1MmNe2tcC" class="gsc_a_at">High dose chemotherapy: Rationale and results in breast carcinoma</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Cancer: Interdisciplinary International Journal of the American Cancer&nbsp;…<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=907807407372279441" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4xDN1ZYqzskC" class="gsc_a_at">EORTC 10968; Phase I study of Caelyx<sup>T</sup><sup>M</sup> at a six week interval in patients with metastatic breast cancer</a><div class="gs_gray">A Hamilton, R Coleman, L Mauriac, A Awada, M Piccart, A Van Vreckem, ...</div><div class="gs_gray">European Journal of Cancer 34 (1005), S19-S19<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=390906260206619239" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ubry08Y2EpUC" class="gsc_a_at">The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.</a><div class="gs_gray">P Thompson, P Wilson, R Osborne, M Slevin, F Wiltshaw, P Blake, ...</div><div class="gs_gray">British journal of cancer 64 (5), 973<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4853580806728790245" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9w-KRoa3VEQC" class="gsc_a_at">Bone metastasis: Mechanisms, therapies, and biomarkers</a><div class="gs_gray">P Clézardin, R Coleman, M Puppo, P Ottewell, E Bonnelye, F Paycha, ...</div><div class="gs_gray">Physiological Reviews 101 (3), 797-855<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8892344609319622862" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5AT-p8ixKR4C" class="gsc_a_at">Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group</a><div class="gs_gray">JE Brown, C Handforth, JE Compston, W Cross, N Parr, P Selby, S Wood, ...</div><div class="gs_gray">Journal of Bone Oncology 25, 100311<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14707848143057689702" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eG7oJ4UONFcC" class="gsc_a_at">Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer</a><div class="gs_gray">C Handforth, R Burkinshaw, J Freeman, JE Brown, JA Snowden, ...</div><div class="gs_gray">Supportive Care in Cancer 27 (5), 1755-1763<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4325869420413644234" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ve7iT2ZEuL4C" class="gsc_a_at">Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)</a><div class="gs_gray">J Abraham, H Caldera, R Coleman, A Elias, MP Goetz, M Kittaneh, ...</div><div class="gs_gray">Breast cancer research and treatment 169 (1), 1-7<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2571066657966362548" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:k8to_Y4Q4_EC" class="gsc_a_at">Denosumab and fracture risk in women with breast cancer.</a><div class="gs_gray">R Coleman, P Hadji</div><div class="gs_gray">Lancet (London, England) 386 (9992), 409-410<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6106879887933003676" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:h9G0ZmjYpDoC" class="gsc_a_at">2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases&nbsp;…</a><div class="gs_gray">O Sartor, RE Coleman, S Nilsson, NJ Vogelzang, K Staudacher, ...</div><div class="gs_gray">European Journal of Cancer 3 (51), S477<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6342569820365090014" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kOdZbmsmKqcC" class="gsc_a_at">Oral surgery: ARONJ masterclass</a><div class="gs_gray">A Moore, T Renton, T Taylor, S Popat, R Popat, Z Sivardeen, I Fogelman, ...</div><div class="gs_gray">British dental journal 216 (9), 488-489<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6080677972709107201" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gKiMpY-AVTkC" class="gsc_a_at">Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from&nbsp;…</a><div class="gs_gray">NJ Vogelzang, C Parker, S Nilsson, RE Coleman, CG O'Bryan-Tear, ...</div><div class="gs_gray">Journal of Clinical Oncology 31 (6_suppl), 11-11<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2454259293242466670" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wvYxNZNCP7wC" class="gsc_a_at">Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.</a><div class="gs_gray">JM Price, BW Hancock, J Tidy, J Everard, RE Coleman</div><div class="gs_gray">The Journal of reproductive medicine 55 (7-8), 301-304<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3437654953339472618" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BJbdYPG6LGMC" class="gsc_a_at">Refining systemic therapy for early breast cancer: difficulties with subtraction.</a><div class="gs_gray">D Dodwell, H Thorpe, R Coleman</div><div class="gs_gray">The Lancet. Oncology 10 (8), 738-739<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5117156122214247351" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hsZV8lGYWTMC" class="gsc_a_at">Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC)</a><div class="gs_gray">JE Brown, A Lipton, RJ Cook, D Michaelson, RE Coleman, F Saad</div><div class="gs_gray">Journal of Clinical Oncology 27 (15_suppl), e16016-e16016<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14584430849876671090" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gVv57TyPmFsC" class="gsc_a_at">Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 587-587<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15321245243196839654" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lRPiJ3GhvscC" class="gsc_a_at">Recovery: Et nyt perspektiv i psykiatrien</a><div class="gs_gray">R Coleman</div><div class="gs_gray">PsykoVision<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6111972818940461516" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:j7_hQOaDUrUC" class="gsc_a_at">Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo</a><div class="gs_gray">PD Ottewell, M Jones, RE Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research 8 (2), 1-1<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2036878594788914312" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rHJHxKgnXwkC" class="gsc_a_at">High‐dose chemotherapy with haematopoietic stem‐cell support in patients with poor prognosis, relapsed or refractory germ cell tumours</a><div class="gs_gray">LM EL‐HELW, JD Naik, JD Chester, JK Joffe, PJ Selby, RE Coleman</div><div class="gs_gray">BJU international 98 (3), 519-525<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5899974667633101758" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tH6gc1N1XXoC" class="gsc_a_at">Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data</a><div class="gs_gray">JJ Body, M Lichinitser, RE Coleman, B Bergström</div><div class="gs_gray">Bone 3 (38), 69<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2617904801990293633" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mWEH9CqjF64C" class="gsc_a_at">Monitoring response to treatment—the role of biochemical markers</a><div class="gs_gray">RE Coleman, JE Brown</div><div class="gs_gray">Textbook of bone metastases, 105-121<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16829921056225631157" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yxmsSjX2EkcC" class="gsc_a_at">Managing metastatic bone disease: three case studies</a><div class="gs_gray">R Coleman, A Heidenreich, R Bell</div><div class="gs_gray">Seminars in oncology 31, 83-86<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14389205069217359014" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6yz0xqPARnAC" class="gsc_a_at">Zoledronic acid is being investigated for the prevention of bone metastases in patients with early-stage breast cancer</a><div class="gs_gray">R Coleman, J Gralow, R Bell, A Lipton</div><div class="gs_gray">Bone 34, S85-S85<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12484722006480025765" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uDGL6kOW6j0C" class="gsc_a_at">Update on the role of bisphosphonates in metastatic breast cancer-Introduction</a><div class="gs_gray">A Lipton, RE Coleman, IJ Diel, G Mundy</div><div class="gs_gray">SEMINARS IN ONCOLOGY 28 (4), 1-1<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14139505226693159904" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7H_MAutzIkAC" class="gsc_a_at">Single agent Taxol [R] versus doxorubicin as first line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover</a><div class="gs_gray">T Gamucci, M Piccart, P Brüning, J Klijn, L Biganzoli, S Houston, ...</div><div class="gs_gray">PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17&nbsp;…<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7598896587486322391,6155370348256111918" class="gsc_a_ac gs_ibl">6</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:7H_MAutzIkAC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rrpmhsargb8C" class="gsc_a_at">Victim to victor</a><div class="gs_gray">R Coleman, M Smith</div><div class="gs_gray">Hansell Publications<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6691100844508936220" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sszUF3NjhM4C" class="gsc_a_at">Imaging of metastatic bone disease</a><div class="gs_gray">J Vinholes, APB Vinholes, RE Coleman</div><div class="gs_gray">IMAGING-OXFORD- 8, 256-273<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16668572211212953832" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:v1_lew4L6wgC" class="gsc_a_at">Advanced breast cancer in Egyptian women: clinical features and response to endocrine therapy. The Anglo-Egyptian Health Agreement Collaborative Study.</a><div class="gs_gray">MA Richards, RE Coleman, R Hamsa, H Khaled, MG El Mawla, I Kadry, ...</div><div class="gs_gray">European journal of surgical oncology: the journal of the European Society&nbsp;…<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13793460784930034335" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:F1b5ZUV5XREC" class="gsc_a_at">Surgery following chemotherapy for metastatic testicular teratoma</a><div class="gs_gray">D Whillis, RE Coleman, AM Lessells, TB Hargreave, MA Cornbleet, ...</div><div class="gs_gray">British journal of urology 68 (3), 292-295<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9921917715271769519" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nRpfm8aw39MC" class="gsc_a_at">Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases.</a><div class="gs_gray">R Coleman, LY Dirix, D Dodwell, M Tubiana, JJ Body, R Becher, ...</div><div class="gs_gray">European journal of cancer 27 (7), 945-946<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16997994036104563544" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kVKjLOQJbwAC" class="gsc_a_at">CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial</a><div class="gs_gray">R Coleman, J Brown, E Rathbone, L Flanagan, A Reid, J Kendall, ...</div><div class="gs_gray">Trials 21 (1), 1-10<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1835663097267207017" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mS4qin7VKjkC" class="gsc_a_at">An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients</a><div class="gs_gray">R Baird, I Banks, D Cameron, J Chester, H Earl, M Flannagan, ...</div><div class="gs_gray">ecancermedicalscience 10<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14738080191828555633" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FtNbRaqWXr4C" class="gsc_a_at">1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the&nbsp;…</a><div class="gs_gray">C Parker, NJ Vogelzang, AO Sartor, D Bottomley, RE Coleman, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), 5070-5070<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12731732864091784073" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:X9ykpCP0fEIC" class="gsc_a_at">Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.</a><div class="gs_gray">MR Smith, RE Coleman, L Klotz, KB Pittman, P Milecki, R Wei, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (4_suppl), 35-35<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6212489968492423337" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IHkkN1K1AlAC" class="gsc_a_at">99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer</a><div class="gs_gray">D Patrick, MR Smith, C Cleeland, L Fallowfield, B Tombal, S Oudard, ...</div><div class="gs_gray">European Urology Supplements 1 (12), e99-e100<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15895219687234112543" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AubyX3KqGToC" class="gsc_a_at">Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant&nbsp;…</a><div class="gs_gray">R Coleman, BR De, H Eidtmann, P Neven, G von Minckwitz, N Martin, ...</div><div class="gs_gray">Cancer Research 71<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2901507214475678283" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vnF2_uLGgtgC" class="gsc_a_at">Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor&nbsp;…</a><div class="gs_gray">A Garcia, A Awada, S Chan, GHM Jerusalem, RE Coleman, MT Huizing, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (27_suppl), 269-269<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6918083258659901205" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-7ulzOJl1JYC" class="gsc_a_at">Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).</a><div class="gs_gray">A Awada, S Chan, GHM Jerusalem, RE Coleman, MT Huizing, A Mehdi, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), 1034-1034<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10163730725909542312" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DkZNVXde3BIC" class="gsc_a_at">Ovarian germ cell malignancy: a heterogeneous tumour requiring supra-regional management.</a><div class="gs_gray">IV Luis, R Coleman</div><div class="gs_gray">European journal of gynaecological oncology 32 (4), 387-392<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18165559463457840128" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MAUkC_7iAq8C" class="gsc_a_at">Abstract P6-11-01: Significant Efficacy in a Phase 2 Study of NKTR-102, a Novel Polymer Conjugate of Irinotecan, in Patients with Pre-Treated Metastatic Breast Cancer (MBC)</a><div class="gs_gray">A Awada, S Chan, G Jerusalem, M Huizing, RE Coleman, A Mehdi, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P6-11-01-P6-11-01<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13701069033630297348" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MhiOAD_qIWkC" class="gsc_a_at">ANZAC: a neoadjuvant biomarker study exploring the anti-tumour activity of the AdditioN of Zoledronic Acid to Chemotherapy in breast cancer</a><div class="gs_gray">MC Winter, SS Cross, CE Ingram, IJ Jolley, I Holen, MQ Hatton, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 20, 55-55<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4980404846917785564" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1yWc8FF-_SYC" class="gsc_a_at">Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.</a><div class="gs_gray">J Berenson, R Cook, A Lipton, R Coleman, E Terpos</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 110 (11), 1499-1499<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15116409047315770853" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:F2UWTTQJPOcC" class="gsc_a_at">Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors</a><div class="gs_gray">N Shirina, RE Coleman, YM Chen</div><div class="gs_gray">Journal of Clinical Oncology 24 (18_suppl), 8529-8529<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9343670978231166141" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CNPyR2KL9-0C" class="gsc_a_at">Predictors of clinical outcome in patients with prostate cancer and bone metastases: prognostic significance of fractures and bone markers</a><div class="gs_gray">F Saad, RE Coleman, R Cook, JE Brown, M Smith, YJ Hei, YM Chen</div><div class="gs_gray">European Urology Supplements 2 (5), 55<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13617974673443032723" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SjuI4pbJlxcC" class="gsc_a_at">Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease</a><div class="gs_gray">J Body, M Lichinitser, S Tjulandin, R Coleman, B Bergström</div><div class="gs_gray">Breast Cancer Research and Treatment 94<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5595696978514985332" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PaBasH6fAo0C" class="gsc_a_at">Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer</a><div class="gs_gray">A Lipton, Y Hei, R Coleman, P Major, M Smith, R Cook, S Milton</div><div class="gs_gray">Breast Cancer Research and Treatment 94<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16636525006670743511" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:48xauSegjOkC" class="gsc_a_at">The use of bisphosphonates in breast cancer</a><div class="gs_gray">J Lester, R Coleman</div><div class="gs_gray">British Menopause Society Journal 11 (1), 12-17<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3452048854295180382" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CdxZDUztZiMC" class="gsc_a_at">Overview of osteoclast inhibitors</a><div class="gs_gray">C Jasmin, JJ Body</div><div class="gs_gray">Textbook of Bone metastases, 291-299<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8845456136885011921" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1taIhTC69MYC" class="gsc_a_at">Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer</a><div class="gs_gray">HL Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S28-S28<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4190582839064107948" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7wO8s98CvbsC" class="gsc_a_at">Adjuvant use of anastrozole in breast cancer</a><div class="gs_gray">J Cuzick, A Buzdar, M Baum, R Bianco, R Coleman, M Constenla, ...</div><div class="gs_gray">Journal of clinical oncology: official journal of the American Society of&nbsp;…<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6527084116987788622" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sJsF-0ZLhtgC" class="gsc_a_at">Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors</a><div class="gs_gray">R Coleman, L Rosen, DM Gleason, M Zheng</div><div class="gs_gray">BONE 34, S84-S85<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11085330048370991597" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CaZNVDsoPx4C" class="gsc_a_at">Evidence-based oncology in cancer treatment reviews.</a><div class="gs_gray">B Djulbegovic, R Coleman, R Stahel, D Singh, G Lyman</div><div class="gs_gray">Cancer treatment reviews 29 (1), 45-50<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2472471058637786933" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3NQIlFlcGxIC" class="gsc_a_at">P-676 Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer</a><div class="gs_gray">R Bukowski, LS Rosen, D Gordon, S Tchekmedyian, V Hirsh, ...</div><div class="gs_gray">Lung Cancer, S262-S263<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16548029284378158286" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7Hz3ACDFbsoC" class="gsc_a_at">Exemestane in metastatic breast cancer: effective therapy after 3rd generation aromatase inhibitor failure</a><div class="gs_gray">N Fernie, J Zekri, R Leonard, R Coleman, D Cameron</div><div class="gs_gray">Breast Cancer Research and Treatment 82<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16302121094904779699" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DBa1UEJaJKAC" class="gsc_a_at">Treatment of tumor induced osteolysis and prevention of skeletal-related events in patients with bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Tumor Bone Diseases and Osteoporosis in Cancer Patients: Pathophysiology&nbsp;…<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5973576197334622944" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6bLC7aUMtPcC" class="gsc_a_at">Bisphosphonates in the prevention and treatment of metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The Breast 8 (2), 57-62<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=775239968759593937" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LPtt_HFRSbwC" class="gsc_a_at">More money is needed to care for patients with cancer.</a><div class="gs_gray">RC Leonard, IE Smith, RE Coleman, JS Malpas, M Nicolson, J Cassidy, ...</div><div class="gs_gray">BMJ: British Medical Journal 315 (7111), 811<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16768962804923113502" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=500&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u-coK7KVo8oC" class="gsc_a_at">The management of bone metastases</a><div class="gs_gray">J Vinholes, R Coleman</div><div class="gs_gray">The Teaching Cases from Annals of Oncology, 29-36<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=199525976851044047" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BzfGm06jWhQC" class="gsc_a_at">The future of bisphosphonates in cancer</a><div class="gs_gray">RE Coleman, OP Kash Purohit, JJ Vinholes</div><div class="gs_gray">Acta Oncologica 35 (sup5), 23-29<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8548950456928740997" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:00hq1xGbIBsC" class="gsc_a_at">Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia</a><div class="gs_gray">I Sestak, GM Blake, R Patel, RE Coleman, J Cuzick, R Eastell</div><div class="gs_gray">Bone 124, 83-88<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3374151114279245627" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_TjUWtciUekC" class="gsc_a_at">Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer–An AZURE (BIG 01/04) sub-study</a><div class="gs_gray">C Wilson, S Hinsley, H Marshall, D Cameron, R Bell, D Dodwell, ...</div><div class="gs_gray">Journal of bone oncology 9, 48-54<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15512643040194114934" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vkuYBMKU6wEC" class="gsc_a_at">Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling</a><div class="gs_gray">WM Gregory, CJ Twelves, R Bell, SW Smye, DR Howard, RE Coleman, ...</div><div class="gs_gray">Breast cancer research and treatment 155 (2), 303-311<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4244340726721351530" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BFa5h04uPMwC" class="gsc_a_at">Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events.</a><div class="gs_gray">L Klotz, MR Smith, RE Coleman, KB Pittman, P Milecki, R Wei, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), 5075-5075<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1579467228000028831" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SAZ1SQo2q1kC" class="gsc_a_at">Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?</a><div class="gs_gray">M Aapro, CJH van de Velde, C Markopoulos, JMS Bartlett, H Putter, ...</div><div class="gs_gray">The Breast 22 (4), 488-494<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11177721923731293308" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TlpoogIpr_IC" class="gsc_a_at">200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed&nbsp;…</a><div class="gs_gray">P Canney, R Coleman, J Morden, P Barrett-Lee, J Banerji, A Wardley, ...</div><div class="gs_gray">European Journal of Cancer, S102<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17533977800025949702" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Br1UauaknNIC" class="gsc_a_at">An open-label, phase IIa, non-randomized study of radium-223 in breast cancer patients with bone dominant disease no longer considered suitable for endocrine therapy</a><div class="gs_gray">R Coleman, P Flamen, B Naume, C Garcia, M Piccart, CG O’Bryan-Tear, ...</div><div class="gs_gray">Bone 2, 9<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14452336746205382326" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SIv7DqKytYAC" class="gsc_a_at">Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Nature Clinical Practice Endocrinology &amp; Metabolism 5 (2), 72-73<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15418491194417173475" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Sw8WaQuuSIgC" class="gsc_a_at">Making Recovery Happen: Module One: Understanding Recovery</a><div class="gs_gray">R Coleman, K Taylor</div><div class="gs_gray">Working to recovery<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13949135778567654378" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jE2MZjpN3IcC" class="gsc_a_at">Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model</a><div class="gs_gray">K Wilson, M Tabberer, M Lees, D Carroll, D Rea, R Coleman</div><div class="gs_gray">EJC Supplements 2 (4), 151<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12206012330209165838" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:L1USKYWJimsC" class="gsc_a_at">The AZURE trial–does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?</a><div class="gs_gray">R Burkinshaw, H Thorpe, S Pollard, R Bell, D Dodwell, D Cameron, ...</div><div class="gs_gray">Bone 3 (38), 70-71<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11720295399210438348,14227857404082931156" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fbc8zXXH2BUC" class="gsc_a_at">Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors</a><div class="gs_gray">A Lipton, R Cook, R Coleman, P Major, N Shirina</div><div class="gs_gray">ANNALS OF ONCOLOGY 17, 254-255<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8278858250430642099" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-nhnvRiOwuoC" class="gsc_a_at">Skeletal effect of exemestane in patients with breast cancer.</a><div class="gs_gray">L Banks, S Girgis, R Coleman, L Porter, G Baffoe, D Price, E Hall, J Bliss, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 20 (9), S327-S327<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9594201540154423319" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XUvXOeBm_78C" class="gsc_a_at">Parathyroid hormone-related protein and bone metastases</a><div class="gs_gray">TJ Martin, JA Danks, MA Henderson, C Jasmin, R Coleman, L Coia, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13457503825024096128" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:buQ7SEKw-1sC" class="gsc_a_at">Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer</a><div class="gs_gray">TRJ Evans, A Yellowlees, E Foster, H Earl, DA Cameron, AW Hutcheon, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 521-521<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5653705187025458933" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lgwcVrK6X84C" class="gsc_a_at">Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901</a><div class="gs_gray">R Paridaens, J Dyczka, EJT Rutgers, R Coleman, T Cufer, J Jassem, ...</div><div class="gs_gray">EJC Supplements 3 (2), 70<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4160822870054228163" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DGpvO1n63MYC" class="gsc_a_at">Working with Self Harm!</a><div class="gs_gray">M Smith, R Coleman</div><div class="gs_gray">Keepwell<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3848398376838061968" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wZJMF1LD7PcC" class="gsc_a_at">Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (vol 91, pg 1191, 2001)</a><div class="gs_gray">JR Berenson, LS Rosen, A Howell, L Porter, RE Coleman, W Morley</div><div class="gs_gray">Cancer 91 (10), 1956-1956<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16618973805715131278" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:prdVHNxh-e8C" class="gsc_a_at">Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy</a><div class="gs_gray">R Coleman, J Apffelstaedt, D Gordon, P Major, J Mackey, A Howell, ...</div><div class="gs_gray">European Journal of Cancer 37, S152<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13956408119773254588" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:owLR8QvbtFgC" class="gsc_a_at">The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases</a><div class="gs_gray">SP Jagdev, PI Croucher, RE Coleman</div><div class="gs_gray">European Journal of Cancer 37, S129-S129<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10392507977210356963" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Xz60mAmATU4C" class="gsc_a_at">EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’or ‘Potentially Hormone Sensitive’metastatic breast cancer</a><div class="gs_gray">A Hamilton, JA Roy, L Beex, M Piccart, L Mauriac, R Coleman, ...</div><div class="gs_gray">Breast cancer research and treatment 60 (2), 181-188<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4292166831670356317" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eO3_k5sD8BwC" class="gsc_a_at">The use of bisphosphonates in the palliative care setting</a><div class="gs_gray">S Heatley, R Coleman</div><div class="gs_gray">International Journal of Palliative Nursing 5 (2), 74-80<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14286635800504085354" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OBSaB-F7qqsC" class="gsc_a_at">1211 Randomised double-blind comparison of pamidronate or clodronate for hypercalcaemia of malignancy: Effects on bone metabolism markers</a><div class="gs_gray">J Vinholes, OP Purohit, CY Guo, R Eastell, AP Vinholes, R Coleman</div><div class="gs_gray">European Journal of Cancer 31, S253<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13436163121696125243,886003563033699796" class="gsc_a_ac gs_ibl">4</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:OBSaB-F7qqsC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QUX0mv85b1cC" class="gsc_a_at">WEEKLY EPIRUBICIN FOR LIVER METASTASES IN BREAST-CANCER</a><div class="gs_gray">CJ Twelves, RE Coleman, S OREILLY, MA Richards, RD Rubens</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 58 (2), 268-268<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15681215488957270690" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KaMxkj08jr0C" class="gsc_a_at">IFOSFAMIDE (I) AND IFOSFAMIDE+ CIS-PLATIN (P) CHEMOTHERAPY FOR ADVANCED CERVICAL-CARCINOMA</a><div class="gs_gray">RE Coleman, J Clarke, ML Slevin, E Wiltshaw, PG Harper</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 58 (2), 273-273<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8187943132173241928" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uVUOdF_882EC" class="gsc_a_at">ASSESSMENT OF OSTEOBLAST ACTIVITY PREDICTS RADIOLOGICAL RESPONSE IN BONE METASTASES FROM BREAST-CANCER</a><div class="gs_gray">RE Coleman, KB Whitaker, G Mashiter, DW Moss, IS FOGELMAN, ...</div><div class="gs_gray">PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 27, 180-180<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1295069141293049973" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jvrRlaHg2sAC" class="gsc_a_at">Ralph J</a><div class="gs_gray">M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ...</div><div class="gs_gray">Lellé<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13563791940761414110" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WTkkuPxyGkUC" class="gsc_a_at">Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences</a><div class="gs_gray">S D'Oronzo, W Gregory, S Nicholson, YK Chong, J Brown, R Coleman</div><div class="gs_gray">Journal of Bone Oncology 28, 100367<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4920930871878334474" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:D_YRMw8gybsC" class="gsc_a_at">Bisphosphonates and breast cancer–From cautious palliation to saving lives</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Bone 140, 115570<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11012235342155424654" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pcWPcJyQGiUC" class="gsc_a_at">Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT–Randomised EuropeAn celecoxib trial)</a><div class="gs_gray">RC Coombes, H Tovey, L Kilburn, J Mansi, C Palmieri, J Bartlett, J Hicks, ...</div><div class="gs_gray">Cancer Research 78 (4 Supplement), GS3-03-GS3-03<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2878713587521654763" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5p9vMBpPSXYC" class="gsc_a_at">Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006.</a><div class="gs_gray">MC Macdonald, BW Hancock, MC Winter, RE Coleman, JA Tidy</div><div class="gs_gray">The Journal of reproductive medicine 61 (7-8), 341-346<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1441373246663763350" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SyxJh60XUSQC" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive&nbsp;…</a><div class="gs_gray">HS Rugo, R Li, O Petrenciuc, A Zhang, RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 34 (15_suppl), TPS621-TPS621<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13297851331926039460" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XR3BWSlh_xcC" class="gsc_a_at">POSNOC: Positive sentinel node—Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in&nbsp;…</a><div class="gs_gray">A Goyal, RE Coleman, DJ Dodwell, L Fallowfield, VA Jenkins, B Mann, ...</div><div class="gs_gray">Journal of Clinical Oncology 33 (15_suppl), TPS1103-TPS1103<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10489976705557747327" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VHM5RxzNINsC" class="gsc_a_at">3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from&nbsp;…</a><div class="gs_gray">C Parker, NJ Vogelzang, AO Sartor, RE Coleman, I Skjorestad, F Fang, ...</div><div class="gs_gray">Journal of Clinical Oncology 33 (15_suppl), e16102-e16102<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9811373093539713184,14621222380751648606" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IyxfXMz2bNAC" class="gsc_a_at">Reasons for patients (pts) discontinuing study treatment (tx) in the phase 3 alsympca trial of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC&nbsp;…</a><div class="gs_gray">J Logue, S Wedel, A Chodacki, O Sartor, S Nilsson, RE Coleman, ...</div><div class="gs_gray">Annals of Oncology 25, iv264<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1933703210645271579" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wBLCggQE-ToC" class="gsc_a_at">The UK TACT2 Trial: Non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC)(CRUK/05/019)</a><div class="gs_gray">P Canney, P Barrett-Lee, J Bartlett, G Bertelli, R Coleman, H Earl, P Ellis, ...</div><div class="gs_gray">European Journal of Cancer 50, S99-S100<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13125516200955738250" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zUl2_INMlC4C" class="gsc_a_at">Quality of life results of the UK TACT2 trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05&nbsp;…</a><div class="gs_gray">G Velikova, P Barrett-Lee, D Bloomfield, M Brunt, P Canney, R Coleman, ...</div><div class="gs_gray">European Journal of Cancer 50, S109-S109<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=332775730869927577" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mVC4hKzE2FoC" class="gsc_a_at">Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial&nbsp;…</a><div class="gs_gray">R Coleman, S Fossa, A Chodacki, S Wedel, O Bruland, K Staudacher, ...</div><div class="gs_gray">European Journal of Cancer 49, S688-S688<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15149611301360001057" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2v_ZtQDX9iAC" class="gsc_a_at">P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study.</a><div class="gs_gray">X Pivot, J Hackmann, A Manikhas, Y Moore, R Parikh, D Kothari, A Joshi, ...</div><div class="gs_gray">Cancer Research 71 (24 Supplement), P4-17-03-P4-17-03<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4547329558744402568" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Zh0EY9V9P6UC" class="gsc_a_at">Biomarkers of bone turnover in oncology: applications in diagnosis and treatment</a><div class="gs_gray">JE Brown, RE Coleman</div><div class="gs_gray">Expert opinion on medical diagnostics 4 (2), 125-138<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15984127884521980325" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1tZ8xJnm2c8C" class="gsc_a_at">The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases</a><div class="gs_gray">JE Lester, JE Brown, RA Hannon, SP Ellis, JM Horsman, OP Purohit, ...</div><div class="gs_gray">Bone 46 (3), 801-805<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7327819983148703234" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Xl6nMSl579sC" class="gsc_a_at">Significant Antitumor Activity in a Randomized Phase 2 Study Comparing Two Schedules of NKTR-102 in Patients With Pre-Treated Metastatic Breast Cancer</a><div class="gs_gray">A Awada, S Chan, G Jerusalem, RE Coleman, M Huizing, A Mehdi, ...</div><div class="gs_gray">Proc. Am. Soc. Clin. Oncol 28 (5013), 4<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3006092976266992639" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WC9gN4BGCRcC" class="gsc_a_at">Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.</a><div class="gs_gray">PD Ottewell, DV Lefley, RE Coleman, I Holen</div><div class="gs_gray">Cancer Research 69 (2 Supplement), 2151<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1493454659499075624" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HJSXoJQnj-YC" class="gsc_a_at">Commentary: Controversies in NICE guidance on metastatic spinal cord compression</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Bmj 337<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17928687630279957443" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Dem6FJhTUoYC" class="gsc_a_at">5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of&nbsp;…</a><div class="gs_gray">TR Evans, A Yellowlees, I Devine, HM Earl, DA Cameron, AW Hutcheon, ...</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 540-540<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12512378256578403396" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KqW5X_olkfQC" class="gsc_a_at">Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer–a multivariate analysis</a><div class="gs_gray">R Coleman, J Brown, R Cook</div><div class="gs_gray">EJC Supplements 7 (6), 189<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8176354147434644983" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1DsIQWDZLl8C" class="gsc_a_at">P61. Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC)</a><div class="gs_gray">R Coleman, J Brown, R Cook</div><div class="gs_gray">Cancer Treatment Reviews 34, 28-29<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18102805617005428386,16359130030682246357" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2l5NCbZemmgC" class="gsc_a_at">Bisphosphonates and prevention of metastases: the AZURE study</a><div class="gs_gray">R Burkinshaw, H Thorpe, R Coleman</div><div class="gs_gray">Breast Cancer Online 10 (11)<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13960254477072291504" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jq04SsiGh3QC" class="gsc_a_at">La leadership è una qualità che va acquisita e coltivata</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Rivista Sperimentale di Freniatria<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3588723366755580164" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5bg8sr1QxYwC" class="gsc_a_at">The benefits and costs of bisphosphonates</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The journal of supportive oncology 5 (10), 483-484<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12300776432125448456" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:e0CZ6poB34oC" class="gsc_a_at">The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro</a><div class="gs_gray">M Michailidou, HL Neville-Webbe, JK Woodward, DV Lefley</div><div class="gs_gray">Hematology Meeting Reports (formerly Haematologica Reports) 2 (3)<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6641295579837306095" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Y9VhQm-5nPIC" class="gsc_a_at">Bone resorption marker directed therapy for metastatic bone disease</a><div class="gs_gray">J Lester, J Horsman, OP Purohit, JE Brown, RE Coleman</div><div class="gs_gray">Bone 3 (38), 79<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6692671026114566129" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Wq2b2clWBLsC" class="gsc_a_at">Non-inferiority of oral ibandronate to intravenous zoledronic acid for reducing markers of bone turnover in metastatic breast cancer patients</a><div class="gs_gray">M Lichinitser, R Coleman, S Tjulandin, B Bergström, J Body</div><div class="gs_gray">Breast Cancer Research and Treatment 94<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10342219709223331580" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kF1pexMAQbMC" class="gsc_a_at">Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?</a><div class="gs_gray">JE Brown, J Lester, S Ellis, S Gutcher, L Turner, OP Purohit, B Hancock, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (16_suppl), 8023-8023<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11970359303751432544" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:U_HPUtbDl20C" class="gsc_a_at">Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro</a><div class="gs_gray">HL Neville-Webbe, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1598-1598<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16573804058014696533" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mKu_rENv82IC" class="gsc_a_at">Chemotherapy, erythropoietin and bloodless surgery in a Jehovah's Witness</a><div class="gs_gray">JE Brown, MQ Hatton, R Melchers, P Goldstraw, RE Coleman</div><div class="gs_gray">Clinical Oncology 15 (7), 371-377<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17201146000191644819" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:q-HalDI95KYC" class="gsc_a_at">An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx™ in metastatic breast cancer patients.</a><div class="gs_gray">R Coleman, L Biganzoli, P Canney, L Mauriac, L Dirix, P Chollet, G Atalay, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 76<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10975374810367928890" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:An6A6Jpfc1oC" class="gsc_a_at">Treatment of Skeletal Complications of Cancer With Zoledronic Acid (Zometa)-Editorial</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Seminars in Oncology-Supplements 29 (21), 1-2<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13483445844760686892" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DyXnQzXoVgIC" class="gsc_a_at">Twenty-five years of reviewing cancer treatment</a><div class="gs_gray">RD Rubens, RE Coleman</div><div class="gs_gray">Cancer treatment reviews 25 (1), 1-2<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3570011608964842417" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jSAVyFp_754C" class="gsc_a_at">30. A randomized phase 11 evaluation of oral pamidronate for advanced bone metastases from breast cancer</a><div class="gs_gray">RE Coleman, RD Rubens, C Rose, OP Purohit, S Houston, J Ford</div><div class="gs_gray">The Breast 3 (4), 235-236<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1302693404990894474" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SGW5VrABaM0C" class="gsc_a_at">Low dose bleomycin with etoposide and cisplatin for metastatic testicular teratoma</a><div class="gs_gray">RE Coleman, D Whillis, GCW Howard, RE Taylor, MA Cornbleet</div><div class="gs_gray">British journal of urology 68 (3), 296-300<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13973418451705148162" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-mN3Mh-tlDkC" class="gsc_a_at">APD FOR THE TREATMENT OF HYPERCALCEMIA OF MALIGNANCY (HOM)-A COMPARISON OF DIFFERENT DOSES AND SCHEDULES OF ADMINISTRATION</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">British Journal of Cancer 60 (3), 448-448<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14248062257929970444" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZZwcLRaXOV4C" class="gsc_a_at">‘African’Genetic Markers in Sicilians</a><div class="gs_gray">R Bleiber, W Eggert, G Reichmann, D Kunze, WRA Osborne, ER Giblett, ...</div><div class="gs_gray">Acta haematologica 63 (3), 174-175<span class="gs_oph">, 1980</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16430072315505308291" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1980</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UFuRdyijzaAC" class="gsc_a_at">Therapeutic treatment of breast cancer based on c-maf status</a><div class="gs_gray">WM Gregory, JC Tercero, R Gomis, RE Coleman</div><div class="gs_gray">US Patent App. 16/303,945<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14898137269618109261" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:H0nRGT7Dr7IC" class="gsc_a_at">Prevention and Treatment of Skeletal Complications</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Management of Breast Cancer in Older Women, 193-218<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8004850368389812579" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BKYZGPsuSFYC" class="gsc_a_at">Der Stellenwert der klassischen Verbundosteosynthese langer Röhrenknochen und des Beckens</a><div class="gs_gray">A Pape, C Hofbauer, C Kleber, J Pyrc, H Fritzsche, KD Schaser</div><div class="gs_gray">OP-JOURNAL 33 (01), 11-17<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1381763767985588751" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:43LB_KcVqeAC" class="gsc_a_at">Relationship between quality of life and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients in ALSYMPCA.</a><div class="gs_gray">S Nilsson, AO Sartor, NJ Vogelzang, RE Coleman, JM O'Sullivan, ...</div><div class="gs_gray">Journal of Clinical Oncology 35 (6_suppl), 177-177<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1401013974281401264" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Np1obAXpBq8C" class="gsc_a_at">Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer</a><div class="gs_gray">R Coleman, A Hall, R Bell, D Cameron, H Marshall, J Jean-Mairet, ...</div><div class="gs_gray">Cancer Research 77<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6540813712433302696" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uEM9VtRl8xsC" class="gsc_a_at">tnAcity: A phase II/III trial of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic&nbsp;…</a><div class="gs_gray">DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Glück, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), TPS1146-TPS1146<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13945246741754407983" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:i_7YvbSbtFEC" class="gsc_a_at">Oral surgery: ARONJ masterclass</a><div class="gs_gray">T Renton, T Taylor, S Popat, R Popat, Z Sivardeen, I Fogelman, ...</div><div class="gs_gray">British Dental Journal 216 (9), 488-489<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9166363529028922791" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rpSJNIKeXWsC" class="gsc_a_at">MP70-10 FURTHER CHARACTERIZATION OF THE EFFECTS OF PRIOR OR NO PRIOR DOCETAXEL THERAPY ON CRPC PATIENTS WITH BONE METASTASES RECEIVING RA-223 IN THE PHASE 3 ALSYMPCA TRIAL</a><div class="gs_gray">N Shore, O Sartor, N Vogelzang, P Hoskin, S Nilsson, R Coleman, ...</div><div class="gs_gray">The Journal of Urology 191 (4S), e809-e809<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17850097667532127928" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lK9BDNCuzFgC" class="gsc_a_at">Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified&nbsp;…</a><div class="gs_gray">P Wiechno, SI Helle, J Logue, S Nilsson, O Sartor, RE Coleman, J Kliment, ...</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 49, S690-S691<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9437907757186824004" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:U0iAMwwPxtsC" class="gsc_a_at">[18F] FDG PET: Changes in uptake as a method to assess radium-223 dichloride (Ra-223) response in bone metastases of breast cancer patients with bone-dominant disease</a><div class="gs_gray">P Flamen, R Coleman, B Naume, G Jerusalem, C Garcia, AK Aksnes, ...</div><div class="gs_gray">Journal of Nuclear Medicine 54 (supplement 2), 647-647<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6399635089689611346" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ef2wPL15CskC" class="gsc_a_at">San Antonio Breast Cancer Symposium</a><div class="gs_gray">R Coleman, M Gnant, A Paterson</div><div class="gs_gray">Abstract S4–07<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1207557632022305779" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hefNtdE4IMkC" class="gsc_a_at">The process of recovery and the implications for working with psychosis</a><div class="gs_gray">R Coleman, K Taylor</div><div class="gs_gray">Psychosis as a Personal Crisis: An Experience-Based Approach, 37<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10536107389207174950" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:o-PowTg_VKEC" class="gsc_a_at">Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An in progress, phase 3 clinical trial</a><div class="gs_gray">RE Coleman, C Barrios, R Bell, DM Finkelstein, H Iwata, M Martin, ...</div><div class="gs_gray">Annals of Oncology 23, ix115<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9067257184580956371" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:S2WlVNSe3u4C" class="gsc_a_at">Genitourinary tumors, prostate</a><div class="gs_gray">G Gravis, K Fizazi, FJ Lobbedez, S Oudard, F Priou, I Latorzeff, R Delva, ...</div><div class="gs_gray">Annals of Oncology 23 (suppl_9)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13221680070264457430" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9tXw7Op4-u0C" class="gsc_a_at">The relative value of anti-Müllerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: Results from the OPTION trial.</a><div class="gs_gray">RCF Leonard, D Adamson, G Bertelli, M McLinden, N Haiying, J Dunlop, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), 1094-1094<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2866833120237238754" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w0F2JDEymm0C" class="gsc_a_at">101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc)</a><div class="gs_gray">A Awada, S Chan, GHM Jerusalem, RE Coleman, MT Huizing, A Mehdi, ...</div><div class="gs_gray">Annals of Oncology 23, ii43<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10623873983493883090" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:I2jIoRS3jIgC" class="gsc_a_at">OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast&nbsp;…</a><div class="gs_gray">PE Goss, CH Barrios, R Bell, D Finkelstein, H Iwata, M Martin, A Braun, ...</div><div class="gs_gray">Cancer Research 71 (24 Supplement), OT1-01-03-OT1-01-03<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=736802298566176702" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ukw-9cB-YDkC" class="gsc_a_at">P2-19-01: Impact of Zoledronic Acid on Fractures, Bone Mineral Density and Bone Remodeling in the AZURE Trial (BIG 01–04).</a><div class="gs_gray">R Coleman, E Woodward, L Turner, H Marshall, M Collinson, D Dodwell, ...</div><div class="gs_gray">Cancer Research 71 (24 Supplement), P2-19-01-P2-19-01<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9128674980932189568" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qkm5LKljiV4C" class="gsc_a_at">A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTRE PHASE 3 STUDY COMPARING DENOSUMAB WITH PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER WHO ARE&nbsp;…</a><div class="gs_gray">R Bell, P Goss, C Barrios, D Finkelstein, H Iwata, M Martin, A Braun, ...</div><div class="gs_gray">Asia-pacific Journal of Clinical Oncology 7<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15771859822787469382" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:27LrP4qxOz0C" class="gsc_a_at">Targeted therapy for prostate cancer metastases to bone</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Nature Reviews Urology 8 (6), 296-298<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17283755800624124455" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:V63Ir2N1OTwC" class="gsc_a_at">One year effect of anastrozole and risedronate on bone mineral density: first results from the IBIS-II bone sub-study</a><div class="gs_gray">S Singh, J Cuzick, GM Blake, D Mesher, R Patel, J Truscott, R Coleman, ...</div><div class="gs_gray">Bone 48 (1), S24-S24<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13328586144433141638" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w1MjKQ0l0TYC" class="gsc_a_at">Denosumab treatment for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer</a><div class="gs_gray">F Saad, M Smith, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ...</div><div class="gs_gray">AUA South Central, 1<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9754622416522427902" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ade32sEp0pkC" class="gsc_a_at">S03 Is caring for the bone also fighting the breast cancer?</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast, S2<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2426275828799943735" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vVJNg6_NJEsC" class="gsc_a_at">DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients.</a><div class="gs_gray">RC Coombes, JM Bliss, M Espie, F Erdkamp, JJ Wals, A Tres, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 536-536<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7489031928798500871" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qe6vwMD2xtsC" class="gsc_a_at">Randomised Placebo Controlled Trial Studying Short Term Biological Effects of the Combination of Letrozole and Zoledronic Acid on Invasive Breast Cancer.</a><div class="gs_gray">N Bundred, A Cramer, J Morris, G Landberg, L Renshaw, M Winter, ...</div><div class="gs_gray">Cancer Research 69 (24 Supplement)<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=786920859185871310,4190999458580663285" class="gsc_a_ac gs_ibl">2</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="UIrmjcIAAAAJ:qe6vwMD2xtsC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ce2CqMG-AY4C" class="gsc_a_at">A345 High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma</a><div class="gs_gray">E Terpos, JR Berenson, A Lipton, R Coleman, R Cook</div><div class="gs_gray">Clinical Lymphoma &amp; Myeloma, S55-S56<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17749949705339570660" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kWvqk_afx_IC" class="gsc_a_at">Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP</a><div class="gs_gray">JE Brown, V Hirsh, PP Major, A Lipton, RJ Cook, CJ Langer, MR Smith, ...</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 19003-19003<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18030204016569650005" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QyXJ3EUuO1IC" class="gsc_a_at">Correlations between N-telopeptide of type I collagen response and zoledronic acid on clinical outcomes in patients with bone metastases from prostate cancer</a><div class="gs_gray">F Saad, R Cook, A Lipton, R Coleman</div><div class="gs_gray">The Journal of Urology 179 (4S), 182-182<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13569174642907856848" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pk6FPx6l9xIC" class="gsc_a_at">PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN&nbsp;…</a><div class="gs_gray">G Dranitsaris, M Lidgren, J Lundkvist, R Coleman</div><div class="gs_gray">Value in Health 3 (11), A71<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15949197815510268550" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7VEv-pLvLSsC" class="gsc_a_at">The AZURE trial for prevention of bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">CLINICAL &amp; EXPERIMENTAL METASTASIS 25, 19-19<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10783110959087476840" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3bvyWxjaHKcC" class="gsc_a_at">OC15. Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer</a><div class="gs_gray">M Winter, H Thorpe, R Burkinshaw, S Beevers, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, 12-13<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7059407108162052573" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rCNdntzdTkkC" class="gsc_a_at">Pharmaceutical Uses of Bisphosphonates</a><div class="gs_gray">R Coleman, I Holen, H Neville-Webbe, C Evans</div><div class="gs_gray">US Patent App. 10/578,290<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14971486169094465504" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aIdbFUkbNIkC" class="gsc_a_at">VI Meeting on Cancer-Induced Bone Disease</a><div class="gs_gray">J Martin, R Coleman, G Mundy</div><div class="gs_gray">Expert review of anticancer therapy 7 (4), 461-464<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3120683910633258846" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1Ye0OR6EYb4C" class="gsc_a_at">Predictors of clinical outcome in patients with bone metastases from prostate cancer</a><div class="gs_gray">F Saad, RE Coleman, R Cook, MR Smith, JE Brown, JY Hei, YM Chen</div><div class="gs_gray">Journal of Clinical Oncology 24 (18_suppl), 4555-4555<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7778073686145366523" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u3T1itk59dMC" class="gsc_a_at">Characteristics and toxicity profile of patients receiving more than 2 years treatment with bisphosphonates for bone metastases from breast cancer</a><div class="gs_gray">JE Lester, L Penty, JE Brown, C Radstone, OP Purohit, RE Coleman</div><div class="gs_gray">Bone 3 (38), 79-80<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9723907900613811552" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=600&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:c1e4I3QdEKYC" class="gsc_a_at">Bone metastases and the role of bisphosphonates</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">EJHP Practice 12 (4), 49-51<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12213106302814096161" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:65Yg0jNCQDAC" class="gsc_a_at">Supportive care in oncology</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Supportive Care in Cancer 13 (12), 959-960<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1751834649295670840" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qwy9JoKyICEC" class="gsc_a_at">Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers</a><div class="gs_gray">M Lichinitser, RE Coleman, SA Tjulandin, B Bergstrom, JJ Body</div><div class="gs_gray">EJC SUPPLEMENTS 3 (2), 113-113<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5220447269524536305" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UmS_249rOGwC" class="gsc_a_at">Meeting report from the Vth international conference on cancer-induced bone disease</a><div class="gs_gray">RE Coleman, TJ Martin, GR Mundy</div><div class="gs_gray">IBMS BoneKEy 2, 15<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3462665307678429782" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:C33y2ycGS3YC" class="gsc_a_at">Osteoblastic metastases</a><div class="gs_gray">PI Croucher</div><div class="gs_gray">Jasmin, C.; Coleman, RE; Coia, LR; Capanna<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10011284159404306427" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yJjnfzR0HrkC" class="gsc_a_at">The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases</a><div class="gs_gray">RE Coleman, CR Dunstan</div><div class="gs_gray">Textbook of bone metastases, 51-62<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18321401510047353193" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zdjWy_NXXwUC" class="gsc_a_at">Prevention of bone metastases</a><div class="gs_gray">RE Coleman, HL Neville‐Webbe</div><div class="gs_gray">Textbook of Bone Metastases, 387-397<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6462765130260886882" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-uzm3Y7AvW0C" class="gsc_a_at">Developing more rational use of bisphosphonates in malignancy</a><div class="gs_gray">R Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S19-S19<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15745642807504285892" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KNjnJ3z-R6IC" class="gsc_a_at">Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to breast cancer</a><div class="gs_gray">A Lipton, L Rosen, N Kohno, R Coleman, M Zheng, S Milton</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S29-S30<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2757292312479699727" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WAzi4Gm8nLoC" class="gsc_a_at">Zoledronic acid for the treatment of malignant bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Industry Science<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10930096639386243869" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WgvcDLhf7hwC" class="gsc_a_at">Straight talk: new approaches in healthcare. Working toward true excellence: employers press for change.</a><div class="gs_gray">K Shannon, HD Marshall, R Coleman</div><div class="gs_gray">Modern healthcare 32 (39), 29-32<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4754965958259188618" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HhcuHIWmDEUC" class="gsc_a_at">Bone marker directed bisphosphonate treatment. A pilot study to determine feasibility</a><div class="gs_gray">JE Brown, S Ellis, S Gutcher, L Turner, OP Purohit, RE Coleman</div><div class="gs_gray">Bone 30 (3), 47S-47S<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3863384944236140164" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UEFpDhwOD2kC" class="gsc_a_at">Failure of adjuvant peripheral progenitor-supported high-dose chemotherapy to improve the prognosis of patients with high-risk breast cancer in a randomized trial with low&nbsp;…</a><div class="gs_gray">J Crown, M Lind, A Gould, M Verril, C Twelves, R Coleman, T Perren, ...</div><div class="gs_gray">Ann Oncol 13 (2)<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13996739950611889016" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IsPWOBWtZBwC" class="gsc_a_at">Alterations in regional decreased cerebral blood flow in patients with irritable bowel syndrome-A PET imaging study</a><div class="gs_gray">Y Ringel, DA Drossman, TG Turkington, BH Bradshaw, RE Coleman, ...</div><div class="gs_gray">Gastroenterology 5 (120), A637<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=954258187585211976" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sfnaS5RM6jYC" class="gsc_a_at">Preliminary results of a phase II study of weekly paclitaxel and etopophos chemotherapy in patients with relapsed ovarian carcinoma</a><div class="gs_gray">SI Ahmed, J Higgins, T Briggs, SD Pledge, RE Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 83, 79-79<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2043280758058731596" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dgXhHFWAKKUC" class="gsc_a_at">Process Validation Issues: A discussion with Robert C. Coleman, USFDA</a><div class="gs_gray">G Amer, RC Coleman</div><div class="gs_gray">Journal of Validation Technology 6 (3), 665-675<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4500084684465986151" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:E10ZYwHxBI8C" class="gsc_a_at">Working to Recovery. Victim to Victor III</a><div class="gs_gray">R Coleman, P Baker, K Taylor</div><div class="gs_gray">Handsell Publishing, Gloucester<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9558351464152311332" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ehoypfNsBj8C" class="gsc_a_at">Phase II randomized study comparing docetaxel (T) to doxorubicin (D) in previously untreated soft tissue sarcomas (STS)</a><div class="gs_gray">ED Di Paola, I Judson, M Lee, W Ruka, J Buesa, R Coleman, C Hermans, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 9, 115-115<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1036768979238582712" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:69ZgNCALVd0C" class="gsc_a_at">Dose-finding study of docetaxel-Carboplatin in untreated advanced epithelial ovarian cancer (EOC)</a><div class="gs_gray">PA Vasey, R Atkinson, R Coleman, SPH Eggleton, J Graham, J Paul, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 9, 66-66<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17036065074584145072" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rTD5ala9j4wC" class="gsc_a_at">The use of cisplatin and paclitaxel as a first line treatment in ovarian cancer</a><div class="gs_gray">SM Beard, R Coleman, J Radford, J Tidy</div><div class="gs_gray">Trent Institute for Health Services Research, Universities of Leicester&nbsp;…<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15672231954292796473" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VN7nJs4JPk0C" class="gsc_a_at">Partnership through ownership</a><div class="gs_gray">P Baker, R Coleman, I Murray, P Thomas</div><div class="gs_gray">Nursing times 93 (27)<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3621316666644935149" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WHdLCjDvYFkC" class="gsc_a_at">From victims to allies</a><div class="gs_gray">P Baker, R Coleman, I Murray, P Thomas</div><div class="gs_gray">Nursing times 93 (27), 40-42<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2823341010544030623" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SnGPuo6Feq8C" class="gsc_a_at">Immunohistochemical detection of parathyroid hormone related protein in the primary tumours of hypercalcaemic breast cancer patients</a><div class="gs_gray">MA Henderson, JA Danks, GW Powell, DM Barnes, RE Coleman, ...</div><div class="gs_gray">The Breast 4 (2), 112-116<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17330247872480254528" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kzcSZmkxUKAC" class="gsc_a_at">Therapeutic use of bisphosphonates in oncology.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">BMJ: British Medical Journal 309 (6963), 1233<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12269450995465885300" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hXkWDDAEazwC" class="gsc_a_at">Metastatic bone disease</a><div class="gs_gray">R Coleman, RD Rubens</div><div class="gs_gray">Parthenon Publishing Group<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7303235565092756664" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pS0ncopqnHgC" class="gsc_a_at">A RANDOMIZED COMPARISON OF LOW AND HIGH-DOSE DEXAMETHASONE IN COMBINATION WITH HALOPERIDOL AND LORAZEPAM FOR CONTROL OF CHEMOTHERAPY-INDUCED VOMITING</a><div class="gs_gray">R Coleman, Z Doran, J Clarke, E Black, C Twelves, S OREILLY, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 60 (3), 455-455<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14436804345309761330" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DPO9WFcz7UcC" class="gsc_a_at">Field guide to slope instability in the Wollongong-Picton-Nattai region of New South Wales</a><div class="gs_gray">RN Chowdhury, ARM Young, RA Coleman, DM Cunningham</div><div class="gs_gray">University of Wollongong<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7330543581656885054" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:raTqNPD5sRQC" class="gsc_a_at">TREATMENT OF HYPERCALCEMIA SECONDARY TO METASTATIC BREAST-CANCER WITH 3 AMINO-1, 1-HYDROXYPROPYLIDENE BIOPHOSPHONATE (APD)</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 54 (1), 203-203<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10897635163161521147" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HmWvvuJwtxYC" class="gsc_a_at">Revolution of the Mind</a><div class="gs_gray">J Brown, J Sanford, R Crimes, F Wesley, J Parker, C Pinckney, B Byrd, ...</div><div class="gs_gray">Polydor<span class="gs_oph">, 1971</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17357195737937767688" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1971</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1DAnfT_YoJgC" class="gsc_a_at">Two-Dimensional Relativistic Quark Model with Exact Solutions</a><div class="gs_gray">RA Coleman, JW Moffat</div><div class="gs_gray">Physical Review 159 (5), 1306<span class="gs_oph">, 1967</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16060914056014720880" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1967</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:X1y8G5kAG8gC" class="gsc_a_at">Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial</a><div class="gs_gray">RC Coombes, H Tovey, L Kilburn, J Mansi, C Palmieri, J Bartlett, J Hicks, ...</div><div class="gs_gray">JAMA oncology 7 (9), 1291-1301<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16057153000896406032" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oi8PhiKYDwsC" class="gsc_a_at">Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials</a><div class="gs_gray">R Bradley, J Braybrooke, R Gray, R Hills, Z Liu, R Peto, L Davies, ...</div><div class="gs_gray">The Lancet Oncology 22 (8), 1139-1150<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11767748668599929523" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WYtWvJut7doC" class="gsc_a_at">Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial</a><div class="gs_gray">TWP Friedl, T Fehm, V Müller, W Lichtenegger, J Blohmer, R Lorenz, ...</div><div class="gs_gray">JAMA oncology 7 (8), 1149-1157<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5683182013788944275" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:D90uR9ClOh8C" class="gsc_a_at">Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases</a><div class="gs_gray">D Lovero, S D’Oronzo, R Palmirotta, P Cafforio, J Brown, S Wood, C Porta, ...</div><div class="gs_gray">British Journal of Cancer, 1-11<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17805019951876661595" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HKuYlFsi-qEC" class="gsc_a_at">M‐EA (methotrexate, etoposide, dactinomycin) and EMA‐CO (methotrexate, etoposide, dactinomycin/cyclophosphamide, vincristine) regimens as first‐line treatment of high‐risk&nbsp;…</a><div class="gs_gray">K Singh, S Gillett, J Ireson, A Hills, JA Tidy, RE Coleman, BW Hancock, ...</div><div class="gs_gray">International Journal of Cancer 148 (9), 2335-2344<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7749579211852522657" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:W91e3rS6dHEC" class="gsc_a_at">Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ</a><div class="gs_gray">I Sestak, J Cuzick, B Bonanni, N Bundred, C Levy, S Loib, P Neven, ...</div><div class="gs_gray">Cancer Research 81 (4 Supplement), GS2-02-GS2-02<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6022385594386969448" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:npT69zEmqdIC" class="gsc_a_at">12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ</a><div class="gs_gray">I Sestak, J Cuzick, B Bonanni, N Bundred, C Levy, S Loib, P Neven, ...</div><div class="gs_gray">CANCER RESEARCH 81 (4)<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18277521251301802617" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2hrGa7H818QC" class="gsc_a_at">Adjuvant denosumab in early breast cancer–Authors' reply</a><div class="gs_gray">R Coleman, Y Zhou, A Chan</div><div class="gs_gray">The Lancet Oncology 21 (3), e125<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9821591986404328493" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YEBtnu9hOHUC" class="gsc_a_at">Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment</a><div class="gs_gray">PD Ottewell, DV Lefley, K Freeman, WM Gregory, AM Hanby, ...</div><div class="gs_gray">Cancer Research 79 (4 Supplement), P1-05-01-P1-05-01<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=556104497818034191" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0klj8wIChNAC" class="gsc_a_at">AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers</a><div class="gs_gray">JFR Robertson, RE Coleman, KL Cheung, A Evans, C Holcombe, ...</div><div class="gs_gray">BRITISH JOURNAL OF SURGERY 105, 24-24<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3737187643126487359" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ltc9rfRcsxEC" class="gsc_a_at">Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole</a><div class="gs_gray">I Sestak, J Cuzick, G Blake, R Patel, R Coleman, R Eastell</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9366244050929875678" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uUvzmPk0f8oC" class="gsc_a_at">Toxicity of Bone-Targeted Agents in Malignancy</a><div class="gs_gray">C Wilson, F Taylor, R Coleman</div><div class="gs_gray">Side Effects of Medical Cancer Therapy, 439-460<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6914603254680868712" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:M7C5BM2v8n8C" class="gsc_a_at">Doing More With Less; Are There Some ‘Easy Wins’ in the Management of Early Breast Cancer?</a><div class="gs_gray">D Dodwell, A Richmond, S Hazell, R Coleman</div><div class="gs_gray">Clinical Oncology 29 (9), 550-552<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=921075805696681066" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AOwgc6nnr1EC" class="gsc_a_at">Testosterone replacement in male cancer survivors improves body composition</a><div class="gs_gray">JS Walsh, H Marshall, DM Greenfield, IL Smith, J Swain, E Best, J Ashton, ...</div><div class="gs_gray">99th Annual Meeting of the Endocrine Society<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16212958461422982527" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dJ_BR67V0s4C" class="gsc_a_at">Abstract P1-09-01: Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer</a><div class="gs_gray">R Coleman, A Hall, R Bell, D Cameron, H Marshall, J Jean-Mairet, ...</div><div class="gs_gray">Cancer Research 77 (4 Supplement), P1-09-01-P1-09-01<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7302989317275582253" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rCzfLUpcSPoC" class="gsc_a_at">Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy±radium-223 dichloride in HER2-negative, hormone receptor–positive breast&nbsp;…</a><div class="gs_gray">RE Coleman, G Fried, O Petrenciuc, A Sawhney, R Li, HS Rugo</div><div class="gs_gray">Cancer Research 77 (4 Supplement), OT1-04-04-OT1-04-04<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1816921367711505340" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OlbiQ0ttILcC" class="gsc_a_at">Erratum to:‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple&nbsp;…</a><div class="gs_gray">DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Glück, ...</div><div class="gs_gray">Trials 17 (1), 1-1<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1636756130905232328" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AbQWx2m_oG8C" class="gsc_a_at">Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid</a><div class="gs_gray">C Wilson, F Nutter, H Brown, R Coleman, I Holen</div><div class="gs_gray">Bone Abstracts 5<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9503196186324790866" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zfsRRabFVBUC" class="gsc_a_at">Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma&nbsp;…</a><div class="gs_gray">J Cuzick, JF Forbes, I Sestak, A Howell, B Bonanni, N Bundred, C Levy, ...</div><div class="gs_gray">Cancer Research 76 (4 Supplement), S6-03-S6-03<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15864085592492481757" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fSKd39tHJ84C" class="gsc_a_at">Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast&nbsp;…</a><div class="gs_gray">DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Glueck, ...</div><div class="gs_gray">Trials 17, 63-63<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12795757100659760581" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lOG7zRu2uA8C" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2<sup>-</sup> hormone receptor<sup>+</sup> breast&nbsp;…</a><div class="gs_gray">RE Coleman, L Huang, O Petrenciuc, P Zaccarini</div><div class="gs_gray">Journal of Clinical Oncology 33 (15_suppl), TPS1104-TPS1104<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8936294749213053312" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gnsKu8c89wgC" class="gsc_a_at">Weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer&nbsp;…</a><div class="gs_gray">DA Yardley, J Cortes, RE Coleman, PF Conte, A Brufsky, ...</div><div class="gs_gray">Journal of Clinical Oncology 33 (15_suppl), TPS1106-TPS1106<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18097659601283157203" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Agc8PWtS8JkC" class="gsc_a_at">tnAcity: A phase II/III trial of nab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple&nbsp;…</a><div class="gs_gray">DA Yardley, RE Coleman, P Conte, J O'Shaughnessy, J Cortes, S Glueck, ...</div><div class="gs_gray">CANCER RESEARCH 75<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2863670500264052917" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6pF0wJmtdfAC" class="gsc_a_at">Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive&nbsp;…</a><div class="gs_gray">A Goldhirsch, RD Gelber, PA Francis, MM Regan, GF Fleming, I Lang, ...</div><div class="gs_gray">Cancer Research 75 (9 Supplement), S3-08-S3-08<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12230553994276195616" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FKYJxdYMdFIC" class="gsc_a_at">Bone metastases–current status of bone-targeted treatments</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Bone Cancer, 677-683<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12783583150576265337" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CMvovTBb2okC" class="gsc_a_at">Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer:" Real world" experience</a><div class="gs_gray">P Sanganalmath, K Purohit, M Winter, J Horsman, S Ramakrishnan, ...</div><div class="gs_gray">European Journal of Cancer 50, S181-S182<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10424215638896150009" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OzeSX8-yOCQC" class="gsc_a_at">Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events: 46</a><div class="gs_gray">K Pittman, M Smith, R Coleman, L Klotz, P Milecki, R Wei, A Balakumaran, ...</div><div class="gs_gray">Bju International 113<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15645302503603436491" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yZoBfgUKqwcC" class="gsc_a_at">869 Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid</a><div class="gs_gray">K Fizazi, R Coleman, L Klotz, K Pittman, P Milecki, L Costa, R Von Moos, ...</div><div class="gs_gray">European Urology Supplements 1 (13), e869-e869a<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15958115806944023232" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xGWFX6Gbr9MC" class="gsc_a_at">Updated Survival, Quality of life (QOL) and Safety-data of Radium223 Dichlorid (Ra223) in patients with castration resistant prostate cancer (CRPC) with bone metastasis from&nbsp;…</a><div class="gs_gray">T Steuber, H Heinzer, A Haese, P Strölin, C Parker, R Coleman, S Nilsson, ...</div><div class="gs_gray">Onkologie 36<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11149882699739046312" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:E7VqQtBCVmcC" class="gsc_a_at">Radium-223 (Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age: 24966</a><div class="gs_gray">O Sartor, R Coleman, S Nilsson, D Heinrich, K Staudacher, ...</div><div class="gs_gray">Bju International 112, 15-16<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3928013533477929337" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eJD0kABLposC" class="gsc_a_at">Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer: Pathophysiology and Clinical Perspectives</a><div class="gs_gray">A Lipton, R Dansey, R Coleman</div><div class="gs_gray">Osteoporosis, 1445-1454<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11757223110664852368" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aCwMkEyfDy8C" class="gsc_a_at">Adjuvant therapy in early breast cancer with zoledronic acid (AZURE-BIG 01/04): final efficacy analysis</a><div class="gs_gray">R Coleman, S Hinsley, R Bell, D Cameron, D Dodwell, V Liversedge, ...</div><div class="gs_gray">European Journal of Cancer 49 (Suppl 3), S5-S5<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16473342441518137691" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wE-fMHVdjMkC" class="gsc_a_at">The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGF beta superfamily.</a><div class="gs_gray">C Wilson, MC Winter, I Holen, JV Freeman, AC Evans, RE Coleman</div><div class="gs_gray">CANCER RESEARCH 72<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6975883547590091738" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ej9njvOgR2oC" class="gsc_a_at">Significant Antitumor Activity in a Randomized Phase 2 Study Comparing Two Schedules of Etirinotecan Pegol (NKTR-102)</a><div class="gs_gray">A Awada, S Chan, GHM Jerusalem, RE Coleman, MT Huizing, A Mehdi, ...</div><div class="gs_gray">Receptor 22, 63<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16884819090188236528" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-cHHJ4ChvFsC" class="gsc_a_at">Bone metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The Breast 20, S19-S20<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8474425934047192691" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MUocvVTjX6cC" class="gsc_a_at">Discordant Treatment Effects According to Menopausal Status Following Adjuvant Zoledronic Acid in Stage II/III Breast Cancer-The AZURE Trial (BIG 01/04)</a><div class="gs_gray">R Coleman, H Marshall, W Gregory, R Bell, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 47, S336-S336<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17179387919717063669" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:G1UMdFYMoxkC" class="gsc_a_at">5019 POSTER DISCUSSION Discordant Treatment Effects According to Menopausal Status Following Adjuvant Zoledronic Acid in Stage ll/lll Breast Cancer-The AZURE Trial (BIG 01/04)</a><div class="gs_gray">R Coleman, H Marshall, W Gregory, R Bell, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">European Journal of Cancer, S336<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=277226869713687429" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Hck25ST_3aIC" class="gsc_a_at">Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid</a><div class="gs_gray">J Body, R Cook, L Costa, J Brown, E Terpos, F Saad, A Lipton, ...</div><div class="gs_gray">Bone 1 (48), S20-S21<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15481772010401756584" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3AIi9tQMIrsC" class="gsc_a_at">Hormone Levels in the OPTION Trial Show No Ovarian Protection by Goserelin in Adjuvant Chemotherapy for Early Breast Cancer-An Anglo-Celtic Collaborative Group and NCRN Trial</a><div class="gs_gray">R Leonard, D Adamson, R Anderson, R Ballinger, G Bertelli, R Coleman, ...</div><div class="gs_gray">CANCER RESEARCH 70<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3383491827600601043" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w7CBUyPWg-0C" class="gsc_a_at">Abstract P5-11-18: Investigating Early Features of Aromatase Inhibitor-Induced Arthralgia</a><div class="gs_gray">OS Din, D Dodwell, RJ Wakefield, M Bradburn, P Emery, G Wilson, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P5-11-18-P5-11-18<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13381107190935410280" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:A8cqit5AE6sC" class="gsc_a_at">Exploring the anti-angiogenic potential of zoledronic acid in combination with neoadjuvant chemotherapy in invasive breast cancer</a><div class="gs_gray">MC Winter, A Evans, I Holen, RE Coleman</div><div class="gs_gray">Bone 47, S310-S310<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11627580728192850196" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:z6xuaG2dYH0C" class="gsc_a_at">Five year efficacy in cancer survivors of single dose zoledronic acid 4 mg in osteopaenia and annual dosing in osteoporosis</a><div class="gs_gray">EJ Woodward, JE Brown, SP Ellis, S Gutcher, JE Lester, O Purohit, ...</div><div class="gs_gray">BONE 47, S310-S311<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11459838193968267485" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5uu-MYFt2EcC" class="gsc_a_at">Prevention and Treatment of Cancer-Associated Thrombosis: A Report on a Roundtable Meeting</a><div class="gs_gray">AK Kakkar, R Coleman</div><div class="gs_gray">British journal of cancer 102<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9227299147584671976" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DIubQTN3OvUC" class="gsc_a_at">496 RIBBON-1: efficacy of capecitabine-bevacizumab in patients with triple-negative metastatic breast cancer (MBC)</a><div class="gs_gray">H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman</div><div class="gs_gray">EJC Supplements 3 (8), 204<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13305438544321505394" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tHtfpZlB6tUC" class="gsc_a_at">EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS</a><div class="gs_gray">R Coleman, R Cook, F Saad, V Hirsh, P Major, R Dias, A Lipton</div><div class="gs_gray">ANNALS OF ONCOLOGY 19, 276-276<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10584434760521851684" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kxd3qP2_5uAC" class="gsc_a_at">nab-Paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries</a><div class="gs_gray">G Dranitsaris, M Lidgren, J Lundkvist, RE Coleman</div><div class="gs_gray">Journal of Clinical Oncology 26 (15_suppl), 6571-6571<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3509128747290729613" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KTwcwpFFj4wC" class="gsc_a_at">Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid</a><div class="gs_gray">PD Ottewell, DV Lefley, RE Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research 10 (2), 1-2<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5587527365066661698" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:natZJ_-F0IUC" class="gsc_a_at">P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo</a><div class="gs_gray">V Hirsh, P Major, A Lipton, R Cook, C Langer, M Smith, J Brown, ...</div><div class="gs_gray">Cancer Treatment Reviews 34, 42<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5687889730857143108" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JP7YXuLIOvAC" class="gsc_a_at">OC10. Prognosis and skeletal disease course in patients with bone metastases from breast cancer (BC) and normal baseline levels of N-telopeptide of type I collagen (NTX)</a><div class="gs_gray">A Lipton, JJ Body, R Cook, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, 10<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15686204044718335723,3621161630297288072" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:v6i8RKmR8ToC" class="gsc_a_at">Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment</a><div class="gs_gray">A Lipton, R Cook, P Major, M Smith, R Coleman, S Milton</div><div class="gs_gray">Breast Cancer Research and Treatment 106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5294831102111580216" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PkcyUWeTMh0C" class="gsc_a_at">Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.</a><div class="gs_gray">E Terpos, R Cook, R Coleman, A Lipton, J Berenson</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 110 (11), 1482-1482<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=656716952511262054" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kcGNQN_anIUC" class="gsc_a_at">2116 POSTER Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective&nbsp;…</a><div class="gs_gray">G Dranitsaris, R Coleman, WJ Gradishar</div><div class="gs_gray">EJC Supplements 4 (5), 219<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2737857414031046716" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:C-Rn0OCouf8C" class="gsc_a_at">304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors</a><div class="gs_gray">A Lipton, RJ Cook, P Major, MR Smith, RE Coleman</div><div class="gs_gray">EJC Supplements 4 (5), 58<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14188747453382372030" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YB4bud6kWLwC" class="gsc_a_at">P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer&nbsp;…</a><div class="gs_gray">A Brufsky, N Bundred, R Coleman, R Lambert-Falls, R Mena, M Dong, ...</div><div class="gs_gray">The Breast, S57<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17891307056292904858" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:__bU50VfleQC" class="gsc_a_at">Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk&nbsp;…</a><div class="gs_gray">C Poole, L Hiller, H Howard, S Loi, J Dunn, P Canney, A Wardley, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 100<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11983784205202288178" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-yGd096yOn8C" class="gsc_a_at">Effects of zoledronic acid on apoptosis in tumour cell lines; repeated low dosing compared to continuous treatment</a><div class="gs_gray">I Holen, R Patel, DV Lefley, HLN Webbe, RE Coleman, JKL Woodward</div><div class="gs_gray">Bone 3 (38), 51-52<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12954012756029137888" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:T_ojBgVMvoEC" class="gsc_a_at">Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease</a><div class="gs_gray">I Holen, RA Hannon, SP Ellis, RE Coleman, JE Brown</div><div class="gs_gray">CANCER TREATMENT REVIEWS 32, S40-S40<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11323971271645954804" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:D_tqNUsBuKoC" class="gsc_a_at">Zoledronic acid (ZOL) and letrozole (LET) induce synergistic levels of apoptosis in breast cancer cells</a><div class="gs_gray">HL Neville-Webbe, D Lefley, RE Coleman, I Holen</div><div class="gs_gray">Bone 3 (38), 58-59<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10682497434737689780" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JTqpx9DYBaYC" class="gsc_a_at">The ARIBON study: Reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronat) treatment during adjuvant therapy for breast cancer.</a><div class="gs_gray">JE Lester, SA Gutcher, S Ellis, R Thorpe, J Horsman, JE Brown, ...</div><div class="gs_gray">CANCER TREATMENT REVIEWS 32, S48-S49<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=299876202267029607" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hGdtkIFZdKAC" class="gsc_a_at">Breast cancer patients with persistently increased bone resorption</a><div class="gs_gray">A Lipton, Y Hei, R Coleman, P Major, M Smith, R Cook</div><div class="gs_gray">EJC SUPPLEMENTS 3 (2), 121-121<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18220589819054450755" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AYInfyleIOsC" class="gsc_a_at">Safety comparison of oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Phase III data</a><div class="gs_gray">JJ Body, M Lichinitser, SA Tjulandin, RE Coleman, B Bergstrom</div><div class="gs_gray">EJC SUPPLEMENTS 3 (2), 114-114<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9724487532654781108" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7H_jS4BsgvYC" class="gsc_a_at">Clinical features and prognosis of bone metastases</a><div class="gs_gray">RE Coleman, TA Plunkett, RD Rubens</div><div class="gs_gray">Textbook of Bone Metastases, 63-75<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4497671108828321624" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WwIwg2wKZ0QC" class="gsc_a_at">Imaging of spinal bone metastases</a><div class="gs_gray">RE Coleman, R Guillevin, JN Vallée, N Martin‐Duverneuil, D Lo, F Lafitte, ...</div><div class="gs_gray">Textbook of bone metastases, 91-104<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15432349467654156936" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ymY9cBF3mdcC" class="gsc_a_at">Cost implications of bisphosphonates</a><div class="gs_gray">RE Coleman, EV McCloskey, JF Guest, RU Ashford, JA Kanis</div><div class="gs_gray">Textbook of Bone Metastases, 415-426<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17154294874978697787" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9DLIHnF0jcYC" class="gsc_a_at">Surgical biopsy of bone metastases</a><div class="gs_gray">RE Coleman, M Salai, I Dudkiewicz</div><div class="gs_gray">Textbook of bone metastases, 123-131<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6943400575813830764" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AzKEL7Gb_04C" class="gsc_a_at">Use in prostate cancer</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Textbook of Bone Metastases, 377-385<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14980328063348117155" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rLGzs9wiiwIC" class="gsc_a_at">Original Reports-SUPPORTIVE CARE AND QUALITY OF LIFE-Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the&nbsp;…</a><div class="gs_gray">RE Coleman, P Major, A Lipton, JE Brown, KA Lee, M Smith, F Saad, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (22), 4925-4935<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5755049519827002922" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BJrgspguQaEC" class="gsc_a_at">Onset of time to first skeletal-related event in patients with advanced cancer metastatic to bone and the clinical benefit of bisphosphonates</a><div class="gs_gray">M Aapro, C Schulman, M Zheng, R Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S24-S24<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17977363490494444950" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8Xgff_V0N9gC" class="gsc_a_at">A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone&nbsp;…</a><div class="gs_gray">JE Brown, E McCloskey, JA Dewar, JJ Body, DA Cameron, OPK Purohit, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 8056-8056<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4463892955963252619" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:k_7cPK9k7w8C" class="gsc_a_at">A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘<i>tAnGo’:</i> A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing&nbsp;…</a><div class="gs_gray">CJ Poole, HC Howard, L Hiller, JA Dunn, AM Wardley, A Bowman, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 821-821<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2008748635287240383" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=700&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lYAcb2jw7qUC" class="gsc_a_at">Zoledronic acid for the prevention of bone metastases in patients with breast cancer</a><div class="gs_gray">R Coleman, J Gralow, R Bell, A Lipton</div><div class="gs_gray">EJC Supplements 3 (2), 74-75<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=610939917956287106" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NxmKEeNBbOMC" class="gsc_a_at">E15. Treatment of metastatic bone disease</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EJC Supplements 3 (2), 32-33<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13307456069776983237" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QsaTk4IG4EwC" class="gsc_a_at">Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations</a><div class="gs_gray">H Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">BONE 34, S67-S68<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2394161141000056769" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LXmCCkuhhTsC" class="gsc_a_at">Association between prior chemotherapy and the adverse event profile of adjuvant anastrozole and tamoxifen: a retrospective analysis of data from the ATAC ('Arimidex&nbsp;…</a><div class="gs_gray">R Coleman</div><div class="gs_gray">ANNALS OF ONCOLOGY 15, 64-64<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2096972796025789681" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zGdJYJv2LkUC" class="gsc_a_at">Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL)</a><div class="gs_gray">H Neville-Webbe, A Evans, R Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research and Treatment 88<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1307993538816552409" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mUJArPsKIAAC" class="gsc_a_at">Navelbine®(NVB) alternating oral and iv plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC): phase II study—final results</a><div class="gs_gray">D Serin, M Verrill, A Jones, T Delozier, R Coleman, B Longerey, ...</div><div class="gs_gray">EJC Supplements 3 (2), 130-131<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16563866416818907557" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aK62MiYD7mUC" class="gsc_a_at">The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.</a><div class="gs_gray">NW Hl, RE Coleman</div><div class="gs_gray">Palliative Medicine 17 (6), 539-553<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1734339626289193423" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QsKbpXNoaWkC" class="gsc_a_at">Breast Cancer: Prognosis, Treatment and Prevention: Edited by Jorge R. Pasqualini, Marcel Dekker, 2002. Price: $165 (£ 105). ISBN 0-8247-07125</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Clinical Oncology 15 (6), 369<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3097402224392119707" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0aBXIfxlw9sC" class="gsc_a_at">Guidelines for the use of bisphosphonates in bone metastases</a><div class="gs_gray">R Coleman</div><div class="gs_gray">European Journal of Cancer Supplements 1 (6), 299-306<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8155763761384090232" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eAUscmXIlQ8C" class="gsc_a_at">Development of a touch screen questionnaire approach for measurement of pain assessment scales in cancer patients with bone metastasis</a><div class="gs_gray">LM Goodhart, JE Brown, S Ellis, S Gutcher, OP Purohit, RE Coleman</div><div class="gs_gray">British Journal of Cancer 88, S67-S67<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16406961644871175961" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xckinRaLORAC" class="gsc_a_at">Untitled</a><div class="gs_gray">WP Coleman, N Lawrence</div><div class="gs_gray">JOURNAL OF FORENSIC SCIENCES 48 (3), 697-697<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12990638447400418809,12467326943385934203" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rbm3iO8VlycC" class="gsc_a_at">Ten-year follow-up of a patient with metastatic Ewing's sarcoma of the pelvis</a><div class="gs_gray">RU Ashford, EV McCLOSKEY, OP Purohit, CE Ingram, RJ Grimer, ...</div><div class="gs_gray">Sarcoma 6 (4), 131-133<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=822586813800619043" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:K4-iKlO5MD4C" class="gsc_a_at">Expression of hypoxia inducible factor-1 in metastatic tumour's in ovarian cancer: link with p53 expression and relevance to hypoxia-targeted gene therapies for disseminated&nbsp;…</a><div class="gs_gray">CJ Baluch, B Burke, K Corke, M Wells, J Smith, J Tidy, R Coleman, ...</div><div class="gs_gray">JOURNAL OF PATHOLOGY 198, 5A-5A<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13015287777462950631" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mel-f30kHHgC" class="gsc_a_at">OPG is a survival factor for breast-and prostate cancer cells in vitro</a><div class="gs_gray">I Holen, PI Croucher, AC Evans, JM Lippitt, FC Hamdy, RE Coleman, ...</div><div class="gs_gray">Bone 30 (3)<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17346916517988770543" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:silx2ntsSuwC" class="gsc_a_at">Relationship between bone resorption and skeletal events in metastatic done disease</a><div class="gs_gray">JE Brown, S Ellis, S Gutcher, C Thompson, OP Purohit, RE Coleman</div><div class="gs_gray">Bone 30 (3), 47S-47S<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3263982071144462317" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:L_l9e5I586QC" class="gsc_a_at">Zometa (R) is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy</a><div class="gs_gray">R Coleman, J Apffelstaedt, D Gordon, P Major, J Mackey, A Howell, ...</div><div class="gs_gray">European Journal of Cancer 37, S152-S152<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10404081087923990447" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qE4H1tSSYIIC" class="gsc_a_at">Is docetaxel-carboplatin an alternative to paclitaxel-carboplatin in ovarian cancer?</a><div class="gs_gray">PA Vasey, R Coleman, SPH Eggleton, J Graham, D Fleming, J Paul, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 80, 14-14<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10383694337024956950" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zwpXiJ37cpgC" class="gsc_a_at">Management of Testicular Tumours</a><div class="gs_gray">LS Dobson, RE Coleman</div><div class="gs_gray">Surgery-Oxford 17 (7), 168-171<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13555719057855974620" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MIg0yeAD4ggC" class="gsc_a_at">Liberated by employment?</a><div class="gs_gray">R Coleman, L Ellis, M Smith</div><div class="gs_gray">A Life in the Day<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11536313597473641134" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WzTVkKNmPSkC" class="gsc_a_at">CMB-401-A new agent for immunotherapy of epithelial ovarian cancer: Immune response and pharmacokinetics</a><div class="gs_gray">TJ Broadhead, AM Gillespie, RE Coleman, J Owen, L Skelton, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 44-44<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8286199811581485306" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2ywjKiB__4kC" class="gsc_a_at">An open phase II study of Taxotere in 42 patients with liver metastases from breast cancer</a><div class="gs_gray">RE Coleman, A Howell, SPH Eggleton, SJ Maling, DW Miles</div><div class="gs_gray">ANNALS OF ONCOLOGY 9, 15-15<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8253486813396543616" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sA9dB-pw3HoC" class="gsc_a_at">Phase I study of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.</a><div class="gs_gray">AM Gillespie, TJ Broadhead, SY Chan, J Owen, AP Farnsworth, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 20-20<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3444955717751850198" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EPG8bYD4jVwC" class="gsc_a_at">Preliminary report of a dose-finding study of a docetaxel-carboplatin combination in untreated advanced epithelial ovarian cancer</a><div class="gs_gray">PA Vasey, R Atkinson, R Coleman, SPH Eggleton, D Fleming, J Graham, ...</div><div class="gs_gray">PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17&nbsp;…<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13035889921847439736" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jlhcAiayVhoC" class="gsc_a_at">0-35. Guiding systemic therapy in metastatic breast cancer by blood tumour markers</a><div class="gs_gray">JFR Robertson, S Kramer, JJ Syzmendera, C Selby, R Coleman, ...</div><div class="gs_gray">The Breast 4 (6), 234<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2268379357073148732" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UuEBAcK4md4C" class="gsc_a_at">A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma</a><div class="gs_gray">MS Highley, N Samandas, N Ziras, MM Morgan, ME Hill, R Stein, S Barker, ...</div><div class="gs_gray">International Journal of Gynecological Cancer 6 (4), 323-327<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1831049989655838800" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CYCckWUYoCcC" class="gsc_a_at">7. Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma</a><div class="gs_gray">RH Reid, P Hoskin, P Ell, R Coleman, D Quick</div><div class="gs_gray">Nuclear Medicine Communications 17 (4), 258<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3901842212640431374" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-6RzNnnwWf8C" class="gsc_a_at">Breast disease-The management of advanced breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">CURRENT PRACTICE IN SURGERY 8, 7-12<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11380690069390052984" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hSRAE-fF4OAC" class="gsc_a_at">Phase II Study of Liarozole in Advanced Breast Cancer Patients</a><div class="gs_gray">JA Roy, J Klijn, L Beex, L Mauriac, R Coleman, G Hoctin-Boes, ...</div><div class="gs_gray">European Journal of Cancer 32 (S2), 45-45<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5227340121825249810" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hvmnpdAuIbkC" class="gsc_a_at">Clinically available evaluation of bone disease in breast cancer--validity and cost effectiveness.</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">The Canadian journal of oncology 5, 69-79<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16989925724375857668" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:s9ia6_kGH2AC" class="gsc_a_at">1168 Etoposide and actinomycin D (EA) for methotrexate (MTX) resistant, low risk, persistent gestational trophoblastic disease (GTD) and EA with MTX (MEA) for high risk GTD</a><div class="gs_gray">PC Lorigan, J Nevin, C Radstone, RE Coleman, BW Hancock</div><div class="gs_gray">European Journal of Cancer 31, S244<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17633651226773547304" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:O0nohqN1r9EC" class="gsc_a_at">513 Trial of oral hexalen for relapsed ovarian carcinoma [OV/CA]: Comparison of CA125 and EORTC response definitions</a><div class="gs_gray">GJS Rustin, SM Crawford, RE Coleman, J Lambert, JA Ledermann, ...</div><div class="gs_gray">European Journal of Cancer 31, S109-S110<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=999354581600804519" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Oj-SLI0tZTcC" class="gsc_a_at">Ra (Patria 6);[Religious Drama for Chorus (4 Tenors, 4 Basses), 2 Percussion, Qanun, ud, Darabukkah, Violin; Tape and Electronic Sounds; Dancers, Actors]</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Notes 50 (3), 1186-1190<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5643695004009043059" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:unp9ATQDT5gC" class="gsc_a_at">The late results of consolidation treatment following induction chemotherapy for small cell lung cancer</a><div class="gs_gray">R Coleman, R Leonard, M Cornbleet, A Gregor, G Newaishy, A Greening, ...</div><div class="gs_gray">Lung cancer 7 (5), 299-307<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12686727682086611366" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4aZ_i-5WJEQC" class="gsc_a_at">Failure of salvage treatment in metastatic testicular teratoma</a><div class="gs_gray">D Whillis, RE Coleman, MA Cornbleet, GCW Howard</div><div class="gs_gray">Clinical oncology 3 (3), 141-146<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15890529822414477005" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-DxkuPiZhfEC" class="gsc_a_at">CHEMOTHERAPY TYPE AND GOOD PERFORMANCE STATUS IMPROVE RESPONSE IN PATIENTS WITH RECURRENT CERVICAL-CANCER</a><div class="gs_gray">J Buxton, R Coleman, K Towlson, P Harper, E Wiltshaw, J Dunn, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 60 (3), 453-453<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5556476301309101167" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rFyVMFCKTwsC" class="gsc_a_at">FREE CME</a><div class="gs_gray">RE Coleman, TA Guise, I Holen, A Lipton, GD Roodman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7659967774502183071" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NMlhSUseqAsC" class="gsc_a_at">Biochemical assessment predicts radiological response in bone metastases from breast cancer</a><div class="gs_gray">RE Coleman, I Fogelman, G Mashiter, KB Whitaker, DW Moss, ...</div><div class="gs_gray">Bone 8 (4), 266<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15162634891087399187" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Y0-TYkg6YM4C" class="gsc_a_at">Robert Coleman</a><div class="gs_gray">R Coleman, E Vergil</div><div class="gs_gray">Cambridge<span class="gs_oph">, 1977</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5257693018240563717" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1977</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NU-BerS4NX4C" class="gsc_a_at">Endocrine therapy of breast cancer</a><div class="gs_gray">WL Donegan</div><div class="gs_gray">Cancer of the Breast, 44-64<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1890260326531875893" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BFeJNCPbDVwC" class="gsc_a_at">Individualized bone protective management in long‐term cancer survivors with bone metastases</a><div class="gs_gray">TD Rachner, R Coleman, P Hadji, LC Hofbauer</div><div class="gs_gray">Journal of Bone and Mineral Research<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:R1TrASrH5esC" class="gsc_a_at">Terapeutisk behandling af brystcancer baseret på c-MAF-status</a><div class="gs_gray">WM Gregory, R Gomis, RE Coleman, JC Tercero</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rVBkUn48wTwC" class="gsc_a_at">Therapeutic treatment of breast cancer based on c-maf status</a><div class="gs_gray">WM Gregory, JC Tercero, RE Coleman, R Gomis</div><div class="gs_gray">US Patent App. 16/766,043<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4p3FJGzxjgAC" class="gsc_a_at">Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial</a><div class="gs_gray">I Sestak, G Blake, R Patel, J Cuzick, A Howell, R Coleman, R Eastell</div><div class="gs_gray">British journal of cancer 124 (8), 1373-1378<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cpgjJtNNFA0C" class="gsc_a_at">Abstract PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON)-Safety and preliminary efficacy findings</a><div class="gs_gray">M Winter, J Kendall, S Brown, E Rathbone, C Wilson, S Howell, ...</div><div class="gs_gray">Cancer Research 81 (4 Supplement), PS14-02-PS14-02<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lRzkMCTRmMwC" class="gsc_a_at">Abstract PS14-01: Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo&nbsp;…</a><div class="gs_gray">RE Coleman, G Fried, SB Kim, I Kuchuk, D Kiesl, M Ramos, J Sohn, ...</div><div class="gs_gray">Cancer Research 81 (4 Supplement), PS14-01-PS14-01<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:knQODA9bSJkC" class="gsc_a_at">Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo-controlled trial</a><div class="gs_gray">RE Coleman, G Fried, SB Kim, I Kuchuk, D Kiesl, M Ramos, J Sohn, ...</div><div class="gs_gray">CANCER RESEARCH 81 (4)<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ECvNt0vk_34C" class="gsc_a_at">Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer</a><div class="gs_gray">C Handforth, R Burkinshaw, J Freeman, JE Brown, JA Snowden, ...</div><div class="gs_gray">Supportive care in cancer: official journal of the Multinational Association&nbsp;…<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EVKlETVVbN8C" class="gsc_a_at">The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials</a><div class="gs_gray">D Preiss, J Armitage, R Holman, R Coleman, E Spata</div><div class="gs_gray">Diabetes Care<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LZ55yeyZZb4C" class="gsc_a_at">A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON)-Safety and preliminary efficacy findings</a><div class="gs_gray">M Winter, J Kendall, S Brown, E Rathbone, C Wilson, SJ Howell, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3ssty3PwuTgC" class="gsc_a_at">Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study</a><div class="gs_gray">P Savage, M Winter, V Parker, V Harding, A Sita‐Lumsden, RA Fisher, ...</div><div class="gs_gray">BJOG: An International Journal of Obstetrics &amp; Gynaecology 127 (9), 1102-1107<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cAUKuAERoUMC" class="gsc_a_at">30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients</a><div class="gs_gray">S D'Oronzo, D Lovero, R Palmirotta, P Cafforio, J Brown, S Wood, M Cives, ...</div><div class="gs_gray">Annals of Oncology 31, S26<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:K1AqHrCRkPsC" class="gsc_a_at">Distribution and Prognosis of Metastatic Disease in Newly Diagnosed Stage IV Breast Cancer</a><div class="gs_gray">X Kong, Q Liu, R Coleman, Y Fang, J Wang</div><div class="gs_gray">Available at SSRN 3633992<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7xtfDMUJqJkC" class="gsc_a_at">Ten-year outcome for women randomized in a Phase III trial comparing Doxorubicin and Cyclophosphamide with Doxorubicin and Docetaxel as primary medical therapy in early breast&nbsp;…</a><div class="gs_gray">C Stavraka, TR Evans, J Dunlop, H Earl, DA Cameron, R Coleman, ...</div><div class="gs_gray">Cancer Res Treat 122, 787-794<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:T0nwzvlCxs8C" class="gsc_a_at">Mammakarzinom: Denosu-mab zögert Knochenmetas-tasierung nicht hinaus</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Lancet Oncol 21, 60-72<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ae0xyBWlIcIC" class="gsc_a_at">Metástasis óseas</a><div class="gs_gray">RE Coleman, J Brown, I Holen</div><div class="gs_gray">Abeloff, oncología clínica, 809-830<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:b8wqy9DyMDUC" class="gsc_a_at">Testosterone Replacement in Young Male cancer Survivors (TRYMS): A six-month double-blind randomised placebo-controlled study</a><div class="gs_gray">JS Walsh, H Marshall, IL Smith, DM Greenfield, J Swain, E Best, J Ashton, ...</div><div class="gs_gray">European Urology Supplements 18 (4), 34<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LLUdpdcEW3AC" class="gsc_a_at">Estimating the magnitude of clinical benefit of bisphosphonates and denosumab in the adjuvant setting</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast 44, S12<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:OC7j4ufeY2cC" class="gsc_a_at">Abstract P2-12-01: Dose-and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the&nbsp;…</a><div class="gs_gray">J Gee, RE Coleman, KL Cheung, A Evans, C Holcombe, A Skene, D Rea, ...</div><div class="gs_gray">Cancer Research 79 (4 Supplement), P2-12-01-P2-12-01<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-0tLmPFCw2kC" class="gsc_a_at">Abstract P1-17-01: Long term survival benefits of adjuvant zoledronic acid associated with maf status of primary tumor</a><div class="gs_gray">R Coleman, W Gregory, J Jean-Mairet, JC Tercero, J Torres-Martin, ...</div><div class="gs_gray">Cancer Research 79 (4 Supplement), P1-17-01-P1-17-01<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:esGtpfCv0y8C" class="gsc_a_at">Dose-and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized&nbsp;…</a><div class="gs_gray">J Gee, RE Coleman, KL Cheung, A Evans, C Holcombe, A Skene, D Rea, ...</div><div class="gs_gray">CANCER RESEARCH 79 (4)<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Q17yWvk9gpwC" class="gsc_a_at">Bone Metastases; Medical Treatment</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Academic Press<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6xXPb0EiZccC" class="gsc_a_at">Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.</a><div class="gs_gray">JM Ubellacker, N Baryawno, N Severe, MJ DeCristo, J Sceneay, ...</div><div class="gs_gray">MOLECULAR CANCER RESEARCH 16 (8), 68-69<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cAWJABFkdiUC" class="gsc_a_at">Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence</a><div class="gs_gray">JM Ubellacker, N Baryawno, N Severe, MJ DeCristo, J Sceneay, ...</div><div class="gs_gray">Molecular Cancer Research 16 (8 Supplement), B13-B13<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4pF9x-cDGsoC" class="gsc_a_at">Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human&nbsp;…</a><div class="gs_gray">JFR Robertson, RE Coleman, KL Cheung, A Evans, C Holcombe, ...</div><div class="gs_gray">Cancer Research 78 (4 Supplement), P4-04-06-P4-04-06<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:S_Qw7xXuMuIC" class="gsc_a_at">Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: results&nbsp;…</a><div class="gs_gray">TWP Friedl, B Rack, T Fehm, V Mueller, W Lichtenegger, JU Blohmer, ...</div><div class="gs_gray">ONCOLOGY RESEARCH AND TREATMENT 41, 32-32<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Iq19BMNozs4C" class="gsc_a_at">Systems and Reliability Modelling for Probabilistic Risk Assessment of Improvised Explosive Device Attacks</a><div class="gs_gray">WCMJ Grant</div><div class="gs_gray">University of Newcastle<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0iM-huCvmk0C" class="gsc_a_at">Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial</a><div class="gs_gray">A Oke, J Knox, J Tan, B Aigret, P Schmid, RE Coleman, J Cuzick, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:o0eFlWRwRSUC" class="gsc_a_at">MP57-10 RELATIONSHIP BETWEEN QUALITY OF LIFE AND OVERALL SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN ALSYMPCA: ANALYSIS BY PRIOR DOCETAXEL SUBGROUP</a><div class="gs_gray">ND Shore, S Nilsson, O Sartor, NJ Vogelzang, RE Coleman, ...</div><div class="gs_gray">The Journal of Urology 197 (4S), e767-e767<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7nQzp1YiEc4C" class="gsc_a_at">Abstract P3-06-03: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT&nbsp;…</a><div class="gs_gray">JFR Roberston, KL Cheung, S Ahmed, RE Coleman, A Evans, ...</div><div class="gs_gray">Cancer Research 77 (4 Supplement), P3-06-03-P3-06-03<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yL7DKRohVA8C" class="gsc_a_at">Abstract OT3-03-02: Maximising recruitment and retention of patients into UK-ANZ POSNOC trial</a><div class="gs_gray">A Goyal, RE Coleman, D Dodwell, L Fallowfield, VA Jenkins, B Mann, ...</div><div class="gs_gray">Cancer Research 77 (4 Supplement), OT3-03-02-OT3-03-02<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GdZ7R06HQM4C" class="gsc_a_at">Abstract P6-17-01: Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up</a><div class="gs_gray">R Coleman, M Collinson, R Bell, H Marshall, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">Cancer Research 77 (4 Supplement), P6-17-01-P6-17-01<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:m03se8k-GH0C" class="gsc_a_at">The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial)</a><div class="gs_gray">JFR Roberston, KL Cheung, S Ahmed, RE Coleman, A Evans, ...</div><div class="gs_gray">CANCER RESEARCH 77<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vbti4gW_9XwC" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy+/-radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients&nbsp;…</a><div class="gs_gray">RE Coleman, G Fried, O Petrenciuc, A Sawhney, R Li, HS Rugo</div><div class="gs_gray">CANCER RESEARCH 77<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5-bGDoUgDrYC" class="gsc_a_at">Long-term follow-up of The Intergroup Exemestane Study</a><div class="gs_gray">A Coates, I Alvarez, J Andersen, G Bertelli, J Bliss, R Coleman, ...</div><div class="gs_gray">American Society of Clinical Oncology<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u1IMlZnpNFQC" class="gsc_a_at">Gemcitabine added to paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for women with early stage breast cancer (tAnGo): an open-label, randomised&nbsp;…</a><div class="gs_gray">HM Earl, L Hiller, HC Howard, JA Dunn, J Young, SJ Bowden, ...</div><div class="gs_gray">Oncology 18 (6), 755-769<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TNEldfgDb5MC" class="gsc_a_at">THU0023 Expression of OSCAR in The Synovium of Early RA Patients</a><div class="gs_gray">TN Crotti, R Coleman, AA Dharmapatni, H Weedon, DR Haynes, ...</div><div class="gs_gray">Annals of the Rheumatic Diseases 75 (Suppl 2), 185-185<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:UY3hNwcQ290C" class="gsc_a_at">TREE-BASED INTERCROPPING SYSTEMS: A POTENTIAL LAND-USE SOLUTION FOR CLIMATE CHANGE MITIGATION IN CANADIAN AGRICULTURAL LANDSCAPES</a><div class="gs_gray">AM Gordon, A Wotherspoon, K Graungaard, K Dunfield, D Jeffries, ...</div><div class="gs_gray">tree, 204<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZJ-noXUx9mkC" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2<sup>-</sup> hormone receptor<sup>+</sup> breast cancer&nbsp;…</a><div class="gs_gray">RE Coleman, R Li, AG Sawhney, O Petrenciuc, HS Rugo</div><div class="gs_gray">Journal of Clinical Oncology 34 (15_suppl), TPS622-TPS622<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YXeC4bxG7-IC" class="gsc_a_at">Data Management Bootcamp 2016: Shane Coleman</a><div class="gs_gray">RS Coleman</div><div class="gs_gray">Virginia Tech Data Management Bootcamp 2016<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DwFgw5hZUzMC" class="gsc_a_at">ADDITIVE EFFECTS OF ANTIRESORPTIVE TREATMENTS BEYOND OSTEOPOROSIS</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">OSTEOPOROSIS INTERNATIONAL 27, S563-S563<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:polMJLZb0X8C" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy+/-radium-223 dichloride in human epidermal growth factor receptor 2-negative, hormone receptor&nbsp;…</a><div class="gs_gray">RE Coleman, L Huang, O Petrenciuc, P Zaccarini, HS Rugo</div><div class="gs_gray">CANCER RESEARCH 76<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XAEgxC7iu0MC" class="gsc_a_at">A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2 negative&nbsp;…</a><div class="gs_gray">HS Rugo, L Huang, O Petrenciuc, P Zaccarini, RE Coleman</div><div class="gs_gray">CANCER RESEARCH 76<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Dmoar05iI2YC" class="gsc_a_at">Abstract OT2-01-11: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor&nbsp;…</a><div class="gs_gray">HS Rugo, L Huang, O Petrenciuc, P Zaccarini, RE Coleman</div><div class="gs_gray">Cancer Research 76 (4 Supplement), OT2-01-11-OT2-01-11<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3WNXLiBY60kC" class="gsc_a_at">Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy±radium-223 dichloride in human epidermal growth factor receptor 2–negative&nbsp;…</a><div class="gs_gray">RE Coleman, L Huang, O Petrenciuc, P Zaccarini, HS Rugo</div><div class="gs_gray">Cancer Research 76 (4 Supplement), OT2-01-05-OT2-01-05<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:B71Od6CY_ssC" class="gsc_a_at">Expression of OSCAR in the Sunovium of Early RA Patiens</a><div class="gs_gray">T Crotti, R Coleman, A Dharmapatni, H Weedon, D Haynes, M Smith, ...</div><div class="gs_gray">Annual European Congress of Rheumatology (EULAR)<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:j6V8Syvup0UC" class="gsc_a_at">3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets&nbsp;…</a><div class="gs_gray">E Koenig, O Sartor, RE Coleman, S Nilsson, N Voyelzang, K Staudacher, ...</div><div class="gs_gray">ONCOLOGY RESEARCH AND TREATMENT 39, 86-86<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CLhUwle04lcC" class="gsc_a_at">Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC&nbsp;…</a><div class="gs_gray">SA Wedel, B Mellado, O Sartor, N Vogelzang, P Hoskin, S Nilsson, ...</div><div class="gs_gray">Oncology Research and Treatment 38, 267-267<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lPDSu1ZU3VAC" class="gsc_a_at">3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA</a><div class="gs_gray">D Amadori, C Rossetti, M Aglietta, C Messina, A Versari, NJ Vogelzang, ...</div><div class="gs_gray">Annals of Oncology 26, vi54<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MqTxh1vmwXEC" class="gsc_a_at">3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA</a><div class="gs_gray">MW Kramer, MA Kuczyk, C Parker, N Vogelzang, O Sartor, RE Coleman, ...</div><div class="gs_gray">Oncology Research and Treatment 38, 266-266<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gI9wzKcniAoC" class="gsc_a_at">Abstract P3-11-04: Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials</a><div class="gs_gray">JR Kroep, A Charehbili, RE Coleman, RL Aft, Y Hasegawa, GJ Liefers, ...</div><div class="gs_gray">Cancer Research 75 (9 Supplement), P3-11-04-P3-11-04<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZYsTHYU9jrMC" class="gsc_a_at">Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience</a><div class="gs_gray">A Giobbie-Hurder, B Thürlimann, B Ejlertsen, P Neven, RE Coleman, ...</div><div class="gs_gray">Cancer Research 75 (9 Supplement), P4-18-03-P4-18-03<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gkldIfsazJcC" class="gsc_a_at">Abstract OT2-2-01: tnAcity: A phase II/III trial of nab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for&nbsp;…</a><div class="gs_gray">DA Yardley, RE Coleman, P Conte, J O'Shaughnessy, J Cortes, S Glück, ...</div><div class="gs_gray">Cancer Research 75 (9 Supplement), OT2-2-01-OT2-2-01<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yBJCJstOu-sC" class="gsc_a_at">Philosopher &amp; Theorist Names</a><div class="gs_gray">J Adler, TW Adorno, G Agamben, A Arendt, J Baehr, K Barad, E Barrett, ...</div><div class="gs_gray">Art's Teachings, Teaching's Art, 243<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rJyh6hJnyfgC" class="gsc_a_at">Chairs and Panel Members</a><div class="gs_gray">F Cardoso, A Costa, L Norton, EP Winer, MS Aapro, F André, S Aparicio, ...</div><div class="gs_gray">The Breast 24 (S3), S6-S7<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CMPXdcK5v8EC" class="gsc_a_at">IN01 LIVING WITH METASTATIC BONE DISEASE–THE POSITIVE IMPACT OF BONE-TARGETED TREATMENTS</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast, S21<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JIEWM9yDoCIC" class="gsc_a_at">Quality of life (QOL) results of the UK TACT2 trial: more intensive chemotherapy for early breast cancer (EBC) has a measurable impact on patient-reported symptoms and&nbsp;…</a><div class="gs_gray">G Velikova, J Morden, P Barrett-Lee, D Bloomfield, M Brunt, P Canney, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g30IDTdgJMgC" class="gsc_a_at">The Editors of the European Journal of Cancer would like to take this opportunity to express their gratitude to all of the individuals who acted as reviewers in the year 2014&nbsp;…</a><div class="gs_gray">J Cuzick, S Suciu, MJ Seckl, CA Stiller, CJ Twelves, R Coleman, ...</div><div class="gs_gray">European Journal of Cancer 51, 124-125<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gFrPXmx1TSsC" class="gsc_a_at">P078 Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC&nbsp;…</a><div class="gs_gray">B Mellado, O Sartor, NJ Vogelzang, P Hoskin, S Nilsson, RE Coleman, ...</div><div class="gs_gray">European Urology Supplements 13 (5), 138<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cOfwuRB03ygC" class="gsc_a_at">1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castrationresistant prostate cancer (CRPC) and symptomatic bone metastases from the&nbsp;…</a><div class="gs_gray">M Kuczyk, C Parker, N Vogelzang, O Sartor, D Bottomley, R Coleman, ...</div><div class="gs_gray">Oncology Research and Treatment 37<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GUYAmugLYisC" class="gsc_a_at">Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified&nbsp;…</a><div class="gs_gray">S Wedel, P Wiechno, S Helle, J Logue, S Nilsson, O Sartor, R Coleman, ...</div><div class="gs_gray">Oncology Research and Treatment 37, 86-87<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=800&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NnTm98qLMbgC" class="gsc_a_at">Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic&nbsp;…</a><div class="gs_gray">PF Conte, DA Yardley, A Brufsky, RE Coleman, J Cortes, S Gluck, ...</div><div class="gs_gray">Annals of Oncology 25, iv135<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-ZoC36zw86wC" class="gsc_a_at">Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial.</a><div class="gs_gray">I Sestak, S Singh, J Cuzick, G Blake, R Patel, R Coleman, M Dowsett, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 29, S110-S110<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tFzHCjejgA0C" class="gsc_a_at">Neurosyphilis in a Penicillin Allergic Patient</a><div class="gs_gray">M Smith, P Gendusa, R Coleman, P Thien</div><div class="gs_gray">JOURNAL OF INVESTIGATIVE MEDICINE 62 (2), 473-474<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5rMqqAh47xYC" class="gsc_a_at">Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with&nbsp;…</a><div class="gs_gray">P Strölin, O Sartor, R Coleman, S Nilsson, N Vogelzang, A Cross, ...</div><div class="gs_gray">Oncology Research and Treatment 37<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4oJvMfeQlr8C" class="gsc_a_at">Updated survivl, Qulity of life (QOL), and safety Dta of Radium-223 Chloride (Ra-223) in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases from the&nbsp;…</a><div class="gs_gray">T Steuber, C Parker, R Coleman, S Nilsson, N Volgelzang, A Lloyd, ...</div><div class="gs_gray">Oncology Research and Treatment 37<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hZ5_QnqxF7AC" class="gsc_a_at">Erratum: Oral surgery: ARONJ masterclass (British Dental Journal (2014) 216 (488-489))</a><div class="gs_gray">A Moore, S Ruggiero, S Rogers, T Taylor, S Popat, R Coleman, S Leyland, ...</div><div class="gs_gray">BRITISH DENTAL JOURNAL 216 (10)<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:d3xjRt2Mi1YC" class="gsc_a_at">Corrigendum to “Breathing during cardiac arrest following exercise: A new function of the respiratory system?”[Respir. Physiol. Neurobiol. 181 (2012) 220–227]</a><div class="gs_gray">P Haouzi, A Van De Louw, A Haouzi</div><div class="gs_gray">Respiratory Physiology &amp; Neurobiology, 48<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SgM-ki2adj0C" class="gsc_a_at">Regulation of osteoclast-associated receptor (OSCAR) production by human peripheral blood derived osteoclast cells</a><div class="gs_gray">R Coleman, A Dharmapatni, K Aldgate, H Weedon, M Cantley, ...</div><div class="gs_gray">Australian Rheumatology Association 55th Annual Scientific Meeting<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pUxgyZctzPYC" class="gsc_a_at">Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II)</a><div class="gs_gray">R Eastell, I Sestak, F Gossiel, R Patel, G Blake, R Coleman, A Howell, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uAPFzskPt0AC" class="gsc_a_at">Abstract P2-11-07: Proteins predictive of bone metastasis development in breast cancer patients</a><div class="gs_gray">JA Westbrook, DA Cairns, J Peng, V Speirs, AM Hanby, I Holen, ...</div><div class="gs_gray">Cancer Research 73 (24 Supplement), P2-11-07-P2-11-07<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4E1Y8I9HL1wC" class="gsc_a_at">Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.</a><div class="gs_gray">I Brana, K Moore, S Welch, R Shapira-Frommer, D Gibbon, H Hirte, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 12 (11 Supplement), B181-B181<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:a2necdfpwlEC" class="gsc_a_at">The Role of Bone-Modifying Agents (BMA) in the Treatment of Bone Metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Annals of Oncology 24, ix26<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pQTOvowfQioC" class="gsc_a_at">Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer</a><div class="gs_gray">W Gregory, H Marshall, D Cameron, C Twelves, R Bell, R Coleman</div><div class="gs_gray">Trials 14 (1), 1-1<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uoRD4RTSUPoC" class="gsc_a_at">Safety of cytotoxic chemotherapy following Radium223-Dichlorid (Ra223)-therapy in the phase 3 ALSYMPCA study in patients with castration resistant prostate cancer (CRPC&nbsp;…</a><div class="gs_gray">P Stroelin, A Haese, H Heinzer, T Steuber, O Sartor, R Coleman, ...</div><div class="gs_gray">Onkologie 36<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:17ZO-CJnx_8C" class="gsc_a_at">DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE)</a><div class="gs_gray">A Chan, P Goss, C Barrios, DM Finkelstein, H Iwata, M Martin, R Coleman, ...</div><div class="gs_gray">ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9, 53-53<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ufKn5pxu7C0C" class="gsc_a_at">The impact of bone metastases on pain: post-hoc analysis of a phase III study of denosumab in men with non-metastatic Castration-Resistant Prostate Cancer (CRPC): 52</a><div class="gs_gray">F Saad, D Patrick, M Smith, C Cleeland, L Fallowfield, B Tombal, ...</div><div class="gs_gray">Bju International 111<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BOlwja0KXvYC" class="gsc_a_at">BISPHOSPHONATES, BONE AND CANCER: MORE THAN INHIBITION OF BONE RESORPTION?</a><div class="gs_gray">R Coleman</div><div class="gs_gray">OSTEOPOROSIS INTERNATIONAL 24, S29-S29<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1Aeql8wG3wEC" class="gsc_a_at">Relationship between Soluble OSCAR and Disease Activity: A 12 Month Study of Newly Diagnosed RA Patients</a><div class="gs_gray">A Dharmapatni, R Coleman, M Lorimer, A Zannettino, H Weedon, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 28<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZqLB7dQ1iF4C" class="gsc_a_at">WEST NILE VIRUS ENCEPHALITIS</a><div class="gs_gray">A Prabhakar, R Coleman, N Kemp, LS Engel, B DeBoisblanc</div><div class="gs_gray">JOURNAL OF INVESTIGATIVE MEDICINE 61 (2), 415-415<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:v_xunPV0uK0C" class="gsc_a_at">JBO-Launched and flying ahead</a><div class="gs_gray">R Coleman, P Hadji</div><div class="gs_gray">JOURNAL OF BONE ONCOLOGY 2 (1), 1-1<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:43B52WW2E64C" class="gsc_a_at">PO55 THE COMBINATION CHEMOTHERAPY OF GEMCITABINE AND VINORELBINE IN HER2-NEGATIVE PATIENTS WITH TAXANE-PRETREATED METASTATIC BREAST CANCER: A PHASE II STUDY OF KINKI&nbsp;…</a><div class="gs_gray">J Yamamura, N Masuda, D Yamamoto, S Tsuyuki, M Yamaguchi, ...</div><div class="gs_gray">The Breast, S38<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Azgs6IHzeyYC" class="gsc_a_at">P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study</a><div class="gs_gray">S Nilsson, AJ Schrader, J Kliment, A Solberg, L Franzén, D Bottomley, ...</div><div class="gs_gray">European Urology Supplements 6 (12), 178<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Lo8V22OuN40C" class="gsc_a_at">A humane solution</a><div class="gs_gray">K Archibald, R Coleman</div><div class="gs_gray">NEW SCIENTIST 216 (2895), 32-33<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4tNoA7Af41QC" class="gsc_a_at">How to stop adverse drug reactions</a><div class="gs_gray">K Archibald, R Coleman</div><div class="gs_gray">New Scientist 216 (2895), 32-33<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qCaWouos7ogC" class="gsc_a_at">Abstract P2-02-04: The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily.</a><div class="gs_gray">C Wilson, MC Winter, I Holen, JV Freeman, AC Evans, RE Coleman</div><div class="gs_gray">Cancer Research 72 (24 Supplement), P2-02-04-P2-02-04<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1_W9tMSvGuwC" class="gsc_a_at">VOICES FROM THE POOREST RURAL TOWN IN THE US: A CBPE PROJECT ON HEALTH ISSUES AND NEEDS</a><div class="gs_gray">K Kopera-Frye, PH Saulsberry, D Ndunda, S Robinson, L Henderson, ...</div><div class="gs_gray">GERONTOLOGIST 52, 711-712<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:h168fVGZblEC" class="gsc_a_at">Bone Oncology—An emerging multi-disciplinary specialty</a><div class="gs_gray">R Coleman, P Hadji</div><div class="gs_gray">Journal of bone oncology 1 (1), 1<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:t-hv7AR41mYC" class="gsc_a_at">Denosumab in castration-resistant prostate cancer–Authors' reply</a><div class="gs_gray">MR Smith, F Saad, R Coleman, Z Ye, C Goessl</div><div class="gs_gray">The Lancet 379 (9828), e50-e51<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:V_vSwabWVtYC" class="gsc_a_at">Nuclear medicine</a><div class="gs_gray">RE Coleman, S Borges-Neto, RH Wilkinson, SM O'Hara, MW Hanson, ...</div><div class="gs_gray">Duke Radiology Case Review: Imaging, Differential Diagnosis, and Discussion&nbsp;…<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6ZzL7HXColQC" class="gsc_a_at">Breast-cancer adjuvant therapy with zoledronic acid REPLY</a><div class="gs_gray">RE Coleman, H Marshall, R Bell, AZURE Investigators</div><div class="gs_gray">New England Journal of Medicine 366 (2), 189-189<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:iWL_APfBKHwC" class="gsc_a_at">Serum Lactate Dehydrogenase ls Prognostic for Survival in</a><div class="gs_gray">JE Brown, RJ Cook, A Lipton, RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MDX3w3dAD3YC" class="gsc_a_at">OC-0367 RADIUM-223 CHLORIDE AND IMPROVED SURVIVAL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES</a><div class="gs_gray">V Lewington, S Boehmer, L Franzén, R Klijer, B Mellado, R Coleman, ...</div><div class="gs_gray">Radiotherapy and Oncology, S147<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TaaCk18tZOkC" class="gsc_a_at">IN15 RANKL signalling: bone metastasis and beyond</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast, S5<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Q3-QASNKTMEC" class="gsc_a_at">P2-17-01: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving&nbsp;…</a><div class="gs_gray">R Coleman, R De Boer, H Eidtmann, P Neven, G von Minckwitz, N Martin, ...</div><div class="gs_gray">Cancer Research 71 (24 Supplement), P2-17-01-P2-17-01<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:X0DADzN9RKwC" class="gsc_a_at">Optimising trial monitoring on the AZURE trial</a><div class="gs_gray">GA Matthews, R Burkinshaw, C Davies, V Hiley, HC Marshall, ...</div><div class="gs_gray">Trials 12 (1), 1-1<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SEKBqlyTJecC" class="gsc_a_at">PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER TREATED WITH DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL: 297</a><div class="gs_gray">M Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ...</div><div class="gs_gray">Asia-pacific Journal of Clinical Oncology 7<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RuPIJ_LgqDgC" class="gsc_a_at">PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL</a><div class="gs_gray">PD Ottewell, H Brown, TL Rogers, DV Lefley, AC Evans, N Wind, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 22, 29-29<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DXE8ND7PrJAC" class="gsc_a_at">Protecting bone density during aromatase inhibitor therapy</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Society for Endocrinology BES 2011 25<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:m8MyhXdlT-4C" class="gsc_a_at">Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial</a><div class="gs_gray">RE Coleman, SH Giordano</div><div class="gs_gray">P and T 36 (3)<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oYwriLWYh5YC" class="gsc_a_at">P344 Long-term zoledronic acid-mediated suppression of bone resorption in patients receiving an aromatase inhibitor</a><div class="gs_gray">A Lipton, CC Baird, JB Kelly, L Demers, S Ali</div><div class="gs_gray">The Breast, S84<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DGzKIA18-3YC" class="gsc_a_at">P293 The effect of zoledronic acid on bone mineral density and bone turnover in patients with early breast cancer on the AZURE trial</a><div class="gs_gray">C Shankland, R Coleman</div><div class="gs_gray">The Breast, S71<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tgTmbKTkO1IC" class="gsc_a_at">Combination vs single agent treatment: The effects of zoledronic acid+/− doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease</a><div class="gs_gray">HK Brown, PD Ottewell, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">Bone 1 (48), S41<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XtJa11BXPS4C" class="gsc_a_at">First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model</a><div class="gs_gray">PD Ottewell, H Brown, CA Evans, NS Wind, NJ Brown, RE Coleman, ...</div><div class="gs_gray">Bone 1 (48), S42<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8uzoZH4hB9AC" class="gsc_a_at">P345 Updated guidance for the prevention of aromatase inhibitor (AI)-associated bone loss (AIBL) in early breast cancer (EBC)</a><div class="gs_gray">P Hadji, J Body, N Bundred, A Brufsky, R Coleman, M Gnant, T Guise, ...</div><div class="gs_gray">The Breast, S84<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:M_lZXyI38BkC" class="gsc_a_at">C176 PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER RECEIVING DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL</a><div class="gs_gray">T Borkowski, M Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, ...</div><div class="gs_gray">European Urology Supplements 9 (10), 656<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JH5k92_tO-AC" class="gsc_a_at">5155 POSTER Reduction in Fractures Following Adjuvant Zoledronic Acid in Stage ll/lll Breast Cancer–the AZURE Trial (BIG 01/04)</a><div class="gs_gray">R Bell, H Marshall, M Collinson, D Cameron, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">European Journal of Cancer, S376<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:60iIaj97TE0C" class="gsc_a_at">Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model</a><div class="gs_gray">HK Brown, PD Ottewell, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">Bone 2 (48), S255<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pYKElYtJMmwC" class="gsc_a_at">10th International Conference on Cancer Induced Bone Disease, 22–25 September 2010, Sheffield, UK</a><div class="gs_gray">J Brown, M Cecchini, R Coleman, P Croucher, T Guise, I Holen, ...</div><div class="gs_gray">Bone 48, S2<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ji7lAbPyDbYC" class="gsc_a_at">Bone health in breast cancer survivors following adjuvant bisphosphonate therapy: AZURE quantitative bone scan sub-study</a><div class="gs_gray">EJ Woodward, JE Brown, MC Barnfield, J Taylor, GM Blake, I Fogelman, ...</div><div class="gs_gray">Bone 48 (1), S29-S29<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eI34FqJmdUoC" class="gsc_a_at">UK innovators in breast cancer: An initiative to support the next generation of breast cancer researchers (on behalf of past and present'UK innovators')</a><div class="gs_gray">JE Brown, D Cameron, R Coleman, L Fallowfield, I Holen, AL Jones, ...</div><div class="gs_gray">Annals of Oncology 22 (S2), ii58<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:naSTrk-c4S8C" class="gsc_a_at">The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer</a><div class="gs_gray">MC Winter, A Evans, I Holen, RE Coleman</div><div class="gs_gray">Bone 1 (48), S30-S31<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jmjb1lOE9QIC" class="gsc_a_at">Towards biomarkers of bone-metastasis using cellular proteomics</a><div class="gs_gray">JA Westbrook, J Peng, DA Cairns, PD Ottewell, I Holen, RE Coleman, ...</div><div class="gs_gray">Bone 1 (48), S33<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wyCGhLAOp5UC" class="gsc_a_at">Abstract P5-11-01: The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The&nbsp;…</a><div class="gs_gray">R DeBoer, N Bundred, H Eidtmann, A Llombert, P Neven, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P5-11-01-P5-11-01<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xyzrkeHX5M4C" class="gsc_a_at">Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy-Emerging Evidence of Anti-Tumour Effects Outside Bone</a><div class="gs_gray">I Holen, PD Ottewell, RE Coleman</div><div class="gs_gray">CANCER RESEARCH 70<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:IvSMUa3B7yYC" class="gsc_a_at">Abstract P5-13-07: Hormone Levels in the OPTION Trial Show No Ovarian Protection by Goserelin in Adjuvant Chemotherapy for Early Breast Cancer—An Anglo-Celtic Collaborative&nbsp;…</a><div class="gs_gray">R Leonard, D Adamson, R Anderson, R Ballinger, G Bertelli, R Coleman, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P5-13-07-P5-13-07<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ei5r6KrKXVQC" class="gsc_a_at">Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC&nbsp;…</a><div class="gs_gray">M Martin, J Mackey, T Pienkowski, J Rolski, JP Guastalla, A Sami, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), S4-3-S4-3<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RJNGbXJAtMsC" class="gsc_a_at">Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy—Emerging Evidence of Anti-Tumour Effects Outside Bone</a><div class="gs_gray">I Holen, PD Ottewell, RE Coleman</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P6-14-03-P6-14-03<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pxXbYLTb8EgC" class="gsc_a_at">Abstract P4-05-05: Stromal Response to 14-Day Preoperative Therapy in Postmenopausal Oestrogen Receptor Positive Breast Cancer</a><div class="gs_gray">C Lo, S Busch, AG Lee, G Searle, R Lamb, A Cramer, MC Winter, ...</div><div class="gs_gray">Cancer Research 70 (24 Supplement), P4-05-05-P4-05-05<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tz746QTLzJkC" class="gsc_a_at">A clinician's perspective</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 37, S278-S278<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fHS53ZCY-AEC" class="gsc_a_at">MACROPHAGE INFILTRATION IS ASSOCIATED WITH POOR OUTCOME IN BREAST CANCER PATIENTS AND A REDUCED TREATMENT RESPONSE TO LETROZOLE AND ZOLEDRONATE</a><div class="gs_gray">A Lee, R Lamb, H Gregson, A Cramer, J Morris, L Renshaw, M Winter, ...</div><div class="gs_gray">EJC SUPPLEMENTS 8 (6), 17-17<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u_mOZUIutIEC" class="gsc_a_at">The use of ultrasound densitometry as a screening tool for osteoporosis in early breast cancer</a><div class="gs_gray">OS Din, JE Brown, SP Ellis, SA Gutcher, RE Coleman</div><div class="gs_gray">BONE 47, S311-S311<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:x21FZCSn4ZoC" class="gsc_a_at">Correlations between N-telopeptide of type I collagen with survival and fractures in patients with metastatic bone disease from renal cell carcinoma</a><div class="gs_gray">J Brown, A Lipton, R Cook, D Michaelson, R Coleman, F Saad</div><div class="gs_gray">BONE 47, S312-S312<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:7Frjd3zlGBUC" class="gsc_a_at">Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone</a><div class="gs_gray">HK Brown, PD Ottewell, DV Lefely, RE Coleman, I Holen</div><div class="gs_gray">BONE 47, S318-S319<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BrOSOlqYqPUC" class="gsc_a_at">Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid</a><div class="gs_gray">PD Ottewell, DV Lefely, SS Cross, RE Coleman, I Holen</div><div class="gs_gray">BONE 47, S317-S317<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:djft3U1LymYC" class="gsc_a_at">Gender Differences in Self-Reported Late Effects, Quality of Life and Satisfaction with Consultations in Survivors of Lymphoma: A-552</a><div class="gs_gray">E Arden-Close, K Absolom, D Greenfield, B Hancock, R Coleman, C Eiser</div><div class="gs_gray">Psycho-oncology 19<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:d4tt_xEv1X8C" class="gsc_a_at">A study of the endocrine, metabolic and nutritional late effects in patients with advanced intensively treated multiple myeloma</a><div class="gs_gray">E Cachia, D Greenfield, Y Ezaydi, L Baxter, SH Ahmedzai, C Eiser, ...</div><div class="gs_gray">BONE MARROW TRANSPLANTATION 45, S396-S397<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lbI08cpqPnQC" class="gsc_a_at">A study of pain, peripheral neuropathy and psychosocial late effects in patients with intensively treated advanced multiple myeloma</a><div class="gs_gray">E Cachia, C Eiser, R Beeken, K McAtamney, D Greenfield, Y Ezaydi, ...</div><div class="gs_gray">BONE MARROW TRANSPLANTATION 45, S396-S396<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PuYkdpj8xa4C" class="gsc_a_at">Membership of the ESM</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of Vascular Research 47 (6), 545-545<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:n1qY4L4uFdgC" class="gsc_a_at">Author Index Vol. 47, 2010</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of Vascular Research 47 (6), 549-550<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LzOrNEA7mwcC" class="gsc_a_at">Contents Vol. 47, 2010</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of Vascular Research 47 (6), I-IV<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ExNiBuTMO9IC" class="gsc_a_at">Thanks to the Reviewers</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of Vascular Research 47 (6), 546-548<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZYLUaBFA95QC" class="gsc_a_at">Subject Index Vol. 47, 2010</a><div class="gs_gray">M Michailidou, HK Brown, DV Lefley, A Evans, SS Cross, RE Coleman, ...</div><div class="gs_gray">Journal of Vascular Research 47 (6), 551-552<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-vzq6BoH5oUC" class="gsc_a_at">Understanding and optimizing bone health in breast cancer</a><div class="gs_gray">A Brufsky, RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vD2iS2Kej30C" class="gsc_a_at">Recent advances in treatment of metastatic breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Breast Cancer Research: BCR 12 (Suppl 1), L3<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HqhvjgTjE9cC" class="gsc_a_at">Stromal response to aromatase inhibition is associated with improved treatment response in breast cancer patients</a><div class="gs_gray">C Lo, S Busch, A Lee, G Searle, R Lamb, A Cramer, J Morris, M Winter, ...</div><div class="gs_gray">European Journal of Surgical Oncology 11 (36), 1099-1100<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GiYFt9mpioMC" class="gsc_a_at">Increased fat mass may be protective of bone mass in young male cancer survivors</a><div class="gs_gray">JS Walsh, R Eastell, RE Coleman, JA Snowden, SM Shalet, RJ Ross, ...</div><div class="gs_gray">Bone, S189-S190<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cSdaV2aYdYsC" class="gsc_a_at">available at www. sciencedirect. com</a><div class="gs_gray">S Aebi, D August, P Autier, A Banham, C Bennett, J Blazeby, F Bonnetain, ...</div><div class="gs_gray">European Journal of Cancer 46, 216<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:T8_be82Iz5gC" class="gsc_a_at">O-46 Macrophage infiltration is associated with poor outcome in breast cancer patients and a reduced treatment response to Letrozole and Zoledronate</a><div class="gs_gray">A Lee, R Lamb, H Gregson, A Cramer, J Morris, L Renshaw, M Winter, ...</div><div class="gs_gray">EJC Supplements 6 (8), 17<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:X5YyAB84Iw4C" class="gsc_a_at">Prevention and Treatment of Skeletal Complications</a><div class="gs_gray">MC Winter, HL Neville-Webbe, RE Coleman</div><div class="gs_gray">Management of Breast Cancer in Older Women, 275-297<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DquSII9TDu4C" class="gsc_a_at">5 Partnership approach to clinical research in the UK</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EJC Supplements 3 (8), 59<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3lUAU8Oskd0C" class="gsc_a_at">Anti-tumor effects of bisphosphonates in man-myth or reality?</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Bone, S18<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yeL6HyUMUGUC" class="gsc_a_at">Causes of low bone mass in breast cancer—time for action?</a><div class="gs_gray">RE Coleman, JS Walsh</div><div class="gs_gray">Nature Reviews Endocrinology 6 (1), 10-12<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9NZAP19TdFAC" class="gsc_a_at">Gestational Trophoblastic Neoplasia Screening for Central Nervous System Disease in Metastatic We reviewed screening for central nervous system involvement, the frequency of&nbsp;…</a><div class="gs_gray">JM Price, BW Hancock, J Tidy, J Everard, RE Coleman</div><div class="gs_gray">Journal of Reproductive Medicine 55 (7), 301<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:dAp6zn-oMfAC" class="gsc_a_at">221 Bone targeted therapy for early breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EJC Supplements 3 (8), 123<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4n0clTBhZ78C" class="gsc_a_at">ASCO 2009: What's new in breast cancer therapy?</a><div class="gs_gray">L Biganzoli, H Bonnefoi, F Cardoso, R Coleman, B Thürlimann</div><div class="gs_gray">Breast Care 4 (4), 268<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8VtEwCQfWZkC" class="gsc_a_at">Advanced Breast Cancer: Diagnosis and Treatment. National Institute for Health and Clinical Excellence Guideline 2009—An Opportunity Missed</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Clinical Oncology 21 (5), 365-367<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:lg2tdxc6qMwC" class="gsc_a_at">Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Breast Cancer Research 11 (1), 1-1<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hNSvKAmkeYkC" class="gsc_a_at">(PREMIER POSTER-AWARD CANDIDATE) INTERGROUP EXEMESTANE BREAST CANCER STUDY: REVERSAL OF SKELETAL EFFECTS FOLLOWING WITHDRAWAL OF ENDOCRINE TREATMENTS</a><div class="gs_gray">L Banks, S Girgis, S Hodgson, J Liao, G Baffoe, L Kilburn, J Bliss, ...</div><div class="gs_gray">OSTEOPOROSIS INTERNATIONAL 20, S280-S280<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oTdOBqtIf_kC" class="gsc_a_at">Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer</a><div class="gs_gray">NJ Bundred, G Landberg, RE Coleman, J Morris, MC Winter, I Holen, ...</div><div class="gs_gray">Journal of Clinical Oncology 27 (15_suppl), e11625-e11625<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:c_xDhezhKKUC" class="gsc_a_at">MANAGING AROMATASE INHIBITOR-ASSOCIATED BONE LOSS: PRACTICAL GUIDANCE</a><div class="gs_gray">P Hadji, J Body, M Aapro, A Brufsky, R Coleman, T Guise, A Lipton, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 20, 32-32<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tFyepMjQr3wC" class="gsc_a_at">CMRF-56+ BDC loaded with prostate TAA as a potential immunotherapy for prostate cancer.</a><div class="gs_gray">R Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WIXB4To3Tx4C" class="gsc_a_at">Preparing patients for discharge from routine hospital follow-up for breast cancer</a><div class="gs_gray">E Coleman, B Colwell, V Freeman, W Reed</div><div class="gs_gray">Psycho-oncology 18 (3), 316-317<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:KI9T_ytC6pkC" class="gsc_a_at">Inhibin B and AMH are NOT predictors of serum testosterone in young men after cancer</a><div class="gs_gray">DM Greenfield, SJ Walters, RJM Ross, RE Coleman, BW Hancock, ...</div><div class="gs_gray">Endocrine Abstracts 19<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-fu4zM_6qcIC" class="gsc_a_at">The European Commission’s Opinion Backing Use of Non-Human Primates in Research is Flawed</a><div class="gs_gray">M Clotworthy, R Coleman, K Archibald</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:JdL-Xu2nR38C" class="gsc_a_at">Why Non-Human Primates Should Not be Used in Research-Scientific advisers in the EU have disregarded evidence against using primates in research and the achievements of new&nbsp;…</a><div class="gs_gray">M Clotworthy, R Coleman, K Archibald</div><div class="gs_gray">Regulatory Affairs Journal-Pharma 20 (3), 141<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Kqc1aDSOPooC" class="gsc_a_at">0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO&nbsp;…</a><div class="gs_gray">A Frassoldati, A Brufsky, N Bundred, R Lambert-Falls, P Hadji, N Schenk, ...</div><div class="gs_gray">The Breast, S51-S52<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g8uWPOAv7ggC" class="gsc_a_at">POD-3.05: N-telopeptide of Type I Collagen (NTX) Response to Zoledronic Acid in Patients with Bone Metastases from Prostate Cancer</a><div class="gs_gray">F Saad, R Cook, R Coleman, A Lipton</div><div class="gs_gray">Urology 72 (5), S39<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nOiSByfp82kC" class="gsc_a_at">Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid</a><div class="gs_gray">DV Lefley, I Holen, RE Coleman, PD Ottewell</div><div class="gs_gray">Breast Cancer Research 10 (2), 1-1<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kk7MRXTjMocC" class="gsc_a_at">OC15. Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer</a><div class="gs_gray">H Thorpe, R Burkinshaw, S Beevers, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34 (1), 12<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3jqAvCjcdfEC" class="gsc_a_at">In the original letter the first author A. Moore was omitted in error. We apologise for any confusion caused.</a><div class="gs_gray">A Moore, S Ruggiero, S Rogers, T Taylor, S Popat, R Coleman, S Leyland, ...</div><div class="gs_gray">Dent 33, 29-33<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=900&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bxPAEoiBajcC" class="gsc_a_at">OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II)</a><div class="gs_gray">S Singh, J Cuzick, S Ferguson, G Blake, J Truscott, R Coleman, R Eastel, ...</div><div class="gs_gray">Cancer Treatment Reviews 34, 10-11<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:beqBT5984LEC" class="gsc_a_at">P53. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: Initial dental safety findings from the AZURE study</a><div class="gs_gray">M Winter, H Thorpe, J Pedlar, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34 (1), 40<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PazO6pb-sMwC" class="gsc_a_at">Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II)</a><div class="gs_gray">S Singh, J Cuzick, S Ferguson, G Blake, J Truscott, R Coleman, R Eastel, ...</div><div class="gs_gray">Cancer Treatment Reviews 34, S53-S54<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RgznTc0nqo4C" class="gsc_a_at">Baseline assessment of fracture risk in women with breast cancer using current and emerging guidance</a><div class="gs_gray">P Hadji, M Ziller, M Kalder, V Ziller, U Wagner, U Albert</div><div class="gs_gray">EJC Supplements 7 (6), 124<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8gBurD7jEYQC" class="gsc_a_at">Recent developments in the management of metastatic bone disease</a><div class="gs_gray">R Coleman</div><div class="gs_gray">EJC Supplements 7 (6), 108<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vjZqxyZ7hS4C" class="gsc_a_at">President’s Welcome</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, S1<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wkm4DBaukwsC" class="gsc_a_at">P18. Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid</a><div class="gs_gray">P Ottewell, R Coleman, I Holen</div><div class="gs_gray">Cancer Treatment Reviews 34, 19<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Oo1CbQkBAzEC" class="gsc_a_at">PL8. 3. Bone targeted therapy</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, 47-48<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Vztgr1qGG8IC" class="gsc_a_at">P62. Prognostic variables for occurrence of skeletal-related events (SREs) in patients with breast cancer metastatic to bone: A multivariate analysis</a><div class="gs_gray">J Brown, R Cook, R Coleman</div><div class="gs_gray">Cancer Treatment Reviews 34, 28<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0ngZmJvimKcC" class="gsc_a_at">New diagnostic and therapeutic approaches for cancer induced bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">CALCIFIED TISSUE INTERNATIONAL 82, S24-S24<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RfUwGJFMQ-0C" class="gsc_a_at">Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial</a><div class="gs_gray">R Eastell, JE Adams, G Clack, A Howell, RA Hannon, J Cuzick, ...</div><div class="gs_gray">CALCIFIED TISSUE INTERNATIONAL 82, S84-S84<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:e84hm74t-eoC" class="gsc_a_at">Adjuvant trastuzumab in routine clinical practice–the Sheffield experience and impact of cardiac monitoring guidelines on treatment delivery</a><div class="gs_gray">LJ Murray, S Ramakrishnan, OR Purohit, IH Manifold, RE Coleman</div><div class="gs_gray">EJC Supplements 7 (6), 124<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:txeM2kYbVNMC" class="gsc_a_at">OC5. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the ARIBON study</a><div class="gs_gray">J Lester, D Dodwell, O Purohit, S Gutcher, S Ellis, R Thorpe, J Horsman, ...</div><div class="gs_gray">Cancer Treatment Reviews 34, 51-52<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nPTYJWkExTIC" class="gsc_a_at">Antitumor properties of bisphosphonates and possible prevention of bone metastases in breast cancer</a><div class="gs_gray">R Burkinshaw, A Brufsky, R Coleman</div><div class="gs_gray">EJC Supplements 7 (6), 129<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xa5BkEQK8BgC" class="gsc_a_at">Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo</a><div class="gs_gray">P Ottewell, B Deux, H Monkkonen, S Cross, R Coleman, P Clezardin, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pRWBApOjXDcC" class="gsc_a_at">The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial</a><div class="gs_gray">R Eastell, R Coleman, R Mansel, A Bianco, T Nagykalnai, J Cuzick</div><div class="gs_gray">Breast Cancer Research and Treatment 106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YPNY0knpFBYC" class="gsc_a_at">Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG): P044</a><div class="gs_gray">J Woodward, D Lefley, N Cross, P Ottewell, D Buttle, R Coleman, I Holen</div><div class="gs_gray">International Journal of Experimental Pathology 88 (6)<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hKjooKYXoHIC" class="gsc_a_at">Role of bisphosphonates in cancer management</a><div class="gs_gray">R Coleman</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 22 (7), 1106-1106<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Vno172sVVMwC" class="gsc_a_at">Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo</a><div class="gs_gray">PD Ottewell, B Deux, H Monkkonen, RE Coleman, P Clezardin, I Holen</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 22 (7), 1111-1111<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aJ-3-MYELVsC" class="gsc_a_at">usos farmacêuticos de bisfosfonatos</a><div class="gs_gray">RE Coleman, I Holen, H Neville-Webbe, CA Evans</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GtqhT-R7ZnwC" class="gsc_a_at">The Effect of a Lifestyle Intervention on Body Weight, Psychological Health Status, and Risk Factors Associated with Disease Recurrence in Women Recovering from Breast Cancer&nbsp;…</a><div class="gs_gray">E Scott, A Daley, N Woodroofe, R Coleman, H Powers, N Mutrie, V Siddall, ...</div><div class="gs_gray">The Journal of Nutrition 137 (1)<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MGPUR4WVBMEC" class="gsc_a_at">515 POSTER Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis</a><div class="gs_gray">P Major, V Hirsh, A Lipton, RJ Cook, RE Coleman</div><div class="gs_gray">EJC Supplements 4 (5), 94<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ojlX30-wUrgC" class="gsc_a_at">Geriatric Oncology (under the auspices of SIOG)</a><div class="gs_gray">SJ Proctor, L Biganzoli, R Coleman, A Minisini, A Hamilton, M Aapro, ...</div><div class="gs_gray">Critical Reviews in Oncology/Hematology 61, 280-281<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Nw_I7GeUguwC" class="gsc_a_at">O-48 Tolerability of zoledronic acid first safety data from the AZURE Trial (BIG01/04)</a><div class="gs_gray">RE Coleman, H Thorpe, D Cameron, R Bell, D Dodwell, M Keane, M Gil, ...</div><div class="gs_gray">EJC Supplements 3 (5), 15<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nWoA1JPTheMC" class="gsc_a_at">1302 POSTER Updated International Society of Geriatric Oncology (SIOG) recommendations for the use of bisphosphonates in elderly cancer patients with bone metastases</a><div class="gs_gray">JJ Body, R Coleman, P Clezardin, C Ripamonti, R Rizzoli, M Aapro</div><div class="gs_gray">EJC Supplements 4 (5), 174<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tBlTYpvFGQIC" class="gsc_a_at">MP-08.24: Zoledronic acid-mediated normalization of NTX levels correlates with increased clinical benefits in patients with bone metastases secondary to prostate cancer</a><div class="gs_gray">F Saad, A Lipton, R Coleman</div><div class="gs_gray">Urology 3 (70), 84-85<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nPT8s1NX_-sC" class="gsc_a_at">Osteoprotegerin (OPG) expression in breast tumors and bone metastases</a><div class="gs_gray">C VAN POZANK, P Otterwell, S Cross, C Hudis, R COLEMAN, I Holen</div><div class="gs_gray">The International Journal of Biological Markers 22 (1), 83-84<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AFmTUeZ1pmEC" class="gsc_a_at">Endocrine evaluation of a large cohort of male cancer survivors compared with healthy controls</a><div class="gs_gray">DM Greenfield, RE Coleman, BW Hancock, HA Davies, J Snowden, ...</div><div class="gs_gray">Endocrine Abstracts 11<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AZju0d2GQJ0C" class="gsc_a_at">An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of metastatic breast cancer (MBC) in the UK&nbsp;…</a><div class="gs_gray">S Bhalla, C Hibbert, M Chetty, C Poole, D Miles, R Coleman, G Bruce, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 100<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xii_ZKWM4-0C" class="gsc_a_at">Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro</a><div class="gs_gray">M Michailidou, N Brown, RE Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research 8 (2), 1-1<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oPLKW5k6eA4C" class="gsc_a_at">Benefits of combined treatments using antiresorptive agents and cytotoxic drugs</a><div class="gs_gray">I Holen, H Neville-Webbe, RE Coleman</div><div class="gs_gray">Breast Cancer Research 8 (2), 1-1<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Gpwnp1kGG20C" class="gsc_a_at">What is the relationship between testosterone and fat mass in young male cancer survivors and healthy controls?</a><div class="gs_gray">DM Greenfield, SJ Walters, R Eastell, RE Coleman, BW Hancock, ...</div><div class="gs_gray">Endocrine Abstracts 12<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zdX0sdgBH_kC" class="gsc_a_at">More BMD loss with anastrozole than tamoxifen in ATAC</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Reactions 1108, 1<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:mu2_AnMl8iYC" class="gsc_a_at">Ultrahigh spatial and temporal resolution ECG gated blood pool micro-SPECT imaging of murine myocardial function</a><div class="gs_gray">B Chin, S Metzler, L Mao, N Petry, N Neihaus, K Greer, T Turkington, ...</div><div class="gs_gray">Journal of Nuclear Medicine 47 (suppl 1), 131P-131P<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cF7EPgIk0B4C" class="gsc_a_at">The members of the Editorial Board and the following referees have assisted the Editors and Publisher in preparing the 2005 volumes of Breast Cancer Research and Treatment&nbsp;…</a><div class="gs_gray">DC Allred, S Anzick, MC Archer, D Arenberg, G Babiera, V Band, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 95, 195-197<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nU66GSXDKhoC" class="gsc_a_at">Efficient use of bisphosphonates in metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">EJC Supplements 2 (4), 46<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:u0Mu_IsstPMC" class="gsc_a_at">Zoledronic acid provides an enhanced reduction in skeletal-related events in patients with more than three metastatic bone lesions</a><div class="gs_gray">RE Coleman, YM Chen</div><div class="gs_gray">CANCER TREATMENT REVIEWS 32, S51-S51<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:N6_Y7JlWxwsC" class="gsc_a_at">Infrequent zoledronic acid produces sustained increases in bone mineral density (BMD) in patients with cancer treatment induced bone loss (CTIBL)</a><div class="gs_gray">JE Brown, SP Ellis, JE Lester, S Gutcher, T Khanna, O Purohit, ...</div><div class="gs_gray">CANCER TREATMENT REVIEWS 32, S19-S19<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NtGNdKbuCngC" class="gsc_a_at">For how long can a single infusion of zoledronic acid suppress bone resorption in patients with cancer treatment induced bone loss (CTIBL)?</a><div class="gs_gray">JE Brown, J Lester, S Ellis, S Gutcher, L Turner, O Purohit, RE Coleman</div><div class="gs_gray">Bone 3 (38), 70<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qPeb-qHga9sC" class="gsc_a_at">Effects of Zoledronic acid and Paclitaxel on endothelial cells in vitro</a><div class="gs_gray">M Michailidou, HL Neville-Webbe, CA Evans, NJ Brown, RE Coleman, ...</div><div class="gs_gray">Bone 3 (38), 57-58<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RXiHnyRawswC" class="gsc_a_at">Service user voices: What's changed in the last 60 years and where should we go from here?</a><div class="gs_gray">P Campbell, T Coldham, R Coleman, D Crepaz-Keay, L Hart, C Ingram, ...</div><div class="gs_gray">OPENMIND-LONDON- 141, 08<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0sTkTiv_uMkC" class="gsc_a_at">Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo</a><div class="gs_gray">PD Ottewell, M Jones, RE Coleman, I Holen</div><div class="gs_gray">CANCER TREATMENT REVIEWS 32, S30-S30<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aDl3D7KC1E4C" class="gsc_a_at">Denosumab suppresses bone turnover markers in breast cancer patients (PTS) with bone metastases (METS) naive to intravenous bisphosphonates (IV BP) regardless of antineoplastic&nbsp;…</a><div class="gs_gray">GG Steger, JJ Body, P Solal-Celigny, R Berardi, P Gascon, M Fan, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 17, 288-289<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:M0leSnx2MbUC" class="gsc_a_at">Osteoprotegerin (OPG) expression in breast tumours and bone metastases</a><div class="gs_gray">C Van Poznak, P Ottewell, S Cross, C Hudis, RE Coleman, I Holen</div><div class="gs_gray">Bone 3 (38), 31-32<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:iyewoVqAXLQC" class="gsc_a_at">Bisphosphonates as adjuvant therapy for breast cancer</a><div class="gs_gray">R Burkinshaw, R Coleman</div><div class="gs_gray">Women’s Health 2 (1), 115-126<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:YTuZlYwrTOUC" class="gsc_a_at">VIII. 1 The use of bisphosphonates in elderly cancer patients: SIOG guidelines</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Critical Reviews in Oncology/Hematology, S16<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TY5xIG7f_2sC" class="gsc_a_at">Breast cancer aftercare; Psychosocial support in primary care (BCAPS)</a><div class="gs_gray">J Thompson, M Jiwa, R Coleman, M Reed</div><div class="gs_gray">PSYCHO-ONCOLOGY 14 (12), 1091-1091<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VjBpw8Hezy4C" class="gsc_a_at">Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.</a><div class="gs_gray">A Lipton, RE Coleman, P Major, JE Brown, KA Lee, M Smith, F Saad, ...</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 106 (11), 3456-3456<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:VRfTbSk87rEC" class="gsc_a_at">Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).</a><div class="gs_gray">RJ Cook, RE Coleman, P Major, A Lipton, JE Brown, KA Lee, M Smith, ...</div><div class="gs_gray">Blood 106 (11), 5015<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:idthP5jqfYAC" class="gsc_a_at">The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro</a><div class="gs_gray">JKL Woodward, H Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 20 (7), 1299-1299<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:R8TPKZP7usQC" class="gsc_a_at">Pharmaceutical uses of bisphosphonates</a><div class="gs_gray">RE Coleman, I Holen, H Neville-Webbe, CA Evans</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:FsLZdJ3BAzkC" class="gsc_a_at">Breast cancer and bone</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">BONE 36, S114-S115<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Amrzk_ktLr0C" class="gsc_a_at">Linking Changes in Visual Functioning According to Changes in Visual Acuity Among Patients With Age–Related Macular Degeneration</a><div class="gs_gray">AM Pleil, JC Cappelleri, JR Thompson, CA Getter, SC Li, R Coleman, ...</div><div class="gs_gray">Investigative Ophthalmology &amp; Visual Science 46 (13), 1917-1917<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xm1hsP5ya-EC" class="gsc_a_at">Cross–Sectional and Longitudinal Assessments of the 25–Item National Eye Institute Visual Function Questionnaire in Patients With Age–Related Macular Degeneration</a><div class="gs_gray">MB Reichel, S Wolf, K Knur, JC Cappelleri, JR Thompson, CA Getter, ...</div><div class="gs_gray">Investigative Ophthalmology &amp; Visual Science 46 (13), 242-242<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zmHQPunddckC" class="gsc_a_at">Parathyroid Hormone‐Related Protein and Bone Metastases</a><div class="gs_gray">RE Coleman, TJ Martin, JA Danks, MA Henderson</div><div class="gs_gray">Textbook of Bone Metastases, 27-39<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:J4E9jCG1tHUC" class="gsc_a_at">Management of Hypercalcaemia</a><div class="gs_gray">RE Coleman, SH Ralston</div><div class="gs_gray">Textbook of Bone Metastases, 351-360<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BPS1z4jHU5cC" class="gsc_a_at">Osteoblastic Metastases</a><div class="gs_gray">RE Coleman, PI Croucher</div><div class="gs_gray">Textbook of Bone Metastases, 41-50<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1EqfMoDn7-AC" class="gsc_a_at">Use in Multiple Myeloma</a><div class="gs_gray">RE Coleman, JR Berenson</div><div class="gs_gray">Textbook of Bone Metastases, 369-376<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sJK75vZXtG0C" class="gsc_a_at">Prevention of Bone Loss</a><div class="gs_gray">RE Coleman, RU Ashford, EV McCloskey, JA Kanis</div><div class="gs_gray">Textbook of Bone Metastases, 399-414<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cB__R-XWw9UC" class="gsc_a_at">Treatment of Lytic Bone Metastases</a><div class="gs_gray">RE Coleman, K Gwyn, R Theriault</div><div class="gs_gray">Textbook of Bone Metastases, 361-368<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:as0KMg8qHbkC" class="gsc_a_at">Antitumour Effects of Bisphosphonates</a><div class="gs_gray">RE Coleman, P Clézardin</div><div class="gs_gray">Textbook of Bone Metastases, 345-350<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kUhpeDhEZMUC" class="gsc_a_at">Mechanisms of Action of Bisphosphonates</a><div class="gs_gray">RE Coleman, MJ Rogers</div><div class="gs_gray">Textbook of Bone Metastases, 323-343<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:G887dSk7Sz8C" class="gsc_a_at">Aromatase inhibitors- Past, present and future</a><div class="gs_gray">R Carpenter</div><div class="gs_gray">British journal of cancer. Supplement<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:HKviVsUxM5wC" class="gsc_a_at">Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid</a><div class="gs_gray">CA Evans, HL Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S36-S36<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:B2rIPIGFPLEC" class="gsc_a_at">REVIEW PAPERS</a><div class="gs_gray">TS Benepal, I Judson, JKL Woodward, RE Coleman, I Holen, P Schmid, ...</div><div class="gs_gray">Anti-Cancer Drugs 16<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bXQfdp6S9ecC" class="gsc_a_at">Tumour endothelial cells express osteoprotegerin (OPG)-A potential role in tumour angiogenesis?</a><div class="gs_gray">SS Cross, Z Yang, JKL Woodward, SP Balasubramanian, MWR Reed, ...</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S37-S38<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PuOEWVtPfzwC" class="gsc_a_at">Do long-term cancer survivors, treated for testicular cancer or lymphoma, suffer chemotherapy-induced bone loss?</a><div class="gs_gray">JE Brown, SP Ellis, P Silcock, SA Gutcher, C Radstone, A Blumsohn, ...</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S46-S46<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BAanoTsO0WEC" class="gsc_a_at">A study to determine whether the bisphosphonate zoledronic acid can be shown to exert a direct anti tumour effect in vivo</a><div class="gs_gray">SP Ellis, JE Brown, JE Everard, HL Neville-Webbe, BW Hancock, ...</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S48-S49<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:I8rxH6phXEkC" class="gsc_a_at">Bisphosphonates and metastasis</a><div class="gs_gray">J Lester, R Coleman</div><div class="gs_gray">Breast Cancer Online 8 (1)<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cBPnxVikjH8C" class="gsc_a_at">Understanding Drug-Sequence Synergistic Induction of Apoptosis by Zoledronic Acid (ZOL) and Doxorubicin (DOX) in Breast Cancer</a><div class="gs_gray">HL Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">Cancer 113 (3), 364-371<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:R-LXmdHK_14C" class="gsc_a_at">The use of point of care devices for the monitoring of urinary NTX levels in metastatic breast cancer</a><div class="gs_gray">JE Lester, JE Brown, SP Ellis, S Gutcher, JM Horsman, RE Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S52-S53<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4Yq6kJLCcecC" class="gsc_a_at">The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro</a><div class="gs_gray">J Woodward, R Coleman, H Neville-Webbe, I Holen</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S43-S43<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LGlY6t8CeOMC" class="gsc_a_at">Breast cancer and treatment induced bone loss questionnaire</a><div class="gs_gray">JE Lester, JM Horsman, S Mori, D Dodwell, RE Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 31, S52-S52<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:I9gX6wnfuA8C" class="gsc_a_at">The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone</a><div class="gs_gray">RJ Cook, RE Coleman, F Saad, M Smith, A Lipton, KA Lee, JE Brown, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1596-1596<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ShjGdcaqzI0C" class="gsc_a_at">An investigation of the long-term effects of chemotherapy on bone in male long-term cancer survivors</a><div class="gs_gray">SP Ellis, JE Brown, SA Gutcher, BW Hancock, MQ Hatton, AS Rigby, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1587-1587<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PVqtIyvKoSUC" class="gsc_a_at">The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer</a><div class="gs_gray">JE Brown, RJ Cook, P Major, A Lipton, KA Lee, M Zheng, YJ Hei, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1596-1596<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GYcXSSpN504C" class="gsc_a_at">Serum concentrations of AMG 162 were maintained and bone resorption was suppressed for 3 months following a single subcutaneous dose in patients with breast cancer-related bone&nbsp;…</a><div class="gs_gray">MC Peterson, SW Martin, BJ Stouch, D Chen, S Bauhman, DL Holloway, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1595-1595<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wSy_KLzO7YEC" class="gsc_a_at">Effect of an annual infusion of zoledronic acid on bone mineral density in cancer survivors following antineoplastic therapy</a><div class="gs_gray">JE Brown, S Ellis, S Gutcher, JE Lester, L Turner, OP Purohit, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (9), 1596-1596<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qCpRzq7zkD8C" class="gsc_a_at">Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 767-767<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BJtnxTr0fRcC" class="gsc_a_at">A retrospective study of the management and outcome of patients with stage 1 (marker negative) teratoma</a><div class="gs_gray">RA Herbertson, MQ Hatton, J Coleman, RE Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 91, S39-S39<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hEXC_dOfxuUC" class="gsc_a_at">Combined treatments of breast cancer cells using bisphosphonates and doxorubicin</a><div class="gs_gray">HL Neville-Webbe, CA Evans, RE Coleman, I Holen</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (6), 1035-1035<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Tfl4UtY-dJUC" class="gsc_a_at">Bisphosphonates and the treatment of tumour-induced bone disease</a><div class="gs_gray">R Coleman</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 19 (6), 1028-1028<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:o4Qvs5Y5TLQC" class="gsc_a_at">Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology...</a><div class="gs_gray">J Brown, RE Coleman, M Stead, A House, T Perren</div><div class="gs_gray">British Journal of Cancer 91, 621-626<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XJogQLJr2CkC" class="gsc_a_at">Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Women's Oncology Review 4 (1), 41-42<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:It0W0vAlS5QC" class="gsc_a_at">Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL)</a><div class="gs_gray">C Van Poznac, SS Cross, M Saggese, JM Lippitt, C Hudis, RE Coleman, ...</div><div class="gs_gray">BONE 34, S29-S29<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NZNkWSpQBv0C" class="gsc_a_at">Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations</a><div class="gs_gray">H Neville-Webbe, R Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research and Treatment 88<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3MwzVuqRcA0C" class="gsc_a_at">Cancer Research UK Phase I/II Committee. A Cancer Research (UK) randomised phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to&nbsp;…</a><div class="gs_gray">SR Johnston, LA Gumbrell, TR Evans, RE Coleman, IE Smith, CJ Twelves, ...</div><div class="gs_gray">Cancer Chemotherapy and Pharmacology 53 (4), 341-348<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:q1zXlPLtbUIC" class="gsc_a_at">Original Reports-BREAST CANCER-Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and&nbsp;…</a><div class="gs_gray">A Bottomley, L Biganzoli, T Cufer, RE Coleman, C Coens, F Efficace, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (13), 2576-2586<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ifOnle78iJkC" class="gsc_a_at">Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death</a><div class="gs_gray">H Neville-Webbe, A Evans, R Coleman, I Holen</div><div class="gs_gray">Breast Cancer Research and Treatment 88<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:In6cVmBjs0IC" class="gsc_a_at">Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death</a><div class="gs_gray">A Evans, H Neville-Webbe, RE Coleman, I Holen</div><div class="gs_gray">BONE 34, S56-S56<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ijdKiLOsEJMC" class="gsc_a_at">Zoledronic acid has long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer</a><div class="gs_gray">R Coleman, L Rosen, M Zheng</div><div class="gs_gray">EJC Supplements 3 (2), 127-128<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:z8nqeaKD1nsC" class="gsc_a_at">Bone loss in long term cancer survivors. A pilot study to evaluate the effect of annual intravenous zoledronic acid on bone mineral density (BMD) and bone turnover markers</a><div class="gs_gray">J Brown, J Lester, S Ellis, S Gutcher, L Turner, O Purohit, B Hancock, ...</div><div class="gs_gray">BONE 34, S93-S93<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:jtI9f0ekYq0C" class="gsc_a_at">Osteoprotegerin expression correlates with ER/PR status in human breast tumors.</a><div class="gs_gray">CH Van Poznak, SS Cross, C Hudis, KS Panageas, RE Coleman, I Holen</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 18, S310-S310<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BW2nPTmhBn4C" class="gsc_a_at">Low risk persistent gestational trophoblastic disease treated with low dose methotrexate</a><div class="gs_gray">FK Khan, J Everard, S Ahmed, RE Coleman, M Aitken, BW Hancock</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 88, S18-S18<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:nqdriD65xNoC" class="gsc_a_at">Bone marrow stromal cell-derived osteoproteger in (OPG) protects breast cancer cells from trail-induced apoptosis</a><div class="gs_gray">HL Neville-Webbe, A Evans, C Eaton, R Coleman, I Holen</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 88, S25-S25<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6_6x9JMR98MC" class="gsc_a_at">Conflict of interest statement</a><div class="gs_gray">C Maxwell, R Swift, M Goode, L Doane, M Rogers, RE Coleman, ...</div><div class="gs_gray">Clinical Journal of Oncology Nursing 7, 403-408<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:CB6W3GmKGOEC" class="gsc_a_at">6. Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedeter C, Grunwald T, et al. Limbic encephalitis not associated with neo-plasm as a cause of temporal lobe epilepsy&nbsp;…</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">REV NEUROL 36 (4), 337-339<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5LPo_wSKItgC" class="gsc_a_at">450 Improving clinical outcomes and treatment convenience with oral ibandronate for metastatic bone disease</a><div class="gs_gray">R Bell, R Coleman, B Bergstrom</div><div class="gs_gray">EJC Supplements 5 (1), S137<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:X4-KO54GjGYC" class="gsc_a_at">Improving clinical outcomes and treatment convenience with oral ibandronate for metastatic bone disease</a><div class="gs_gray">R Bell, R Coleman, B Bergstrom</div><div class="gs_gray">Breast Cancer Research and Treatment 82<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rbGdIwl2e6cC" class="gsc_a_at">Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors</a><div class="gs_gray">C Van Poznak, S Cross, C Hudis, L Norton, K Panageas, R Coleman, ...</div><div class="gs_gray">Breast Cancer Research and Treatment 82<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1000&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xyvS_IvSCKsC" class="gsc_a_at">The Multidisciplinary Approach to Bone Metastases-The Article Reviewed</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Oncology-Melville 17 (6), 863-867<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RMgMIBzvq-4C" class="gsc_a_at">454 A phase II study of vinorebline (VRL) alterning oral and intravenous (IV) plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC)</a><div class="gs_gray">M Verrill, D Serin, A Jones, T Delozier, R Coleman</div><div class="gs_gray">EJC Supplements 5 (1), S138-S139<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ndLnGcHYRF0C" class="gsc_a_at">153Sm-Lexidronam for the treatment of painful bone metastases in hormone-efactory prostate cancer</a><div class="gs_gray">RH Reid, PJ Hoskin, DP Quick, PJ Ell, RE Coleman, JA Kotler, ...</div><div class="gs_gray">Journal of the National Cancer Institute<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZysSsiWj_g4C" class="gsc_a_at">Sequential tumour biopsies in phase I trials</a><div class="gs_gray">F Cardoso</div><div class="gs_gray">Breast Cancer Research 4 (1), 1-3<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hHIA4WEVY-EC" class="gsc_a_at">bcl-2: a convergence point for multiple signal transduction pathways that influence cell survival?</a><div class="gs_gray">JMW Gee</div><div class="gs_gray">Breast Cancer Research 4 (1), 1-3<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:GFxP56DSvIMC" class="gsc_a_at">Introduction: Setting New Standards in Bisphosphonate Therapy</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">American Journal of Clinical Oncology 25 (6), S1-S2<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1r-w4gtu6w8C" class="gsc_a_at">Health Related Quality of Life of Metastatic Breast Cancer (MBC) Patients Undergoing Doxorubicin (A)/Taxol (T) Versus Doxorubicin/Cyclophosphamide (C) as First Line&nbsp;…</a><div class="gs_gray">A Bottomley, L Biganzoli, T Cufer, P Bruning, RE Coleman, C Coen, ...</div><div class="gs_gray">Quality of Life Research, 659-659<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rQKKVauEoioC" class="gsc_a_at">Failure of adjuvant (adj) peripheral blood progenitor (PBP)-supported high-dose chemotherapy (HDC) to improve the prognosis (prog) of patients (pts) with high-risk breast&nbsp;…</a><div class="gs_gray">J Crown, M Lind, A Gould, M Verrill, C Twelves, R Coleman, T Perren, ...</div><div class="gs_gray">Annals of Oncology 13<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5o6HiIVP414C" class="gsc_a_at">Phase II study of alternating iv and oral vinorelbine (VRL) plus epirubicin as first line chemotherapy of metastatic breast cancer (MBC0): Preliminary results</a><div class="gs_gray">M Verrill, D Serin, A Jones, R Coleman, T Delozier, M Namer, K Mross, ...</div><div class="gs_gray">Annals of Oncology 13<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:sJPMR1oEGYQC" class="gsc_a_at">The role of osteoprotegerin in breast and prostate cancer</a><div class="gs_gray">I Holen, JM Wells, PI Croucher, CA Evans, JM Lippitt, RE Coleman, ...</div><div class="gs_gray">JOURNAL OF BONE AND MINERAL RESEARCH 17 (7)<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4QKQTXcH0q8C" class="gsc_a_at">Bone marker directed bisphosphonate therapy in metastatic bone disease</a><div class="gs_gray">JE Brown, S Ellis, S Gutcher, L Turner, OP Purohit, RE Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 86, S19-S19<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:g_UdREhPGEoC" class="gsc_a_at">Management of patients with advanced germ cell tumours (GCT): Is there a role for POMB-ACE?</a><div class="gs_gray">N Bhala, J George, JM Coleman, CR Radstone, JM Horsman, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 86, S65-S65<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3_LpOwP6eMYC" class="gsc_a_at">An evaluation of patients with persistent gestational trophoblastic disease (PGTD) with lung metastases only on chest X-ray or CT scan of the chest, is there extra benefit from&nbsp;…</a><div class="gs_gray">SY Abdallah, J Everard, CE Ingram, R Nakielny, RE Coleman, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 86, S45-S45<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ThYxFsVAhEkC" class="gsc_a_at">Breakthroughs in oncology: setting new standards in bisphosphonate therapy</a><div class="gs_gray">RE COLEMAN</div><div class="gs_gray">American journal of clinical oncology 25 (6)<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:z-B63o8J19IC" class="gsc_a_at">Molecular Systematics of Fishes Molecular Systematics of Fishes, 1997</a><div class="gs_gray">I REXROAD, RL COLEMAN, AL GUSTAFSON, WK HERSHBERGER, ...</div><div class="gs_gray">Marine biotechnology 4 (1), 12-16<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3BvdIg-l-ZAC" class="gsc_a_at">Guido PH Band, K. Richard Ridderinkhof, and Sidney Segalowitz. Explaining Neurocognitive</a><div class="gs_gray">HBM Uylings, JM de Brabander, MP Milham, KI Erickson, MT Banich, ...</div><div class="gs_gray">Brain and Cognition 49, 182-183<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:l6Q3WhenKVUC" class="gsc_a_at">Petr Hluštık, Ana Solodkin, Rao P. Gullapalli, Douglas C. Noll, and Steven L. Small. Functional</a><div class="gs_gray">H Romijn, BE Morton, ES Valenstein, ID Grachev, PS Thomas, ...</div><div class="gs_gray">Brain and Cognition 48, 227-228<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SrKkpNFED5gC" class="gsc_a_at">ORIGINAL REPORTS-Breast Cancer-Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European&nbsp;…</a><div class="gs_gray">L Biganzoli, T Cufer, P Bruning, R Coleman, L Duchateau, AH Calvert, ...</div><div class="gs_gray">Journal of Clinical Oncology 20 (14), 3114-3121<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3A3nxV7CjKIC" class="gsc_a_at">Alpherts, WCJ, 114 Armilio, Maria L., 402</a><div class="gs_gray">A Arsenault, GPH Band, MT Banich, A Beaulieu, R Borowsky, ...</div><div class="gs_gray">Brain and Cognition 49, 438<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:L24QuVWYgZ0C" class="gsc_a_at">Phase I and pharmacokinetics-EORTC 10968: A phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx (R), Doxil (R)) at a 6-week interval in</a><div class="gs_gray">A Hamilton, L Biganzoli, R Coleman, L Mauriac, P Hennebert, A Awada, ...</div><div class="gs_gray">Annals of Oncology-English Edition 13 (6), 910-918<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_mQi-xiA4oYC" class="gsc_a_at">Zoledronic acid and paclitaxel have synergistic effects on breast cancer cell apoptosis in vitro evidence from isobolgram and graft software analysis.</a><div class="gs_gray">S Jagdev, P Croucher, A Rostami-H, R Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 85, 47-47<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yIeBiWEAh44C" class="gsc_a_at">tAnGo-A phase III, randomised trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for higher risk, early stage, breast cancer</a><div class="gs_gray">CJ Poole, J Carmichael, RE Coleman, HM Earl, D Dodwell, M Verrill, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 85, 50-50<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bVQMTfhMCi4C" class="gsc_a_at">Impact of CT fusion on camera-based PET (CBPET) for clinical oncology applications.</a><div class="gs_gray">SD Brown, TZ Wong, T Turkington, RE Coleman</div><div class="gs_gray">JOURNAL OF NUCLEAR MEDICINE 42 (5), 35P-36P<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ZbXHRDTBJTgC" class="gsc_a_at">Pharmacokinetic phase I study of Caelyx in metastatic breast cancer patients</a><div class="gs_gray">P Hennebert, L Biganzoli, I Van Hoorebeeck, A Awada, R Coleman, ...</div><div class="gs_gray">Proceedings of the Pharmacology and Molecular Mechanisms Group Winter&nbsp;…<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:C6rTQemI8T8C" class="gsc_a_at">Introduction: Seminars in Oncology</a><div class="gs_gray">A Lipton, RE Coleman, IJ Diel, G Mundy</div><div class="gs_gray">Seminars in oncology 28 (4 SUPPL. 11)<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rwEhk56xNqMC" class="gsc_a_at">Brief infusion of 2 or 4 mg zoledronate is as effective as prolonged infusion of 90 mg pamidronate for osteolytic metastases</a><div class="gs_gray">PP Major</div><div class="gs_gray">Evidence-based Oncology 4 (2), 191-192<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0kLwNjf3oFwC" class="gsc_a_at">The aim of Cancer Chemotherapy and Pharmacology is the communication of significant research documented by accurate, unambiguous data that are presented in an easily readable&nbsp;…</a><div class="gs_gray">MS Aapro, SP Ackland, PC Adamson, GW Aherne, S Ahmad, JA Ajani, ...</div><div class="gs_gray">Cancer Chemother Pharmacol 47, 95-96<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_AeoHAGD03cC" class="gsc_a_at">Fractionated Navelbine and Doxorubicin (NA) as front line chemotherapy in metastatic breast cancer (MBC)</a><div class="gs_gray">J Carmichael, R Coleman, S Hill, F Armitage, V Potter, D Epurescu</div><div class="gs_gray">European Journal of Cancer, S192<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cRMvf6lLvU8C" class="gsc_a_at">Zoledronate induces apoptosis of breast cancer cells in vitro in combination with paclitaxel and tamoxifen: Evidence for synergistic effects</a><div class="gs_gray">S Jagdev, P Croucher, R Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 83, 67-67<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DQNrXyjhriIC" class="gsc_a_at">Ten year review of survival of patients with advanced non-seminomatous germ cell tumours (NSGCT): The Weston Park experience</a><div class="gs_gray">SI Ahmed, J George, JM Coleman, CR Radstone, JM Horsman, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 83, 78-78<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SNyOjmPOlygC" class="gsc_a_at">CLINICAL ONCOLOGY-Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA&nbsp;…</a><div class="gs_gray">LS Dobson, PC Lorigan, RE Coleman, BW Hancock</div><div class="gs_gray">British Journal of Cancer 82 (9), 1547-1552<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8moDcb_GFzgC" class="gsc_a_at">A randomized phase II study of Taxotere versus doxorubicin in first and second line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults.</a><div class="gs_gray">J Verweij, SM Lee, W Ruka, J Buesa, R Coleman, R van Hoesel, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:kQqwFFzsCTwC" class="gsc_a_at">A dose finding study of docetaxel/carboplatin as first‐line. Chemotherapy for epithelial ovarian cancer‐final results</a><div class="gs_gray">R Atkinson, PA Vasey, R Coleman, M Crawford, M Cruickshank, ...</div><div class="gs_gray">International Journal of Gynecology &amp; Obstetrics 70, D72-D72<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:feST4K8J0scC" class="gsc_a_at">ORIGINAL REPORTS-Sarcoma-Randomized Phase H Study of Docetaxel Versus Doxorubicin in First-and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas&nbsp;…</a><div class="gs_gray">J Verweij, SM Lee, W Ruka, J Buesa, R Coleman, R Hoessel, ...</div><div class="gs_gray">Journal of Clinical Oncology 18 (10), 2081-2086<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:i91s68tWr-MC" class="gsc_a_at">Bone metastases and impending pathological fractures</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">Breast cancer: diagnosis and management, 429<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wGzT3bKASkAC" class="gsc_a_at">AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study.(originally presented at ASCO&nbsp;…</a><div class="gs_gray">MJ Piccart, T Cufer, P Bruning, RE Coleman, HA Calvert, T Gamucci, ...</div><div class="gs_gray">Annals of Oncology 11, 155-155<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:q0uBw5dMOAkC" class="gsc_a_at">ORIGINAL REPORTS-Breast Cancer-Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and&nbsp;…</a><div class="gs_gray">R Paridaens, L Biganzoli, P Bruning, JGM Klijn, T Gamucci, S Houston, ...</div><div class="gs_gray">Journal of Clinical Oncology 18 (4), 724-733<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eH23hyXCXa4C" class="gsc_a_at">The reputation of a Journal is in part related to the quality of its reviewers. The following have been involved in reviewing papers for The Breast and their contribution is&nbsp;…</a><div class="gs_gray">MEDC Anderson, I Andersson, TJ Anderson, MA Baildman, J Bartlett, ...</div><div class="gs_gray">The Breast 9, 362<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:W8gSVh4kTHQC" class="gsc_a_at">Technology innovations in psychosocial oncology</a><div class="gs_gray">E Coleman, C Messner, Y Colon, D Blum</div><div class="gs_gray">PSYCHO-ONCOLOGY 8 (6), 40-40<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:52neCvzbxIwC" class="gsc_a_at">Evaluating the barriers to pain relief</a><div class="gs_gray">E Coleman, D Patterson, D Blum</div><div class="gs_gray">PSYCHO-ONCOLOGY 8 (6), 22-22<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:aEW5N-EHWIMC" class="gsc_a_at">Calman-Hine and the new funding systems in the oncology setting, implementation and progress in North Trent.</a><div class="gs_gray">ME Abbey, BW Hancock, RE Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 80, 70-70<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:R22Rs3tN8aoC" class="gsc_a_at">6th International Congress on Oral Cancer</a><div class="gs_gray">M Adams, AH Calvert, J Carmichael, PI Clark, RE Coleman, HM Earl, ...</div><div class="gs_gray">Radiology 17, 19<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vxA22ZmNLkoC" class="gsc_a_at">The Guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom</a><div class="gs_gray">HM Bishop, DA Cameron, R Coleman, AM Davies, JA Dewar, A Evans, ...</div><div class="gs_gray">EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 25 (1), 4-23<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1Lk_dUza_R0C" class="gsc_a_at">Clinical Oncology-The objective measurement of remission and progression in metastatic breast cancer by use of serum 47 tumour markers</a><div class="gs_gray">JFR Robertson, W Jaeger, JJ Syzmendera, C Selby, R Coleman, ...</div><div class="gs_gray">European Journal of Cancer 35 (1)<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5N-NJrZHaHcC" class="gsc_a_at">A UTHOR INDEX</a><div class="gs_gray">AR Ha, N Abeyasinghe, A Aggrawal, ML Amariti, JJ Barnard, AH Battah, ...</div><div class="gs_gray">Journal of Clinical Forensic Medicine 6, 284-285<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Vr2j17o0sqMC" class="gsc_a_at">The management and clinical course of testicular seminoma: 15 years' experience at a single institution-Reply</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">CLINICAL ONCOLOGY 11 (2), 137-137<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_9Xh93LWpsYC" class="gsc_a_at">Reply to the letter from Robertson to Blamey</a><div class="gs_gray">RE Coleman, RD Rubens</div><div class="gs_gray">British Journal of Cancer 78 (10), 1397-1397<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:tswL-GKFg8UC" class="gsc_a_at">Interview With the FDA: William E. Hall, Ph. D., Gets Close With The FDA's Robert (Bob) Coleman, National Expert Drug Investigator</a><div class="gs_gray">WE Hall, R Coleman</div><div class="gs_gray">JOURNAL OF VALIDATION TECHNOLOGY 5, 6-13<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:AdGrMoNItN4C" class="gsc_a_at">Chemotherapy for ovarian cancer-a consensus statement on standard practice</a><div class="gs_gray">RE Coleman, S kumar Ganesan, JA Ledermann, G Rustin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TiLqlu47W2oC" class="gsc_a_at">European Study Group for Serum Tumour Markers in Breast Cancer</a><div class="gs_gray">JFR Robertson, E Bombardieri, R Molina, R Coleman, PE Jonsson</div><div class="gs_gray">Tumori Journal 84 (1), 104-105<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:MtS25d97-7AC" class="gsc_a_at">Supplementary Document: The Use of Paclitaxel in the First Line Treatment of Ovarian Cancer</a><div class="gs_gray">SM Beard, RE Coleman, J Radford, JA Tidy</div><div class="gs_gray">Trent Institute for Health Services Research, Universities of Leicester&nbsp;…<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WMtz-WDmgKQC" class="gsc_a_at">Possible adverse effects of curative chemotherapy on bone mass in men: Use of bone ultrasound to evaluate bone architecture</a><div class="gs_gray">J Zekri, RE Coleman</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 12-12<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Nnq8S6OXqDYC" class="gsc_a_at">Is computed tomography necessary to evaluate pulmonary metastases in patients with persistent trophoblastic disease?</a><div class="gs_gray">AM Gillespie, RE Coleman, BW Hancock</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 42-42<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LWqeokA2EBkC" class="gsc_a_at">Toxicity associated with etoposide and Dactinomycin (EA) for methotrexate (MTX) resistant, low risk persistent trophoblastic disease (PTD) and EA with MTX (MEA) for high risk PTD</a><div class="gs_gray">LS Dobson, PC Lorigan, RE Coleman, BW Hancock</div><div class="gs_gray">Annals of Oncology 9, 66-67<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Gb6Hms-Uo9kC" class="gsc_a_at">EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration</a><div class="gs_gray">A Awada, T Cufer, L Beex, R Coleman, R Paridaens, P Bruning, J Klijn, ...</div><div class="gs_gray">European Journal of Cancer 34 (1005), S21-S21<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zzCxg_vo7cAC" class="gsc_a_at">Treosulphan monotherapy for metastatic breast cancer-A phase II study.</a><div class="gs_gray">LS Dobson, S Clive, L Dawson, A Anderson, RCF Leonard, I Kunkler, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 42-42<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eFf2swCANGcC" class="gsc_a_at">Does central nervous system chemoprophylaxis have a role in the management of gestational trophoblastic disease?</a><div class="gs_gray">AM Gillespie, N Siddiqui, RE Coleman, BW Hancock</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 78, 13-13<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:G36d5HCDkJYC" class="gsc_a_at">Developments in the palliation of metastatic bone disease</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">European Journal of Cancer 34 (1005), S90-S90<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w2UhwfzvF0QC" class="gsc_a_at">CMB-401: A cytotoxic immunoconjugate for targeted therapy of epithelial ovarian cancer</a><div class="gs_gray">TJ Broadhead, AM Gillespie, RE Coleman, J Owen, L Skelton, ...</div><div class="gs_gray">ANNALS OF ONCOLOGY 9, 85-85<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:I858iXPj1OkC" class="gsc_a_at">High dose chemotherapy for soft tissue Ewing's sarcomas.</a><div class="gs_gray">RE Hough, S Browne, LM El-Helw, RE Coleman, MH Robinson, ...</div><div class="gs_gray">British Journal of Cancer 78 (Supp 2), 42<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:TEVcCiyi8yIC" class="gsc_a_at">Breast cancer 2000-Preface</a><div class="gs_gray">R Coleman, S Libretto</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 1-1<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SpPTWFSNUtQC" class="gsc_a_at">The role of genetic testing in breast cancer by the year 2000-Questions and Answers</a><div class="gs_gray">R Coleman, S Carr, A Howell, C Martin, R Sainsbury, I Manifold</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 19-22<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PlWzFYVEG4EC" class="gsc_a_at">Prognostic and response markers in the management of breast cancer-Questions and Answers</a><div class="gs_gray">R Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 48-48<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PQEM9vzQD9gC" class="gsc_a_at">Breast cancer tumour vaccines-Questions and Answers</a><div class="gs_gray">A Howell, R Rubens, R Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 83-85<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:N4u4nq0IxgcC" class="gsc_a_at">Developments in radiotherapy-Questions and Answers</a><div class="gs_gray">M Alhilaly, A Howell, S Karp, R Coleman</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 30-32<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qmtmRrLr0tkC" class="gsc_a_at">New endocrine agents-Questions and Answers</a><div class="gs_gray">R Rubens, R Sainsbury, J Mackay, R Coleman, J Robertson</div><div class="gs_gray">CANCER TREATMENT REVIEWS 23, 56-57<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yBxuCEhX224C" class="gsc_a_at">The VEDex regimen: An effective and well tolerated palliative treatment for relapsed non-Hodgkin's lymphoma (NHL)[BJC]</a><div class="gs_gray">L El-Helw, PC Lorigan, RE Coleman, BW Hancock</div><div class="gs_gray">British Journal of Cancer 76 (Supplement 1), 51<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EsrhoZGmrkoC" class="gsc_a_at">'From Victim to Victor': Self-help book for voice-hearers</a><div class="gs_gray">M Smith, R Coleman</div><div class="gs_gray">OPENMIND-LONDON-, 14-14<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ybfzIt2tCtgC" class="gsc_a_at">The vedex regimen: An effective and well tolerated palliative treatment for non-Hodgkin's lymphoma (NHL)</a><div class="gs_gray">L El-Helw, PC Lorigan, RE Coleman, BW Hancock</div><div class="gs_gray">European Journal of Cancer 33 (S8), S266-S266<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:4e5Qn2KL_jwC" class="gsc_a_at">Diseases of the Breast</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">British Journal of Cancer 75 (7), 1088<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QKtdBID3u5MC" class="gsc_a_at">New Bisphosphonates</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">European Journal of Cancer 32 (S2), 44-44<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:inmFHauC9wsC" class="gsc_a_at">Detection of Liver Metastases in Advanced Breast Cancer</a><div class="gs_gray">APB Vinholes, RE Coleman</div><div class="gs_gray">European Journal of Cancer 32 (S2), 51-51<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9shLKfS_uJEC" class="gsc_a_at">Increased interleukin-IO serum levels in patients with solid tumours C. Fortis. M. Foppoli, L. Gianotti. L. Galli, G. Citterio, G. Consogno, 0. Gentihni, M. Braga (Milan, Italy&nbsp;…</a><div class="gs_gray">DJKBS Han, B Ahn, KK Lee, JS Kang, H Tsuda, PC Lorigan, AJ Grierson, ...</div><div class="gs_gray">Cancer Letters 104, 239-240<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wyM6WWKXmoIC" class="gsc_a_at">Assessment of Response in Bone within an EORTC Randomised Trial of Bisphosphonate Treatment (10924)</a><div class="gs_gray">J Vinholes, R Coleman, D Lacombe, F Mignolet, C Rose, R Leonard, ...</div><div class="gs_gray">European Journal of Cancer 32 (S2), 50-50<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Ic1VZgkJnDsC" class="gsc_a_at">Biochemical Markers of Bone Resorption Predict Response to Bisphosphonate Treatment</a><div class="gs_gray">I Vinholes, O Purohit, R Eastell, R Coleman</div><div class="gs_gray">European Journal of Cancer 32 (S2), 51-52<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LK8CI43ZvvMC" class="gsc_a_at">Long-Term Palliation of Metastatic Bone Pain with Intermittent Pamidronate</a><div class="gs_gray">I Zekri, J Vinholes, O Purohit, R Coleman</div><div class="gs_gray">European Journal of Cancer 32 (S2), 52-52<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hXZnTIgIr50C" class="gsc_a_at">Etoposide and actinomycin D (EA) for methotrexate (MTX) resistant, low risk, persistent gestational trophoblastic disease (GTD) and EA with MTX (MEA) for high risk GTD</a><div class="gs_gray">PC Lorigan, J Nevin, C Radstone, RE Coleman, BW Hancock</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 31, 1168-1168<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8_tS2Vw13FcC" class="gsc_a_at">A phase II study of alternating paclitaxel and carboplatin in patients with advanced ovarian cancer</a><div class="gs_gray">M Adams, D Mort, R Coleman, L Wiliams, A Evans, M Thompson</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 31, 496-496<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:m4fbC6XIj1kC" class="gsc_a_at">496 A phase II study of alternating paclitaxel and carboplatin in patients with advanced ovarian cancer</a><div class="gs_gray">M Adams, D Mort, R Coleman, L Williams, A Evans, M Thompson</div><div class="gs_gray">European Journal of Cancer 31, S106<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:uPCvBZYD9qUC" class="gsc_a_at">31. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A prospective randomized double-blind placebocontrolled trial</a><div class="gs_gray">R Hultbom, S Rydén, S Gundersen, E Holmberg, UB Wallgren</div><div class="gs_gray">The Breast 3 (4), 236<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ynsZFq2pu0MC" class="gsc_a_at">12 Assessment of response in bone metastases from breast cancer</a><div class="gs_gray">R Coleman</div><div class="gs_gray">The Breast 1 (4), 67-68<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:1xBWf43XMUgC" class="gsc_a_at">29. Evaluation of new bone resorption markers in a comparison of pamidronate or clodronate for hypercalcaemia of malignancy</a><div class="gs_gray">J Vinholes, CY Guo, OP Purohit, R Eastell, APB Vinholes, R Coleman</div><div class="gs_gray">The Breast 3 (4), 235<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:m92CDrhVnKEC" class="gsc_a_at">Neridronic acid is effective in treating malignant hypemdcaemia</a><div class="gs_gray">NP O'Rourke, S Rosini, RE Coleman, JA Kanis</div><div class="gs_gray">British Journal of Can 69, 914-917<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:f2PrUAIjnKUC" class="gsc_a_at">Cancer Chemotherapy</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">BMJ: British Medical Journal 307 (6910), 1014-1014<span class="gs_oph">, 1993</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1993</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:onKP9CxGSkIC" class="gsc_a_at">Osteosarcoma in adolescents and young adults: New developments and controversies, G. Humphrey, HS Koops, WM Molenaar (Eds.), Kluwer (1993), ISBN: 0-7923-1905-2</a><div class="gs_gray">R Coleman</div><div class="gs_gray">Clinical Oncology 5 (5), 333<span class="gs_oph">, 1993</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1993</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:DOLguN9Lh8sC" class="gsc_a_at">Contents, Vol. 49, No. 4, 1992</a><div class="gs_gray">M Tonato, J Smyth, MB Tyers, AJ Freeman, IN Olver, GW Brown, D Paes, ...</div><div class="gs_gray">Oncology 49 (4), 257-259<span class="gs_oph">, 1992</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1992</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:fXCg-C-QWH4C" class="gsc_a_at">Two oral formulations of pamidronate (APD): report of a multicentre phase I/II study</a><div class="gs_gray">LY Dirix, D Dodwell, R Coleman, M Tubiana, J Body, R Becker, G White, ...</div><div class="gs_gray">Osteoclast inhibition on the management of malignancyrelated bone disorders&nbsp;…<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2Q0AJrNhS-QC" class="gsc_a_at">A PHASE-II STUDY OF CYPROTERONE-ACETATE IN ADVANCED OVARIAN-CANCER</a><div class="gs_gray">P THOMPSON, R OSBORNE, M SLEVIN, P WRIGLEY, E WILTSHIRE, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 62 (3), 518-518<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oynPyU19kbsC" class="gsc_a_at">MODIFIED BEP CHEMOTHERAPY FOR METASTATIC TESTICULAR TERATOMA</a><div class="gs_gray">RE COLEMAN, D WHILLIS, GCW HOWARD, RE TAYLOR, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 62 (3), 520-521<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:zDhyt2jClVkC" class="gsc_a_at">APD (pamidronate) for the treatment of bone metastases</a><div class="gs_gray">RE COLEMAN, RD RUBENS</div><div class="gs_gray">Disodium Pamidronate (APD) in the Treatment of Malignancy-related Disorders&nbsp;…<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:wuD5JclIwkYC" class="gsc_a_at">EFFERVESCENT ORAL APD TREATMENT OF BONE METASTASES FROM BREAST-CANCER</a><div class="gs_gray">RE COLEMAN, PJ WOLL, RD RUBENS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 61 (1), 175-176<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EsEWqaRxkBgC" class="gsc_a_at">A phase I/II evaluation of a novel oral formulation of APD for the treatment of bone metastases</a><div class="gs_gray">RE COLEMAN, PJ WOLL, RD RUBENS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 60 (3), 456-456<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:-qpA3cGbmHsC" class="gsc_a_at">New Approaches to the Assessment and Treatment of Bone Metastases</a><div class="gs_gray">RE Coleman</div><div class="gs_gray">King's College School of Medicine and Dentistry<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:Yw6v6SrDvuUC" class="gsc_a_at">RECOVERY OF RENAL-FUNCTION FOLLOWING PROLONGED OLIGO-ANURIA-A 3-YEAR-STUDY</a><div class="gs_gray">RF SPURNEY, RE COLEMAN, SJ SCHWAB</div><div class="gs_gray">KIDNEY INTERNATIONAL 35 (1), 232-232<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:adHtZc2wMuEC" class="gsc_a_at">METHOTREXATE (M), VINBLASTINE (V), ADRIAMYCIN (A) AND CISPLATIN (C) FOR ADVANCED BLADDER-CANCER</a><div class="gs_gray">CJ TWELVES, JA CLARKE, RE COLEMAN, T OLIVER, PG HARPER</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 58 (2), 276-276<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:NtCmTCuxid4C" class="gsc_a_at">APD TREATMENT OF BONE METASTASES FROM BREAST-CANCER</a><div class="gs_gray">RE COLEMAN, P WOLL, RD RUBENS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 58 (2), 268-269<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cdwqcPQS8ssC" class="gsc_a_at">Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.</a><div class="gs_gray">RE Coleman, CA Meier, RD Rubens, I Fogelman</div><div class="gs_gray">Nuclear medicine communications 9 (7), 481-485<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:ujxm2eEBZHIC" class="gsc_a_at">BISPHOSPHONATE TREATMENT OF BONE METASTASES FROM BREAST-CANCER</a><div class="gs_gray">RE COLEMAN, P WOLL, RD RUBENS</div><div class="gs_gray">PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 29, 199-199<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8xglSJ46CyEC" class="gsc_a_at">34. NEW APPROACHES TO THE EVALUATION AND TREATMENT OF BONE METASTASES</a><div class="gs_gray">RD Rubens, RE Coleman</div><div class="gs_gray">Current Perspectives in Breast Cancer: Proceedings of the International&nbsp;…<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6IBXqrN-DEwC" class="gsc_a_at">The Editor wishes to thank the following reviewers who served during the year 1987</a><div class="gs_gray">RE COLEMAN</div><div class="gs_gray">Clin. Oncol 24 (4), 575-517<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1100&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:urP0JZOBBUsC" class="gsc_a_at">Are liver metastases involved in the pathogenesis of hypercalcaemia of malignancy (HM)?</a><div class="gs_gray">RE Coleman, I Fogelman, RD Rubens</div><div class="gs_gray">Bone 8 (4), 267<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:e3CVSTJ63dQC" class="gsc_a_at">A PROSPECTIVE-STUDY OF ALTERNATIVE RESPONSE CRITERIA FOR BONE METASTASES FROM BREAST-CANCER</a><div class="gs_gray">RE COLEMAN, G MASHITER, KB WHITAKER, DW MOSS, IS FOGELMAN, ...</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 53 (3), 431-431<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yaBp1wUtcLsC" class="gsc_a_at">Postoperative Thromboseprophylaxe mit niedrig dosiertem Heparin bei gynäkologischen Malignomen: eine prospektive, kontrollierte Studie</a><div class="gs_gray">DL Clarke-Pearson, E Coleman, IS Synan, W Hinshaw, WT Creasman</div><div class="gs_gray">Gynäkologisch-geburtshilfliche Rundschau 24 (1), 45-47<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:isU91gLudPYC" class="gsc_a_at">MITOXANTRONE, A PHASE-II STUDY IN ADVANCED BREAST-CANCER</a><div class="gs_gray">RE COLEMAN, MN MAISEY, RK KNIGHT, RD RUBENS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 49 (3), 390-390<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:qt-6tCTBDsQC" class="gsc_a_at">THE DILATED CYSTIC DUCT SIGN-A POTENTIAL CAUSE OF FALSE-NEGATIVE CHOLESCINTIGRAPHY</a><div class="gs_gray">RE COLEMAN, JE FREITAS, DM FINKBENNETT, RL BREE</div><div class="gs_gray">JOURNAL OF NUCLEAR MEDICINE 24 (5), P97-P97<span class="gs_oph">, 1983</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1983</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:5UUbrqTvKfUC" class="gsc_a_at">THE INFLUENCE OF SCAN AND PATHOLOGICAL CRITERIA UPON THE SPECIFICITY OF CHOLESCINTIGRAPHY</a><div class="gs_gray">RE COLEMAN, JE FREITAS, CE NAGLE, RL BREE, KD KREWER, ...</div><div class="gs_gray">JOURNAL OF NUCLEAR MEDICINE 24 (5), P8-P8<span class="gs_oph">, 1983</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1983</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:BSZS1fLCB98C" class="gsc_a_at">DISCUSSION OF COLEMAN RF</a><div class="gs_gray">BALOGH, RF COLEMAN, LEHRER, WATTENBE.</div><div class="gs_gray">JOURNAL OF HISTOCHEMISTRY &amp; CYTOCHEMISTRY 14 (11), 811-&amp;<span class="gs_oph">, 1966</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1966</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3s2jc9hNhkQC" class="gsc_a_at">World Agriculture Editorial Board</a><div class="gs_gray">Y Bangjie, MD Epstein, C Tickell, D Frape, R Cook, Z Ming, B Aldiss, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:3q5vy9RXY8EC" class="gsc_a_at">The ESMO Guidelines Working Group acknowledges and thanks the following people who have acted as reviewers for these ESMO Clinical Practice Guidelines.</a><div class="gs_gray">M Aapro, F Andre, J Baars, E Baudin, C Bokemeyer, H Bonnefoi, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:bYbwfsIO_fQC" class="gsc_a_at">ERRATUM Open Access</a><div class="gs_gray">DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Glück, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rCuJAniQoLoC" class="gsc_a_at">Volume 13AuthorIndex</a><div class="gs_gray">PC Adamson, JT Adler, MA Alderfer, J Almeida, D Amadori, F Amant, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6B7w4NK6UsoC" class="gsc_a_at">Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomized trials</a><div class="gs_gray">A Charehbili, JR Kroep, RE Coleman, RL Aft, Y Hasegawa, GJ Liefers, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:eP5N1itS6b0C" class="gsc_a_at">Capivasertib (AZD5363), an AKT inhibitor, rapidly and effectively targets key AKT pathway and proliferation biomarkers: the STAKT pre-surgical breast cancer study</a><div class="gs_gray">JFR Robertson, RE Coleman, KL Cheung, A Evans, C Holcombe, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:vkDViGfkvYEC" class="gsc_a_at">MBBS, MD, FRCP, FRCPE</a><div class="gs_gray">RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:8EvVLpklxGMC" class="gsc_a_at">European Society for Medical Oncology and the Japanese Society of Medical Oncology</a><div class="gs_gray">R Raghupathy, T Mok, P Radice, PDP Pharoah, P Peterlongo, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:6MVT8mER-OMC" class="gsc_a_at">Eniluracil 5-fluorouracil in metastatic colorectal cancer</a><div class="gs_gray">TJ Postma, JJ Heimans, WA Beeker, NH Mulder, J Hermans, RE Coleman, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:LYDvBi7O6RsC" class="gsc_a_at">European Society for Medical Oncology and the Japanese Society of Medical Oncology Volume 12| No. 12| December 2011</a><div class="gs_gray">AT Meadows, M Gray, P Naredi, N Bacon, DJ Kerr, P Hadji, MS Aapro, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:gPamCmV4epEC" class="gsc_a_at">Evolution of a Specialist Gestational Trophoblastic Disease Service with a Major Nursing Component</a><div class="gs_gray">RGN Jane Ireson, RGN Kamaljit Singh, RGN Sarah Gillett, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cocyvO7vrcwC" class="gsc_a_at">Final Results of NKTR-102 a Topoisomerase I Final Results of NKTR 102, a Topoisomerase I Inhibitor-Polymer Conjugate, in Patients with Pretreated Metastatic Breast Cancer&nbsp;…</a><div class="gs_gray">AA Garcia, A Awada, S Chan, RE Coleman, M Huizing, A Mehdi, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:38eRAUXPO10C" class="gsc_a_at">GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer</a><div class="gs_gray">RCF Leonard, DJA Adamson, G Bertelli, J Mansi, A Yellowlees, J Dunlop, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:0uG9q0SNyf4C" class="gsc_a_at">Testimony of Rev. Coleman.</a><div class="gs_gray">R Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:w_ORaKkuc5QC" class="gsc_a_at">94 Proffered Papers</a><div class="gs_gray">P Major, V Hirsh, A Lipton, RJ Cook, RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:9fRKRCJz75UC" class="gsc_a_at">journal homepage: www. elsevier. com/locate/jbo</a><div class="gs_gray">M Oda, K Iwaya, R Kikuchi, T Kobayashi, T Yoneda, K Nishikawa, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:PcT55Ow6fAIC" class="gsc_a_at">of Zoledronic Acid to Chemotherapy in breast cancer</a><div class="gs_gray">MC Winter, SS Cross, CE Ingram, IJ Jolley, I Holen, MQ Hatton, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:S_fw-_riRmcC" class="gsc_a_at">OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases</a><div class="gs_gray">R Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:URGbnSt0D2cC" class="gsc_a_at">IMPAKT 2015 Officers</a><div class="gs_gray">D Cameron, HJ Senn, R Coleman, C Sotiriou, G Curigliano, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:pYRxIbzCxX0C" class="gsc_a_at">Effects of an exercise and hypocaloric healthy eating program</a><div class="gs_gray">RE Coleman, N Mutrie, II Crank, HJPJM Saxton</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RgMnzfD6kpIC" class="gsc_a_at">Breast Cancer Aftercare; using qualitative methods to inform the development of a psychosocial intervention.</a><div class="gs_gray">R Coleman, N Mathers, M Reed</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:RdUpO4xyVKMC" class="gsc_a_at">Phase II Study with Special Attention to Cardiotoxicity</a><div class="gs_gray">RE COLEMAN, MN MAISEY, RK KNIGHT, RD RUBENS</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:hrkNWuzUpWwC" class="gsc_a_at">Matthew C. Winter", Caroline Wilson', Stuart P. Syddall', Simon S. Cross”</a><div class="gs_gray">CEI Alyson Evans, IJ Jolley, MQ Hatton, JV Freeman, IH Stefano Mori, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2_BaaiyHPJIC" class="gsc_a_at">Keeping Up Appearances: Prescriptive Possession of Servitudes</a><div class="gs_gray">U Promise, WB Advocating, RJ Coleman, M Rauber, B Michel</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:cww_0JKUTDwC" class="gsc_a_at">Placental site trophoblastic tumour: Clinical features and management</a><div class="gs_gray">R Coleman, B Hancock</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:SWgZeABleR0C" class="gsc_a_at">The ESMO Guidelines Working Group acknowledges and thanks the following people who have acted as reviewers for these ESMO Clinical Recommendations.</a><div class="gs_gray">S Aamdal, M Aapro, S Aebi, A Ardizzoni, P Baas, D Bafaloukos, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:htyGaKyDgHMC" class="gsc_a_at">Adjuvant Endocrine Therapy for a Postmenopausal Patient at Intermediate Risk of Recurrence</a><div class="gs_gray">RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:oYLFIHfuHKwC" class="gsc_a_at">Hematopoietic Stem Cell Transplantation 2008 Education Supplement</a><div class="gs_gray">MRM van den Brink, FR Appelbaum, KR Cooke, SM Davies, J DiPersio, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:c1AJUTjuCtUC" class="gsc_a_at">Referees for 1997</a><div class="gs_gray">H Andrews, SA Baird, C Baylies, P Bearcroft, LA Berger, JJ Bolger, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:EBV337fEn3EC" class="gsc_a_at">Aapro, M., see Biganzoli, L. 61, 84 Aapro, MS, see Jordan, K. 61, 162 Andreoli, C., see Gennari, R. 61, 97 Aoki, E., see Oki, Y. 61, 140 Azmi, W., see Narta, UK 61, 208</a><div class="gs_gray">L Biganzoli, R Coleman, A Minisini, A Hamilton</div><div class="gs_gray">breast cancer 61, 84<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:XAp-VaTZjjwC" class="gsc_a_at">Burgon, K. see Shelley, MD 237 Buyyounouski, M. see Kaminski, JM 49</a><div class="gs_gray">I Chau, D Cunningham, A Clamp, M Clemons, WC Cole, KN Prasad, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QaSi33NTfwYC" class="gsc_a_at">YEOMAN LJ, 127</a><div class="gs_gray">MEDC Anderson, TJ Anderson, MA Baildam, MH Bishop, N UK, S Ciatto, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:WWeOtg8bX_EC" class="gsc_a_at">Bouchier-Hayes, DJ, 297 Bruix, J., 99</a><div class="gs_gray">AU Buzdar, MS Cairo, G Carrum, E Cellarier, L Cetina, YM Chen, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:rOcdG6UcVlcC" class="gsc_a_at">Welcome to the first edition of OncoFacts for 2010. As in past years, we will be reporting relevant and breaking issues on a monthly basis. In this issue, I will be&nbsp;…</a><div class="gs_gray">JM Bliss, LS Kilburn, RE Coleman</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:H7nrzBkawXsC" class="gsc_a_at">Index to Volume 22</a><div class="gs_gray">JJ Body, RE Coleman, M Piccart, L Canobbio, L Miglietta, F Boccardo</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:xm0LlTxljI0C" class="gsc_a_at">Carboplatin vs Radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates.</a><div class="gs_gray">RTD Oliver, GM Mead, GJS Rustin, JK Joffe, N Aass, R Coleman, R Gabe, ...</div><div class="gs_gray">Journal of Clinical Oncology<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:_tF6a-HnqWAC" class="gsc_a_at">RIBBON-1: efficacy of capecitabine plus bevacizumab in patients with triple-negative metastatic breast cancer</a><div class="gs_gray">H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman</div><div class="gs_gray">Age 462 (153), 65<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:2vr6o8x5NLkC" class="gsc_a_at">CANCER TREATMENT</a><div class="gs_gray">RE Coleman, RA Stahel, K Hellmann, SK Carter, MD Abeloff, HH Hansen</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:yY3RG6sOEgwC" class="gsc_a_at">The following elections were approved on March 6, 1958 by the Membership Committee by authority given to it by the Board of Managers.</a><div class="gs_gray">CA Bishof, CW Bowden Jr, JK Brown, LB Bureau, MP Chinitz, DW Cobb, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:QVtou7C4vgoC" class="gsc_a_at">Axelsson-Jacobson, C., 1321</a><div class="gs_gray">RE Coleman, R Coniglione</div><div class="gs_gray">Bone 500 (934), 1571<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=UIrmjcIAAAAJ&amp;cstart=1200&amp;pagesize=100&amp;citation_for_view=UIrmjcIAAAAJ:s85pQhAUCrAC" class="gsc_a_at">Update on the Role of Bisphosphonates in Metastatic Breast Cancer</a><div class="gs_gray">JJ Body, R Coleman, N Roche, I Die, P LoRusso, G Mundy, A Paterson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr></tbody></table><div id="gsc_a_sp" class=""></div><div id="gsc_a_err" class="gs_alrt">The system can't perform the operation now. Try again later.</div></div><div id="gsc_lwp"><span id="gsc_a_nn">Articles 1–1247</span><div id="gsc_bpf"><button type="button" id="gsc_bpf_more" class="gs_btnPD gs_in_ib gs_btn_flat gs_btn_lrge gs_btn_lsu" disabled=""><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Show more</span></span></button></div></div></form></div></div></div></div><div id="gs_ftr_sp" role="presentation"></div><div id="gs_ftr" role="contentinfo"><div id="gs_ftr_rt"><a href="/intl/en/scholar/about.html">Help</a><a href="//www.google.com/intl/en/policies/privacy/">Privacy</a><a href="//www.google.com/intl/en/policies/terms/">Terms</a></div></div></div></body></html>